0000937556-21-000124.txt : 20211026 0000937556-21-000124.hdr.sgml : 20211026 20211026170801 ACCESSION NUMBER: 0000937556-21-000124 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 99 CONFORMED PERIOD OF REPORT: 20211002 FILED AS OF DATE: 20211026 DATE AS OF CHANGE: 20211026 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MASIMO CORP CENTRAL INDEX KEY: 0000937556 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 330368882 STATE OF INCORPORATION: DE FISCAL YEAR END: 0101 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33642 FILM NUMBER: 211349527 BUSINESS ADDRESS: STREET 1: 52 DISCOVERY CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: 949-297-7000 MAIL ADDRESS: STREET 1: 52 DISCOVERY CITY: IRVINE STATE: CA ZIP: 92618 10-Q 1 masi-20211002.htm 10-Q masi-20211002
false2021Q30000937556January 100009375562021-01-032021-10-02xbrli:shares00009375562021-10-02iso4217:USD00009375562021-01-02iso4217:USDxbrli:shares00009375562021-07-042021-10-0200009375562020-06-282020-09-2600009375562019-12-292020-09-260000937556us-gaap:CommonStockMember2021-01-020000937556us-gaap:TreasuryStockMember2021-01-020000937556us-gaap:AdditionalPaidInCapitalMember2021-01-020000937556us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-020000937556us-gaap:RetainedEarningsMember2021-01-020000937556us-gaap:CommonStockMember2021-01-032021-04-030000937556us-gaap:AdditionalPaidInCapitalMember2021-01-032021-04-0300009375562021-01-032021-04-030000937556us-gaap:TreasuryStockMember2021-01-032021-04-030000937556us-gaap:RetainedEarningsMember2021-01-032021-04-030000937556us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-032021-04-030000937556us-gaap:CommonStockMember2021-04-030000937556us-gaap:TreasuryStockMember2021-04-030000937556us-gaap:AdditionalPaidInCapitalMember2021-04-030000937556us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-030000937556us-gaap:RetainedEarningsMember2021-04-0300009375562021-04-030000937556us-gaap:CommonStockMember2021-04-042021-07-030000937556us-gaap:AdditionalPaidInCapitalMember2021-04-042021-07-0300009375562021-04-042021-07-030000937556us-gaap:RetainedEarningsMember2021-04-042021-07-030000937556us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-042021-07-030000937556us-gaap:CommonStockMember2021-07-030000937556us-gaap:TreasuryStockMember2021-07-030000937556us-gaap:AdditionalPaidInCapitalMember2021-07-030000937556us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-030000937556us-gaap:RetainedEarningsMember2021-07-0300009375562021-07-030000937556us-gaap:CommonStockMember2021-07-042021-10-020000937556us-gaap:AdditionalPaidInCapitalMember2021-07-042021-10-020000937556us-gaap:RetainedEarningsMember2021-07-042021-10-020000937556us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-042021-10-020000937556us-gaap:CommonStockMember2021-10-020000937556us-gaap:TreasuryStockMember2021-10-020000937556us-gaap:AdditionalPaidInCapitalMember2021-10-020000937556us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-10-020000937556us-gaap:RetainedEarningsMember2021-10-020000937556us-gaap:CommonStockMember2019-12-280000937556us-gaap:TreasuryStockMember2019-12-280000937556us-gaap:AdditionalPaidInCapitalMember2019-12-280000937556us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-280000937556us-gaap:RetainedEarningsMember2019-12-2800009375562019-12-280000937556us-gaap:CommonStockMember2019-12-292020-03-280000937556us-gaap:AdditionalPaidInCapitalMember2019-12-292020-03-2800009375562019-12-292020-03-280000937556us-gaap:TreasuryStockMember2019-12-292020-03-280000937556us-gaap:AccountingStandardsUpdate201613Memberus-gaap:RetainedEarningsMember2019-12-292020-03-280000937556us-gaap:RetainedEarningsMember2019-12-292020-03-280000937556us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-292020-03-280000937556us-gaap:CommonStockMember2020-03-280000937556us-gaap:TreasuryStockMember2020-03-280000937556us-gaap:AdditionalPaidInCapitalMember2020-03-280000937556us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-280000937556us-gaap:RetainedEarningsMember2020-03-2800009375562020-03-280000937556us-gaap:CommonStockMember2020-03-292020-06-270000937556us-gaap:AdditionalPaidInCapitalMember2020-03-292020-06-2700009375562020-03-292020-06-270000937556us-gaap:TreasuryStockMember2020-03-292020-06-270000937556us-gaap:RetainedEarningsMember2020-03-292020-06-270000937556us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-292020-06-270000937556us-gaap:CommonStockMember2020-06-270000937556us-gaap:TreasuryStockMember2020-06-270000937556us-gaap:AdditionalPaidInCapitalMember2020-06-270000937556us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-270000937556us-gaap:RetainedEarningsMember2020-06-2700009375562020-06-270000937556us-gaap:CommonStockMember2020-06-282020-09-260000937556us-gaap:AdditionalPaidInCapitalMember2020-06-282020-09-260000937556us-gaap:RetainedEarningsMember2020-06-282020-09-260000937556us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-282020-09-260000937556us-gaap:CommonStockMember2020-09-260000937556us-gaap:TreasuryStockMember2020-09-260000937556us-gaap:AdditionalPaidInCapitalMember2020-09-260000937556us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-260000937556us-gaap:RetainedEarningsMember2020-09-2600009375562020-09-260000937556us-gaap:LandBuildingsAndImprovementsMembersrt:MinimumMember2021-01-032021-10-020000937556us-gaap:LandBuildingsAndImprovementsMembersrt:MaximumMember2021-01-032021-10-020000937556srt:MinimumMemberus-gaap:ComputerEquipmentMember2021-01-032021-10-020000937556srt:MaximumMemberus-gaap:ComputerEquipmentMember2021-01-032021-10-020000937556masi:DemonstrationUnitsMember2021-01-032021-10-020000937556masi:FurnitureandOfficeEquipmentMembersrt:MinimumMember2021-01-032021-10-020000937556masi:FurnitureandOfficeEquipmentMembersrt:MaximumMember2021-01-032021-10-020000937556srt:MinimumMemberus-gaap:MachineryAndEquipmentMember2021-01-032021-10-020000937556srt:MaximumMemberus-gaap:MachineryAndEquipmentMember2021-01-032021-10-020000937556srt:MinimumMemberus-gaap:TransportationEquipmentMember2021-01-032021-10-020000937556srt:MaximumMemberus-gaap:TransportationEquipmentMember2021-01-032021-10-020000937556us-gaap:PatentsMember2021-01-032021-10-020000937556us-gaap:TrademarksMember2021-01-032021-10-02masi:segment0000937556srt:MinimumMember2024-07-032021-10-0200009375562027-07-03srt:MaximumMember2021-10-020000937556srt:MinimumMember2021-01-032021-10-020000937556srt:MaximumMember2021-01-032021-10-020000937556us-gaap:RestrictedStockUnitsRSUMembersrt:ChiefExecutiveOfficerMember2019-12-292020-09-260000937556us-gaap:RestrictedStockUnitsRSUMembersrt:ChiefExecutiveOfficerMember2021-01-032021-10-020000937556masi:CercacorLaboratoriesMember2021-07-042021-10-020000937556masi:CercacorLaboratoriesMember2020-06-282020-09-260000937556masi:CercacorLaboratoriesMember2021-01-032021-10-020000937556masi:CercacorLaboratoriesMember2019-12-292020-09-26utr:sqft0000937556masi:LeasedPropertyMember2021-01-032021-10-020000937556masi:SubleasedPropertyDomain2021-01-032021-10-020000937556masi:CercacorLaboratoriesMember2021-10-020000937556masi:CercacorLaboratoriesMember2021-01-020000937556masi:NotforProfitOrganizationMember2020-06-282020-09-260000937556masi:NotforProfitOrganizationMember2021-07-042021-10-020000937556masi:NotforProfitOrganizationMember2021-01-032021-10-020000937556masi:NotforProfitOrganizationMember2019-12-292020-09-260000937556masi:LikeMindedEntertainmentMember2021-07-042021-10-020000937556masi:LikeMindedEntertainmentMember2021-01-032021-10-020000937556masi:LikeMindedEntertainmentMember2020-06-282020-09-260000937556masi:LikeMindedEntertainmentMember2019-12-292020-09-260000937556masi:LikeMindedEntertainmentMember2021-01-020000937556masi:LikeMindedEntertainmentMember2021-10-020000937556masi:LikeMindedLabsMember2021-10-020000937556us-gaap:PurchaseCommitmentMembermasi:VantrixCorpMember2021-07-082021-07-080000937556masi:VantrixCorpMemberus-gaap:OptionMember2021-07-082021-07-080000937556masi:ReimbursementFeeMember2021-01-032021-10-020000937556masi:ReimbursementFeeMember2020-06-282020-09-260000937556masi:ReimbursementFeeMember2019-12-292020-09-260000937556masi:ReimbursementFeeMember2021-07-042021-10-020000937556us-gaap:BuildingAndBuildingImprovementsMember2021-10-020000937556us-gaap:BuildingAndBuildingImprovementsMember2021-01-020000937556us-gaap:MachineryAndEquipmentMember2021-10-020000937556us-gaap:MachineryAndEquipmentMember2021-01-020000937556us-gaap:LandMember2021-10-020000937556us-gaap:LandMember2021-01-020000937556us-gaap:TransportationEquipmentMember2021-10-020000937556us-gaap:TransportationEquipmentMember2021-01-020000937556us-gaap:ComputerEquipmentMember2021-10-020000937556us-gaap:ComputerEquipmentMember2021-01-020000937556us-gaap:LeaseholdImprovementsMember2021-10-020000937556us-gaap:LeaseholdImprovementsMember2021-01-020000937556us-gaap:FurnitureAndFixturesMember2021-10-020000937556us-gaap:FurnitureAndFixturesMember2021-01-020000937556masi:DemonstrationUnitsMember2021-10-020000937556masi:DemonstrationUnitsMember2021-01-020000937556us-gaap:ConstructionInProgressMember2021-10-020000937556us-gaap:ConstructionInProgressMember2021-01-020000937556us-gaap:PatentsMember2021-10-020000937556us-gaap:PatentsMember2021-01-020000937556masi:AcquiredTechnologyMember2021-10-020000937556masi:AcquiredTechnologyMember2021-01-020000937556us-gaap:CustomerRelationshipsMember2021-10-020000937556us-gaap:CustomerRelationshipsMember2021-01-020000937556us-gaap:TrademarksMember2021-10-020000937556us-gaap:TrademarksMember2021-01-020000937556us-gaap:LicensingAgreementsMember2021-10-020000937556us-gaap:LicensingAgreementsMember2021-01-020000937556us-gaap:LicensingAgreementsMembermasi:CercacorLaboratoriesMember2021-10-020000937556us-gaap:LicensingAgreementsMembermasi:CercacorLaboratoriesMember2021-01-020000937556us-gaap:OtherIntangibleAssetsMember2021-10-020000937556us-gaap:OtherIntangibleAssetsMember2021-01-020000937556masi:PatentsAndTrademarksMember2021-07-042021-10-020000937556masi:PatentsAndTrademarksMember2020-06-282020-09-260000937556masi:PatentsAndTrademarksMember2021-01-032021-10-020000937556masi:PatentsAndTrademarksMember2019-12-292020-09-26xbrli:pure00009375562026-10-012021-10-0200009375562022-10-012021-10-020000937556us-gaap:RevolvingCreditFacilityMember2018-12-170000937556us-gaap:RevolvingCreditFacilityMember2018-12-170000937556us-gaap:ForeignLineOfCreditMember2018-12-170000937556us-gaap:RevolvingCreditFacilityMember2021-10-020000937556us-gaap:RevolvingCreditFacilityMember2021-01-020000937556us-gaap:RevolvingCreditFacilityMember2020-06-282020-09-260000937556us-gaap:RevolvingCreditFacilityMember2021-07-042021-10-020000937556us-gaap:RevolvingCreditFacilityMember2019-12-292020-09-260000937556us-gaap:RevolvingCreditFacilityMember2021-01-032021-10-020000937556masi:A2021RepurchaseProgramMemberus-gaap:CommonStockMemberus-gaap:SubsequentEventMember2021-10-290000937556masi:A2021RepurchaseProgramMemberus-gaap:CommonStockMemberus-gaap:SubsequentEventMember2021-10-292024-10-290000937556masi:A2018RepurchaseProgramMemberus-gaap:CommonStockMember2018-07-010000937556masi:A2018RepurchaseProgramMemberus-gaap:CommonStockMember2018-09-112021-09-110000937556masi:A2017EquityIncentivePlanDomainsrt:MinimumMember2021-10-020000937556masi:A2017EquityIncentivePlanDomain2021-07-042021-10-020000937556masi:A2017EquityIncentivePlanDomainsrt:MaximumMember2021-10-020000937556srt:MaximumMembermasi:A2007StockIncentivePlanDomain2021-10-020000937556us-gaap:EmployeeStockOptionMember2021-07-042021-10-020000937556us-gaap:EmployeeStockOptionMember2020-06-282020-09-260000937556us-gaap:EmployeeStockOptionMember2021-01-032021-10-020000937556us-gaap:EmployeeStockOptionMember2019-12-292020-09-260000937556us-gaap:EmployeeStockOptionMember2021-10-020000937556us-gaap:RestrictedStockUnitsRSUMember2021-01-020000937556us-gaap:RestrictedStockUnitsRSUMember2021-01-032021-10-020000937556us-gaap:RestrictedStockUnitsRSUMember2021-10-020000937556us-gaap:RestrictedStockUnitsRSUMember2021-07-042021-10-020000937556us-gaap:RestrictedStockUnitsRSUMember2020-06-282020-09-260000937556us-gaap:RestrictedStockUnitsRSUMember2019-12-292020-09-260000937556us-gaap:PerformanceSharesMember2021-01-020000937556srt:MinimumMemberus-gaap:PerformanceSharesMember2021-01-032021-10-020000937556us-gaap:PerformanceSharesMember2021-01-032021-10-020000937556us-gaap:PerformanceSharesMember2021-10-020000937556srt:MinimumMemberus-gaap:PerformanceSharesMembermasi:A2021PSUGrantDomain2021-01-032021-10-020000937556srt:MinimumMemberus-gaap:PerformanceSharesMembermasi:A2021PSUGrantDomain2021-10-020000937556srt:MaximumMemberus-gaap:PerformanceSharesMembermasi:A2021PSUGrantDomain2021-10-020000937556srt:MaximumMemberus-gaap:PerformanceSharesMembermasi:A2021PSUGrantDomain2021-01-032021-10-020000937556us-gaap:PerformanceSharesMember2021-07-042021-10-020000937556us-gaap:PerformanceSharesMember2020-06-282020-09-260000937556us-gaap:PerformanceSharesMember2019-12-292020-09-260000937556srt:ChiefExecutiveOfficerMemberus-gaap:CashDistributionMember2017-07-272017-07-270000937556us-gaap:RestrictedStockUnitsRSUMembersrt:ChiefExecutiveOfficerMember2017-07-272017-07-270000937556srt:ChiefExecutiveOfficerMember2021-01-032021-10-02masi:Agreement0000937556us-gaap:SalesRevenueProductLineMember2021-07-042021-10-020000937556us-gaap:SalesRevenueProductLineMember2020-06-282020-09-260000937556us-gaap:SalesRevenueProductLineMember2021-01-032021-10-020000937556us-gaap:SalesRevenueProductLineMember2019-12-292020-09-26masi:distributor0000937556us-gaap:SalesMember2021-07-042021-10-020000937556us-gaap:SalesMember2020-06-282020-09-260000937556us-gaap:SalesMember2021-01-032021-10-020000937556us-gaap:SalesMember2019-12-292020-09-26masi:Customer0000937556us-gaap:AccountsReceivableMember2021-10-020000937556us-gaap:AccountsReceivableMember2021-01-020000937556masi:MasimovsFormerAgencyTenderMember2018-04-012018-06-300000937556masi:MasimovsFormerAgencyTenderMember2019-12-292020-06-2700009375562019-07-082019-07-080000937556masi:Masimovs.PhysiciansHealthsourceInc.Member2014-01-022014-01-030000937556country:USsrt:ReportableGeographicalComponentsMember2021-07-042021-10-020000937556us-gaap:GeographicConcentrationRiskMembercountry:USus-gaap:SalesRevenueNetMember2021-07-042021-10-020000937556country:USsrt:ReportableGeographicalComponentsMember2020-06-282020-09-260000937556us-gaap:GeographicConcentrationRiskMembercountry:USus-gaap:SalesRevenueNetMember2020-06-282020-09-260000937556country:USsrt:ReportableGeographicalComponentsMember2021-01-032021-10-020000937556us-gaap:GeographicConcentrationRiskMembercountry:USus-gaap:SalesRevenueNetMember2021-01-032021-10-020000937556country:USsrt:ReportableGeographicalComponentsMember2019-12-292020-09-260000937556us-gaap:GeographicConcentrationRiskMembercountry:USus-gaap:SalesRevenueNetMember2019-12-292020-09-260000937556srt:ReportableGeographicalComponentsMemberus-gaap:EMEAMember2021-07-042021-10-020000937556us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMemberus-gaap:EMEAMember2021-07-042021-10-020000937556srt:ReportableGeographicalComponentsMemberus-gaap:EMEAMember2020-06-282020-09-260000937556us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMemberus-gaap:EMEAMember2020-06-282020-09-260000937556srt:ReportableGeographicalComponentsMemberus-gaap:EMEAMember2021-01-032021-10-020000937556us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMemberus-gaap:EMEAMember2021-01-032021-10-020000937556srt:ReportableGeographicalComponentsMemberus-gaap:EMEAMember2019-12-292020-09-260000937556us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMemberus-gaap:EMEAMember2019-12-292020-09-260000937556srt:AsiaPacificMembersrt:ReportableGeographicalComponentsMember2021-07-042021-10-020000937556us-gaap:GeographicConcentrationRiskMembersrt:AsiaPacificMemberus-gaap:SalesRevenueNetMember2021-07-042021-10-020000937556srt:AsiaPacificMembersrt:ReportableGeographicalComponentsMember2020-06-282020-09-260000937556us-gaap:GeographicConcentrationRiskMembersrt:AsiaPacificMemberus-gaap:SalesRevenueNetMember2020-06-282020-09-260000937556srt:AsiaPacificMembersrt:ReportableGeographicalComponentsMember2021-01-032021-10-020000937556us-gaap:GeographicConcentrationRiskMembersrt:AsiaPacificMemberus-gaap:SalesRevenueNetMember2021-01-032021-10-020000937556srt:AsiaPacificMembersrt:ReportableGeographicalComponentsMember2019-12-292020-09-260000937556us-gaap:GeographicConcentrationRiskMembersrt:AsiaPacificMemberus-gaap:SalesRevenueNetMember2019-12-292020-09-260000937556srt:AmericasMembersrt:ReportableGeographicalComponentsMember2021-07-042021-10-020000937556srt:AmericasMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-07-042021-10-020000937556srt:AmericasMembersrt:ReportableGeographicalComponentsMember2020-06-282020-09-260000937556srt:AmericasMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-06-282020-09-260000937556srt:AmericasMembersrt:ReportableGeographicalComponentsMember2021-01-032021-10-020000937556srt:AmericasMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-01-032021-10-020000937556srt:AmericasMembersrt:ReportableGeographicalComponentsMember2019-12-292020-09-260000937556srt:AmericasMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2019-12-292020-09-260000937556country:USsrt:ReportableGeographicalComponentsMember2021-10-020000937556country:USsrt:ReportableGeographicalComponentsMember2021-01-020000937556srt:ReportableGeographicalComponentsMemberus-gaap:NonUsMember2021-10-020000937556srt:ReportableGeographicalComponentsMemberus-gaap:NonUsMember2021-01-02
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
________________________________________________
FORM 10-Q
________________________________________________
(Mark One)
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended October 2, 2021
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _________ to _________
Commission File Number 001-33642
masi-20211002_g1.jpg
________________________________________________
MASIMO CORPORATION
(Exact Name of Registrant as Specified in its Charter)
________________________________________________
Delaware33-0368882
(State or Other Jurisdiction of
Incorporation or Organization)		(I.R.S. Employer
Identification Number)
52 DiscoveryIrvine,California92618
(Address of Principal Executive Offices)(Zip Code)
(949)297-7000
(Registrant’s Telephone Number, Including Area Code)
Securities Registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value
MASI
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.        Yes☒
No
☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).      
Yes
☒
No
☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.)     
Yes☐
No
☒
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:
Class
Number of Shares Outstanding as of
October 2, 2021
Common stock, $0.001 par value
55,221,689

MASIMO CORPORATION
FORM 10-Q FOR THE QUARTER ENDED OCTOBER 2, 2021
TABLE OF CONTENTS
 
Item 1.
Item 2.
Item 3.
Item 4.
Item 1.
Item 1A.
Item 6.

2
PART I. FINANCIAL INFORMATION
Item 1.     Financial Statements
MASIMO CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited, in thousands, except par values)
October 2,
2021		January 2,
2021
ASSETS
Current assets
Cash and cash equivalents$652,354 $641,447 
Trade accounts receivable, net of allowance for credit losses of $2,081 and $1,603 at October 2, 2021 and January 2, 2021, respectively
191,332 141,350 
Inventories202,328 215,952 
Other current assets91,772 102,416 
Total current assets1,137,786 1,101,165 
Lease receivable, noncurrent66,955 57,666 
Deferred costs and other contract assets22,599 20,076 
Property and equipment, net274,929 272,511 
Intangible assets, net74,089 73,923 
Goodwill101,242 103,206 
Deferred tax assets39,294 39,363 
Other non-current assets49,886 44,642 
Total assets$1,766,780 $1,712,552 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable$60,710 $64,061 
Accrued compensation69,785 71,601 
Deferred revenue and other contract liabilities, current46,641 44,935 
Other current liabilities51,118 53,239 
Total current liabilities228,254 233,836 
Other non-current liabilities70,377 71,076 
Total liabilities298,631 304,912 
Commitments and contingencies - (Note 21)
Stockholders’ equity
Preferred stock, $0.001 par value; 5,000 shares authorized; 0 shares issued and outstanding
— — 
Common stock, $0.001 par value; 100,000 shares authorized; 55,222 and 55,251 shares issued and outstanding at October 2, 2021 and January 2, 2021, respectively
55 55 
Treasury stock, 16,540 and 15,993 shares at October 2, 2021 and January 2, 2021, respectively
(767,653)(638,736)
Additional paid-in capital736,575 703,693 
Accumulated other comprehensive (loss) income(3,432)1,413 
Retained earnings1,502,604 1,341,215 
Total stockholders’ equity1,468,149 1,407,640 
Total liabilities and stockholders’ equity$1,766,780 $1,712,552 

The accompanying notes are an integral part of these condensed consolidated financial statements.
3
MASIMO CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited, in thousands, except per share amounts)
 
Three Months EndedNine Months Ended
October 2,
2021		September 26,
2020		October 2,
2021		September 26,
2020
Product revenue$307,414 $278,112 $911,575 $848,690 
Cost of goods sold103,750 99,186 318,124 292,551 
Gross profit203,664 178,926 593,451 556,139 
Operating expenses:
Selling, general and administrative100,647 90,376 291,180 278,714 
Research and development35,406 28,852 103,860 86,971 
Litigation awards— — — (474)
Total operating expenses136,053 119,228 395,040 365,211 
Operating income67,611 59,698 198,411 190,928 
Non-operating (loss) income(78)1,357 (735)6,108 
Income before provision for income taxes67,533 61,055 197,676 197,036 
Provision for income taxes9,762 11,650 36,287 27,403 
Net income$57,771 $49,405 $161,389 $169,633 
Net income per share:
Basic$1.05 $0.90 $2.93 $3.11 
Diluted$1.00 $0.85 $2.80 $2.92 
Weighted-average shares used in per share calculations:
Basic55,143 54,997 55,125 54,543 
Diluted57,664 58,280 57,651 58,033 

The accompanying notes are an integral part of these condensed consolidated financial statements.
4
MASIMO CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(unaudited, in thousands)
 
Three Months EndedNine Months Ended
October 2,
2021		September 26,
2020		October 2,
2021		September 26,
2020
Net income$57,771 $49,405 $161,389 $169,633 
Other comprehensive income, net of tax:
Unrealized (losses) gains from foreign currency translation adjustments(3,165)2,653 (4,845)1,504 
Total comprehensive income$54,606 $52,058 $156,544 $171,137 

The accompanying notes are an integral part of these condensed consolidated financial statements.
5

MASIMO CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(in thousands)
Three and Nine Months Ended October 2, 2021
Common StockTreasury StockAdditional
Paid-In
Capital		Accumulated
Other
Comprehensive
Income (Loss)		Retained
Earnings		Total
Stockholders’
Equity
SharesAmountSharesAmount
Balance at January 2, 202155,251 $55 15,993 $(638,736)$703,693 $1,413 $1,341,215 $1,407,640 
Stock options exercised61 — — — 2,886 — — 2,886 
Restricted/Performance stock units vested303 — — — — — — — 
Shares paid for tax withholding(68)— — — (16,691)— — (16,691)
Stock-based compensation— — — — 12,708 — — 12,708 
Repurchases of common stock(547)— 547 (128,917)— — — (128,917)
Net income— — — — — — 53,383 53,383 
Foreign currency translation adjustment— — — — — (2,884)— (2,884)
Balance at April 3, 202155,000 55 16,540 (767,653)702,596 (1,471)1,394,598 1,328,125 
Stock options exercised52 — — — 3,442 — — 3,442 
Restricted/Performance stock units vested4 — — — — — — — 
Shares paid for tax withholding1 — — — (33)— — (33)
Stock-based compensation— — — — 8,262 — — 8,262 
Net income— — — — — — 50,235 50,235 
Foreign currency translation adjustment— — — — — 1,204 — 1,204 
Balance at July 3, 202155,057 55 16,540 (767,653)714,267 (267)1,444,833 1,391,235 
Stock options exercised165 — — — 9,748 — — 9,748 
Stock-based compensation— — — — 12,560 — — 12,560 
Net income— — — — — — 57,771 57,771 
Foreign currency translation adjustment— — — — — (3,165)— (3,165)
Balance at October 2, 202155,222 $55 16,540 $(767,653)$736,575 $(3,432)$1,502,604 $1,468,149 

6
Three and Nine Months Ended September 26, 2020
Common StockTreasury StockAdditional
Paid-In
Capital		Accumulated
Other
Comprehensive
Loss		Retained
Earnings		Total
Stockholders’
Equity
SharesAmountSharesAmount
Balance at December 28, 201953,696 $54 15,530 $(526,580)$600,624 $(6,718)$1,100,494 $1,167,874 
Stock options exercised384 — — — 13,495 — — 13,495 
Restricted/Performance stock units vested46 — — — — — — — 
Shares paid for tax withholding(8)— — — (1,424)— — (1,424)
Stock-based compensation— — — — 11,272 — — 11,272 
Repurchases of common stock(3)— 3 (371)— — — (371)
Cumulative effect of adoption of ASU 2016-13— — — — — — 439 439 
Net income— — — — — — 64,456 64,456 
Foreign currency translation adjustment— — — — — (2,463)— (2,463)
Balance at March 28, 202054,115 54 15,533 (526,951)623,967 (9,181)1,165,389 1,253,278 
Stock options exercised825 1 — — 21,212 — — 21,213 
Restricted/Performance stock units vested9 — — — — — — — 
Stock-based compensation— — — — 13,188 — — 13,188 
Repurchases of common stock(1)— 1 (220)— — — (220)
Net income— — — — — — 55,772 55,772 
Foreign currency translation adjustment— — — — — 1,314 — 1,314 
Balance at June 27, 202054,948 55 15,534 (527,171)658,367 (7,867)1,221,161 1,344,545 
Stock options exercised107 — — — 6,314 — — 6,314 
Restricted/Performance stock units vested1 — — — — — — — 
Shares paid for tax withholding(1)— — — (25)— — (25)
Stock-based compensation— — — — 11,912 — — 11,912 
Net income— — — — — — 49,405 49,405 
Foreign currency translation adjustment— — — — — 2,653 — 2,653 
Balance at September 26, 202055,055 $55 15,534 $(527,171)$676,568 $(5,214)$1,270,566 $1,414,804 
The accompanying notes are an integral part of these condensed consolidated financial statements.
7
MASIMO CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited, in thousands)
Nine Months Ended
October 2,
2021		September 26,
2020
Cash flows from operating activities:
Net income$161,389 $169,633 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization26,449 21,200 
Stock-based compensation33,530 36,372 
Loss on disposal of equipment, intangibles and other assets371 202 
Provision for credit losses647 5 
Provision for deferred income taxes— 136 
Changes in operating assets and liabilities:
Increase in accounts receivable(50,967)(9,459)
Decrease (increase) in inventories12,329 (86,815)
Decrease (increase) in other current assets4,433 (23,461)
Increase in lease receivable, net(9,312)(6,279)
Increase in deferred costs and other contract assets(2,573)(1,964)
Increase in other non-current assets(144)(775)
(Decrease) increase in accounts payable(4,290)31,793 
(Decrease) increase in accrued compensation(1,298)3,654 
(Decrease) increase in accrued liabilities(3,969)4,691 
Decrease in income tax payable(1,456)(2,756)
Increase in deferred revenue and other contract-related liabilities1,378 9,973 
Increase in other non-current liabilities634 395 
Net cash provided by operating activities167,151 146,545 
Cash flows from investing activities:
Maturities of short-term investments— 70,000 
Purchases of property and equipment, net(20,680)(60,017)
Increase in intangible assets(8,185)(5,763)
Business combinations, net of cash acquired— (78,310)
Other strategic investing activities(2,600)(6,750)
Net cash used in investing activities(31,465)(80,840)
Cash flows from financing activities:
Proceeds from issuance of common stock18,975 40,994 
Payroll tax withholdings on behalf of employees for vested equity awards(16,724)(1,449)
Repurchases of common stock(128,917)(591)
Net cash (used in) provided by financing activities(126,666)38,954 
Effect of foreign currency exchange rates on cash(89)(294)
Net increase in cash, cash equivalents and restricted cash8,931 104,365 
Cash, cash equivalents and restricted cash at beginning of period645,004 568,075 
Cash, cash equivalents and restricted cash at end of period$653,935 $672,440 
The accompanying notes are an integral part of these condensed consolidated financial statements.
8
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

1. Description of the Company
Masimo Corporation (the Company) is a global medical technology company that develops, manufactures and markets a variety of noninvasive patient monitoring technologies, hospital automation solutions, home monitoring devices and consumer products. The Company’s mission is to improve patient outcomes, reduce the cost of care and take noninvasive monitoring to new sites and applications. The Company’s patient monitoring solutions generally incorporate a monitor or circuit board, proprietary single-patient use or reusable sensors, software and/or cables. The Company primarily sells its products to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, long-term care facilities, and consumers through its direct sales force, distributors and original equipment manufacturer (OEM) partners.
Masimo’s core measurement technologies are based on Measure-through Motion and Low Perfusion™ pulse oximetry, known as Masimo Signal Extraction Technology® (SET®) pulse oximetry, and advanced rainbow® Pulse CO-Oximetry parameters such as noninvasive hemoglobin (SpHb®), alongside many other modalities, including brain function monitoring, hemodynamic monitoring, regional oximetry, acoustic respiration rate monitoring, capnography, nasal high-flow respiratory support therapy, patient position and activity tracking and neuromodulation technology for the reduction of symptoms associated with opioid withdrawal. Masimo’s measurement technologies are available on many types of devices, from bedside hospital monitors like the Root® Patient Monitoring and Connectivity Hub, to various handheld and portable devices, and to the tetherless Masimo SafetyNet™ remote patient surveillance solution. The Masimo Hospital Automation™ Platform facilitates data integration, connectivity, and interoperability through solutions like Patient SafetyNet™(1), Replica®, and UniView™ to facilitate more efficient clinical workflows and to help clinicians provide the best possible care, both in-person and remotely. Leveraging the Company’s expertise in hospital-grade technologies, the Company has also expanded its suite of products intended for use outside the hospital to products for consumers, including Sleep™, a sleep quality solution and the Radius Tº™ wireless, wearable continuous thermometer.
______________
(1)    The use of the trademark Patient SafetyNet™ is under license from the University HealthSystem Consortium.
2. Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) have been condensed or omitted pursuant to such rules and regulations. The accompanying condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, including normal recurring accruals, necessary to present fairly the Company’s condensed consolidated financial statements. The accompanying condensed consolidated balance sheet as of January 2, 2021 was derived from the Company’s audited consolidated financial statements at that date. The accompanying condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes contained in the Company’s Annual Report on Form 10-K for the fiscal year ended January 2, 2021 (fiscal year 2020), filed with the SEC on February 23, 2021. The results for the three and nine months ended October 2, 2021 are not necessarily indicative of the results to be expected for the fiscal year ending January 1, 2022 (fiscal year 2021) or for any other interim period or for any future year.
Fiscal Periods
The Company follows a conventional 52/53 week fiscal year. Under a conventional 52/53 week fiscal year, a 52 week fiscal year includes four quarters of 13 weeks while a 53 week fiscal year includes three 13 week fiscal quarters and one 14 week fiscal quarter. The Company’s last 53 week fiscal year was fiscal year 2020. Fiscal year 2021 is a 52 week fiscal year ending January 1, 2022. All references to years in these notes to condensed consolidated financial statements are fiscal years unless otherwise noted.
Reclassifications
Certain amounts in the accompanying condensed consolidated financial statements have been reclassified to conform to the current period presentation.
9
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
Use of Estimates
The Company prepares its financial statements in conformity with GAAP, which requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates include the determination of standalone selling prices, variable consideration, total consideration allocated to each performance obligation within a contract, inventory valuation, valuation of the Company’s equity awards, valuation of identifiable assets and liabilities connected with business combinations, deferred taxes and any associated valuation allowances, deferred revenue, uncertain income tax positions, and litigation costs and related accruals. Actual results could differ from such estimates.
Business Combinations
The Company accounts for business combinations using the acquisition method of accounting, which requires that once control is obtained, all the assets acquired, liabilities assumed and noncontrolling interests in the acquired entity, if applicable, are recorded at their respective fair values at the date of acquisition. The excess of the purchase price over the fair values of identifiable assets, liabilities and noncontrolling interests in the acquired entity, if applicable, is recorded as goodwill. The Company finalizes the purchase price allocation within one year from the acquisition date.
Fair Value Measurements
Authoritative guidance describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:
●    Level 1—Quoted prices in active markets for identical assets or liabilities.
●    Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active; or other inputs that can be corroborated by observable market data for substantially the full term of the assets or liabilities.
●    Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
Pursuant to current authoritative guidance, entities are allowed an irrevocable option to elect the fair value for the initial and subsequent measurement for specified financial assets and liabilities on a contract-by-contract basis. The Company did not elect to apply the fair value option under this guidance to specific assets or liabilities on a contract-by-contract basis. There were no transfers between Level 1, Level 2 and Level 3 inputs during either the nine months ended October 2, 2021 or September 26, 2020. The Company carries cash and cash equivalents, at cost, which approximates fair value.
For certain other financial assets and liabilities, including restricted cash, accounts receivable, accounts payable and other current assets and liabilities, the carrying amounts approximate their fair value primarily due to the relatively short maturity of these balances. The Company also measures certain non-financial assets at fair value on a non-recurring basis, primarily goodwill, intangible assets and operating lease right-of-use assets, in connection with periodic evaluations for potential impairment.
Cash and Cash Equivalents
The Company considers all highly liquid investments with an original maturity from date of purchase of three months or less, or highly liquid investments that are readily convertible into known amounts of cash, to be cash equivalents.
Accounts Receivable and Allowance for Credit Losses
Accounts receivable consist of trade receivables recorded at the time of invoicing of product sales, reduced by reserves for estimated bad debts and returns. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Credit is extended based on an evaluation of the customer’s financial condition. Collateral is generally not required. The Company records an allowance for credit losses that it does not expect to collect based on relevant information, including historical experience, current conditions, and reasonable and supportable forecasts. Accounts are charged off against the allowance when the Company believes they are uncollectible.
10
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
Inventory
Inventories are stated at the lower of cost or net realizable value. Cost is determined using a standard cost method, which approximates the first in, first out method, and includes material, labor and overhead costs. Inventory valuation adjustments are recorded for inventory items that have become excess or obsolete or are no longer used in current production and for inventory items that have a market price less than carrying value in inventory. The Company generally determines inventory valuation adjustments based on an evaluation of the expected future use of its inventory on an item by item basis and applies historical obsolescence rates to estimate the loss on inventory expected to have a recovery value below cost. The Company also records other specific inventory valuation adjustments when it becomes aware of unique events or circumstances that result in an expected recovery value below cost. For inventory items that have been written down, the reduced value becomes the new cost basis.
Property and Equipment
Property and equipment are stated at cost. Depreciation is calculated using the straight-line method over estimated useful lives as follows:
Useful Lives
Building and building improvements
7 to 39 years
Computer equipment and software
2 to 12 years
Demonstration units3 years
Furniture and office equipment
2 to 6 years
Leasehold improvementsLesser of useful life or term of lease
Machinery, equipment and tooling
3 to 10 years
Transportation, vehicles and other
4 to 20 years
Land is not depreciated and construction-in-progress is not depreciated until placed in service. Normal repair and maintenance costs are expensed as incurred, whereas significant improvements that materially increase values or extend useful lives are capitalized and depreciated over the remaining estimated useful lives of the related assets. Upon sale or retirement of depreciable assets, the related cost and accumulated depreciation or amortization are removed from the accounts and any gain or loss on the sale or retirement is recognized in income.
Intangible Assets
Intangible assets consist primarily of patents, trademarks, software development costs, customer relationships and acquired technology. Costs related to patents and trademarks, which include legal and application fees, are capitalized and amortized over the estimated useful lives using the straight-line method. Patent and trademark amortization commences once final approval of the patent or trademark has been obtained. Patent costs are amortized over the lesser of 10 years or the patent’s remaining legal life, which assumes renewals, and trademark costs are amortized over 17 years, and their associated amortization cost is included in selling, general and administrative expense in the accompanying condensed consolidated statements of operations. For intangibles purchased in an asset acquisition or business combination, which mainly include patents, trademarks, customer relationships and acquired technologies, the useful life is determined largely by valuation estimates of remaining economic life. The Company’s policy is to renew its patents and trademarks. Costs to renew patents and trademarks are capitalized and amortized over the remaining useful life of the intangible asset. The Company periodically evaluates the amortization period and carrying basis of patents, trademarks and other intangible assets to determine whether any events or circumstances warrant a revised estimated useful life or reduction in value. Capitalized application costs are charged to operations when it is determined that the patent or trademark will not be obtained or is abandoned.
11
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
Impairment of Goodwill, Intangible Assets and Other Long-Lived Assets
Goodwill is recorded as the difference, if any, between the aggregate consideration paid for an acquisition and the fair value of the acquired net tangible and intangible assets. Goodwill is not amortized, but instead is tested annually for impairment, or more frequently when events or changes in circumstances indicate that goodwill might be impaired. In assessing goodwill impairment, the Company has the option to first assess the qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. The Company’s qualitative assessment of the recoverability of goodwill considers various macroeconomic, industry-specific and Company-specific factors, including: (i) severe adverse industry or economic trends; (ii) significant Company-specific actions; (iii) current, historical or projected deterioration of the Company’s financial performance; or (iv) a sustained decrease in the Company’s market capitalization below its net book value. If, after assessing the totality of events or circumstances, the Company determines it is unlikely that the fair value of a reporting unit is less than its carrying amount, then a quantitative analysis is unnecessary. However, if the Company concludes otherwise, or if the Company elects to bypass the qualitative analysis, then the Company must perform a quantitative analysis that compares the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill is not considered impaired; otherwise, a goodwill impairment loss is recognized for the lesser of: (a) the amount that the carrying amount of a reporting unit exceeds its fair value; or (b) the amount of the goodwill allocated to that reporting unit. The annual impairment test is performed during the fourth fiscal quarter.
The Company reviews long-lived assets and identifiable intangibles for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted operating cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair value of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less costs to sell.
Revenue Recognition, Deferred Revenue and Other Contract Liabilities
The Company derives the majority of its product revenue from four primary sources: (i) direct sales under deferred equipment agreements with end-user hospitals where the Company provides up-front monitoring equipment at no up-front charge in exchange for a multi-year sensor purchase commitment; (ii) other direct sales of noninvasive monitoring solutions to end-user hospitals, emergency medical response organizations and other direct customers; (iii) sales of noninvasive monitoring solutions to distributors who then typically resell to end-user hospitals, emergency medical response organizations and other customers; and (iv) sales of integrated circuit boards to OEM customers who incorporate the Company’s embedded software technology into their multiparameter monitoring devices. Subject to customer credit considerations, the majority of such sales are made on open account using industry standard payment terms based on the geography within which the specific customer is located.
The Company generally recognizes revenue following a single, principles-based five-step model to be applied to all contracts with customers and generally provides for the recognition of revenue in an amount that reflects the consideration to which the Company expects to be entitled, net of allowances for estimated returns, discounts or sales incentives, as well as taxes collected from customers that are remitted to government authorities, when control over the promised goods or services are transferred to the customer. Revenue related to equipment supplied under sales-type lease arrangements is recognized once control over the equipment is transferred to the customer, while revenue related to equipment supplied under operating-type lease arrangements is generally recognized on a straight-line basis over the term of the lease.
While the majority of the Company’s revenue contracts and transactions contain standard business terms and conditions, there are some transactions that contain non-standard business terms and conditions. As a result, contract interpretation, judgment and analysis is required to determine the appropriate accounting, including: (i) the amount of the total consideration, as well as variable consideration, (ii) whether the arrangement contains an embedded lease, and if so, whether such embedded lease is a sales-type lease or an operating lease, (iii) the identification of the distinct performance obligations contained within the arrangement, (iv) how the arrangement consideration should be allocated to each performance obligation when multiple performance obligations exist, including the determination of standalone selling price, and (v) when to recognize revenue on the performance obligations. Changes in judgments on these assumptions and estimates could materially impact the timing of revenue recognition.

12
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
The Company enters into agreements to sell its monitoring solutions and services, sometimes as a part of arrangements with multiple performance obligations that include various combinations of product sales, equipment leases and services. In the case of contracts with multiple performance obligations, the authoritative guidance provides that the total consideration be allocated to each performance obligation on the basis of relative standalone selling prices. When a standalone selling price is not readily observable, the Company estimates the standalone selling price by considering multiple factors including, but not limited to, features and functionality of the product, geographies, type of customer, contractual prices pursuant to Group Purchasing Organization (GPO) contracts, the Company’s pricing and discount practices, and other market conditions.
Sales under deferred equipment agreements are generally structured such that the Company agrees to provide certain monitoring-related equipment, software, installation, training and/or warranty support at no up-front charge in exchange for the customer’s commitment to purchase sensors over the term of the agreement, which generally ranges from three years to six years. The Company allocates contract consideration under deferred equipment agreements containing fixed annual sensor purchase commitments to the underlying lease and non-lease components at contract inception. In determining whether any underlying lease components are related to a sales-type lease or an operating lease, the Company evaluates the customer’s rights and ability to control the use of the underlying equipment throughout the contract term, including any equipment substitution rights retained by the Company, as well as the Company’s expectations surrounding potential contract/lease extensions or renewals and the customer’s likelihood to exercise any purchase options. Revenue allocable to non-lease performance obligations is generally recognized as such non-lease performance obligations are satisfied. Revenue allocable to lease components under sales-type lease arrangements is generally recognized when control over the equipment is transferred to the customer. Revenue allocable to lease components under operating lease arrangements is generally recognized over the term of the operating lease. The Company generally does not expect to derive any significant value in excess of such asset’s unamortized book value from equipment underlying its operating lease arrangements after the end of the agreement.
Revenue from the sale of products to end-user hospitals, emergency medical response organizations, other direct customers, distributors and OEM customers, is recognized by the Company when control of such products transfer to the customer based upon the terms of the contract or underlying purchase order.
Revenue related to OEM rainbow® parameter software licenses is recognized by the Company upon the OEM’s shipment of its product to its customer, as reported to the Company by the OEM.
The Company provides certain customers with various sales incentives that may take the form of discounts or rebates. The Company records estimates related to these programs as a reduction to revenue at the time of sale. In general, customers do not have a right of return for credit or refund. However, the Company allows returns under certain circumstances. At the end of each period, the Company estimates and accrues for these returns as a reduction to revenue. The Company estimates the revenue constraints related to these forms of variable consideration based on various factors, including expected purchasing volumes, prior sales and returns history, and specific contractual terms and limitations.
Shipping and Handling Costs and Fees
All shipping and handling costs are expensed as incurred and are recorded as a component of cost of goods sold in the accompanying condensed consolidated statements of operations. Charges for shipping and handling billed to customers are included as a component of product revenue.
Taxes Collected From Customers and Remitted to Governmental Authorities
The Company’s policy is to present revenue net of taxes collected from customers and remitted to governmental authorities.
Deferred Costs and Other Contract Assets
The costs of monitoring-related equipment provided to customers under operating lease arrangements within the Company’s deferred equipment agreements are generally deferred and amortized to cost of goods sold over the life of the underlying contracts. Some of the Company’s deferred equipment agreements also contain provisions for certain allowances to be made directly to the end-user hospital customer at the inception of the arrangement. These allowances are generally allocated to the lease and non-lease components and recognized as a reduction to revenue as the underlying performance obligations are satisfied.

13
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
The Company generally invoices its customers under deferred equipment agreements as sensors are provided to the customer. However, the Company may recognize revenue for certain non-lease performance obligations under deferred equipment agreements with fixed annual commitments at the time such performance obligations are satisfied and prior to the customer being invoiced. When this occurs, the Company records an unbilled contract receivable related to such revenue until the customer has been invoiced pursuant to the terms of the underlying deferred equipment agreement.
The incremental costs of obtaining a contract with a customer are capitalized and deferred if the Company expects such costs to be recoverable over the life of the contract and the contract term is greater than one year. Such deferred costs generally relate to certain incentive sales commissions earned by the Company’s internal sales team in connection with the execution of deferred equipment agreements and are amortized to expense over the expected term of the underlying contract.
Product Warranty
The Company generally provides a warranty against defects in material and workmanship for a period ranging from six months to forty-eight months, depending on the product type. In traditional sales activities, including direct and OEM sales, the Company establishes an accrued liability for the estimated warranty costs at the time of revenue recognition, with a corresponding provision to cost of goods sold. Customers may also purchase extended warranty coverage or service level upgrades separately or as part of a deferred equipment agreement. Revenue related to extended warranty coverage and service level upgrades is generally recognized over the life of the contract, which reasonably approximates the period over which such services will be provided. The related extended warranty and service level upgrade costs are expensed as incurred.
Changes in the product warranty accrual were as follows (in thousands):
Nine Months Ended
October 2,
2021		September 26,
2020
Warranty accrual, beginning of period$2,740 $3,395 
Accrual for warranties issued3,442 428 
Changes in pre-existing warranties (including changes in estimates)(2,347)(97)
Settlements made(891)(883)
Warranty accrual, end of period$2,944 $2,843 
Litigation Costs and Contingencies
The Company records a charge equal to at least the minimum estimated liability for a loss contingency or litigation settlement when both of the following conditions are met: (i) information available prior to issuance of the financial statements indicates that it is probable that a liability had been incurred at the date of the financial statements, and (ii) the range of loss can be reasonably estimated. The determination of whether a loss contingency or litigation settlement is probable or reasonably possible involves a significant amount of management judgment, as does the estimation of the range of loss given the nature of contingencies. Liabilities related to litigation settlements with multiple elements are recorded based on the fair value of each element. Legal and other litigation related expenses are recognized as the services are provided. The Company records insurance and other indemnity recoveries for litigation expenses when both of the following conditions are met: (a) the recovery is probable, and (b) collectability is reasonably assured. Insurance recoveries are only recorded to the extent the litigation costs to which they relate have been incurred and recognized in the financial statements.
Comprehensive Income
Comprehensive income includes foreign currency translation adjustments and any related tax benefits that have been excluded from net income and reflected in stockholders’ equity.
14
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
Net Income Per Share
A computation of basic and diluted net income per share is as follows (in thousands, except per share data):
Three Months EndedNine Months Ended
October 2,
2021		September 26,
2020		October 2,
2021		September 26,
2020
Net income$57,771 $49,405 $161,389 $169,633 
Basic net income per share:
Weighted-average shares outstanding - basic55,143 54,997 55,125 54,543 
Net income per basic share$1.05 $0.90 $2.93 $3.11 
Diluted net income per share:
Weighted-average shares outstanding - basic55,143 54,997 55,125 54,543 
Diluted share equivalent: stock options, RSUs and PSUs2,521 3,283 2,526 3,490 
Weighted-average shares outstanding - diluted57,664 58,280 57,651 58,033 
Net income per diluted share$1.00 $0.85 $2.80 $2.92 
Basic net income per share is computed by dividing net income by the weighted-average number of shares outstanding during the period. Net income per diluted share is computed by dividing the net income by the weighted-average number of shares and potential shares outstanding during the period, if the effect of potential shares is dilutive. Potential shares include incremental shares of stock issuable upon the exercise of stock options and the vesting of both restricted share units (RSUs) and performance share units (PSUs). For each of the three months ended October 2, 2021 and September 26, 2020, weighted options to purchase 0.1 million shares of common stock were outstanding but not included in the computation of diluted net income per share because the effect of including such shares would have been antidilutive in the applicable period. For the nine months ended October 2, 2021 and September 26, 2020, weighted options to purchase 0.2 million and 0.3 million shares of common stock, respectively, were outstanding but not included in the computation of diluted net income per share because the effect of including such shares would have been antidilutive in the applicable period. Certain RSUs are considered contingently issuable shares as their vesting is contingent upon the occurrence of certain future events. Since such events had not occurred and were not considered probable of occurring as of each of October 2, 2021 and September 26, 2020, 2.7 million weighted-average shares related to such RSUs have been excluded from the calculation of potential shares for each of the three and nine month periods then ended.
15
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
Supplemental Cash Flow Information
Supplemental cash flow information includes the following (in thousands):
Nine Months Ended
October 2,
2021		September 26,
2020
Cash paid during the year for:
Interest expense
$202 $194 
Income taxes
36,898 35,961 
Operating lease liabilities
5,567 4,699 
Non-cash operating activities:
ROU assets obtained in exchange for lease liabilities
$4,917 $9,900 
Non-cash investing activities:
Unpaid purchases of property and equipment$3,182 $3,988 
       Settlement of promissory note receivable in connection with business combination— 5,100 
Unpaid strategic investments3,400 — 
Deposit release to acquire noncontrolling interest(1)
3,374 — 
Non-cash financing activities:
       Unsettled common stock proceeds from option exercises$112 $27 
       Fair value of common stock received for payment of stock option exercise price— 220 
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents
$652,354 $669,056 
Restricted cash
1,581 3,384 
Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows$653,935 $672,440 
______________
(1)     See Note 5.
Segment Information
The Company uses the “management approach” in determining reportable business segments. The management approach designates the internal organization used by management for making operating decisions and assessing performance as the source for determining the Company’s reportable segments. Based on this assessment, management has determined it operates in one reportable business segment, which is comprised of patient monitoring and related products.





16
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
Recently Adopted Accounting Pronouncements
In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12). The standard simplifies the accounting for income taxes by removing exceptions to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income or a gain from other items, to the requirement to recognize a deferred tax liability for equity method investments when a foreign subsidiary becomes an equity method investment, to the ability not to recognize a deferred tax liability for a foreign subsidiary when a foreign equity method investment becomes a subsidiary, and to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. In addition, the standard requires that an entity recognize a franchise tax that is partially based on income as an income-based tax and account for any incremental amount incurred as a non-income-based tax, evaluate when a step up in the tax basis of goodwill should be considered part of the business combination in which the book goodwill was originally recognized and when it should be considered a separate transaction, reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date, and specifies that an entity is not required to allocate the consolidated amount of current and deferred tax expense to a legal entity that is not subject to tax in its separate financial statements; however, an entity may elect to do so (on an entity-by-entity basis) for a legal entity that is both not subject to tax and disregarded by the taxing authority. The Company’s adoption of this standard, effective as of January 3, 2021, did not have a material impact on its consolidated financial statements.
In October 2020, the FASB issued ASU No. 2020-10, Codification Improvements. The standard provides updates for technical corrections, clarifications to guidance, simplifications to wording or structure of guidance, and other minor improvements across various areas of accounting within GAAP. ASU No. 2020-10 is effective after December 15, 2020 on a retrospective basis. Early adoption is permitted. The Company’s adoption of this standard, effective as of January 3, 2021, did not have a material impact on its consolidated financial statements.
Recently Issued Accounting Pronouncements
In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (ASU 2020-04). The new standard provides temporary optional expedients and exceptions to the guidance in GAAP on contract modifications and hedge accounting to ease the financial reporting burdens related to the expected market transition from the London Interbank Offered Rate (LIBOR) and other interbank offered rates to alternative reference rates, such as the Secured Overnight Financing Rate (SOFR). Entities can make a one-time election to sell and/or reclassify held-to-maturity debt securities that reference an interest rate affected by reference rate reform. ASU 2020-04 is effective beginning on March 12, 2020, and the Company may elect to apply this standard prospectively through December 31, 2022. The relief is temporary and generally cannot be applied to contract modifications that occur after December 31, 2022 or hedging relationships entered into or evaluated after that date. However, certain optional expedients can be applied to hedging relationships evaluated in periods after December 31, 2022. The Company is currently evaluating the expected impact of this standard, but does not expect it to have a material impact on its consolidated financial statements upon adoption.
In January 2021, the FASB issued ASU No. 2021-01, Reference Rate Reform (Topic 848): Scope (ASU 2021-01). The new standard clarified the scope and application of the original guidance. ASU No. 2021-01 is effective as of March 12, 2020 through December 31, 2022 and may be applied to contract modifications and hedging relationships from the beginning of an interim period that includes or is subsequent to March 12, 2020. The Company is currently evaluating the expected impact of this standard, but does not expect it to have a material impact on its consolidated financial statements upon adoption.
In May 2021, the FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt - Modifications and Extinguishments (Subtopic 470-50), Compensation - Stock Compensation (Topic 718), and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (ASU 2021-04). The new standard addresses modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another topic. ASU No. 2021-04 is effective after December 15, 2021 on a prospective basis, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period and should be applied as of the beginning of the fiscal year that includes the interim period. The Company is currently evaluating the expected impact of this standard, but does not expect it to have a material impact on its consolidated financial statements upon adoption.
17
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
In July 2021, the FASB issued ASU No. 2021-05, Leases (Topic 842), Lessors - Certain Leases with Variable Lease Payments (ASU 2021-05). This new standard amends the original ASU No. 2016-02 lease standard by requiring lessors to classify leases as operating leases if they have variable lease payments that do not depend on an index or rate and would have selling losses at lease commencement if they were classified as sales-type. ASU 2021-05 is effective for annual reporting periods beginning after December 15, 2021, and for interim periods within those years, and may be adopted either prospectively or on a retrospective basis for leases that commenced or were modified after the date of initial adoption of ASC 842. Early adoption is permitted. The Company is currently evaluating the expected impact of this standard on its consolidated financial statements upon adoption, but anticipates that, among other things, the classification of certain leases for which the Company is the lessor will change from sales-type leases to operating leases under this new standard, resulting in the initial deferral and subsequent expensing of equipment costs over time under certain leases that are currently recognized immediately upon lease commencement. Similarly, any revenue that is currently recognized for these leases on the date of lease commencement will now be recognized over the term of the operating lease upon adoption of this new standard. The Company currently expects to complete its assessment of the full financial impact of this new standard during the next three to six months.
3. Related Party Transactions
The Company’s Chairman and Chief Executive Officer (CEO) is also the Chairman and CEO of Cercacor Laboratories, Inc. (Cercacor). The Company is a party to the following agreements with Cercacor:
•Cross-Licensing Agreement - The Company and Cercacor are parties to a cross-licensing agreement (Cross-Licensing Agreement), which governs each party’s rights to certain intellectual property held by the two companies. The Company is subject to certain annual minimum aggregate royalty obligations for use of the rainbow® licensed technology. The current annual minimum royalty obligation is $5.0 million. Aggregate liabilities payable to Cercacor arising under the Cross-Licensing Agreement were $2.9 million and $3.5 million for the three months ended October 2, 2021 and September 26, 2020, respectively. Aggregate liabilities payable to Cercacor arising under the Cross-Licensing Agreement were $9.6 million and $9.7 million for the nine months ended October 2, 2021 and September 26, 2020, respectively.
•Administrative Services Agreement - The Company is a party to an administrative services agreement with Cercacor (G&A Services Agreement), which governs certain general and administrative services that the Company provides to Cercacor. Amounts charged by the Company pursuant to the G&A Services Agreement were less than $0.1 million for each of the three months ended October 2, 2021 and September 26, 2020. Amounts charged by the Company pursuant to the G&A Services Agreement were $0.2 million for each of the nine months ended October 2, 2021 and September 26, 2020.
•Lease and Sublease Agreements - Effective December 2019, the Company entered into a lease agreement with Cercacor for approximately 34,000 square feet of office, research and development space at one of the Company’s owned facilities in Irvine (Cercacor Lease). The term of the Cercacor Lease expires on December 31, 2024. In March 2016, the Company entered into a sublease agreement with Cercacor for approximately 16,830 square feet of excess office and laboratory space located at 40 Parker, Irvine, California (Cercacor Sublease). The Cercacor Sublease began on May 1, 2016 and expired on December 15, 2019. The Company recognized approximately $0.3 million of lease income for each of the three months ended October 2, 2021 and September 26, 2020. The Company recognized approximately $0.9 million and $0.8 million of lease income for the nine months ended October 2, 2021 and September 26, 2020, respectively.
Net amounts due to Cercacor at October 2, 2021 and January 2, 2021 were approximately $3.3 million and $3.6 million, respectively.
The Company’s CEO is also the Chairman of the Masimo Foundation for Ethics, Innovation and Competition in Healthcare (Masimo Foundation), a non-profit organization that was founded in 2010 to provide a platform for encouraging ethics, innovation and competition in healthcare. In addition, the Company’s Executive Vice President (EVP), Chief Financial Officer (CFO) serves as the Treasurer of the Masimo Foundation and the Company’s EVP, General Counsel and Corporate Secretary serves as the Secretary for the Masimo Foundation. During the three months ended October 2, 2021 and September 26, 2020, the Company made no cash contributions to the Masimo Foundation. During the nine months ended October 2, 2021, the Company made no contributions to the Masimo Foundation. During the nine months ended September 26, 2020, the Company made cash contributions of approximately $1.5 million to the Masimo Foundation.
During the three and nine months ended October 2, 2021 and September 26, 2020, the Company made various in-kind contributions to the Masimo Foundation, mainly in the form of donated administrative services.
18
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
The Company’s CEO is also a co-founder and a member of the board of directors of Like Minded Media Ventures (LMMV), a team of storytellers that create content focused in the areas of true stories, social causes and science. LMMV creates stories with a multi-platform strategy, bridging the gap between film, television, digital and social media. The Company entered into a marketing service agreement with LMMV for audiovisual production services promoting brand awareness, including television commercials and digital advertising, during the second quarter of 2020. During the three and nine months ended October 2, 2021, the Company incurred no marketing expenses to LMMV under the marketing service agreement. During the three and nine months ended September 26, 2020, the Company incurred $0.2 million and $3.5 million, respectively, in marketing expenses to LMMV under the marketing service agreement. At October 2, 2021 and January 2, 2021, there was no amount due to LMMV for services rendered.
The Company entered into a software license and professional services agreement with Like Minded Labs (LML), a subsidiary of LMMV, during the second quarter of 2021. Pursuant to the software license agreement, LML granted the Company a perpetual, non-exclusive and fully paid-up right and license to integrate LML’s software into the Company’s products in exchange for a $3.0 million one-time license fee. Pursuant to the professional services agreement, LML will provide professional services to the Company, including the development of custom software intended to support the integration of the licensed software into the Company’s products, as well as future support services upon the Company’s acceptance of deliverables.
In July 2021, the Company entered into a patent purchase and option agreement with Vantrix Corporation (Vantrix), an acquiree of LML, for certain patents for $0.5 million, and the right to purchase two pools of additional patents from Vantrix for an exercise fee of up to $1.1 million. The agreements with LML and Vantrix include sublicensing provisions whereby the software and patents are licensed back to LML or Vantrix, respectively, for further advancement of the technologies.
The Company maintains an aircraft time share agreement, pursuant to which the Company has agreed from time to time to make its aircraft available to the Company’s CEO for lease on a time-sharing basis. The Company charges the Company’s CEO for personal use based on agreed upon reimbursement rates. For each of the three and nine months ended October 2, 2021 and September 26, 2020, the Company charged the Company’s CEO less than $0.1 million related to such disbursements.
4. Inventories
Inventories consist of the following (in thousands):
October 2,
2021		January 2,
2021
Raw materials$121,593 $133,098 
Work-in-process14,383 15,985 
Finished goods66,352 66,869 
     Total inventories$202,328 $215,952 
19
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
5. Other Current Assets
Other current assets consist of the following (in thousands):
October 2,
2021		January 2,
2021
Prepaid expenses$30,351 $30,235 
Lease receivable, current26,685 23,206 
Prepaid income taxes15,501 14,782 
Indirect taxes receivable10,715 14,545 
Prepaid rebates and royalties, current3,066 3,081 
Restricted cash(1)
1,496 3,397 
Customer notes receivable1,359 2,283 
Deposit to acquire noncontrolling interest(2)
— 3,374 
Other current assets2,599 7,513 
     Total other current assets$91,772 $102,416 
______________
(1)     Restricted cash includes funds received from the Bill and Melinda Gates Foundation. As the Company incurs costs associated with research and development related to this project, on a quarterly basis, the Company reclasses amounts from the grant to offset costs incurred.
(2)     During the year ended January 2, 2021, the Company obtained a controlling interest in a provider of advanced hemodynamic monitoring solutions. The Company made a deposit to acquire the noncontrolling interest of the acquiree. During the first quarter of 2021, the Company acquired the remaining noncontrolling interest. The impact of the noncontrolling interest is immaterial in all periods presented.
6. Lease Receivable
The Company recognizes revenue and costs, as well as a lease receivable, at the time the lease commences pursuant to deferred equipment agreements containing embedded sales-type leases. Lease revenue related to both operating-type and sales-type leases for the three months ended October 2, 2021 and September 26, 2020 was approximately $12.0 million and $13.0 million, respectively, and is included within product revenue in the accompanying condensed consolidated statements of operations. Lease revenue related to both operating-type and sales-type leases for the nine months ended October 2, 2021 and September 26, 2020 was approximately $40.0 million and $31.0 million, respectively, and is included within product revenue in the accompanying condensed consolidated statements of operations. Costs related to embedded leases within the Company’s deferred equipment agreements are included in cost of goods sold in the accompanying condensed consolidated statements of operations.
Lease receivable consists of the following (in thousands):
October 2,
2021		January 2,
2021
Lease receivable$93,879 $81,074 
Allowance for credit loss(239)(202)
     Lease receivable, net93,640 80,872 
Less: current portion of lease receivable(26,685)(23,206)
     Lease receivable, noncurrent$66,955 $57,666 
20
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
As of October 2, 2021, estimated future maturities of customer sales-type lease receivables for each of the following fiscal years are as follows (in thousands):
Fiscal yearAmount
2021 (balance of year)$6,888 
202225,995 
202321,371 
202417,349 
202511,535 
Thereafter10,502 
    Total$93,640 
Estimated future operating lease payments expected to be received from customers under deferred equipment agreements are not material as of October 2, 2021.
7. Deferred Costs and Other Contract Assets
Deferred costs and other contract assets consist of the following (in thousands):
October 2,
2021		January 2,
2021
Deferred commissions$9,976 $7,477 
Prepaid contract allowances6,820 7,336 
Unbilled contract receivables4,317 3,925 
Equipment leased to customers, net1,486 1,338 
     Deferred costs and other contract assets$22,599 $20,076 
8. Property and Equipment, net
Property and equipment, net, consists of the following (in thousands):
October 2,
2021		January 2,
2021
Building and building improvements$141,990 $122,310 
Machinery, equipment and tooling101,833 90,843 
Land56,938 57,151 
Transportation, vehicles and other33,114 33,175 
Computer equipment and software32,131 24,693 
Leasehold improvements20,885 19,295 
Furniture and office equipment14,186 13,567 
Demonstration units1,049 1,024 
Construction-in-progress (CIP)23,955 44,589 
     Total property and equipment426,081 406,647 
Accumulated depreciation(151,152)(134,136)
     Property and equipment, net$274,929 $272,511 
For the three months ended October 2, 2021 and September 26, 2020, depreciation expense of property and equipment was $6.5 million and $5.8 million, respectively. For the nine months ended October 2, 2021 and September 26, 2020, depreciation expense of property and equipment was $18.8 million and $16.0 million, respectively.
21
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
The balance in CIP at October 2, 2021 related primarily to the capitalized implementation costs related to a new enterprise resource planning software system and costs related to equipment and other facility improvements, the underlying assets for which have not been completed or placed into service. The decrease in CIP balance from January 2, 2021 primarily relates to the Company’s European headquarters building in Switzerland being placed into service along with a phase of the new enterprise resource planning software system for certain subsidiaries being placed into service.
The balance in CIP at January 2, 2021 related primarily to acquisition and improvement costs for a portion of the Company’s European headquarters building in Switzerland, capitalized implementation costs related to a new enterprise resource planning software system and costs related to manufacturing equipment and other facility improvements, the underlying assets for which had not been placed into service.
9. Intangible Assets, net
Intangible assets, net, consist of the following (in thousands):
October 2,
2021		January 2,
2021
Patents$30,528 $26,875 
Acquired technologies28,567 29,039 
Customer relationships24,636 24,666 
Trademarks12,080 11,708 
Licenses8,108 5,108 
Licenses-related party7,500 7,500 
Other6,257 5,693 
     Total intangible assets117,676 110,589 
Accumulated amortization(43,587)(36,666)
     Intangible assets, net$74,089 $73,923 
Intangible assets have a weighted-average amortization period of twelve years. Total amortization expense for the three months ended October 2, 2021 and September 26, 2020 was $2.7 million and $1.6 million, respectively. Total amortization expense for the nine months ended October 2, 2021 and September 26, 2020 was $7.6 million and $5.2 million, respectively.
Total renewal costs for patents and trademarks for the three months ended October 2, 2021 and September 26, 2020 were $0.9 million and $0.6 million, respectively. Total renewal costs for patents and trademarks for the nine months ended October 2, 2021 and September 26, 2020 were $1.3 million and $1.2 million, respectively. As of October 2, 2021, the weighted-average number of years until the next renewal was two years for patents and four years for trademarks.
Estimated amortization expense for each of the next fiscal years is as follows (in thousands):
Fiscal yearAmount
2021 (balance of year)$9,211 
20228,377 
20237,964 
20247,352 
20256,274 
Thereafter34,911 
     Total$74,089 
22
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
10. Goodwill
Changes in goodwill were as follows (in thousands):
Nine Months Ended
October 2,
2021
Goodwill, beginning of period$103,206 
Foreign currency translation adjustment(1,964)
Goodwill, end of period$101,242 
11. Lessee ROU Assets and Lease Liabilities
The Company leases certain facilities in North and South America, Europe, the Middle East and Asia-Pacific regions under operating lease agreements expiring at various dates through January 2032. In addition, the Company leases equipment in the U.S. and Europe, and these leases are classified as operating leases and expire at various dates through August 2026. The majority of these leases are non-cancellable and generally do not contain any material restrictive covenants, material residual value guarantees or other material guarantees. The Company recognizes lease costs under these agreements using a straight-line method based on total lease payments. Certain facility leases contain predetermined price escalations and in some cases renewal options, the longest of which is for five years.
The Company generally estimates the applicable discount rate used to determine the net present value of lease payments based on available information at the lease commencement date. As of October 2, 2021, the weighted-average discount rate used by the Company for all operating leases was approximately 2.6%.
The balance sheet classifications for amounts related to the Company’s operating leases for which it is the lessee are as follows (in thousands):
Balance sheet classificationOctober 2,
2021		January 2,
2021
Lessee ROU assetsOther non-current assets$31,561 $32,324 
Lessee current lease liabilitiesOther current liabilities6,147 5,975 
Lessee non-current lease liabilitiesOther non-current liabilities27,471 28,373 
     Total operating lease liabilities$33,618 $34,348 
As of October 2, 2021 and January 2, 2021, accumulated amortization for lessee ROU assets was $13.0 million and $9.2 million, respectively. The weighted-average remaining lease term for the Company’s operating leases was 6.7 years as of October 2, 2021.
23
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
As of October 2, 2021, estimated future operating lease payments for each of the following fiscal years were as follows (in thousands):
Fiscal yearAmount
2021 (balance of year)$1,509 
20227,093 
20236,649 
20245,123 
20253,998 
Thereafter(1)
12,317 
   Total36,689 
   Imputed interest(3,071)
   Present value$33,618 
______________
(1)     Includes optional renewal period for certain leases.
During the three months ended October 2, 2021 and September 26, 2020, operating lease costs were approximately $2.1 million and $1.8 million, respectively. During the nine months ended October 2, 2021 and September 26, 2020, operating lease costs were approximately $6.2 million and $5.2 million, respectively.
12. Other Non-Current Assets
Other non-current assets consist of the following (in thousands):
October 2,
2021		January 2,
2021
Lessee ROU assets, net$31,561 $32,324 
Strategic investments13,928 8,002 
Prepaid deposits and other4,397 4,316 
Total other non-current assets$49,886 $44,642 
13. Deferred Revenue and Other Contract Liabilities, Current
Deferred revenue and other contract liabilities consist of the following (in thousands):
October 2,
2021		January 2,
2021
Deferred revenue$34,392 $33,221 
Accrued rebates and allowances11,322 12,127 
Accrued customer reimbursements4,744 3,829 
     Total deferred revenue and other contract liabilities50,458 49,177 
Less: Non-current portion of deferred revenue(3,817)(4,242)
     Deferred revenue and other contract liabilities - current$46,641 $44,935 
Deferred revenue relates to contracted amounts that have been invoiced to customers for which remaining performance obligations must be completed before the Company can recognize the revenue. These amounts primarily relate to undelivered equipment, sensors and services under deferred equipment agreements, extended warranty agreements and maintenance agreements.
24
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
Changes in deferred revenue were as follows (in thousands):
Nine Months Ended
October 2,
2021
Deferred revenue, beginning of the period$33,221 
  Revenue deferred during the period23,425 
  Recognition of revenue deferred in prior periods(22,254)
     Deferred revenue, end of the period$34,392 
Expected revenue from remaining contractual performance obligations (Unrecognized Contract Revenue) includes deferred revenue, as well as other amounts that will be invoiced and recognized as revenue in future periods, when the Company completes its performance obligations. While Unrecognized Contract Revenue is similar in concept to backlog, Unrecognized Contract Revenue excludes revenue allocable to monitoring-related equipment that is effectively leased to customers under deferred equipment agreements and other contractual obligations for which neither party has performed.
As of October 2, 2021, the Company had approximately $987.3 million of Unrecognized Contract Revenue related to executed contracts with an original duration of one year or more. The Company expects to recognize approximately $272.7 million of this amount as revenue within the next twelve months and the remaining balance thereafter.
The estimated timing of this revenue is based, in part, on management’s estimates and assumptions about when its performance obligations will be completed. As a result, the actual timing of this revenue in future periods may vary, possibly materially.
14. Other Current Liabilities
Other current liabilities consist of the following (in thousands):
October 2,
2021		January 2,
2021
Accrued indirect taxes payable$12,081 $14,365 
Accrued expenses12,046 6,794 
Lessee lease liabilities, current 6,147 5,975 
Income tax payable4,443 5,910 
Accrued legal fees3,947 4,058 
Related party payables3,446 3,655 
Accrued warranty2,944 2,740 
Accrued property taxes1,686 1,682 
Accrued donations1,307 495 
Other current liabilities3,071 4,096 
Noncontrolling interest(1)
— 3,469 
     Total other current liabilities$51,118 $53,239 
______________
(1)During the year ended January 2, 2021, the Company obtained a controlling interest in a provider of advanced hemodynamic monitoring solutions. The noncontrolling interest of the acquiree was recorded within other current liabilities as of January 2, 2021, as the noncontrolling interest shares were mandatorily redeemable. During the first quarter of 2021, the Company acquired the remaining noncontrolling interest. The impact of the noncontrolling interest is immaterial in all periods presented.
25
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
15. Credit Facility
The Company currently maintains a credit facility with various lenders that provides for up to $150.0 million of unsecured borrowings, with an option, subject to certain conditions, for the Company to increase the aggregate borrowing capacity up to $550.0 million in the future with such lenders and additional lenders, as required. The credit facility also provides for a sublimit of up to $25.0 million for the issuance of letters of credit and a sublimit of $75.0 million for borrowings in specified foreign currencies. All unpaid principal under the credit facility will become due and payable on December 17, 2023. Proceeds from the credit facility are expected to be used for general corporate, capital investment and working capital needs. As of October 2, 2021 and January 2, 2021, the credit facility had no outstanding draws and $2.4 million and $1.7 million of outstanding letters of credit, respectively. The Company was in compliance with all covenants under the credit facility as of October 2, 2021 and January 2, 2021.
For each of the three months ended October 2, 2021 and September 26, 2020, the Company incurred total interest expense of $0.1 million under the credit facility. For each of the nine months ended October 2, 2021 and September 26, 2020, the Company incurred total interest expense of $0.2 million under the credit facility.
16. Other Non-Current Liabilities
Other non-current liabilities consist of the following (in thousands):
October 2,
2021		January 2,
2021
Lessee non-current lease liabilities$27,471 $28,373 
Income tax payable, non-current16,980 19,245 
Unrecognized tax benefits15,352 11,777 
Deferred tax liabilities6,063 6,247 
Other4,511 5,434 
     Total other non-current liabilities$70,377 $71,076 
Unrecognized tax benefits relate to the Company’s long-term portion of tax liability associated with uncertain tax positions. Authoritative guidance prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. See Note 20 to these condensed consolidated financial statements for further details.
26
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
17. Stock Repurchase Program
In October 2021, the Company’s Board of Directors (Board) approved a stock repurchase program, authorizing the Company to purchase up to 3.0 million shares of its common stock over a period of up to three years (2021 Repurchase Program). The Company expects to fund the 2021 Repurchase Program through its available cash, cash expected to be generated from future operations, the credit facility and other potential sources of capital. The 2021 Repurchase Program can be carried out at the discretion of a committee comprised of the CEO and CFO through open market purchases, one or more Rule 10b5-1 trading plans, block trades and privately negotiated transactions.
In July 2018, the Company’s Board approved a stock repurchase program, authorizing the Company to purchase up to 5.0 million additional shares of its common stock over a period of up to three years (2018 Repurchase Program). During the third quarter of 2021, the 2018 Repurchase Program expired.
The following table provides a summary of the Company’s stock repurchase activities (in thousands, except per share amounts):
Three Months EndedNine Months Ended
October 2,
2021		September 26,
2020		October 2,
2021		September 26,
2020
Shares repurchased(1)
— — 547 4 
Average cost per share$— $— $235.88 $164.44 
Value of shares repurchased$— $— $128,917 $591 
______________
(1)     Excludes shares withheld from the shares of its common stock actually issued in connection with the vesting of PSU or RSU awards to satisfy certain U.S. federal and state tax withholding obligations.
18. Stock-Based Compensation
Total stock-based compensation expense for the three months ended October 2, 2021 and September 26, 2020 was $12.6 million and $11.9 million, respectively. Total stock-based compensation expense for the nine months ended October 2, 2021 and September 26, 2020 was $33.5 million and $36.4 million, respectively. As of October 2, 2021, an aggregate of 10.7 million shares of common stock were reserved for future issuance under the Company’s equity plans, of which 4.4 million shares were available for future grant under the Masimo Corporation 2017 Equity Incentive Plan (2017 Equity Plan). Additional information related to the Company’s current equity incentive plans, stock-based award activity and valuation of stock-based awards is included below.
Equity Incentive Plans
2017 Equity Incentive Plan
On June 1, 2017, the Company’s stockholders ratified and approved the 2017 Equity Plan. The 2017 Equity Plan permits the grant of stock options, restricted stock, RSUs, stock appreciation rights, PSUs, performance shares, performance bonus awards and other stock or cash awards to employees, directors and consultants of the Company and employees and consultants of any parent or subsidiary of the Company. Upon its effectiveness, an aggregate of 5.0 million shares were available for issuance under the 2017 Equity Plan. In May 2020, the Company’s stockholders approved an increase of 2.5 million shares to the 2017 Equity Plan. The aggregate number of shares that may be awarded under the 2017 Equity Plan is 7.5 million shares. The 2017 Equity Plan provides that at least 95% of the equity awards issued under the 2017 Equity Plan must vest over a period of not less than one year following the date of grant. The exercise price per share of each option granted under the 2017 Equity Plan may not be less than the fair market value of a share of the Company’s common stock on the date of grant, which is generally equal to the closing price of the Company’s common stock on the Nasdaq Global Select Market on the grant date.
2007 Stock Incentive Plan
Effective June 1, 2017, upon the approval and ratification of the 2017 Equity Plan, the Company’s 2007 Stock Incentive Plan (2007 Equity Plan) terminated, provided that awards outstanding under the 2007 Equity Plan will continue to be governed by the terms of that plan. In addition, upon the effectiveness of the 2017 Equity Plan, an aggregate of 5.0 million shares of the Company’s common stock registered under prior registration statements for issuance pursuant to the 2007 Equity Plan were deregistered and concurrently registered under the 2017 Equity Plan.
27
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
Stock-Based Award Activity
Stock Options
The number and weighted-average exercise price of options issued and outstanding under all of the Company’s equity plans are as follows (in thousands, except for weighted-average exercise prices):
Nine Months Ended
October 2, 2021
SharesWeighted-Average
Exercise Price
Options outstanding, beginning of period3,448 $77.44 
Granted85 250.15 
Canceled(150)146.62 
Exercised(278)57.88 
Options outstanding, end of period3,105 $80.55 
Options exercisable, end of period2,255 $55.57 
Total stock option expense for the three months ended October 2, 2021 and September 26, 2020 was $3.2 million and $3.8 million, respectively. Total stock option expense for the nine months ended October 2, 2021 and September 26, 2020 was $9.9 million and $11.9 million, respectively. As of October 2, 2021, the Company had $30.7 million of unrecognized compensation cost related to non-vested stock options that are expected to vest over a weighted-average period of approximately 2.6 years. The weighted-average remaining contractual term of options outstanding with an exercise price less than the closing price of the Company’s common stock as of October 2, 2021 was 5.3 years. The weighted-average remaining contractual term of options exercisable, with an exercise price less than the closing price of the Company’s common stock as of October 2, 2021, was 4.4 years.
RSUs
The number of RSUs issued and outstanding under all of the Company’s equity plans are as follows (in thousands, except for weighted-average grant date fair value amounts):
Nine Months Ended
October 2, 2021
UnitsWeighted-Average Grant
 Date Fair Value
RSUs outstanding, beginning of period2,862 $99.66 
Granted89 248.57 
Canceled(17)199.02 
Expired— — 
Vested(34)163.57 
RSUs outstanding, end of period2,900 $102.88 
Total RSU expense for the three months ended October 2, 2021 and September 26, 2020 was $2.4 million and $1.5 million, respectively. Total RSU expense for the nine months ended October 2, 2021 and September 26, 2020 was $6.7 million and $4.0 million, respectively. As of October 2, 2021, the Company had $34.7 million of unrecognized compensation cost related to non-vested RSU awards expected to be recognized and vest over a weighted-average period of approximately 3.6 years.
28
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
PSUs
The number of PSUs outstanding under all of the Company’s equity plans are as follows (in thousands, except for weighted-average grant date fair value amounts):
Nine Months Ended
October 2, 2021
UnitsWeighted-Average Grant
 Date Fair Value
PSUs outstanding, beginning of period444 $120.28 
Granted(1)
148 162.99 
Canceled(17)166.84 
Expired— — 
Vested(273)86.95 
PSUs outstanding, end of period302 $168.68 
______________
(1)     On February 22, 2021, the Audit Committee approved the weighted payout percentage for the 2018 PSU awards (three-year performance period), which were based upon the actual fiscal 2020 performance against pre-established performance objectives. Included in the granted amount are those additional PSUs earned based on actual performance achieved. These PSUs were originally awarded at target.
During the first quarter of 2021, the Company awarded 68,600 PSUs that will vest three years from the award date, based on the achievement of certain 2024 performance criteria approved by the Board. If earned, the PSUs granted will vest upon achievement of the performance criteria after the year in which the performance achievement level has been determined. The number of shares that may be earned can range from 0% to 200% of the target amount; therefore, the maximum number of shares that can be issued under these awards is twice the original award of 68,600 PSUs, or 137,200 shares. Based on management’s estimate of the number of units expected to vest, total PSU expense for the three months ended October 2, 2021 and September 26, 2020 was $7.0 million and $6.6 million, respectively. Based on management’s estimate of the number of units expected to vest, total PSU expense for the nine months ended October 2, 2021 and September 26, 2020 was $16.9 million and $20.5 million, respectively. As of October 2, 2021, the Company had $41.1 million of unrecognized compensation cost related to non-vested PSU awards expected to be recognized and vest over a weighted-average period of approximately 1.1 years.
Valuation of Stock-Based Award Activity
The fair value of each RSU and PSU is determined based on the closing price of the Company’s common stock on the grant date.
The Black-Scholes option pricing model is used to estimate the fair value of options granted under the Company’s stock-based compensation plans. The range of assumptions used and the resulting weighted-average fair value of options granted at the date of grant were as follows:
Three Months EndedNine Months Ended
October 2,
2021(1)
September 26,
2020		October 2,
2021		September 26,
2020
Risk-free interest rate
—%
0.2% to 0.3%
0.3% to 0.9%
0.2% to 1.7%
Expected term (in years)0.05.15.65.1
Estimated volatility
—%
32.7% to 33.6%
30.9% to 34.7%
26.9% to 35.5%
Expected dividends0%0%0%0%
Weighted-average fair value of options granted$—$66.24$75.72$50.39
__________________
(1)    No stock options were granted during the three months ended October 2, 2021.
29
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
The aggregate intrinsic value of options is calculated as the positive difference, if any, between the market value of the Company’s common stock on the date of exercise or the respective period end, as appropriate, and the exercise price of the options. The aggregate intrinsic value of options outstanding with an exercise price less than the closing price of the Company’s common stock as of October 2, 2021 was $589.6 million. The aggregate intrinsic value of options exercisable with an exercise price less than the closing price of the Company’s common stock as of October 2, 2021 was $484.5 million. The aggregate intrinsic value of options exercised during the three months ended October 2, 2021 was $35.4 million. The aggregate intrinsic value of options exercised during the nine months ended October 2, 2021 was $56.9 million.
19. Non-operating (loss) income
Non-operating (loss) income consists of the following (in thousands):
Three Months EndedNine Months Ended
October 2,
2021		September 26,
2020		October 2,
2021		September 26,
2020
Interest income$242 $797 $677 $5,120 
Interest expense(87)(84)(259)(250)
Realized and unrealized foreign currency (losses) gains(233)647 (1,153)1,246 
Other — (3)— (8)
Total
$(78)$1,357 $(735)$6,108 
20. Income Taxes
The Company has provided for income taxes in fiscal year 2021 interim periods based on the estimated effective income tax rate for the complete fiscal year, as adjusted for discrete tax events, including excess tax benefits or deficiencies related to stock-based compensation, in the period such events occur. The estimated annual effective tax rate is computed based on the expected annual pretax income of the consolidated entities located within each taxing jurisdiction based on legislation enacted as of the balance sheet date. For the three months ended October 2, 2021 and September 26, 2020, the Company recorded discrete tax benefits of approximately $6.4 million and $3.1 million, respectively, related to excess tax benefits realized from stock-based compensation. For the nine months ended October 2, 2021 and September 26, 2020, the Company recorded discrete tax benefits of approximately $12.0 million and $20.2 million, respectively, related to excess tax benefits realized from stock-based compensation.
Deferred tax assets and liabilities are determined based on the future tax consequences associated with temporary differences between income and expenses reported for accounting and tax purposes. A valuation allowance for deferred tax assets is recorded to the extent that the Company cannot determine that the ultimate realization of the net deferred tax assets is more likely than not. Realization of deferred tax assets is principally dependent upon the achievement of future taxable income, the estimation of which requires significant judgment by the Company’s management. The judgment of the Company’s management regarding future profitability may change due to many factors, including future market conditions and the Company’s ability to successfully execute its business plans or tax planning strategies. These changes, if any, may require material adjustments to these deferred tax asset balances.
As of October 2, 2021, the liability for income taxes associated with uncertain tax positions was approximately $21.6 million. If fully recognized, approximately $19.6 million (net of federal benefit on state taxes) would impact the Company’s effective tax rate. It is reasonably possible that the amount of unrecognized tax benefits in various jurisdictions may change in the next twelve months due to the expiration of statutes of limitation and audit settlements. However, due to the uncertainty surrounding the timing of these events, an estimate of the change within the next twelve months cannot currently be made.
The Company conducts business in multiple jurisdictions and, as a result, one or more of the Company’s subsidiaries files income tax returns in U.S. federal, various state, local and foreign jurisdictions. The Company has concluded all U.S. federal income tax matters through fiscal year 2016. All material state, local and foreign income tax matters have been concluded through fiscal year 2012. The Company does not believe that the results of any tax authority examination would have a significant impact on its consolidated financial statements.
30
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
21. Commitments and Contingencies
Employee Retirement Savings Plan
The Company sponsors a qualified defined contribution plan or 401(k) plan, the Masimo Retirement Savings Plan (MRSP), covering the Company’s full-time U.S. employees who meet certain eligibility requirements. In general, the Company matches an employee’s contribution up to 3% of the employee’s compensation, subject to a maximum amount. The Company may also contribute to the MRSP on a discretionary basis. The Company contributed $0.9 million and $0.8 million to the MRSP for the three months ended October 2, 2021 and September 26, 2020, respectively, all in the form of matching contributions. The Company contributed $2.8 million and $2.4 million to the MRSP for the nine months ended October 2, 2021 and September 26, 2020, respectively, all in the form of matching contributions. In addition, the Company sponsors various defined contribution plans in certain locations outside of the United States, the contributions to which were not material for any period.
Employment and Severance Agreements
In July 2017, the Company entered into the First Amendment to the certain Amended and Restated Employment Agreement entered into between the Company and Mr. Kiani on November 4, 2015 (as amended, the Amended Employment Agreement). Pursuant to the terms of the Amended Employment Agreement, upon a “Qualifying Termination” (as defined in the Amended Employment Agreement), Mr. Kiani will be entitled to receive a cash severance benefit equal to two times the sum of his then-current base salary and the average annual bonus paid to Mr. Kiani during the immediately preceding three years, the full amount of the “Award Shares” (as defined in the Amended Employment Agreement) and the full amount of the “Cash Payment” (as defined in the Amended Employment Agreement). In addition, in the event of a “Change in Control” (as defined in the Amended Employment Agreement) prior to a Qualifying Termination, on each of the first and second anniversaries of the Change in Control, 50% of the Cash Payment and 50% of the Award Shares will vest, subject in each case to Mr. Kiani’s continuous employment through each such anniversary date; however, in the event of a Qualifying Termination or a termination of Mr. Kiani’s employment due to death or disability prior to either of such anniversaries, any unvested amount of the Cash Payment and all of the unvested Award Shares shall vest and be paid in full.
Additionally, in the event of a Change in Control prior to a Qualifying Termination, Mr. Kiani’s stock options and any other equity awards will vest in accordance with their terms, but in no event later than in two equal installments on each of the one year and two year anniversaries of the Change in Control, subject in each case to Mr. Kiani’s continuous employment through each such anniversary date. As of October 2, 2021, the expense related to the Award Shares and Cash Payment that would be recognized in the Company’s consolidated financial statements upon the occurrence of a Qualifying Termination under the Restated Employment Agreement was approximately $292.9 million.
As of October 2, 2021, the Company had severance plan participation agreements with five executive officers. The participation agreements (the Agreements) are governed by the terms and conditions of the Company’s 2007 Severance Protection Plan (the Severance Plan), which became effective on July 19, 2007 and which was amended effective December 31, 2008. Under each of the Agreements, the applicable executive officer may be entitled to receive certain salary, equity, medical and life insurance benefits if he is terminated by the Company without cause or if he terminates his employment for good reason under certain circumstances. The executive officers are also required to give the Company six months’ advance notice of their resignation under certain circumstances.
Purchase Commitments
Pursuant to contractual obligations with vendors, the Company had $155.9 million of purchase commitments as of October 2, 2021 that are expected to be purchased within one year. These purchase commitments have been made for certain inventory items in order to secure sufficient levels of those items, other critical inventory and manufacturing supplies, and to achieve better pricing.
Other Contractual Commitments
In the normal course of business, the Company may provide bank guarantees to support government hospital tenders in certain foreign jurisdictions. As of October 2, 2021, the Company had approximately $3.4 million in outstanding unsecured bank guarantees.
31
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
In certain circumstances, the Company also provides limited indemnification within its various customer contracts whereby the Company indemnifies the parties to whom it sells its products with respect to potential infringement of intellectual property, and against bodily injury caused by a defective Company product. It is not possible to predict the maximum potential amount of future payments under these or similar agreements, due to the conditional nature of the Company’s obligations and the unique facts and circumstances involved. As of October 2, 2021, the Company had not incurred any significant costs related to contractual indemnification of its customers.
Concentrations of Risk
The Company is exposed to credit loss for the amount of its cash deposits with financial institutions in excess of federally insured limits. The Company invests a portion of its excess cash with major financial institutions. As of October 2, 2021, the Company had $652.4 million of bank balances, of which $5.0 million was covered by either the U.S. Federal Deposit Insurance Corporation limit or foreign countries’ deposit insurance organizations.
The Company’s ability to sell its products to U.S. hospitals depends in part on its relationships with GPOs. Many existing and potential customers for the Company’s products become members of GPOs. GPOs negotiate pricing arrangements and contracts, sometimes exclusively, with medical supply manufacturers and distributors, and these negotiated prices are made available to a GPO’s affiliated hospitals and other members. During the three months ended October 2, 2021 and September 26, 2020, revenue from the sale of the Company’s products to customers that are members of GPOs approximated 55.0% and 48.1% of product revenue, respectively. During the nine months ended October 2, 2021 and September 26, 2020, revenue from the sale of the Company’s products to customers that are members of GPOs approximated 51.8% and 49.6% of product revenue, respectively.
For the three months ended October 2, 2021, the Company had sales through two just-in-time distributors that represented 15.0% and 10.4% of product revenue, respectively. For the three months ended September 26, 2020, the Company had sales through the same two just-in-time distributors that represented 11.0% and 9.3% of product revenue, respectively.
For the nine months ended October 2, 2021, the Company had sales through two just-in-time distributors that represented 14.6% and 10.4% of product revenue, respectively. For the nine months ended September 26, 2020, the Company had sales through the same two just-in-time distributors that represented 11.2% and 10.0% of product revenue, respectively.
As of October 2, 2021 and January 2, 2021, one customer represented 9.4% and 9.1%, respectively, of the Company’s accounts receivable balance. The receivable balance related to such customer is fully secured by a letter of credit.
32
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
Litigation
During the third quarter of fiscal year 2017, the Company became aware that certain amounts had been paid by a foreign government customer to the Company’s former appointed foreign agent in connection with a foreign government tender, but had not been remitted by such agent to the Company in accordance with the agency agreement. On December 28, 2017, the Company initiated arbitration proceedings against this foreign agent after unsuccessful attempts to recover such remittances. As a result, the Company recorded a net charge of approximately $10.5 million during the fourth quarter of fiscal year 2017 in connection with this dispute, of which $2.0 million was recovered during the year ended December 28, 2019. An arbitration hearing was held on February 11, 2019. On July 8, 2019, the arbitrator awarded the Company $10.5 million in damages, fees and costs. On January 12, 2020, the Company received notice that bankruptcy restructuring proceedings had been initiated for the foreign agent. The Company filed its claim with the bankruptcy trustee on January 16, 2020. In July 2020, the Company was notified that a bankruptcy reorganization proposal had been submitted for voting by creditors in August 2020. The reorganization proposal was rejected by a vote of the creditors on August 26, 2020. On October 22, 2020, the Company filed a petition seeking to enforce the arbitration award. Although the Company intends to vigorously pursue the collection of the arbitration award, there is no guarantee that the Company will be successful in these efforts.
On January 2, 2014, a putative class action complaint was filed against the Company in the U.S. District Court for the Central District of California (District Court) by Physicians Healthsource, Inc. The complaint alleges that the Company sent unsolicited facsimile advertisements in violation of the Junk Fax Protection Act of 2005 and related regulations. The complaint seeks $500 for each alleged violation, treble damages if the District Court finds the alleged violations to be knowing, plus interest, costs and injunctive relief. On March 26, 2019, an amended complaint was filed adding Radha Geismann, M.D. PC as an additional named plaintiff. On June 17, 2019, the plaintiffs filed their motion for class certification. On September 10, 2019, the parties filed motions for summary judgment. On September 30, 2019, the Company filed its opposition to the motion for class certification, and the plaintiffs filed their reply on October 7, 2019. On November 21, 2019, the District Court issued an order denying the plaintiffs’ motion for class certification and granting in part and denying in part the Company’s motion for summary judgment, and deferring ruling on the plaintiffs’ motion for summary judgment. On December 5, 2019, the plaintiffs filed a petition for permission to appeal the order denying class certification, which was denied on January 24, 2020. Trial of the individual plaintiffs’ claims was scheduled for June 2, 2020, but on April 1, 2020, the District Court vacated the trial date and directed the parties to conduct an in-person mediation. The mediation has not occurred and no new trial date has been set. On July 13, 2020, the District Court issued an order granting in part and denying in part the plaintiffs’ motion for summary judgment.
The Company believes it has good and substantial defenses to the claims, but there is no guarantee that the Company will prevail. The Company is unable to determine whether any loss will ultimately occur or to estimate the range of such loss; therefore, no amount of loss has been accrued by the Company in the accompanying condensed consolidated financial statements.
On January 9, 2020, the Company filed a complaint against Apple Inc. (Apple) in the District Court for infringement of a number of patents, for trade secret misappropriation, and for ownership and correction of inventorship of a number of Apple patents listing one of its former employees as an inventor. Apple filed petitions for Inter Partes review of the asserted patents in the U.S. Patent and Trademark Office (PTO). The PTO has instituted Inter Partes review of the asserted patents. On October 13, 2020, the District Court stayed the patent infringement claims pending completion of the Inter Partes review proceedings. On February 5, 2021, the Company filed a fourth amended complaint. On February 26, 2021, Apple filed a partial motion to dismiss the trade secrets claim in the fourth amended complaint. On April 21, 2021, the District Court issued an order granting in part and denying in part the motion to dismiss. On May 5, 2021, Apple filed its answer to the fourth amended complaint. The Company is seeking damages, injunctive relief, and declaratory judgment regarding ownership of the Apple patents.
On June 30, 2021, the Company filed a complaint with the U.S. International Trade Commission (ITC) against Apple for infringement of a number of other patents. The Company filed an amended complaint on July 12, 2021. On August 13, 2021, the ITC issued a Notice of Institution of Investigation on the asserted patents. An evidentiary hearing is scheduled for June 6-10, 2022, and the target date for completion of the ITC investigation is January 16, 2023. The Company is seeking an exclusion order and a permanent cease and desist order. Although the Company intends to vigorously pursue all of its legal remedies, there is no guarantee that the Company will be successful in these efforts.
From time to time, the Company may be involved in other litigation and investigations relating to claims and matters arising out of its operations in the normal course of business. The Company believes that it currently is not a party to any other legal proceedings which, individually or in the aggregate, would have a material adverse effect on its consolidated financial position, results of operations or cash flows.
33
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
22. Segment Information and Enterprise Reporting
The Company operates in one segment based upon the Company’s organizational structure and the way in which the Company’s chief operating decision maker, the CEO, reviews financial information presented on a consolidated basis, accompanied by disaggregated information about revenues by geographic region, for purposes of making operating decisions and assessing financial performance. In addition, the Company’s assets are primarily located in the U.S. The Company does not produce reports for, or measure the performance of, its geographic regions on any asset-based metrics. Therefore, geographic information is presented only for revenues and long-lived assets.
The following schedule presents an analysis of the Company’s product revenues based upon the geographic area to which the product was shipped (in thousands, except percentages):
Three Months EndedNine Months Ended
October 2,
2021		September 26,
2020		October 2,
2021		September 26,
2020
Geographic area by destination:
United States (U.S.)$207,060 67.4 %$186,919 67.2 %$613,197 67.3 %$571,158 67.3 %
Europe, Middle East and Africa56,223 18.3 54,257 19.5 177,053 19.4 176,781 20.8 
Asia and Australia34,878 11.3 27,583 9.9 94,134 10.3 73,155 8.6 
North and South America (excluding the U.S.)9,252 3.0 9,353 3.4 27,190 3.0 27,596 3.3 
     Product revenue$307,413 100.0 %$278,112 100.0 %$911,574 100.0 %$848,690 100.0 %
The Company’s consolidated long-lived assets (tangible non-current assets) by geographic area are (in thousands, except percentages):
October 2,
2021		January 2,
2021
Long-lived assets by geographic area:
United States$239,435 86.6 %$238,094 86.9 %
International36,980 13.4 35,755 13.1 
     Total long-lived assets$276,415 100.0 %$273,849 100.0 %
34
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
This Quarterly Report on Form 10-Q contains “forward-looking statements” as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, in connection with the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially and adversely from those expressed or implied by such forward-looking statements. Such forward-looking statements include any expectation of earnings, revenues or other financial items; any statements of the plans, strategies and objectives of management for future operations; factors that may affect our operating results or financial condition; statements concerning new products, technologies or services; statements related to future capital expenditures; statements related to future economic conditions or performance; statements related to our stock repurchase program; statements as to industry trends and other matters that do not relate strictly to historical facts or statements of assumptions underlying any of the foregoing. These statements are often identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may” or “will,” the negative versions of these terms and similar expressions or variations. These statements are based on the beliefs and assumptions of our management based on information currently available to management. Such forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results and the timing of certain events to differ materially and adversely from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled “Risk Factors” included elsewhere in this Quarterly Report on Form 10-Q and in our other Securities and Exchange Commission (SEC) filings, including our Annual Report on Form 10-K for the fiscal year ended January 2, 2021, which we filed with the SEC on February 23, 2021. Furthermore, such forward-looking statements speak only as of the date of this report. We undertake no obligation to update any forward-looking statements to reflect events or circumstances occurring after the date of such statements.
Executive Overview
We are a global medical technology company that develops, manufactures and markets a variety of noninvasive patient monitoring technologies, hospital automation solutions, home monitoring devices and consumer products. Our mission is to improve patient outcomes, reduce the cost of care and take noninvasive monitoring to new sites and applications. Our patient monitoring solutions generally incorporate a monitor or circuit board, proprietary single-patient use or reusable sensors, software and/or cables. We primarily sell our products to hospitals, emergency medical service (EMS) providers, home care providers, physician offices, veterinarians, long-term care facilities and consumers through our direct sales force, distributors and original equipment manufacturer (OEM) partners. We were incorporated in California in May 1989 and reincorporated in Delaware in May 1996.
Our core measurement technologies are Measure-through Motion and Low Perfusion™ pulse oximetry, known as Masimo Signal Extraction Technology® (SET®) pulse oximetry, and advanced rainbow® Pulse CO-Oximetry parameters such as noninvasive hemoglobin (SpHb®), alongside many other modalities, including brain function monitoring, hemodynamic monitoring, regional oximetry, acoustic respiration rate monitoring, capnography, nasal high-flow respiratory support therapy, patient position and activity tracking and neuromodulation technology for the reduction of symptoms associated with opioid withdrawal. Masimo’s measurement technologies are available on many types of devices, from bedside hospital monitors like the Root® Patient Monitoring and Connectivity Hub, to various handheld and portable devices, and to the tetherless Masimo SafetyNet™ remote patient surveillance solution. The Masimo Hospital Automation™ Platform facilitates data integration, connectivity, and interoperability through solutions like Patient SafetyNet™, Replica® and UniView™ to facilitate more efficient clinical workflows and to help clinicians provide the best possible care, both in-person and remotely. Leveraging our expertise in hospital-grade technologies, we are also expanding our suite of products intended for use outside the hospital and products for consumers, including Sleep™, a sleep quality solution and the Radius Tº™ wireless, wearable continuous thermometer. For an overview of our product offerings and technologies, please refer to “Business” in Part I, Item 1 of our Annual Report on Form 10-K for the fiscal year ended January 2, 2021, filed with the SEC on February 23, 2021.
In January 2021, we announced the global launch of iSirona™, a compact, versatile connectivity hub designed to maximize interoperability across the continuum of care. The iSirona™ hub offers an efficient way to physically connect up to six medical devices at the bedside and automatically route the data to the Masimo Hospital Automation™ Platform. The iSirona™ hub helps ensure that whatever the source, all patient data can be accurately and efficiently captured and presented to clinicians in the most suitable ways.

35
In February 2021, we announced the full market release of Masimo SafetyNet-OPEN™, a web and mobile app solution that helps businesses, schools and other organizations screen, trace and manage users entering their facilities with respect to COVID-19 and other infectious illnesses, such as seasonal flu. SafetyNet-OPEN™ helps organizations bring their people back to the workplace responsibly and stay open safely. Tailored for each organization’s safety protocols and needs, SafetyNet-OPEN™ is capable of covering all stages of back-to-work management, including risk screening, exposure contact tracing and recovery management.
Also in February 2021, we announced the U.S. introduction of softFlow®, which provides nasal high-flow warmed and humidified respiratory gases to spontaneously breathing patients. The technology offers adult patients high-flow respiratory support through a soft nasal cannula by generating a consistent high flow of warm, humidified air or air/oxygen mixture.
In March 2021, we announced the CE Marking of the Rad-G™ with temperature, a rugged handheld device that provides clinically proven SET® pulse oximetry, respiration rate from the pleth (RRp®) parameter and other important parameters alongside clinical-grade, non-contact infrared thermometry. With its long-lasting rechargeable battery, robust rubber casing, light weight and integrated noninvasive, real-time forehead temperature measurement, Rad-G™ with temperature makes it easier for clinicians to quickly assess patients and make informed care decisions anywhere pulse oximetry or vital signs monitoring is needed in a compact, portable form factor. Coupled with the universal Mini-Clip™ pulse oximeter sensor to provide the ultimate in handheld versatility, Rad-G™ with temperature can be used in a variety of settings, including but not limited to, entry screening, physicians’ offices, outpatient services, long-term care facilities, wellness clinics, first-response scenarios and limited-resource environments both indoors and in the field. Rad-G™ can provide both spot-check measurement and continuous monitoring.
In April 2021, we announced that Radius PCG™, a portable real-time capnograph with wireless Bluetooth® connectivity, received FDA 510(k) clearance. Radius PCG™ connects with the Root® Patient Monitoring and Connectivity Platform to provide seamless, tetherless mainstream capnography for patients of all ages. Radius PCG™ offers Masimo SET® Measure-through Motion and Low Perfusion pulse oximetry, continuous temperature measurements with no routine calibration, along with accurate end-tidal carbon dioxide (EtCO2) and respiration rate measurements.
In June 2021, we announced that Radius T°™, a wearable, wireless thermometer that measures body temperature continuously and noninvasively, received FDA 510(k) clearance for both prescription and over-the-counter use on patients and consumers five years and older. Featuring continuously trending temperature measurements and Bluetooth® connectivity, Radius T°™ automates remote, continuous body temperature status for clinicians through its paired connection to a Masimo patient monitoring or telehealth solution, and for consumers through the Masimo Radius T°™ smartphone application.
In July 2021, we announced the release of the MX-7™ board, our latest and most advanced rainbow SET® board. Designed for integration into the more than 200 multi-parameter monitors available from our more than 90 OEM partners, MX-7™ has the ability to support all 13 of Masimo’s SET® pulse oximetry and rainbow® Pulse CO-Oximetry measurements in an advanced module re-engineered to reduce power needs.
In August 2021, we announced the launch of Masimo SafetyNet Alert™, an arterial blood oxygen saturation monitoring and alert system designed for use at home. Masimo SafetyNet Alert™ features a Masimo SET® fingertip pulse oximetry sensor that communicates wirelessly to an accompanying Home Medical Hub and smartphone app. The system provides escalating visual and audible alerts that are designed to alert the patient, or anyone nearby, to help prompt action if oxygen levels continue to decline and designated emergency contacts are also notified via text message. Masimo SafetyNet Alert™ has received the CE Mark in Europe.
In September 2021, we announced the launch of the single-patient-use rainbow® SuperSensor™, compatible for use with both Masimo monitors and third-party monitors with Masimo rainbow® technology inside. The rainbow® SuperSensor™ uses 12 LEDs to simultaneously offer 12 noninvasive, continuous Masimo SET® and rainbow® parameters, providing a comprehensive and convenient fingertip solution for assessing patient status. The rainbow® SuperSensor™ has received the CE Mark in Europe.
36
COVID-19 Pandemic
The COVID-19 pandemic has created significant uncertainty in the U.S. and around the globe, resulting in both challenges and opportunities for our business. We are committed to being as transparent as possible with our investors, employees, customers, suppliers and business partners as we collectively work to respond to this crisis. In response to this situation, we implemented a number of precautionary measures at our facilities, including: requiring certain personnel to work remotely from home and enacting social distancing, requiring face masks and mandatory screening for symptoms associated with COVID-19 for critical personnel that are required to report to our facilities to work. We also introduced new products, such as Masimo SafetyNet™ and Masimo SafetyNet-OPEN™ to help combat the COVID-19 pandemic and made pledges to various charitable organizations to support global COVID-19 relief efforts. We currently believe that our existing liquidity position will be sufficient to fund these ongoing initiatives and our response efforts.
Given the continuing uncertainties related to the COVID-19 pandemic, we cannot predict how it will continue to affect our product demand or our product mix. In addition, the increase in demand we have experienced due to the COVID-19 pandemic could result in potential reductions in future demand if our customers have over purchased our products and need to consume their excess inventory before purchasing additional products. Furthermore, we continue to be exposed to potential disruptions to our manufacturing operations and disruptions in the supply of critical manufacturing components and in our workforce as circumstances surrounding the global impact of the COVID-19 pandemic continue to change. In addition, given the recent presidential executive order mandating federal contractors and subcontractors to be fully vaccinated against COVID-19 by November 22, 2021, we expect that our employees will be required to be vaccinated per the federal mandate, and current employees and candidates seeking employment with Masimo may be opposed to being vaccinated and may risk possible termination or may seek employment with an employer that is not required to follow the federal mandate. Please see “Risks Related to Our Revenues” and “Risks Related to our Business and Operations” in Part II, Item 1A of this Quarterly Report on Form 10-Q for additional information on potential negative impacts to us resulting from the COVID-19 pandemic.
Cercacor
Cercacor Laboratories, Inc. (Cercacor) is an independent entity spun off from us to our stockholders in 1998. Joe Kiani, our Chairman and Chief Executive Officer (CEO), is also the Chairman and CEO of Cercacor. We are a party to a cross-licensing agreement with Cercacor, which was amended and restated effective January 1, 2007 (the Cross-Licensing Agreement), which governs each party’s rights to certain intellectual property held by the two companies. See Note 3 to our accompanying condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q for additional information related to Cercacor.
37
Results of Operations
The following table sets forth, for the periods indicated, our results of operations expressed as U.S. Dollar amounts and as a percentage of revenue (dollars in thousands).
Three Months EndedNine Months Ended
October 2,
2021		Percentage
of Revenue		September 26,
2020		Percentage
of Revenue		October 2,
2021		Percentage
of Revenue		September 26,
2020		Percentage
of Revenue
Product revenue$307,414 100.0 %$278,112 100.0 %$911,575 100.0 %$848,690 100.0 %
Cost of goods sold103,750 33.7 99,186 35.7 318,124 34.9 292,551 34.5 
Gross profit203,664 66.3 178,926 64.3 593,451 65.1 556,139 65.5 
Operating expenses:
Selling, general and administrative100,647 32.7 90,376 32.5 291,180 31.9 278,714 32.8 
Research and development35,406 11.5 28,852 10.4 103,860 11.4 86,971 10.2 
Litigation awards— — — — — — (474)(0.1)
Total operating expenses136,053 44.3 119,228 42.9 395,040 43.2 365,211 43.0 
Operating income67,611 22.0 59,698 21.5 198,411 21.8 190,928 22.5 
Non-operating (loss) income(78)— 1,357 0.5 (735)(0.1)6,108 0.7 
Income before provision for income taxes67,533 21.9 61,055 22.0 197,676 21.7 197,036 23.2 
Provision for income taxes9,762 3.2 11,650 4.2 36,287 4.0 27,403 3.2 
Net income$57,771 18.7 %$49,405 17.8 %$161,389 17.6 %$169,633 20.0 %

Comparison of the Three Months ended October 2, 2021 to the Three Months ended September 26, 2020
Revenue. Product revenue increased $29.3 million, or 10.5%, to $307.4 million for the three months ended October 2, 2021 from $278.1 million for the three months ended September 26, 2020. The following table details our product revenues by the geographic area to which the products were shipped for each of the three months ended October 2, 2021 and September 26, 2020 (dollars in thousands):
Three Months Ended
October 2,
2021		September 26,
2020		Increase/
(Decrease)		Percentage
Change
United States (U.S.)$207,060 67.4 %$186,919 67.2 %$20,141 10.8 %
Europe, Middle East and Africa56,223 18.3 54,257 19.5 1,966 3.6 
Asia and Australia34,878 11.3 27,583 9.9 7,295 26.4 
North and South America (excluding the U.S.)9,252 3.0 9,353 3.4 (101)(1.1)
     Product revenue$307,413 100.0 %$278,112 100.0 %$29,301 10.5 %
This increase was primarily due to higher revenue from consumables, parameters and services, as well as the impact of approximately $1.3 million of favorable foreign exchange rate movements from the prior year that increased the U.S. Dollar translation of foreign sales that were denominated in various foreign currencies. During the three months ended October 2, 2021, we shipped approximately 74,600 noninvasive technology boards and instruments.
Product revenue generated through our direct and distribution sales channels increased $56.5 million, or 25.7%, to $275.7 million for the three months ended October 2, 2021, compared to $219.3 million for the three months ended September 26, 2020. Revenues from our OEM channel decreased $27.2 million, or 46.1%, to $31.7 million for the three months ended October 2, 2021 as compared to $58.8 million for the three months ended September 26, 2020.
38
Gross Profit. Gross profit consists of product revenue less cost of goods sold. Our gross profit for the three months ended October 2, 2021 and September 26, 2020 was as follows (dollars in thousands):
Gross Profit
Three Months Ended
October 2, 2021		Percentage of
 Net Revenues		Three Months Ended
September 26, 2020		Percentage of
Net Revenues		Increase/
(Decrease)		Percentage
Change
$203,66466.3%$178,92664.3%$24,73813.8%
Cost of goods sold includes labor, material, overhead and other similar costs related to the production, supply, distribution and support of our products. Cost of goods sold increased $4.6 million for the three months ended October 2, 2021, compared to the three months ended September 26, 2020, primarily due to higher material, manufacturing and distribution costs associated with the increase in product sales.
Gross profit increased to 66.3% for the three months ended October 2, 2021, compared to 64.3% for the three months ended September 26, 2020, primarily due to an increase in product sales and favorable revenue mix.
Selling, General and Administrative. Selling, general and administrative expenses consist primarily of salaries, stock-based compensation and related expenses for sales, marketing and administrative personnel, sales commissions, advertising and promotion costs, professional fees related to legal, accounting and other outside services, public company costs and other corporate expenses. Selling, general and administrative expenses for the three months ended October 2, 2021 and September 26, 2020 were as follows (dollars in thousands):
Selling, General and Administrative
Three Months Ended
October 2, 2021		Percentage of
 Net Revenues		Three Months Ended
September 26, 2020		Percentage of
Net Revenues		Increase/
(Decrease)		Percentage
Change
$100,64732.7%$90,37632.5%$10,27111.4%
Selling, general and administrative expenses increased $10.3 million, or 11.4%, for the three months ended October 2, 2021, compared to the three months ended September 26, 2020. This increase was primarily attributable to higher compensation and other employee-related costs of approximately $11.0 million, higher legal and professional fees of $4.2 million, higher occupancy and other office-related costs of approximately $1.5 million and higher travel costs of approximately $1.4 million, which were partially offset by lower advertising and marketing-related costs of approximately $8.5 million.
Research and Development. Research and development expenses consist primarily of salaries, stock-based compensation and related expenses for engineers and other personnel engaged in the design and development of our products. These expenses also include third-party fees paid to consultants, prototype and engineering supply expenses and the costs of clinical trials. Research and development expenses for the three months ended October 2, 2021 and September 26, 2020 were as follows (dollars in thousands):
Research and Development
Three Months Ended
October 2, 2021		Percentage of
 Net Revenues		Three Months Ended
September 26, 2020		Percentage of
Net Revenues		Increase/
(Decrease)		Percentage
Change
$35,40611.5%$28,85210.4%$6,55422.7%
Research and development expenses increased $6.6 million, or 22.7%, for the three months ended October 2, 2021, compared to the three months ended September 26, 2020, primarily due to higher compensation and employee-related costs of approximately $4.6 million and higher engineering project costs of approximately $2.0 million.
Non-operating (Loss) Income. Non-operating (loss) income consists primarily of interest income, interest expense and foreign exchange gains and losses. Non-operating (loss) income for the three months ended October 2, 2021 and September 26, 2020 was as follows (dollars in thousands):
Non-operating (Loss) Income
Three Months Ended
October 2, 2021		Percentage of
 Net Revenues		Three Months Ended
September 26, 2020		Percentage of
Net Revenues		Increase/
(Decrease)		Percentage
Change
$(78)—%$1,3570.5%$(1,435)(105.7)%
39
Non-operating (loss) income was less than $0.1 million for the three months ended October 2, 2021, as compared to $1.4 million of non-operating income for the three months ended September 26, 2020. This decrease of approximately $1.4 million was primarily due to lower interest yields realized on our invested cash.
Provision for Income Taxes. Our provision for income taxes for the three months ended October 2, 2021 and September 26, 2020 was as follows (dollars in thousands):
Provision for Income Taxes
Three Months Ended
October 2, 2021		Percentage of
 Net Revenues		Three Months Ended
September 26, 2020		Percentage of
Net Revenues		Increase/
(Decrease)		Percentage
Change
$9,7623.2%$11,6504.2%$(1,888)(16.2)%
For the three months ended October 2, 2021, we recorded a provision for income taxes of approximately $9.8 million, or an effective tax provision rate of 14.5%, as compared to a provision for income taxes of approximately $11.7 million, or an effective tax provision rate of 19.1%, for the three months ended September 26, 2020. The decrease in our effective tax rate for the three months ended October 2, 2021 resulted primarily from an increase in the amount of excess tax benefits realized from stock-based compensation of approximately $3.3 million compared to the three months ended September 26, 2020.
Comparison of the Nine Months ended October 2, 2021 to the Nine Months ended September 26, 2020
Revenue. Product revenue increased $62.9 million, or 7.4%, to $911.6 million for the nine months ended October 2, 2021 from $848.7 million for the nine months ended September 26, 2020. The following table details our product revenues by the geographic area to which the products were shipped for each of the nine months ended October 2, 2021 and September 26, 2020 (dollars in thousands):
Nine Months Ended
October 2,
2021		September 26,
2020		Increase/
(Decrease)		Percentage
Change
United States (U.S.)$613,197 67.3 %$571,158 67.3 %$42,039 7.4 %
Europe, Middle East and Africa177,053 19.4 176,781 20.8 272 0.2 
Asia and Australia94,134 10.3 73,155 8.6 20,979 28.7 
North and South America (excluding the U.S.)27,190 3.0 27,596 3.3 (406)(1.5)
     Product revenue$911,574 100.0 %$848,690 100.0 %$62,884 7.4 %
This increase was primarily due to higher revenue from consumables, services and parameters, as well as the impact of approximately $9.5 million of favorable foreign exchange rate movements from the prior year period that increased the U.S. Dollar translation of foreign sales that were denominated in various foreign currencies. During the nine months ended October 2, 2021, we shipped approximately 213,100 noninvasive technology boards and instruments.
Product revenue generated through our direct and distribution sales channels increased $112.4 million, or 16.1%, to $810.4 million for the nine months ended October 2, 2021, compared to $698.0 million for the nine months ended September 26, 2020. Revenues from our OEM channel decreased $49.5 million, or 32.8%, to $101.2 million for the nine months ended October 2, 2021 as compared to $150.7 million for the nine months ended September 26, 2020.
Gross Profit. Gross profit consists of total revenue less cost of goods sold. Our gross profit for the nine months ended October 2, 2021 and September 26, 2020 was as follows (dollars in thousands):
Gross Profit
Nine Months Ended
October 2, 2021		Percentage of
 Net Revenues		Nine Months Ended
September 26, 2020		Percentage of
Net Revenues		Increase/
(Decrease)		Percentage
Change
$593,45165.1%$556,13965.5%$37,3126.7%
Cost of goods sold increased $25.6 million for the nine months ended October 2, 2021 compared to the nine months ended September 26, 2020, primarily due to higher material, manufacturing and distribution costs associated with the increase in product sales.
Gross profit decreased to 65.1% for the nine months ended October 2, 2021 compared to 65.5% for the nine months ended September 26, 2020, primarily due to costs associated with an elevated level of customer installations and higher material, manufacturing and distribution costs, offset by favorable revenue mix.
40
Selling, General and Administrative. Selling, general and administrative expenses for the nine months ended October 2, 2021 and September 26, 2020 were as follows (dollars in thousands):
Selling, General and Administrative
Nine Months Ended
October 2, 2021		Percentage of
 Net Revenues		Nine Months Ended
September 26, 2020		Percentage of
Net Revenues		Increase/
(Decrease)		Percentage
Change
$291,18031.9%$278,71432.8%$12,4664.5%
Selling, general and administrative expenses increased $12.5 million, or 4.5%, for the nine months ended October 2, 2021 compared to the nine months ended September 26, 2020. This increase was primarily due to higher compensation and other employee-related costs of approximately $14.8 million, higher legal and professional fees of approximately $12.8 million, higher occupancy and other office-related costs of approximately $4.4 million and higher travel-related costs of approximately $0.5 million, which were partially offset by lower advertising and marketing-related costs of approximately $18.4 million and lower charitable contributions of approximately $3.1 million.
Research and Development. Research and development expenses for the nine months ended October 2, 2021 and September 26, 2020 were as follows (dollars in thousands):
Research and Development
Nine Months Ended
October 2, 2021		Percentage of
 Net Revenues		Nine Months Ended
September 26, 2020		Percentage of
Net Revenues		Increase/
(Decrease)		Percentage
Change
$103,86011.4%$86,97110.2%$16,88919.4%
Research and development expenses increased $16.9 million, or 19.4%, for the nine months ended October 2, 2021 compared to the nine months ended September 26, 2020, primarily due to higher compensation-related costs of approximately $11.6 million and higher engineering project costs of approximately $5.7 million, which were partially offset by lower professional service fees of $1.0 million.
Non-operating (Loss) Income. Non-operating (loss) income consists primarily of interest income, interest expense and foreign exchange gains and losses. Non-operating (loss) income for the nine months ended October 2, 2021 and September 26, 2020 was as follows (dollars in thousands):
Non-operating (Loss) Income
Nine Months Ended
October 2, 2021		Percentage of
 Net Revenues		Nine Months Ended
September 26, 2020		Percentage of
Net Revenues		Increase/
(Decrease)		Percentage
Change
$(735)(0.1)%$6,1080.7%$(6,843)(112.0)%
Non-operating (loss) income decreased by $6.8 million for the nine months ended October 2, 2021 compared to the nine months ended September 26, 2020, primarily due to lower interest yields realized on our invested cash of approximately $4.5 million and a decrease in net realized and unrealized gains on foreign currency denominated transactions of approximately $2.4 million.
Provision for Income Taxes. Our provision for income taxes for the nine months ended October 2, 2021 and September 26, 2020 was as follows (dollars in thousands):
Provision for Income Taxes
Nine Months Ended
October 2, 2021		Percentage of
 Net Revenues		Nine Months Ended
September 26, 2020		Percentage of
Net Revenues		Increase/
(Decrease)		Percentage
Change
$36,2874.0%$27,4033.2%$8,88432.4%
For the nine months ended October 2, 2021, we recorded a provision for income taxes of approximately $36.3 million, or an effective tax rate of 18.4%, as compared to a provision for income taxes of approximately $27.4 million, or an effective tax rate of 13.9%, for the nine months ended September 26, 2020. The increase in our tax rate for the nine months ended October 2, 2021 resulted primarily from a decrease in the amount of excess tax benefits realized from stock-based compensation of approximately $8.2 million as compared to the nine months ended September 26, 2020.


41
Liquidity and Capital Resources
Our principal sources of liquidity consist of our existing cash and cash equivalent balances, future funds expected to be generated from operations and available borrowing capacity under our credit facility. As of October 2, 2021, we had approximately $909.5 million in working capital, of which approximately $652.4 million was in cash and cash equivalents. In addition to net working capital, we had approximately $147.6 million of available borrowing capacity (net of outstanding letters of credit) under our credit facility.
In managing our day-to-day liquidity and capital structure, we generally do not rely on foreign earnings as a source of funds. As of October 2, 2021, we had cash totaling $91.8 million held outside of the U.S., of which approximately $50.3 million was accessible without additional tax cost and approximately $41.5 million was accessible at an incremental estimated tax cost of up to $0.4 million. We currently have sufficient funds on-hand and cash held outside the U.S. that is available without additional tax cost to fund our global operations. In the event funds that are treated as permanently reinvested are repatriated, we may be required to accrue and pay additional U.S. taxes to repatriate these funds.
Cash Flows
The following table summarizes our cash flows (in thousands):
Nine Months Ended
October 2,
2021		September 26,
2020
Net cash provided by (used in):
Operating activities$167,151 $146,545 
Investing activities(31,465)(80,840)
Financing activities(126,666)38,954 
Effect of foreign currency exchange rates on cash(89)(294)
Increase in cash, cash equivalents and restricted cash$8,931 $104,365 
Operating Activities. Cash provided by operating activities was approximately $167.2 million for the nine months ended October 2, 2021, generated primarily from net income from operations of $161.4 million. Non-cash activity included stock-based compensation of $33.5 million and depreciation and amortization of $26.4 million. An additional source of cash included a decrease in other inventories and other current assets and an increase in deferred revenue and other contract-related liabilities and other non-current liabilities of $12.3 million, $4.4 million, $1.4 million and $0.6 million, respectively. These sources of cash were partially offset by other changes in operating assets and liabilities, including a decrease in accounts payable, accrued liabilities, income taxes payable and accrued compensation of approximately $4.3 million, $4.0 million, $1.5 million and $1.3 million, respectively, primarily due to the timing of payments; an increase in accounts receivable of approximately $51.0 million, primarily due to the timing of cash receipts; an increase in lease receivable of approximately $9.3 million and an increase in deferred costs and other contract assets of approximately $2.6 million.
For the nine months ended September 26, 2020, cash provided by operating activities was approximately $146.5 million, generated primarily from net income from operations of $169.6 million. Non-cash activity included stock-based compensation of $36.4 million and depreciation and amortization of $21.2 million. Additional sources of cash included an increase in accounts payable, deferred revenue and other contract-related liabilities, accrued liabilities and accrued compensation of $31.8 million, $10.0 million, $4.7 million and $3.7 million, respectively. These sources of cash were partially offset by other changes in operating assets and liabilities, including a decrease in income tax payable of approximately $2.8 million, an increase in inventory of approximately $86.8 million, an increase in other current assets of approximately $23.5 million, an increase in accounts receivable of approximately $9.5 million, primarily due to the timing of cash receipts and an increase in lease receivable of approximately $6.3 million.
Investing Activities. Cash used in investing activities for the nine months ended October 2, 2021 was approximately $31.5 million, consisting primarily of approximately $20.7 million for purchases of property and equipment, approximately $8.2 million of capitalized intangible asset costs related primarily to patent and trademark costs and license fees and approximately $2.6 million for strategic investments.


42
For the nine months ended September 26, 2020, cash used in investing activities was approximately $80.8 million, consisting primarily of approximately $78.3 million for business combinations, $60.0 million for purchases of property and equipment, $6.8 million for strategic investments and $5.8 million of capitalized intangible asset costs related primarily to patent and trademark costs, which were partially offset by cash provided by maturities of short-term investments of approximately $70.0 million.
Financing Activities. Cash used in financing activities for the nine months ended October 2, 2021 was approximately $126.7 million, consisting primarily of repurchases of our common stock of approximately $128.9 million and withholding of shares for employee payroll taxes for vested equity awards of approximately $16.7 million, which were partially offset by the proceeds from the issuance of common stock related to employee equity awards of approximately $19.0 million.
For the nine months ended September 26, 2020, cash provided by financing activities was approximately $39.0 million, consisting primarily of proceeds from the issuance of common stock related to employee equity awards of approximately $41.0 million, which was partially offset by the withholding of shares for employee payroll taxes for vested equity awards of approximately $1.4 million and repurchases of our common stock of approximately $0.6 million.
Capital Resources and Prospective Capital Requirements
We expect to fund our future operating, investing and financing activities through our available cash, future cash from operations, our credit facility and other potential sources of capital. In addition to funding our working capital requirements, we anticipate additional capital expenditures primarily related to investments in infrastructure growth. Possible additional uses of cash may include acquisitions of and/or strategic investments in technologies or technology companies, investments in property and repurchases of common stock under our authorized stock repurchase program. However, any repurchases of common stock will be subject to numerous factors, including the availability of our common stock, general market conditions, the trading price of our common stock, availability of capital, alternative uses for capital and our financial performance. In addition, the amount and timing of our actual investing activities will vary significantly depending on numerous factors, including the timing and amount of capital expenditures, costs of product development efforts, our timetable for infrastructure expansion, any stock repurchase activity and costs related to our domestic and international regulatory requirements. Despite these investment requirements and potential expenditures, we anticipate that our existing cash and cash equivalents and amounts available under our credit facility will be sufficient to meet our working capital requirements, capital expenditures and other operational funding needs for at least the next 12 months. For additional information related to our credit facility, please see Note 15 to our accompanying condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.
Off-Balance Sheet Arrangements
We do not currently have, nor have we ever had, any relationships with unconsolidated entities or financial partnerships, such as entities referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or for other contractually narrow or limited purposes. In addition, we do not engage in trading activities involving non-exchange traded contracts. As a result, we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in these relationships. As of October 2, 2021, we did not have any off-balance sheet arrangements, as defined in Item 303(a)(4)(ii) of Regulation S-K promulgated by the SEC.
Critical Accounting Policies and Estimates
The discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these condensed consolidated financial statements requires management to make estimates and judgments that affect the reported amounts of net revenues, expenses, assets and liabilities. We regularly evaluate our estimates and assumptions related to our critical accounting policies, including revenue recognition, inventory valuation, lessee right-of-use (ROU) assets and lease liabilities, stock-based compensation, business combinations, deferred taxes and related valuation allowances, uncertain tax positions, tax contingencies, litigation costs and loss contingencies.
These estimates and judgments are based on historical experience and on various other factors that we believe to be reasonable under the circumstances, and form the basis for making management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effects of matters that are inherently uncertain. Although we regularly evaluate these estimates and assumptions, changes in judgments and uncertainties relating to these estimates could potentially result in materially different results under different assumptions and conditions. If these estimates differ significantly from actual results, the impact to the condensed consolidated financial statements may be material.
43
There have been no material changes to any of our critical accounting policies during the nine months ended October 2, 2021. For a description of these critical accounting policies, please refer to “Critical Accounting Estimates” in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our Annual Report on Form 10-K for the fiscal year ended January 2, 2021, which was filed with the SEC on February 23, 2021.
Recent Accounting Pronouncements
For details regarding any recently adopted and recently issued accounting standards, see Note 2 to our accompanying condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
We are exposed to various market risks that may arise from adverse changes in market rates and prices, such as interest rates, foreign exchange fluctuations and inflation. We do not enter into derivatives or other financial instruments for trading or speculative purposes.
Interest Rate Risk
Our exposure to market risk for changes in interest rates relates to the increase or decrease in the amount of interest income we can earn on our cash and cash equivalents and on the increase or decrease in the amount of interest expense we must pay with respect to our various outstanding debt instruments. As of October 2, 2021, the carrying value of our cash equivalents approximated fair value. We currently do not have any significant risks associated with interest rates fluctuations related to interest expense. Under our current policies, we do not use interest rate derivative instruments to manage exposure to interest rate changes. Therefore, declines in interest rates over time will reduce our interest income while increases in interest rates will increase our interest income. A hypothetical 100 basis point change in interest rates along the entire interest rate yield curve would increase or decrease our interest rate yields on our investments and interest income by approximately $0.1 million for each $10.0 million in interest-bearing investments.
Foreign Currency Exchange Rate Risk
A majority of our assets and liabilities are maintained in the United States in U.S. Dollars and a majority of our sales and expenditures are transacted in U.S. Dollars. However, we also transact with foreign customers in currencies other than the U.S. Dollar. These foreign currency revenues, when converted into U.S. Dollars, can vary depending on average exchange rates during a respective period. In addition, certain of our foreign subsidiaries transact in their respective country’s local currency, which is also their functional currency. As a result, expenses of these foreign subsidiaries, when converted into U.S. Dollars can also vary depending on average monthly exchange rates during a respective period.
We are exposed to foreign currency gains or losses on outstanding foreign currency denominated receivables and payables, as well as our foreign currency denominated cash balances and certain intercompany transactions. In addition, other transactions between us or our subsidiaries and a third-party, denominated in a currency different from the functional currency, are foreign currency transactions. Realized and unrealized foreign currency gains or losses on these transactions are also included in our statements of operations as incurred.
The balance sheets of each of our foreign subsidiaries whose functional currency is not the U.S. Dollar are translated into U.S. Dollars at the rate of exchange at the balance sheet date and the statements of comprehensive income and cash flows are translated into U.S. Dollars using an approximation of the average monthly exchange rates applicable during the period. Any foreign exchange gain or loss as a result of translating the balance sheets of our foreign subsidiaries whose functional currency is not the U.S. Dollar is included in equity as a component of accumulated other comprehensive income.
Our foreign currency exchange rate exposures are primarily with the Canadian Dollar, Euro, Japanese Yen, Swedish Krona, the British Pound, Mexican Peso, Turkish Lira and Australian Dollar. Foreign currency exchange rates may experience significant volatility from one period to the next. Specifically, during the nine months ended October 2, 2021, we estimate fluctuations in the exchange rates between the U.S. Dollar and other foreign currencies, including the Euro, the Australian Dollar, the Canadian Dollar, the British Pound and the South Korean Won, favorably impacted our revenues by $9.5 million.
44
We currently do not enter into forward exchange contracts to hedge exposures denominated in foreign currencies and do not use derivative financial instruments for trading or speculative purposes. The effect of additional changes in foreign currency exchange rates could have a material effect on our future operating results or cash flows, depending on which foreign currency exchange rates change and depending on the directional change (either a strengthening or weakening against the U.S. Dollar). We estimate that the potential impact of a hypothetical 10% adverse change in all applicable foreign currency exchange rates from the rates in effect as of October 2, 2021 would have resulted in an estimated reduction of $13.0 million in reported pre-tax income for the nine months ended October 2, 2021. As our foreign operations continue to grow, our exposure to foreign currency exchange rate risk may become more significant.
Inflation Risk
We do not believe that inflation has had a material effect on our business, financial condition or results of operations during the periods presented. If our costs were to become subject to significant inflationary pressures, we may not be able to fully offset such higher costs through price increases. Our inability or failure to do so could have a material adverse effect on our business, financial condition and results of operations.
Item 4. Controls and Procedures
We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended (the Exchange Act), is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s (SEC) regulations, rules and forms and that such information is accumulated and communicated to our management, including our CEO and Chief Financial Officer (CFO), as appropriate, to allow for timely decisions regarding required disclosure.
In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. As required by Rule 13a-15(b) or Rule 15d-15(b) promulgated by the SEC under the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our CEO and CFO, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on the foregoing, our CEO and CFO concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Quarterly Report on Form 10-Q. During the three months ended October 2, 2021, there were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
The information set forth in Note 21 to our accompanying condensed consolidated financial statements under the caption “Litigation” included in Part I, Item 1 of this Quarterly Report on Form 10-Q is incorporated herein by reference.
45
Item 1A. Risk Factors
The following risk factors and other information included in this Quarterly Report on Form 10-Q should be carefully considered. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we presently deem less significant may also impair our business operations. If any of the following risks come to fruition, our business, financial condition, results of operations and future growth prospects would likely be materially and adversely affected. In these circumstances, the market price of our common stock could decline, and you could lose all or part of your investment. Risk factors marked with an asterisk (*) below include a substantive change from or an update to the risk factors included in our Annual Report on Form 10-K for the fiscal year ended January 2, 2021, filed with the SEC on February 23, 2021.
Summary of Material Risk Factors
Below is a summary of the principal factors that make an investment in our securities speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this summary, and other risks that we face, can be found following this summary and should be carefully considered together with all of the other information appearing in this Quarterly Report on Form 10-Q.
•We currently derive the majority of our revenue from our Masimo SET® platform, Masimo rainbow SET® platform and related products. If these technologies and related products do not continue to achieve market acceptance, our business, financial condition and results of operations would be adversely affected.
•Some of our products are in development or have been recently introduced into the market and may not achieve market acceptance, which could limit our growth and adversely affect our business, financial condition and results of operations.
•Our ability to commercialize new products, new or improved technologies and additional applications for Masimo SET® and our licensed rainbow® technology is limited to certain markets by our Cross-Licensing Agreement with Cercacor Laboratories, Inc. (Cercacor), which may impair our growth and adversely affect our business, financial condition and results of operations.
•We face competition from other companies, many of which have substantially greater resources than we do. If we do not successfully develop and commercialize enhanced or new products that remain competitive with products or alternative technologies developed by others, we could lose revenue opportunities and customers, and our ability to grow our business would be impaired, adversely affecting our financial condition and results of operations.
•We depend on our domestic and international OEM partners for a portion of our revenue. If they do not devote sufficient resources to the promotion of products that use our technologies, our business would be harmed.
•If we fail to maintain or develop relationships with GPOs, sales of our products would decline.
•Inadequate levels of coverage or reimbursement from governmental or other third-party payers for our products, or for procedures using our products, may cause our revenue to decline or prevent us from realizing revenues from future products.
•Consolidation in the healthcare industry could lead to demands for price concessions or to the exclusion of existing market participants from certain markets, which could have an adverse effect on our business, results of operations or financial condition.
•Our customers may reduce, delay or cancel purchases due to a variety of factors, such as lower hospital census levels or third-party guidelines, which could adversely affect our business, financial condition and results of operations.
•The loss of any large customer or distributor, or any cancellation or delay of a significant purchase by a large customer, could reduce our net sales and harm our operating results.
•Counterfeit Masimo sensors and third-party reprocessed single-patient-use Masimo sensors may harm our reputation. Also, these counterfeit and third-party reprocessed sensors, as well as genuine Masimo reprocessed sensors, are sold at lower prices than new Masimo sensors and could cause our revenue to decline, which may adversely affect our business, financial condition and results of operations.
•If the patents we own or license, or our other intellectual property rights, do not adequately protect our technologies, we may lose market share to our competitors and be unable to operate our business profitably.
•If third parties claim that we infringe their intellectual property rights, we may incur liabilities and costs and may have to redesign or discontinue selling certain products.
•We believe competitors may currently be violating and may in the future violate our intellectual property rights. As a result, we may initiate litigation to protect and enforce our intellectual property rights, which may result in substantial expense and may divert management’s attention from implementing our business strategy.
46
•The laws of foreign countries may not adequately protect our intellectual property rights.
•Our failure to obtain and maintain FDA clearances or approvals on a timely basis, or at all, would prevent us from commercializing our current, upgraded or new products in the U.S., which could severely harm our business.
•The failure of our OEM partners to obtain required FDA clearances or approvals for products that incorporate our technologies could have a negative impact on our revenue.
•If we or our suppliers fail to comply with ongoing regulatory requirements, or if we experience unanticipated problems with our products, these products could be subject to restrictions or withdrawal from the market.
•Failure to obtain regulatory authorizations in foreign jurisdictions may prevent us from marketing our products abroad.
•Modifications to our marketed devices may require new regulatory clearances or premarket approvals, or may require us to cease marketing or to recall the modified devices until clearances or approvals are obtained.
•Regulatory reforms may impact our ability to develop and commercialize our products and technologies.
•If our products cause or contribute to a death or serious injury, or malfunction in a way that would likely cause or contribute to a death or serious injury, we will be subject to medical device reporting regulations, and may need to initiate voluntary corrective actions or in certain circumstances be required to take corrective actions, such as the recall of our products.
•Promotion of our products using claims that are off-label, unsubstantiated, false or misleading could subject us to substantial penalties.
•The regulatory environment governing information, cybersecurity and privacy is increasingly demanding and continues to evolve.
•We may be subject to or otherwise affected by federal and state healthcare laws, including fraud and abuse laws, and could face substantial penalties if we are unable to fully comply with these laws.
•Legislative and regulatory changes in the healthcare industry could have a negative impact on our financial performance. Furthermore, our business, financial condition, results of operations and cash flows could be significantly and adversely affected by healthcare reform legislation in the U.S. or in our key international markets.
•Our business, financial condition and results of operations may be adversely affected by the COVID-19 pandemic.
•If our employees become ill or otherwise incapacitated, our operations may be adversely impacted.
•We may experience conflicts of interest with Cercacor with respect to business opportunities and other matters.
•We will be required to assign to Cercacor and pay Cercacor for the right to use certain products and technologies we develop that relate to the monitoring of non-vital sign parameters, including improvements to Masimo SET®.
•In the event that the Cross-Licensing Agreement is terminated for any reason, or Cercacor grants a license to rainbow® technology to a third-party, our business would be adversely affected.
•We may not be able to commercialize our products incorporating licensed rainbow® technology cost-effectively or successfully.
•Rights provided to Cercacor in the Cross-Licensing Agreement may impede a change in control of our company.
•If we are unable to obtain key materials and components from sole or limited source suppliers, we will not be able to deliver our products to customers.
•Future strategic initiatives, including acquisitions of businesses and strategic investments, could negatively affect our business, financial condition and results of operations if we fail to integrate the acquired businesses successfully into our existing operations or achieve the desired results of our investment.
•Our credit agreement contains certain covenants and restrictions that may limit our flexibility in operating our business.
•Concentration of ownership of our stock among our existing directors, executive officers and principal stockholders may prevent new investors from influencing significant corporate decisions.
•Our corporate documents and Delaware law contain provisions that could discourage, delay or prevent a change in control of our company, prevent attempts to replace or remove current management and reduce the market price of our stock.
•Our bylaws provide that the state or federal courts located within the State of Delaware are the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
47

Risks Related to Our Revenues
We currently derive the majority of our revenue from our Masimo SET® platform, Masimo rainbow SET® platform and related products. If these technologies and related products do not continue to achieve market acceptance, our business, financial condition and results of operations would be adversely affected.
We are highly dependent upon the continued success and market acceptance of our proprietary Masimo SET® and Masimo rainbow SET® technologies that serve as the basis of our primary product offerings. Continued market acceptance of products incorporating these technologies will depend upon us continuing to provide evidence to the medical community that our products are cost-effective and offer significantly improved performance compared to conventional pulse oximeters. Healthcare providers that currently have significant investments in competitive pulse oximetry products may be reluctant to purchase our products. If hospitals and other healthcare providers do not believe our Masimo SET® and Masimo rainbow SET® platforms are cost-effective, safe or more accurate or reliable than competitive pulse oximetry products, they may not buy our products in sufficient quantities to enable us to generate revenue growth from the sale of these products. In addition, allegations regarding the safety and effectiveness of our products, whether or not substantiated, may impair or impede the acceptance of our products.
*Some of our products are in development or have been recently introduced into the market and may not achieve market acceptance, which could limit our growth and adversely affect our business, financial condition and results of operations.
Many of our noninvasive measurement technologies are considered disruptive. These technologies have performance levels that we believe are acceptable for many clinical environments but may be insufficient in others. In addition, these technologies may perform better in some patients and settings than others. Over time, we hope to continue to improve the performance of these technologies and educate the clinical community on how to properly evaluate them. If we are successful in these endeavors, we expect these technologies will become more useful in more environments and will become more widely adopted. Our product portfolio continues to expand, and we are investing significant resources to enter into, and in some cases create, new markets for these products. We are continuing to invest in sales and marketing resources to achieve market acceptance of these products, but are unable to guarantee that our technologies will achieve general market acceptance.
The degree of market acceptance of these products will depend on a number of factors, including but not limited to:
•perceived clinical benefits from our products;
•perceived cost effectiveness of our products;
•perceived safety and effectiveness of our products;
•reimbursement available through government and private healthcare programs for using some of our products; and
•introduction and acceptance of competing products or technologies.
If our products do not gain market acceptance or if our customers prefer our competitors’ products, our potential revenue growth would be limited, which would adversely affect our business, financial condition and results of operations.
Our ability to commercialize new products, new or improved technologies and additional applications for Masimo SET® and our licensed rainbow® technology is limited to certain markets by our Cross-Licensing Agreement with Cercacor Laboratories, Inc. (Cercacor), which may impair our growth and adversely affect our business, financial condition and results of operations.
Since 1998, we have been a party to a cross-licensing agreement with Cercacor, (as amended, the Cross-Licensing Agreement), under which we granted Cercacor:
•an exclusive, perpetual and worldwide license, with sublicense rights, to use all Masimo SET® technology owned by us, including all improvements to this technology, for the monitoring of non-vital signs parameters and to develop and sell devices incorporating Masimo SET® for monitoring non-vital signs parameters in any product market in which a product is intended to be used by a patient or pharmacist rather than by a professional medical caregiver, which we refer to as the “Cercacor Market”; and
•a non-exclusive, perpetual and worldwide license, with sublicense rights, to use all Masimo SET® technology owned by us for measurement of vital signs in the “Cercacor Market.”

48
Non-vital signs measurements consist of body fluid constituents other than vital signs measurements, including, but not limited to, carbon monoxide, methemoglobin, blood glucose, hemoglobin and bilirubin. Under the Cross-Licensing Agreement, we are only permitted to sell devices utilizing Masimo SET® for the monitoring of non-vital signs parameters in markets where the product is intended to be used by a professional medical caregiver, including, but not limited to, hospital caregivers and alternate care facility caregivers, rather than by a patient or pharmacist, which we refer to as the “Masimo Market.” Accordingly, our ability to commercialize new products, new or improved technologies and additional applications for Masimo SET® is limited. In particular, our inability to expand beyond the “Masimo Market” may limit our ability to maintain or increase our revenue and impair our growth.
Pursuant to the Cross-Licensing Agreement, we have licensed from Cercacor the right to make and distribute products in the “Masimo Market” that utilize rainbow® technology for certain noninvasive measurements. As a result, the opportunity to expand the market for our products incorporating rainbow® technology is also limited, which could limit our ability to maintain or increase our revenue and impair our growth.
*We face competition from other companies, many of which have substantially greater resources than we do. If we do not successfully develop and commercialize enhanced or new products that remain competitive with products or alternative technologies developed by others, we could lose revenue opportunities and customers, and our ability to grow our business would be impaired, adversely affecting our financial condition and results of operations.
The medical device industry is intensely competitive and is significantly affected by new product introductions and other market activities of industry participants. A number of our competitors have substantially greater capital resources, larger product portfolios, larger customer bases, larger sales forces and greater geographic presence, have established stronger reputations with specific customers, and have built relationships with Group Purchasing Organizations and other hospital purchasing groups (collectively, GPOs) that may be more effective than ours. Our Masimo SET® platform faces additional competition from companies developing products for use with third-party monitoring systems, as well as from companies that currently market their own pulse oximetry monitors. In addition, competitors with larger product portfolios than ours are engaging in bundling practices, whereby they offer increased discounts to hospitals that purchase their requirements for a variety of different products from the competitor, including products that we do not offer, effectively pricing their competing products at a loss.
Continuing technological advances and new product introductions within the medical device industry place our products at risk of obsolescence. Our long-term success depends upon the development and successful commercialization of new products, new or improved technologies and additional applications for our existing technologies. The research and development process is time-consuming and costly and may not result in products or applications that we can successfully commercialize. In particular, we may not be able to successfully commercialize our products for applications other than arterial blood oxygen saturation and pulse rate monitoring, such as for respiration rate, hemoglobin, carboxyhemoglobin and methemoglobin monitoring. In addition, we may not be able to develop and successfully commercialize new products and technologies that we acquire.
If we do not successfully adapt our products and applications both within and outside these measurements, we could lose revenue opportunities and customers. Furthermore, one or more of our competitors may develop products that are substantially equivalent to those of our products that are cleared or approved for use, or those of our original equipment manufacturer (OEM) partners, in which case a competitor of ours may use our products or those of our OEM partners as predicate devices to more quickly obtain regulatory clearance or approval of their competing products. Competition could result in pressure from our customers to reduce the price of our products and could cause them to place fewer orders for our products, which could, in turn, cause a reduction in our revenues and product gross margins, thereby adversely impacting our business, financial condition and results of operations.
Some of the world’s largest technology companies that have not historically operated in the healthcare or medical device space, such as Alphabet Inc., Apple Inc., Samsung Electronics Co., Ltd. and others, have developed or may develop products and technologies that may compete with our current or future products and technologies. For example, in September 2020, Apple, Inc. announced that its Apple Watch Series 6 includes a pulse oximetry monitoring feature, which may compete with certain of our existing products and products in development, including the consumer versions of our iSpO2® and MightySat® pulse oximeters. In addition, in September 2021, Apple, Inc. announced that its Apple Watch Series 7 includes a blood oxygen level monitoring feature and a sleep tracking function, both of which compete with our existing products. These companies have substantially greater capital, research and development, and sales resources than we have. If we are unable to successfully compete against them, our financial performance could decline.

49
We depend on our domestic and international OEM partners for a portion of our revenue. If they do not devote sufficient resources to the promotion of products that use our technologies, our business would be harmed.
We are, and will continue to be, dependent upon our domestic and international OEM partners for a portion of our revenue through their marketing, selling and distribution of certain of their products that incorporate our technologies. Although we expect that our OEM partners will accept and actively market, sell and distribute products that incorporate our technologies, they may not do so. Because products that incorporate our technologies may represent a relatively small percentage of business for some of our OEM partners, they may have less incentive to promote these products over other products that do not incorporate these technologies.
In addition, some of our OEM partners offer products that compete with ours and also may be involved in intellectual property disputes with us. Therefore, we cannot guarantee that our OEM partners, or any company that may acquire any of our OEM partners, will vigorously promote products incorporating our technologies. The failure of our OEM partners to successfully market, sell or distribute products incorporating our technologies, the termination of OEM agreements, the loss of OEM partners or the inability to enter into future OEM partnership agreements would have a material adverse effect on our business, financial condition and results of operations.
If we fail to maintain or develop relationships with GPOs, sales of our products would decline.
Our ability to sell our products to hospitals depends, in part, on our relationships with GPOs. Many existing and potential customers for our products are members of GPOs. GPOs negotiate pricing arrangements and contracts with medical supply manufacturers and distributors that may include provisions for sole sourcing and bundling, which generally reduce the choices available to member hospitals.
These negotiated prices are made available to a GPO’s members. If we are not one of the providers selected by a GPO, the GPO’s members may be less likely or unlikely to purchase our products. If a GPO has negotiated a strict sole source, market share compliance or bundling contract for another manufacturer’s products, we may be prohibited from making sales to members of such GPO for the duration of such contractual arrangement. Shipments of our pulse oximetry products to customers that are members of GPOs represent approximately 50% of our U.S. product sales. Our failure to renew our contracts with GPOs may cause us to lose market share and could have a material adverse effect on our business, financial condition and results of operations. In addition, if we are unable to develop new relationships with GPOs, our competitive position would likely suffer and our opportunities to grow our revenues and business would be harmed.
Inadequate levels of coverage or reimbursement from governmental or other third-party payers for our products, or for procedures using our products, may cause our revenue to decline or prevent us from realizing revenues from future products.
Sales of our products depend in part on the reimbursement and coverage policies of governmental and private healthcare payers. The lack of adequate coverage and reimbursement for our products or the procedures in which our products are used may deter customers from purchasing our products.
We cannot guarantee that governmental or third-party payers will reimburse or begin reimbursing a customer for the cost of our products or the procedures in which our products are used. For example, some insurance carriers have issued policies denying coverage for transcutaneous hemoglobin measurement on the grounds that the technology is investigational in the outpatient setting. Other payers are continuing to investigate our products to determine if they will provide reimbursement for the use of such products.
These trends could lead to pressure to reduce prices for our current and future products, hinder our ability to obtain market adoption, cause a decrease in the size of the market or potentially increase competition, any of which could have a material adverse effect on our business, financial condition and results of operations.
We do not control payer decision-making with respect to coverage and payment levels for our products. Additionally, we expect many payers to continue to explore cost-containment strategies (e.g., comparative and cost-effectiveness analyses, so-called “pay-for-performance” programs implemented by various public government healthcare programs and private third-party payers, and expansion of payment bundling initiatives, and other such methods that shift medical cost risk to providers) that may potentially impact coverage and/or payment levels for our current products or products we develop in the future.
Outside of the U.S., reimbursement systems vary by country. These systems are often subject to the same pressures to curb rising healthcare costs and control healthcare expenditures as those in the U.S. In addition, as economies of emerging markets develop, these countries may implement changes in their healthcare delivery and payment systems. If adequate levels of reimbursement from third-party payers outside of the U.S. are not obtained, sales of our products outside of the U.S. may be adversely affected.
50
Consolidation in the healthcare industry could lead to demands for price concessions or to the exclusion of existing market participants from certain markets, which could have an adverse effect on our business, results of operations or financial condition.
Because healthcare costs have risen significantly over the past decade, numerous initiatives and reforms initiated by legislators, regulators and third-party payers to curb these costs have resulted in a consolidation trend in the healthcare industry to aggregate purchasing power. As the healthcare industry consolidates, competition to provide products and services to industry participants has become, and will continue to become, more intense. This has resulted in, and will likely continue to result in, greater pricing pressures and the exclusion of certain existing market participants from important market segments as GPOs, independent delivery networks and large single accounts continue to use their market power to consolidate purchasing decisions for hospitals.
We expect that market demand, government regulation, third-party coverage and reimbursement policies and societal pressures will continue to impact the worldwide healthcare industry, resulting in further business consolidations and alliances among our customers, which may reduce competition, exert further downward pressure on the prices of our products and adversely impact our business, financial condition and results of operations.
Our customers may reduce, delay or cancel purchases due to a variety of factors, such as lower hospital census levels or third-party guidelines, which could adversely affect our business, financial condition and results of operations.
Our customers are facing growing levels of uncertainties, including variations in overall hospital census for paying patients and the impact of such census variations on hospital budgets. As a result, many hospitals are reevaluating their entire cost structure, including the amount of capital they allocate to medical device technologies and products. In addition, certain of our products, including our rainbow® measurements such as carbon monoxide, methemoglobin and hemoglobin, that are sold with upfront license fees and more complex and expensive sensors, could also be impacted by hospital budget reductions. Any reductions in capital spending budgets by hospitals could have a significant negative impact on our OEM customers who, due to their traditionally larger capital equipment sales model, could see declines in purchases from their hospital customers. This, in turn, could reduce our board sales to our OEM customers.
From time to time, states and other local regulatory authorities may issue guidelines regarding the appropriate scope and use of our products. For example, some of our noninvasive monitoring devices may be subject to authorization by individual states as part of the Emergency Medical Services (EMS) scope of practice procedures. A lack of inclusion into scope of practice procedures may limit adoption of our products.
Additionally, increases in demand resulting from global medical crises such as the COVID-19 pandemic may be short lived. If the increased demand results in a stockpiling of our products by, or excess inventory at, our customers, future orders may be delayed or canceled until such on-hand inventory is consumed.
*The loss of any large customer or distributor, or any cancellation or delay of a significant purchase by a large customer, could reduce our net sales and harm our operating results.
We have a concentration of OEM, distributor and direct customers. For example, sales to two just-in-time distributors each represented 10% or more of our product sales for the fiscal quarter ended October 2, 2021. We cannot provide any assurances that we will retain our current customers, groups of customers or distributors, or that we will be able to attract and retain additional customers in the future. If for any reason we were to lose our ability to sell to a specific group or class of customers or through a distributor, we could experience a significant reduction in revenue, which would adversely impact our operating results.
Our sales could also be negatively affected by any rebates, discounts or fees that are required by, or offered to, GPOs and customers, including wholesalers or distributors. Additionally, some of our just-in-time distributors have been demanding higher fees, which we may be obligated to pay in order to continue to offer products to our customers through these distributors or which may obligate us to distribute our products directly to our customers. The loss of any large customer or distributor, an increase in distributor fees or the risks associated with selling directly to our customers could have a material adverse effect on our business, financial condition and results of operations.

51
Counterfeit Masimo sensors and third-party reprocessed single-patient-use Masimo sensors may harm our reputation. Also, these counterfeit and third-party reprocessed sensors, as well as genuine Masimo reprocessed sensors, are sold at lower prices than new Masimo sensors and could cause our revenue to decline, which may adversely affect our business, financial condition and results of operations.
We believe that other entities are manufacturing and selling counterfeit Masimo sensors. In addition, certain medical device reprocessors have been collecting our used single-patient-use sensors from hospitals and then reprocessing, repackaging and reselling those sensors to hospitals. These counterfeit and third-party reprocessed sensors are sold at lower prices than new Masimo sensors. Our experience with both these counterfeit sensors and third-party reprocessed sensors is that they provide inferior performance, increased sensor consumption, reduced comfort and a number of monitoring problems. Notwithstanding these limitations, some of our customers have indicated a willingness to purchase some of their sensor requirements from these counterfeit manufacturers and third-party reprocessors in an effort to reduce their sensor costs.
These counterfeit and reprocessed sensors have led and may continue to lead to confusion with our genuine Masimo products, have reduced and may continue to reduce our revenue, and, in some cases, have harmed and may continue to harm our reputation if customers conclude incorrectly that these counterfeit or reprocessed sensors are original Masimo sensors.
In addition, we have expended a significant amount of time and expense investigating issues caused by counterfeit and reprocessed sensors, troubleshooting problems stemming from such sensors, educating customers about why counterfeit and reprocessed sensors do not perform to their expectations, enforcing our proprietary rights against the counterfeit manufacturers and reprocessors, and enforcing our contractual rights.
In response to these counterfeit sensors and third-party reprocessors, we have incorporated X-Cal® technology into certain products to ensure our customers get the performance they expect by using genuine Masimo sensors and that such sensors do not continue to be used beyond their useful life. However, some customers may object to the X-Cal® technology, potentially resulting in the loss of customers and revenues.
We also offer our own Masimo reprocessed sensors, which meet the same performance specifications as our new Masimo sensors, to our customers. Reprocessed sensors sold by us are also offered at a lower price and, therefore, may reduce certain customer demand for our new sensors. As a result, increased sales of our own Masimo reprocessed sensors may result in lower revenues, which could negatively impact our business, financial condition and results of operations.
Risks Related to Our Intellectual Property
If the patents we own or license, or our other intellectual property rights, do not adequately protect our technologies, we may lose market share to our competitors and be unable to operate our business profitably.
Our success depends significantly on our ability to protect our rights to the technologies used in our products. Our utilization of patent protection, trade secrets and a combination of copyright and trademark laws, as well as nondisclosure, confidentiality and other contractual arrangements, to protect our intellectual property afford us only limited protection and may not adequately protect our rights or permit us to gain or maintain any competitive advantage.
Certain of our patents related to our technologies have begun to expire. Upon the expiration of our issued or licensed patents, we generally lose some of our rights to exclude competitors from making, using, selling or importing products using the technology based on the expired patents. Furthermore, in recent years, the U.S. Supreme Court has ruled on several patent cases and several laws have been enacted that, in certain situations, potentially narrow the scope of patent protection available and weaken the rights of patent owners. There can be no assurance that we will be successful in securing additional patents on commercially desirable improvements, that such additional patents will adequately protect our innovations or offset the effect of expiring patents, or that competitors will not be able to design around our patents.
In addition, third parties may challenge our issued patents through procedures such as Inter-Partes Review (IPR). In many IPR challenges, the U.S. Patent and Trademark Office (PTO) cancels or significantly narrows issued patent claims. IPR challenges could increase the uncertainties and costs associated with the maintenance, enforcement and defense of our issued and future patents and could have a material adverse effect on our business, financial condition and results of operations.
We also utilize unpatented proprietary technology and know-how and often rely on confidentiality agreements and intellectual property assignment agreements with our employees, OEM partners, independent distributors and consultants to protect such unpatented proprietary technology and know-how. However, such agreements may not be enforceable or may not provide meaningful protection for our proprietary information in the event of unauthorized use or disclosure or other breaches of the agreements, or in the event that our competitors discover or independently develop similar or identical designs or other proprietary information.
52
We rely on the use of registered and common law trademarks with respect to the brand names of some of our products. Common law trademarks provide less protection than registered trademarks. Loss of rights in our trademarks could adversely affect our business, financial condition and results of operations.
If third parties claim that we infringe their intellectual property rights, we may incur liabilities and costs and may have to redesign or discontinue selling certain products.
Searching for existing intellectual property rights may not reveal important intellectual property and our competitors may also have filed for patent protection, which may not be publicly-available information, or claimed trademark rights that have not been revealed through our searches. In addition, some of our employees were previously employed at other medical device companies. We may be subject to claims that our employees have disclosed, or that we have used, trade secrets or other proprietary information of our employees’ former employers. Our efforts to identify and avoid infringing on third parties’ intellectual property rights may not always be successful. Any claims of patent or other intellectual property infringement against us, even those without merit, could:
•be expensive and time-consuming to defend and result in payment of significant damages to third parties;
•force us to stop making or selling products that incorporate the intellectual property;
•require us to redesign, reengineer or rebrand our products, product candidates and technologies;
•require us to enter into royalty agreements that would increase the costs of our products;
•require us to indemnify third parties pursuant to contracts in which we have agreed to provide indemnification for intellectual property infringement claims;
•divert the attention of our management and other key employees; and
•result in our customers or potential customers deferring or limiting their purchase or use of the affected products impacted by the claims until the claims are resolved;
any of which could have a material adverse effect on our business, financial condition and results of operations. In addition, new patents obtained by our competitors could threaten the continued commercialization of our products in the market even after they have already been introduced.
We believe competitors may currently be violating and may in the future violate our intellectual property rights. As a result, we may initiate litigation to protect and enforce our intellectual property rights, which may result in substantial expense and may divert management’s attention from implementing our business strategy.
We believe that the success of our business depends, in part, on obtaining patent protection for our products and technologies, defending our patents and preserving our trade secrets. We were previously involved in significant litigation to protect our patent positions related to some of our pulse oximetry signal processing patents that resulted in various settlements. We believe some of the new market entrants in the healthcare and monitoring space, including some of the world’s largest technology companies, may be infringing our intellectual property, and we may be required to engage in additional litigation to protect our intellectual property in the future. In addition, we believe that certain individuals who previously held high level technical and clinical positions with us misappropriated our intellectual property for the benefit of themselves and other companies. For example, on January 9, 2020, we initiated litigation against Apple Inc. for infringement of a number of patents, for trade secret misappropriation and for ownership and correction of inventorship of a number of Apple, Inc. patents that list one of our former employees as an inventor. Our ongoing and future litigation could result in significant additional costs and further divert the attention of our management and key personnel from our business operations and the implementation of our business strategy and may not be successful or adequate to protect our intellectual property rights.
The laws of foreign countries may not adequately protect our intellectual property rights.
Intellectual property protection laws in foreign countries differ substantially from those in the U.S. If we fail to apply for intellectual property protection in foreign countries, or if we cannot adequately protect our intellectual property rights in these foreign countries, our competitors may be able to compete more effectively against us, which could adversely affect our competitive position, as well as our business, financial condition and results of operations.


53
Risks Related to Our Regulatory Environment
Our failure to obtain and maintain FDA clearances or approvals on a timely basis, or at all, would prevent us from commercializing our current, upgraded or new products in the U.S., which could severely harm our business.
Unless an exemption applies, each medical device that we market in the U.S. must first undergo premarket review pursuant to the Federal Food, Drug, and Cosmetic Act (FDCA) by receiving clearance of a 510(k) premarket notification, receiving clearance through the de novo classification review process or obtaining approval of a premarket approval (PMA) application. Even if regulatory clearance or approval of a product is granted, the U.S. Food and Drug Administration (FDA) may clear or approve our products only for limited indications for use. Additionally, the FDA may not grant 510(k) clearance on a timely basis, if at all, for new products or new uses that we propose for Masimo SET® or licensed rainbow® technology.
The traditional FDA 510(k) clearance process for our products has generally taken between four to nine months. However, our more recent experience and interactions with the FDA, along with information we have received from other medical device manufacturers, suggests that, in some cases, the FDA is requiring applicants to provide additional or different information and data for 510(k) clearance than it had previously required, and that the FDA may not rely on approaches that it had previously accepted to support 510(k) clearance. As a result, FDA 510(k) clearance can be delayed for our products in some cases.
To support our product applications to the FDA, we frequently are required to conduct clinical testing of our products. Such clinical testing must be conducted in compliance with FDA requirements pertaining to human research. Among other requirements, we must obtain informed consent from study subjects and approval by institutional review boards before such studies may begin. We must also comply with other FDA requirements such as monitoring, record-keeping, reporting and the submission of information regarding certain clinical trials to a public database maintained by the National Institutes of Health. In addition, if the study involves a significant risk device, we are required to obtain the FDA’s approval of the study under an Investigational Device Exemption (IDE). Compliance with these requirements can require significant time and resources. In addition, public health emergencies and other extraordinary circumstances may disrupt the conduct of our clinical trials. If the FDA determines that we have not complied with such requirements, the FDA may refuse to consider the data to support our applications or may initiate enforcement actions.
Even though 510(k) clearances have been obtained, if safety or effectiveness problems are identified with our products, we may need to initiate a recall of such products. Furthermore, our new products or significantly modified marketed products could be denied 510(k) clearance and be required to undergo the more burdensome PMA or de novo classification review processes. The process of obtaining a de novo classification or PMA approval is much more costly, lengthy and uncertain than the process for obtaining 510(k) clearance.
De novo classification review generally takes six months to one year from the time of submission of the de novo request, although it can take longer. Approval of a PMA generally takes one year from the time of submission of the PMA, but may be longer.
We sell consumer versions of our iSpO2® and MightySat® pulse oximeters that are not intended for medical use. Some of our products or product features may not be subject to the 510(k) process and/or other regulatory requirements in accordance with specific FDA guidance and policies, such as the FDA guidance related to mobile medical applications. In addition, some of our products or product features may not be subject to device regulation pursuant to Section 520(o) of the FDCA, which excludes certain software functions from the statutory definition of a device. In addition, we may market certain products pursuant to enforcement discretion policies the FDA has recently announced to address the need for these products as a result of the COVID-19 pandemic. Such policies only remain in effect during the public health emergency, such that we will need to seek clearance or approval of such products to continue marketing these products at the end of the COVID-19 pandemic. If the FDA changes its policies or concludes that our marketing of these products is not in accordance with its current policies and/or Section 520(o) of the FDCA, we may be required to seek clearance or approval of these devices through the 510(k), de novo classification review or PMA processes.
The failure of our OEM partners to obtain required FDA clearances or approvals for products that incorporate our technologies could have a negative impact on our revenue.
Our OEM partners are required to obtain their own FDA clearances in the U.S. for most products incorporating Masimo technologies. The FDA clearances we have obtained may not make it easier for our OEM partners to obtain clearances of products incorporating these technologies, or the FDA may not grant clearances on a timely basis, if at all, for any future products incorporating Masimo technologies that our OEM partners propose to market.
54
If we or our suppliers fail to comply with ongoing regulatory requirements, or if we experience unanticipated problems with our products, these products could be subject to restrictions or withdrawal from the market.
Our products, along with the manufacturing processes, labeling and promotional activities for our products, are subject to continual review and periodic inspections by the FDA and other regulatory bodies. Among other requirements, we and certain of our suppliers are required to comply with the FDA’s Quality System Regulation (QSR), which governs the methods and documentation of the design, control testing, production, component suppliers control, quality assurance, complaint handling, labeling control, packaging, storage and shipping of our products. The FDA enforces the QSR through announced and unannounced inspections. We are also subject to similar state requirements and licenses.
In addition to the FDA, from time to time we are subject to inspections by the California Food and Drug Branch, international regulatory authorities and other similar governmental agencies. The standards used by these regulatory authorities are complex and may differ from those used by the FDA.
Failure by us or one of our suppliers to comply with statutes and regulations administered by the FDA and other regulatory bodies or failure to adequately respond to any FDA Form 483 observations, any California Food and Drug Branch notices of violation or any similar reports could result in, among other things, any of the following:
•warning letters or untitled letters issued by the FDA;
•fines, civil penalties, in rem forfeiture proceedings, injunctions, consent decrees and criminal prosecution;
•import alerts;
•unanticipated expenditures to address or defend such actions;
•delays in clearing or approving, or refusal to clear or approve, our products;
•withdrawals or suspensions of clearance or approval of our products or those of our third-party suppliers by the FDA or other regulatory bodies;
•product recalls or seizures;
•orders for physician notification or device repair, replacement or refund;
•interruptions of production or inability to export to certain foreign countries; and
•operating restrictions.
If any of these events were to occur, it would harm our reputation and adversely affect our business, financial condition and results of operations.
Failure to obtain regulatory authorizations in foreign jurisdictions may prevent us from marketing our products abroad.
We currently market and intend to continue to market our products internationally. Outside of the U.S., we can generally market a product only if we receive a marketing authorization (and/or meet certain pre-marketing requirements) and, in some cases, pricing approval, from the appropriate regulatory authorities. The regulatory registration/licensing process varies among international jurisdictions and may require additional or different product testing than required to obtain FDA clearance. FDA clearance does not ensure new product registration/licensing by foreign regulatory authorities, and we may be unable to obtain foreign regulatory registration/licensing on a timely basis, if at all.
In addition, clearance by one foreign regulatory authority does not ensure clearance by any other foreign regulatory authority or by the FDA. If we fail to receive necessary approvals to commercialize our products in foreign jurisdictions on a timely basis, or at all, our business, financial condition and results of operations could be adversely affected.
Furthermore, foreign regulatory requirements may change from time to time, which could adversely affect our ability to market new products, and/or continue to market existing products, internationally. Certain significant changes in the international regulatory landscape have recently taken place or will take place in the near future. These include the new European Union Medical Devices Regulation (EU) 2017/745 (MDR), which came into effect on May 26, 2021 and a new regulatory regime in the UK effective as of January 1, 2021 as a result of the UK’s exit from the EU and the expiry of the transitional periods, on December 31, 2020 (Brexit).

55
Modifications to our marketed devices may require new regulatory clearances or premarket approvals, or may require us to cease marketing or to recall the modified devices until clearances or approvals are obtained.
We have made modifications to our devices in the past and we may make additional modifications in the future. Any modification to a device that is cleared by the FDA that could significantly affect its safety or effectiveness or that could constitute a major change in its intended use would require a new clearance or approval and certain modifications to devices cleared or approved by foreign regulatory authorities may also require a new clearance or approval.
We may not be able to obtain such clearances or approvals in a timely fashion, or at all. Delays in obtaining future clearances would adversely affect our ability to introduce new or enhanced products in a timely manner, which in turn would have an adverse effect on our business, financial condition and results of operations.
For device modifications that we conclude do not require a new regulatory clearance or approval, we may be required to recall and to stop marketing the modified devices if the government agency disagrees with our conclusion and requires new clearances or approvals for the modifications. This could have an adverse effect on our business, financial condition and results of operations.
During the COVID-19 pandemic, the FDA has issued enforcement policies under which the agency has said it will not require clearance of a new 510(k) for certain modifications to 510(k)-cleared non-invasive vital-sign patient monitoring devices. However, these policies remain in effect only during the COVID-19 pandemic. Manufacturers that make modifications pursuant to these policies will need to stop marketing the modifications at the end of the COVID-19 pandemic unless the manufacturer receives 510(k) clearance for the modifications.
Regulatory reforms may impact our ability to develop and commercialize our products and technologies.
From time to time, legislation is drafted and introduced by governments that could significantly change the statutory provisions governing the clearance or approval, manufacture and marketing of medical devices. For example, in August 2017, Congress enacted the FDA Reauthorization Act of 2017 (FDARA). FDARA reauthorized the FDA to collect device user fees, including a new user fee for de novo classification requests, and contained substantive amendments to the device provisions of the FDCA. Among other changes, FDARA required that the FDA update and revise its processes for scheduling inspections of device establishments, communicating about those inspections with manufacturers and providing feedback on the manufacturer’s responses to Form 483s. The statute also required that the FDA study the impact of device servicing, including third-party services, and created a new process for device sponsors to request classification of accessory devices as part of the PMA application for the parent device or to request a separate classification of accessory devices.
In addition, regulations and guidance are often revised or reinterpreted by the government agency in ways that may significantly affect our business or products. Future regulatory changes could make it more difficult for us to obtain or maintain approval to develop and commercialize our products and technologies. Public health emergencies may also prompt temporary or permanent regulatory reforms that could change the processes governing the clearance or approval, manufacture and marketing of medical devices.
In the EU, for example, the MDR became applicable to our medical devices from May 26, 2021. The MDR requires medical devices and their manufacturers to comply with more stringent standards than before. The MDR also imposes new and enhanced obligations on importers and distributors of medical devices in the EU. Although the MDR is subject to certain transitional periods, both we and others involved in the distribution and commercialization of our medical devices in the EU will need to comply with more stringent EU rules.
Due to Brexit, from January 1, 2021, a new regulatory framework applies to medical devices commercialized in Great Britain (England, Scotland and Wales). This is now separate from the regime in the EU. Although certain transition periods apply until June 30, 2023, the medical devices we intend to commercialize in Great Britain will need to conform to different requirements than the requirements in the EU. These factors are likely to add more complexity to our regulatory compliance obligations in Europe and our ability to commercialize medical devices in European markets.

56
*If our products cause or contribute to a death or serious injury, or malfunction in a way that would likely cause or contribute to a death or serious injury, we will be subject to medical device reporting regulations, and may need to initiate voluntary corrective actions or in certain circumstances be required to take corrective actions, such as the recall of our products.
Regulatory agencies in many countries require us to report anytime our products cause or contribute to a death or serious injury, or malfunction in a way that would likely cause or contribute to a death or serious injury. For example, under the FDA medical device reporting regulations, we are required to report to the FDA any incident in which a product of ours may have caused or contributed to a death or serious injury or in which a product of ours malfunctioned and, if the malfunction were to recur, would be likely to cause or contribute to death or serious injury. In addition, all manufacturers placing medical devices on the market in the EU are legally required to report any serious or potentially serious incidents involving devices produced or sold by the manufacturer to the relevant authority in those jurisdictions where any such incident occurred.
The FDA and similar foreign regulatory authorities have the authority to require the recall of our commercialized products in the event of material deficiencies or defects in, for example, design, labeling or manufacture. The FDA must find that there is a reasonable probability that the device would cause serious adverse health consequences or death in order to require a recall. The standard for recalling deficient products may be different in foreign jurisdictions. Manufacturers may, under their own initiative, recall a product if any material deficiency is found in a device or they become aware of a safety issue involving a marketed product. A government-mandated or voluntary recall by us or by one of our distributors could occur as a result of component failures, manufacturing errors, design or labeling defects or other deficiencies and issues.
We may initiate certain field actions, such as a product correction or removal of our products in the future. In addition, third parties that commercialize products incorporating our technologies may initiate similar actions or product corrections. Any correction or removal initiated by us to reduce a health risk posed by our device, or to remedy a violation of the FDCA or other regulations caused by the device that may present a risk to health, must be reported to the FDA. If the FDA subsequently determines that a report was required for a correction or removal of our products that we did not believe required a report, we could be subject to enforcement actions.
Any recalls or corrections of our products or third party products that incorporate our technologies, or enforcement actions would divert managerial and financial resources and could have an adverse effect on our financial condition and results of operations. In addition, given our dependence upon patient and physician perceptions, any negative publicity associated with any recalls could materially and adversely affect our business, financial condition, results of operations and growth prospects.
Promotion of our products using claims that are off-label, unsubstantiated, false or misleading could subject us to substantial penalties.
Obtaining 510(k) clearance permits us to promote our products for the uses cleared by the FDA. Use or promotion of a device outside its cleared or approved indications is known as “off-label” use or promotion, respectively. Physicians may use our products off-label because the FDA does not restrict or regulate a physician’s choice of treatment within the practice of medicine, but we may not promote our products “off-label.” While we may request additional cleared indications for our current products, the FDA may deny those requests, require additional expensive clinical data to support any additional indications or impose limitations on the intended use of any cleared product as a condition of clearance. If the FDA determines that our products were promoted for off-label use or that false, misleading or inadequately substantiated promotional claims have been made by us or our OEM partners, it could request that we or our OEM partners modify those promotional materials or it could take regulatory or enforcement actions, including the issuance of an untitled letter, warning letter, injunction, seizure, civil fine and criminal penalties. While certain U.S. courts have held that truthful, non-misleading, off-label information is protected under the First Amendment under certain circumstances, the FDA continues to take the position that off-label promotion is subject to enforcement action.
It is also possible that other federal, state or foreign enforcement authorities may take action if they consider our communications, including promotional or training materials, to constitute promotion of an uncleared or unapproved use. If not successfully defended, enforcement actions related to off-label promotion could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement. In any such event, our reputation could be damaged, adoption of our products could be impaired and we could be subject to extensive fines and penalties.
Additionally, we must have adequate substantiation for the claims we make for our products. If any of our claims are determined to be false, misleading or deceptive, our products could be considered misbranded under the FDCA or in violation of the Federal Trade Commission Act. We could also face lawsuits from our competitors under the Lanham Act alleging that our marketing materials are false or misleading.
57
The regulatory environment governing information, cybersecurity and privacy is increasingly demanding and continues to evolve.
Personal privacy and data security have become significant issues in the U.S., Europe and many other jurisdictions where we offer our products. The regulatory framework for privacy and security issues worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future.
Certain U.S. and foreign laws, such as the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), govern the transmission, security and privacy of individually identifiable information and sensitive health and other personal information that we may obtain or have access to in connection with the operation of our business, including the conduct of clinical research trials or other research studies that may provide us with access to this information. We may be required to make costly system modifications to comply with these data privacy and security requirements. In addition, if we do not properly comply with applicable laws and regulations related to the protection of this information, we could be subject to criminal or civil sanctions. The California Consumer Privacy Act of 2018 (CCPA), which became effective on January 1, 2020, requires us to make new disclosures to consumers about our data collection, use and sharing practices. The CCPA also allows consumers to opt out of certain data sales to third parties, affords new consumer rights, and provides a new cause of action for data breaches with the possibility of significant statutory damage awards as well as injunctive or declaratory relief if there has been unauthorized access, theft or disclosure of specified personal information due to failure to implement reasonable security procedures. Other U.S. states have implemented or are in the process of implementing analogous legislation. The impact of the CCPA and these other state legislations on our business is yet to be determined, but it could result in increased operating expenses as well as additional exposure to the risk of litigation by or on behalf of consumers.
Internationally, the General Data Protection Regulation (GDPR) took effect in May 2018 within the European Economic Area (EEA), and many EEA jurisdictions have also adopted their own data privacy and protection laws in addition to the GDPR. Furthermore, other international jurisdictions, including Singapore, South Korea, China, Brazil, Mexico and Australia, have also implemented laws relating to data privacy and protection. Although we believe that we are complying with the GDPR and similar laws, these laws are still relatively new. Therefore, as international data privacy and protection laws continue to evolve, and as new regulations, interpretive guidance and enforcement information become available, we may incur incremental costs to modify our business practices to comply with these requirements. In addition, our internal control policies and procedures may not always protect us from reckless, intentional or criminal acts committed by our employees or agents.
Violations of these laws, or allegations of such violations, could subject us to monetary and non-monetary penalties for noncompliance, disrupt our operations, involve significant management distraction, subject us to class action lawsuits and result in a material adverse effect on our business, financial condition and results of operations.
We may be subject to or otherwise affected by federal and state healthcare laws, including fraud and abuse laws, and could face substantial penalties if we are unable to fully comply with these laws.
Healthcare fraud and abuse laws potentially applicable to our operations include, but are not limited to:
•the federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving any bribe, kickback or other remuneration intended to induce the purchase, order or recommendation of an item or service reimbursable under a federal healthcare program (such as the Medicare or Medicaid programs);
•the federal False Claims Act and other federal laws which prohibit, among other things, knowingly and willfully presenting, or causing to be presented, claims for payment from Medicare, Medicaid, other government payers or other third-party payers that are false or fraudulent;
•the Physician Payments Sunshine Act, which requires medical device companies to track and publicly report, with limited exceptions, all payments and transfers of value to physicians and teaching hospitals in the U.S.; and
•state laws analogous to each of the above federal laws, such as state anti-kickback and false claims laws that may apply to items or services reimbursed by governmental programs and non-governmental third-party payers, including commercial insurers.
If we are found to have violated any such laws or other similar governmental regulations, including their foreign counterparts, that are directly or indirectly applicable to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion of our products from reimbursement under Medicare, Medicaid and other federal healthcare programs, and the curtailment or restructuring of our operations. Any penalties could adversely affect our ability to operate our business and our financial results. Any action against us for violation of these laws, even if we successfully defend against such action, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business.
58
Legislative and regulatory changes in the healthcare industry could have a negative impact on our financial performance. Furthermore, our business, financial condition, results of operations and cash flows could be significantly and adversely affected by healthcare reform legislation in the U.S. or in our key international markets.
Changes in the healthcare industry in the U.S. and abroad could adversely affect the demand for our products and the way in which we conduct our business. For example, the Patient Protection and Affordable Care Act (the ACA), enacted in 2010, required most individuals to have health insurance, established new regulations on health plans, created insurance-pooling mechanisms and reduced Medicare spending on services provided by hospitals and other providers. The long-term viability of the ACA, and its impact on our business and results of operations, remains uncertain. There have also been recent U.S. Congressional actions to repeal and replace the ACA, and future actions are expected. For example, the Tax Cuts and Jobs Act of 2017 (TCJA), among other things, eliminated the individual mandate requiring most Americans (other than those who qualify for a hardship exemption) to carry a minimum level of health coverage effective January 1, 2019.
In December 2018, a federal district court judge in Texas found the ACA’s individual mandate to be unconstitutional; and therefore, the entire law to be invalid. In December 2019, the Fifth Circuit affirmed the ruling regarding the individual mandate but remanded the case to the district court for additional analysis of the question of severability and whether portions of the law remain valid. In June 2021, the U.S. Supreme Court held that the states and individuals that brought the lawsuit do not have standing to challenge the law, effectively ending the case without ruling on the constitutionality of the individual mandate. Although we cannot predict the ultimate content or timing of any healthcare reform legislation or court challenges to the ACA, potential changes resulting from any amendment, repeal, replacement or invalidation of these programs, including any reduction in the future availability of healthcare insurance benefits, may decrease the number of people who are insured, which could adversely affect our business and future results of operations.
Our medical devices and business activities are subject to rigorous regulation by the FDA and other federal, state and international governmental authorities. These authorities and members of Congress have been increasing their scrutiny over the medical device industry. In recent years, Congress, the Department of Justice, the Office of Inspector General of the Department of Health and Human Services and the Department of Defense have issued subpoenas and other requests for information to medical device manufacturers, primarily related to financial arrangements with healthcare providers, regulatory compliance and marketing and product promotional practices. Furthermore, certain state governments have enacted legislation to limit and/or increase transparency of interactions with healthcare providers, pursuant to which we are required by law to disclose payments and other transfers of value to healthcare providers licensed by certain states.
We anticipate that the government will continue to scrutinize our industry closely, and any new regulations or statutory provisions could result in delays or increased costs during the periods of product development, clinical trials and regulatory review and approval, as well as increased costs to assure compliance.
59
Risks Related to Our Business and Operations
*Our business, financial condition and results of operations may be adversely affected by the COVID-19 pandemic.
In December 2019, COVID-19 was reported to have surfaced in Wuhan, China and has since spread to many other countries, including the United States, where we have our principal executive offices and principal operations, Switzerland, where we have our international headquarters, and Mexico, where we have significant manufacturing operations. Government-imposed travel restrictions have resulted, and may continue to result, in direct operational and administrative disruptions to our domestic and foreign facilities. In addition, quarantines, shelter-in-place and similar orders by local governments have impacted and could further impact the productivity of our manufacturing, engineering, sales and administrative staff and facilities in the United States and other countries. Our operations would be disrupted if any of our employees or employees of our business partners were suspected of having contracted COVID-19, which could require quarantine of some or all such employees or closure of our facilities for disinfection.
Although the pace of the COVID-19 pandemic has recently slowed in the U.S. and certain other jurisdictions where we operate, our business operations could be further delayed or interrupted in countries that are still experiencing high levels of infections. Further, any resurgence in infections in the U.S. or other countries where government restrictions have been fully or partially lifted could result in a re-imposition of such restrictions, causing renewed disruptions to our business. In the event that government and health authorities announce new or extend existing restrictions or vaccine or testing mandates, we may be required to make further adjustments to our operations in order to comply with any such restrictions. For example, on September 9, 2021, the President of the United States issued Executive Order (EO) 14042, requiring that employees of federal contractors and subcontractors be fully vaccinated against COVID-19. Masimo is a federal contractor and therefore we are required to mandate COVID-19 vaccines for our employees. The President of the United States also directed the Federal Occupational Safety and Health Administration (Fed-OSHA) to issue Emergency Temporary Standards (ETS) that will direct large employers (those with 100+ employees) to mandate COVID-19 vaccinations for their employees. Fed-OSHA has not yet issued the ETS, so we are not yet able to determine what the ETS will require or how they might affect our business and operations. Though it is difficult to predict the impact of the EO mandate, we may experience workforce constraints due to shortages of vaccinated personnel, strains on the labor market, limitations on hiring new employees and, difficulty retaining and securing employees who are vaccinated, all of which could negatively affect our business and operations.
Furthermore, global supply chains and the timely availability of raw materials, component parts and products may be materially disrupted by the COVID-19 pandemic and measures taken to combat COVID-19, such as quarantines, government mandates surrounding vaccinations, factory slowdowns or shutdowns, border closings and travel restrictions. In addition, our suppliers have experienced, and may continue to experience, difficulties in delivering raw materials, components and products to us as transportation networks and distribution facilities have been disrupted, resulting in delays at ports of arrival. Furthermore, the availability of shipping containers has decreased and there have been global changes in the types of goods being shipped, all of which have resulted in increased shipping costs, which may affect the availability of raw materials, component parts and products to meet our sales demand. For example, we utilize semiconductor chips in certain products that we manufacture. Semiconductor chips have been recently subject to an ongoing global supply shortage and our ability to source semiconductor chips or the components that use semiconductor chips may be adversely affected in the future. Component delivery lead times have increased and are expected to continue to increase, which may cause delays in our production of products and increase the cost to obtain semiconductor chips and components that use semiconductor chips. If this semiconductor chip shortage or shortages of other component parts continues, we may experience delays, production interruptions, increased costs and an inability to fulfill engineering design changes or customer demand, each of which could adversely affect our business and financial performance.
The adverse effects of the COVID-19 pandemic on our business could be material in future periods, particularly if there are significant and prolonged economic slowdowns in regions where we derive a significant amount of our revenue or profit, or where our suppliers are located, or if we are forced to close facilities and limit or cease manufacturing operations for extended periods of time. We could also experience delays in receipt of customer payments. In addition, our ability to fulfill orders placed with us within the order’s specified time line and for the cost we estimated when we accepted the order may be negatively affected. Furthermore, we have experienced unusual fluctuations in the demand for our products throughout the COVID-19 pandemic and we may continue to experience these fluctuations for the foreseeable future. These factors could lead to a reduction in revenues, unfavorable gross margin impact due to product mix, and/or a delay in cash flows in future periods and have a material adverse effect on our business, financial condition and results of operations.


60
The COVID-19 pandemic has also led to extreme volatility in capital markets and a decline in interest rates, and has adversely affected, and may continue to adversely affect, the market price of our common stock. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic may be difficult to assess or predict, a continued or widespread pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could negatively affect our liquidity in the future. The extent to which COVID-19 impacts our business and financial results continues to depend on numerous evolving factors that we may not be able to accurately predict.
*If our employees become ill or otherwise incapacitated, our operations may be adversely impacted.
At the outset of the COVID-19 pandemic, we implemented telework policies wherever possible for appropriate categories of employees in response to various stay at home/shelter in place orders (Stay at Home Orders) implemented by state and local governments. In response to the lifting or partial lifting of the Stay at Home Orders, we have reopened our facilities to both “nonessential” and “essential” employees. We have implemented a number of safety measures for our facilities, including social distancing, face covering, temperature checking and increased sanitation standards. We are following guidance from the Center for Disease Control and the Occupational Safety and Health Administration regarding suspension of nonessential travel, self-isolation recommendations for employees returning from certain geographic areas, confirmed reports of any COVID-19 diagnosis among our employees and the return of such employees to our workplace. Pursuant to updated guidance from the Equal Employment Opportunity Commission, we are engaging in limited and appropriate inquiries of employees regarding potential COVID-19 exposure, based on the direct threat that such exposure may present to our workforce. While we have developed and implemented, and continue to develop and implement, health and safety guidelines in an effort to try to mitigate the negative impact of COVID-19, there can be no assurances that our measures will be sufficient to protect our employees in our workplace or that our employees will not otherwise be exposed to COVID-19 outside of our workplace. If a number of our employees become ill, incapacitated or are otherwise unable to continue working during the current or any future pandemic or epidemic, our operations may be adversely impacted.
We may experience conflicts of interest with Cercacor with respect to business opportunities and other matters.
Prior to our initial public offering in August 2007, our stockholders owned 99% of the outstanding shares of capital stock of Cercacor, and we believe that a number of our stockholders, including certain of our directors and executive officers, continue to own shares of Cercacor stock. Joe Kiani, our Chairman and Chief Executive Officer (CEO), is also the Chairman and CEO of Cercacor.
Due to the interrelated nature of Cercacor with us, conflicts of interest may arise with respect to: transactions involving business dealings between us and Cercacor, potential acquisitions of businesses or products, the development and ownership of technologies and products, the sale of products, markets and other matters in which our best interests and the best interests of our stockholders may conflict with the best interests of the stockholders of Cercacor. In addition, we and Cercacor may disagree regarding the interpretation of certain terms in the Cross-Licensing Agreement. We cannot guarantee that any conflict of interest will be resolved in our favor, or that, with respect to our transactions with Cercacor, we will negotiate terms that are as favorable to us as if such transactions were with another third-party.
We will be required to assign to Cercacor and pay Cercacor for the right to use certain products and technologies we develop that relate to the monitoring of non-vital sign parameters, including improvements to Masimo SET®.
Under the Cross-Licensing Agreement, if we develop certain products or technologies that relate to the noninvasive monitoring of non-vital sign parameters, including improvements to Masimo SET® for the noninvasive monitoring of non-vital sign parameters, we would be required to assign these developments to Cercacor and then license the technology back from Cercacor in consideration for upfront payments and royalty obligations to Cercacor. Therefore, these products and technologies would be deemed to have been developed or improved exclusively by Cercacor.
In addition, we will not be reimbursed by Cercacor for our expenses relating to the development or improvement of any such products or technologies, which expenses may be significant. As a result of these terms, we may not generate any revenue from the further development of certain products and technologies for the monitoring of non-vital sign parameters, including improvements to Masimo SET®, which could adversely affect our business, financial condition and results of operations.
61
In the event that the Cross-Licensing Agreement is terminated for any reason, or Cercacor grants a license to rainbow® technology to a third-party, our business would be adversely affected.
Cercacor owns all of the proprietary rights to certain rainbow® technology developed with our proprietary Masimo SET® for products intended to be used in the “Cercacor Market”, and all rights to any non-vital signs measurement for which we do not exercise an option pursuant to the Cross-Licensing Agreement. In addition, Cercacor has the right to terminate the Cross-Licensing Agreement or grant licenses covering rainbow® technology to third parties if we breach certain terms of the agreement, including any failure to meet our minimum royalty payment obligations or failure to use commercially reasonable efforts to develop or market products incorporating licensed rainbow® technology. If we lose our exclusive license to rainbow® technology, we would lose the ability to prevent others from making, using, selling or importing products using rainbow® technology in our market. As a result, we would likely be subject to increased competition within our market, and Cercacor or competitors who obtain a license to rainbow® technology from Cercacor would be able to offer related products.
We may not be able to commercialize our products incorporating licensed rainbow® technology cost-effectively or successfully.
As a result of the royalties that we must pay to Cercacor, it is generally more expensive for us to make products that incorporate licensed rainbow® technology than products that do not include licensed rainbow® technology.
We cannot assure that we will be able to sell products incorporating licensed rainbow® technology at a price the market is willing to accept. If we cannot commercialize our products incorporating licensed rainbow® technology successfully, we may not be able to generate sufficient product revenue from these products to be profitable, which could adversely affect our business, financial condition and results of operations.
Rights provided to Cercacor in the Cross-Licensing Agreement may impede a change in control of our company.
Under the Cross-Licensing Agreement, a change in control includes the resignation or termination of Joe Kiani from his position as CEO of either Masimo or Cercacor. A change in control also includes other customary events, such as the sale or merger of Masimo or Cercacor to a non-affiliated third-party or the acquisition of 50% or more of the voting power of Masimo or Cercacor by a non-affiliated third-party. In the event we undergo a change in control, we are required to immediately pay a $2.5 million fee to exercise an option to license technology developed by Cercacor for use in blood glucose monitoring.
Additionally, our per product royalties payable to Cercacor will become subject to specified minimums, and the minimum aggregate annual royalties for licensed rainbow® measurements payable to Cercacor related to carbon monoxide, methemoglobin, fractional arterial oxygen saturation, hemoglobin and blood glucose will increase to $15.0 million, plus up to $2.0 million for other rainbow® measurements. Also, if the surviving or acquiring entity ceases to use “Masimo” as a company name and trademark following a change in control, all rights to the “Masimo” trademark will automatically be assigned to Cercacor. This could delay or discourage transactions involving an actual or potential change in control of us, including transactions in which our stockholders might otherwise receive a premium for their shares over our then-current trading price. In addition, our requirement to assign all future improvements for non-vital signs to Cercacor could impede a change in control of our company.
If we are unable to obtain key materials and components from sole or limited source suppliers, we will not be able to deliver our products to customers.
We depend on certain sole or limited source suppliers for certain key materials and components, including digital signal processor chips and analog-to-digital converter chips, for our noninvasive patient monitoring solutions. These suppliers are located around the world, and the production and shipment of such materials and components may be constrained globally due to the COVID-19 pandemic. We may experience manufacturing problems related to these suppliers and other outside sources if such suppliers fail to develop, manufacture or ship products and components to us on a timely basis, or provide us with products and components that do not meet our quality standards and required quantities. In addition, from time to time there have been industry-wide shortages of certain components that we use in our noninvasive blood constituent patient monitoring solutions. We may also experience price increases for materials or components, with no guarantee that such increases can be passed along to our customers, which could adversely impact our gross margins.
If any of these problems occur, we may be unable to obtain substitute sources for these products and components on a timely basis or on terms acceptable to us, which could harm our ability to manufacture our own products and components profitably or on time.
62
Future strategic initiatives, including acquisitions of businesses and strategic investments, could negatively affect our business, financial condition and results of operations if we fail to integrate the acquired businesses successfully into our existing operations or achieve the desired results of our investment.
We have acquired several businesses since our inception and we may acquire additional businesses in the future. Future acquisitions may require debt or equity financing, which could be dilutive to our existing stockholders or reduce our earnings per share. Even if we complete acquisitions, there are many factors that could affect whether such acquisition will be beneficial to our business, including, without limitation:
•payment of above-market prices for acquisitions and higher than anticipated acquisition costs;
•issuance of common stock as part of the acquisition price or a need to issue stock options or other equity to newly-hired employees of target companies, resulting in dilution of ownership to our existing stockholders;
•reduced profitability if an acquisition is not accretive to our business over either the short-term or the long-term;
•difficulties in integrating any acquired companies, personnel, products and other assets into our existing business;
•delays in realizing the benefits of the acquired company, products or other assets;
•regulatory challenges;
•cybersecurity and compliance-related issues;
•diversion of our management’s time and attention from other business concerns;
•limited or no direct prior experience in new markets or countries we may enter;
•unanticipated issues dealing with unfamiliar suppliers, service providers or other collaborators of the acquired company;
•higher costs of integration than we anticipated;
•write-downs or impairments of goodwill or other intangible assets associated with the acquired company;
•difficulties in retaining key employees of the acquired business who are necessary to manage these acquisitions;
•negative impacts on our relationships with our employees, clients or collaborators;
•litigation, other claims or liabilities in connection with the acquisition; and
•changes in the overall financial model as certain acquired companies may have a different revenue, gross profit margin or operating expense profile.
Further, our ability to benefit from future acquisitions and/or external strategic investments depends on our ability to successfully conduct due diligence, negotiate acceptable terms, evaluate prospective opportunities and bring acquired technologies and/or products to market at acceptable margins and operating expense levels. For example, we acquired TNI medical AG® (TNI®) and added softFlow® technology to our product portfolio. In addition, we acquired LiDCO Group, Plc, which specializes in hemodynamic monitoring solutions. As these are our first therapeutic and hemodynamic monitoring solutions, the integration of these technologies may require substantial management time and attention and may divert attention and resources from other important areas, including our existing business and product lines, and we may not be able to sell the softFlow® technology and hemodynamic monitoring solutions at acceptable margins and operating expense levels. Our failure in any of these tasks could result in unforeseen liabilities associated with an acquired company, acquiring a company on unfavorable terms or selecting and eventually acquiring a suboptimal acquisition target.
We may also discover deficiencies in internal controls, data adequacy and integrity, product quality, regulatory compliance, product liabilities or other undisclosed liabilities that we did not uncover prior to our acquisition or investment, which could result in us becoming subject to penalties, other liabilities or asset impairments. In addition, if we do not achieve the anticipated benefits of an acquisition or other external investment as rapidly as expected, or at all, investors or analysts may downgrade our stock.
We also expect to continue to carry out internal strategic initiatives that we believe are necessary to grow our revenues and expand our business, both in the U.S. and abroad. For example, we have continued to invest in international expansion programs designed to increase our worldwide presence and take advantage of market expansion opportunities around the world. Although we believe our investments in these initiatives continue to be in the long-term best interests of Masimo and our stockholders, there are no assurances that such initiatives will yield favorable results for us. Accordingly, if these initiatives are not successful, our business, financial condition and results of operations could be adversely affected.
If these risks materialize, our stock price could be materially adversely affected. Any difficulties in the integration of acquired businesses or unexpected penalties, liabilities or asset impairments in connection with such acquisitions or investments could have a material adverse effect on our business, financial condition and results of operations.
63
Our credit agreement contains certain covenants and restrictions that may limit our flexibility in operating our business.
Our credit agreement dated December 17, 2018 (Credit Facility) with JPMorgan Chase Bank, N.A., as Administrative Agent and a lender, and Bank of the West, a lender (each and both, Lender(s)), contains various affirmative covenants and restrictions that limit our ability to engage in specified types of transactions, including:
•incurring specified types of additional indebtedness (including guarantees or other contingent obligations);
•paying dividends on, repurchasing or making distributions in respect of our common stock or making other restricted payments, subject to specified exceptions;
•making specified investments (including loans and advances);
•selling or transferring certain assets;
•creating certain liens;
•consolidating, merging, selling or otherwise disposing of all or substantially all of our assets; and
•entering into certain transactions with any of our affiliates.
In addition, under our Credit Facility, we are required to satisfy and maintain specified financial ratios and other affirmative covenants. Our ability to meet those financial ratios and affirmative covenants could be affected by events beyond our control and, therefore, we cannot be assured that we will be able to continue to satisfy these requirements. A breach of any of these ratios or covenants could result in a default under our Credit Facility. Upon the occurrence of an event of default, the Lenders could elect to declare all amounts outstanding under the Credit Facility immediately due and payable, terminate all commitments to extend further credit and pursue legal remedies for recovery, all of which could adversely affect our business and financial condition. See Note 15 to our accompanying condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q for additional information on our Credit Facility.

Risks Related to Our Stock
Concentration of ownership of our stock among our existing directors, executive officers and principal stockholders may prevent new investors from influencing significant corporate decisions.
As of October 2, 2021, our current directors and executive officers and their affiliates, in the aggregate, beneficially owned approximately 9.1% of our outstanding stock. Subject to any fiduciary duties owed to our other stockholders under Delaware law, these stockholders may be able to exercise significant influence over matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions, and will have some control over our management and policies in their roles as stockholders. Some of these persons or entities may have interests that are different from yours. For example, these stockholders may support proposals and actions with which you may disagree or which are not in your best interests.
The concentration of ownership could delay or prevent a change in control of us, or otherwise discourage a potential acquirer from attempting to obtain control of us, which in turn could reduce the price of our stock.
In addition, these stockholders could use their voting influence to maintain our existing management and directors in office or support or reject other management and Board of Directors (Board) proposals that are subject to stockholder approval, such as amendments to our employee stock plans and approvals of significant financing transactions.
Our corporate documents and Delaware law contain provisions that could discourage, delay or prevent a change in control of our company, prevent attempts to replace or remove current management and reduce the market price of our stock.
Provisions in our certificate of incorporation and bylaws may discourage, delay or prevent a merger or acquisition involving us that our stockholders may consider favorable. For example, our certificate of incorporation authorizes our Board to issue up to 5.0 million shares of “blank check” preferred stock. As a result, without further stockholder approval, our Board has the authority to attach special rights, including voting and dividend rights, to this preferred stock, including pursuant to a stockholder rights plan. With these rights, preferred stockholders could make it more difficult for a third-party to acquire us.

64
In addition, our certificate of incorporation provides for a staggered Board, whereby directors serve for three-year terms, with one-third of the directors coming up for reelection each year. A staggered Board will make it more difficult for a third-party to obtain control of our Board through a proxy contest, which may be a necessary step in an acquisition of us that is not favored by our Board.
We are also subject to anti-takeover provisions under the General Corporation Law of the State of Delaware. Under these provisions, if anyone becomes an “interested stockholder,” we may not enter into a “business combination” with that person for three years without special approval, which could discourage a third-party from making a takeover offer and could delay or prevent a change in control of us. For purposes of these provisions, an “interested stockholder” generally means someone owning 15% or more of our outstanding voting stock or an affiliate of ours that owned 15% or more of our outstanding voting stock during the past three years, subject to certain exceptions as described in the General Corporation Law of the State of Delaware.
Our bylaws provide that the state or federal courts located within the State of Delaware are the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
Our bylaws provide that the state or federal courts located within the State of Delaware are the sole and exclusive forum for: (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of fiduciary duty owed by any of our directors, officers or other employees or stockholders to our stockholders, (iii) any action asserting a claim against us arising pursuant to the General Corporation Law of the State of Delaware, our certificate of incorporation or our bylaws or as to which the General Corporation Law of the State of Delaware confers jurisdiction on the Court of Chancery of the State of Delaware, or (iv) any action asserting a claim governed by the internal affairs doctrine. However, this choice of forum provision does not apply to (a) actions in which the Court of Chancery in the State of Delaware concludes that an indispensable party is not subject to the jurisdiction of Delaware courts, or (b) actions in which a federal court has assumed exclusive jurisdiction to a proceeding. This choice of forum provision is not intended to apply to any actions brought under the Securities Act of 1933, as amended (the Securities Act), or the Securities Exchange Act of 1934, as amended (the Exchange Act). Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. As a result, the exclusive forum provision will not apply to suits brought to enforce any duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. This choice of forum provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees or stockholders, which may discourage such lawsuits against us and our directors, officers and other employees or stockholders.
Furthermore, the enforceability of similar choice of forum provisions in other companies’ certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find the choice of forum provision in our bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business, financial condition and results of operations.
General Risk Factors
We may experience significant fluctuations in our periodic financial results and may not maintain our current levels of profitability in the future.
Our operating results have fluctuated in the past and are likely to fluctuate in the future. Many of the countries in which we operate, including the U.S. and several of the members of the EU, have experienced and continue to experience uncertain economic conditions resulting from global as well as local factors. In addition, continuing strength and growth in the U.S. economy may raise the probability of inflationary pressures and contribute to future interest rate volatility.
Our business or financial results may be adversely impacted by these uncertain economic conditions, including: adverse changes in interest rates, foreign currency exchange rates, tax laws or tax rates; inflation; contraction in the availability of credit in the marketplace due to legislation or other economic conditions, which may potentially impair our ability to access the capital markets on terms acceptable to us or at all; and the effects of government initiatives to manage economic conditions.
We are also unable to predict how changing global economic conditions or potential global health concerns such as the COVID-19 pandemic will affect our critical customers, suppliers and distributors. Any negative impact of such matters on our critical customers, suppliers or distributors may also have an adverse impact on our results of operations or financial condition. Our expense levels are based, in part, on our expectations regarding future revenue levels and are relatively fixed in the short term.
65
As a result, if our revenue for a particular period was below our expectations, we would not be able to proportionately reduce our operating expenses for that period. Any revenue shortfall would have a disproportionately negative effect on our operating results for the period.
In addition, the methods, estimates and judgments that we use in applying our accounting policies are, by their nature, subject to substantial risks, uncertainties and assumptions. Factors may arise over time that lead us to change our methods, estimates and judgments, the impact of which could significantly affect our results of operations. See “Critical Accounting Policies and Estimates” contained in Part I, Item 2 of this Quarterly Report on Form 10-Q.
Recent accounting changes related to our embedded leases within certain deferred equipment agreements have also resulted in the acceleration of the timing related to our recognition of revenue and expenses associated with certain equipment provided to customers at no up-front charge. Since we cannot control the timing of when our customers will request us to deliver such equipment, our revenue and costs with respect to leased equipment could vary substantially in any given quarter or year, which could further increase quarterly or annual fluctuations within our financial results.
Due to these and other factors, you should not rely on our results for any one quarter as an indication of our future performance. If our operating results fail to meet or exceed the expectations of securities analysts or investors, our stock price could drop suddenly and significantly.
Future changes in accounting pronouncements and tax laws, or the interpretation thereof, could have a significant impact on our reported results, and may affect our historical reporting of previous transactions.
New accounting pronouncements or taxation rules, and evolving interpretations thereof, have occurred and are likely to occur in the future. Future changes made by new accounting standards may apply prospectively or retrospectively, depending on the method of adoption, and may recast previously reported results. For additional information related to the impact of new accounting pronouncements, please see Note 2 to our accompanying condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.
In addition, future changes to the U.S. tax code and its regulations could have a material impact on our effective tax rate and its implementation could require us to make substantial changes to our business practices, allocate resources, and increase our costs, which could negatively affect our business, results of operations and financial condition.
If we lose the services of our key personnel, or if we are unable to attract and retain other key personnel, we may not be able to manage our operations or meet our growth objectives.
We are highly dependent on our senior management, especially Joe Kiani, our CEO, and other key officers. We are also heavily dependent on our engineers and field sales team, including sales representatives and clinical specialists. The loss of the services of members of our key personnel, including as a result of the COVID-19 pandemic, or the inability to attract and retain qualified personnel in the future could prevent the implementation and completion of our objectives, including the development and introduction of our products. In general, our key personnel may terminate their employment at any time and for any reason without notice, unless the individual is a participant in our 2007 Severance Protection Plan, in which case the individual has agreed to provide us with six months’ notice if such individual decides to voluntarily resign. We do not maintain any “key person” life insurance policies with respect to any of our key personnel.
We are involved, and may become involved in the future, in disputes and other legal or regulatory proceedings that, if adversely decided or settled, could materially and adversely affect our business, financial condition and results of operations.
We are, and may in the future become, party to litigation, regulatory proceedings or other disputes. In general, claims made by or against us in disputes and other legal or regulatory proceedings can be expensive and time-consuming to bring or defend against, requiring us to expend significant resources and divert the efforts and attention of our management and other personnel from our business operations. These potential claims may include, but are not limited to, personal injury and class action lawsuits, intellectual property claims and regulatory investigations relating to the advertising and promotional claims about our products and employee claims against us based on, among other things, discrimination, harassment or wrongful termination. Any one of these claims, even those without merit, may divert our financial and management resources that would otherwise be used to benefit the future performance of our operations. Any adverse determination against us in these proceedings, or even the allegations contained in the claims, regardless of whether they are ultimately found to be without merit, may also result in settlements, injunctions or damages that could have a material adverse effect on our business, financial condition and results of operations.
66
*Changes to government immigration regulations may materially affect our workforce and limit our supply of qualified professionals, or increase our cost of securing workers.
We recruit professionals on a global basis and must comply with the immigration laws in the countries in which we operate, including the U.S. Some of our employees are working under Masimo-sponsored temporary work visas, including H1-B visas. Statutory law limits the number of new H1-B temporary work permit petitions that may be approved in a fiscal year. Furthermore, there is a possibility that the current U.S. immigration visa program may be significantly overhauled, and the number of H1-B visas available, as well as the process to obtain them, may be subject to significant change. Any resulting changes to this visa program could impact our ability to recruit, hire and retain qualified skilled personnel. If we are unable to obtain work visas in sufficient quantities or at a sufficient rate for a significant period of time, our business, operating results and financial condition could be adversely affected.
The risks inherent in operating internationally, including the purchase, sale and shipment of our components and products across international borders, may adversely impact our business, financial condition and results of operations.
We currently derive approximately 33% of our net sales from international operations. In addition, we purchase a portion of our raw materials and components from international sources. The sale and shipment of our products across international borders, as well as the purchase of materials and components from international sources, subject us to extensive U.S. and foreign governmental trade regulations, including those related to duties, tariffs, and conflict minerals. Compliance with such regulations is costly and we could be exposed to potentially significant penalties, fines and interest if we are found not to be in compliance with such regulations. Any failure to comply with applicable legal and regulatory obligations could impact us in a variety of ways that include, but are not limited to, significant criminal, civil and administrative penalties, including imprisonment of individuals, fines and penalties, denial of export privileges, seizure of shipments, restrictions on certain business activities, and exclusion or debarment from government contracting. For example, we have had sales of medical products destined for Iran. Although these activities have not been financially material to our business, financial condition or results of operations, and were undertaken in accordance with general licenses authorizing such activities issued by the U.S. Treasury Department’s Office of Foreign Assets Control, we may not be successful in ensuring compliance with limitations or restrictions on business in Iran or any other countries subject to economic sanctions and embargoes imposed by the United States. Also, the failure to comply with applicable legal and regulatory obligations could result in the disruption of our shipping, manufacturing and sales activities. Any material decrease in our international sales would adversely affect our business, financial condition and results of operations.
In June 2016, the United Kingdom (UK) held a referendum pursuant to which voters elected to leave the EU, commonly referred to as Brexit. The UK formally left the EU on January 31, 2020 and began a transition period that ended on December 31, 2020. Although the long-term effects of Brexit have yet to be seen, and the UK is in the process of negotiating trade deals with other countries, Brexit has created additional uncertainties that may ultimately result in new regulatory costs and challenges for medical device companies and increased restrictions on imports and exports throughout Europe, which could adversely affect our ability to conduct and expand our operations in Europe and which may have an adverse effect on our business, financial condition and results of operations. Additionally, Brexit may increase the possibility that other countries may decide to leave the EU in the future.
In addition, our international operations expose us and our representatives, agents and distributors to risks inherent in operating in foreign jurisdictions. These risks include, but are not limited to:
•the imposition of additional U.S. and foreign governmental controls or regulations;
•the imposition of costly and lengthy new export licensing requirements;
•a shortage of high-quality sales people and distributors;
•the loss of any key personnel who possess proprietary knowledge, or who are otherwise important to our success in certain international markets;
•changes in duties and tariffs, license obligations and other non-tariff barriers to trade;
•the imposition of new trade restrictions;
•the imposition of restrictions on the activities of foreign agents, representatives and distributors;
•compliance with foreign tax laws, regulations and requirements;
•pricing pressure;
•changes in foreign currency exchange rates;
•laws and business practices favoring local companies;
•political instability and actual or anticipated military or political conflicts;
67
•financial and civil unrest worldwide;
•outbreaks of illnesses, pandemics or other local or global health issues;
•the inability to collect amounts paid by foreign government customers to our appointed foreign agents;
•longer payment cycles, increased credit risk and different collection remedies with respect to receivables; and
•difficulties in enforcing or defending intellectual property rights.
The U.S. government initiated substantial changes in U.S. trade policy and U.S. trade agreements, including the tariffs on certain foreign goods. In response to these tariffs, certain foreign governments instituted or are considering imposing tariffs on certain U.S. goods. In addition, the U.S. has negotiated new trade agreements that could impact us, including the United States-Mexico-Canada Agreement (USMCA), which went into force on July 1, 2020 and replaced the North American Free Trade Agreement. A trade war, trade barriers or other governmental actions related to tariffs, international trade agreements, import or export restrictions or other trade policies could adversely impact demand for our products, our costs, customers, suppliers and/or the U.S. economy or certain sectors thereof and, therefore, adversely affect our business, financial condition and results of operations.
The U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws in non-U.S. jurisdictions generally prohibit companies and their intermediaries from promising or making improper payments to foreign officials for the purpose of obtaining an advantage to secure or retain business. Because of the predominance of government-sponsored healthcare systems around the world, many of our customer relationships outside of the U.S. are with governmental entities and are therefore subject to such anti-bribery laws. We have adopted policies and practices that help us ensure compliance with these anti-bribery laws. However, such policies and practice may require us to invest in additional monitoring resources or forgo certain business opportunities in order to ensure global compliance with these laws.
Our operations may be adversely impacted by our exposure to risks related to foreign currency exchange rates.
We market our products in certain foreign markets through our subsidiaries and other international distributors. As a result, events that result in global economic uncertainty could significantly affect our results of operations in the form of gains and losses on foreign currency transactions and potential devaluation of the local currencies of our customers relative to the U.S. Dollar.
While a majority of our sales are transacted in U.S. Dollars, some of our sales agreements with foreign customers provide for payment in currencies other than the U.S. Dollar. These foreign currency revenues, when converted into U.S. Dollars, can vary depending on the approximation of the exchange rates applied during a respective period. Similarly, certain of our foreign subsidiaries transact business in their respective country’s local currency, which is also their functional currency. In addition, certain production costs related to our manufacturing operations in Mexico are denominated in Mexican Pesos. As a result, expenses of these foreign subsidiaries and certain production costs, when converted into U.S. Dollars, can vary depending on average monthly exchange rates during a respective period.
We are also exposed to foreign currency gains or losses on outstanding foreign currency denominated receivables and payables, as well as cash deposits. When converted to U.S. Dollars, these receivables, payables and cash deposits can vary depending on the monthly exchange rates at the end of the period. In addition, certain intercompany transactions may give rise to realized and unrealized foreign currency gains or losses based on the currency underlying such intercompany transactions. Accordingly, our operating results are subject to fluctuations in foreign currency exchange rates.
The balance sheets of our foreign subsidiaries whose functional currency is not the U.S. Dollar are translated into U.S. Dollars at the rate of exchange at the balance sheet date and the statements of operations and cash flows are translated into U.S. Dollars using an approximation of the average monthly exchange rates applicable during the period. Any foreign currency exchange gain or loss as a result of translating the balance sheets of our foreign subsidiaries whose functional currency is not the U.S. Dollar is included in equity as a component of accumulated other comprehensive income (loss).
We currently do not hedge our foreign currency exchange rate risk. As a result, changes in foreign exchange rates could have a material adverse effect on our business, financial condition and results of operations. For additional information related to our foreign currency exchange rate risk, please see Quantitative and Qualitative Disclosures about Market Risk in Part I, Item 3 of this Quarterly Report on Form 10-Q.
68
We currently manufacture our products at a limited number of locations and any disruption to, expansion of, or changes in trade programs related to such manufacturing operations could adversely affect our business, financial condition and results of operations.
We rely on manufacturing facilities in California, New Hampshire and Mexico that may be affected by natural or man-made disasters. Earthquakes are of particular significance since some of our facilities are located in earthquake-prone areas. We are also vulnerable to damage from other types of disasters, including power loss, attacks from extremist or terrorist organizations, epidemics, communication failures, fire, floods and similar events. Our facilities and the manufacturing equipment we use to produce our products would be difficult to replace and could require substantial time to repair if significant damage were to result from any of these occurrences.
If one of our manufacturing facilities was affected by a natural or man-made disaster, we would be forced to rely on third-party manufacturers if we could not shift production to our other manufacturing facilities. Furthermore, our insurance for damage to our property and the disruption of our business from casualties may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, or at all. If the lease for any of our leased facilities is terminated, we are unable to renew any of our leases or we are otherwise forced to seek alternative facilities, or if we voluntarily expand one or more of our manufacturing operations to new locations, we may incur additional transition costs and experience a disruption in the supply of our products until the new facilities are available and operating. Additionally, we have occasionally experienced seasonality among our manufacturing workforce, and if we continue to experience such seasonality or other workforce shortages or otherwise have issues retaining employees or contractors at our manufacturing facilities, we may not be able to meet our customers’ demands.
Our global manufacturing and distribution are dependent upon our manufacturing facilities in Mexico, and the expedient importation of raw materials and exportation of finished goods between the U.S. and Mexico. Undue delays and/or closures of the proximal cross-border transit facilities, or any restrictions by the U.S. federal administration related to the movement of goods across the U.S. and Mexico border, may adversely affect our ability to fulfill orders and supply our healthcare provider customers with essential replenishment supplies, as well as adversely impact our business, operating results and financial condition.
In addition, our manufacturing facilities in Mexico are authorized to operate under the Mexican Maquiladora (IMMEX) program. The IMMEX program allows us to import certain items from the U.S. into Mexico duty-free, provided that such items, after processing, are exported from Mexico within a stipulated timeframe. Maquiladora status, which is renewed periodically, is subject to various restrictions and requirements, including compliance with the terms of the IMMEX program and other local regulations. Failure to comply with the IMMEX program regulations, including any changes thereto, could increase our manufacturing costs and adversely affect our business, operating results and financial condition.
If we do not accurately forecast customer demand, we may hold suboptimal inventory levels that could adversely affect our business, financial condition and results of operations.
If we are unable to meet the demand of our customers, our customers may cancel orders or purchase products from our competitors, which could reduce our revenue and gross profit margin. Conversely, if product demand decreases, we may be unable to timely adjust our manufacturing cost structure, resulting in excess capacity, which would lower gross product margins. Similarly, if we are unable to forecast demand accurately, we could be required to record charges related to excess or obsolete inventory, which would also lower our gross margin.
If we fail to comply with the reporting obligations of the Exchange Act, or if we fail to maintain adequate internal control over financial reporting, our business, results of operations and financial condition and investors’ confidence in us could be adversely affected.
We are required to prepare and disclose certain information under the Exchange Act, in a timely manner and meet our reporting obligations in their entirety, and our failure to do so could subject us to penalties under federal securities laws and regulations of The Nasdaq Stock Market LLC, expose us to lawsuits and restrict our ability to access financing on favorable terms, or at all.
If we fail to maintain adequate internal controls over financial reporting, we may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting in accordance with the Sarbanes-Oxley Act. Moreover, any material weakness in our internal control environment could result in the loss of investor confidence in the reliability of our financial statements, which in turn could harm our business, negatively impact the trading price of our stock, and adversely affect investors’ confidence in our company and our ability to access capital markets for financing.
69
Changing laws and increasingly complex corporate governance and public disclosure requirements could have an adverse effect on our business and operating results.
Changing laws, regulations and standards relating to corporate governance and public disclosure, including the Dodd-Frank Wall Street Reform and Consumer Protection Act (Dodd-Frank Act), the California Transparency in Supply Chains Act, the UK Modern Slavery Act and new regulations issued by the SEC and The Nasdaq Stock Market LLC, have created, and will create, additional compliance requirements for us. For example, the Dodd-Frank Act includes provisions regarding, among other things, advisory votes on named executive officer compensation and “conflict minerals” reporting. Complying with these rules and regulations has increased and will increase our legal and financial compliance costs, make some activities more difficult, time-consuming or costly and increase demand on our systems and resources. As a result, management’s attention may be diverted from other business concerns, which could adversely affect our business, financial condition and results of operations.
We may also need to hire additional employees or engage outside consultants to comply with these requirements, which will increase our costs and expenses. To maintain high standards of corporate governance and public disclosure, we have invested in, and intend to continue to invest in, reasonably necessary resources to comply with evolving standards.
In addition, stockholder litigation surrounding executive compensation and disclosure of executive compensation has increased with the passage of the Dodd-Frank Act. Furthermore, our stockholders may not continue to approve our advisory vote on named executive officer compensation that is being voted on by our stockholders annually pursuant to the Dodd-Frank Act. If we are involved in a lawsuit related to compensation matters or any other matters not covered by our directors’ and officers’ liability insurance, we may incur significant expenses in defending against such lawsuits, or be subject to significant fines or required to take significant remedial actions, each of which could adversely affect our business, financial condition and results of operations.
If product liability claims are brought against us, we could face substantial liability and costs.
Our products are predominantly used in patient care and expose us to product liability claims and product recalls, including, but not limited to, those that may arise from unauthorized off-label use, malfunctions, design flaws or manufacturing defects related to our products or the use of our products with incompatible components or systems. In addition, as we continue to expand our product portfolio, we may enter or create new markets, including consumer markets, that may expose us to additional product liability risks. For example, with the acquisition of TNI® in March 2020, we added softFlow® technology to our product portfolio. While this technology provides efficient, quiet and comfortable respiratory support to patients, it may present increased risk of infection to caregivers.
We cannot be certain that our product liability insurance will be sufficient to cover any or all damages for product liability claims that may be brought against us in the future. Furthermore, we may not be able to obtain or maintain insurance in the future at satisfactory rates or in adequate amounts to protect us against any product liability claims.
Additionally, the laws and regulations regarding product liability are constantly evolving, both through the passage of new legislation at the state and federal levels and through new interpretations of existing legislation. For example, in February 2017, the Washington Supreme Court determined that, under the Washington Product Liability Act, medical device manufacturers have a duty to warn hospitals of any potential risks posed by their products. As the legal and regulatory landscape surrounding product liability change, we may become exposed to greater liability than currently anticipated.
Any losses that we may suffer from product liability claims, and the effect that any product liability litigation may have upon the reputation and marketability of our technology and products, together with the corresponding diversion of the attention of our key employees, may subject us to significant damages and could adversely affect our business, financial condition and results of operations.
We may incur environmental and personal injury liabilities related to certain hazardous materials used in our operations.
Certain manufacturing processes for our products may involve the storage, use, generation and disposal of certain hazardous materials and wastes, including silicone adhesives, solder and solder paste, sealants, epoxies and various solvents such as methyl ethyl ketone, acetone and isopropyl alcohol. As a result, we are subject to certain environmental laws, as well as certain other laws and regulations, that restrict the materials that can be used in our products or in our manufacturing processes. For example, products that we sell in Europe are subject to regulation in the EU markets under the Restriction of the Use of Hazardous Substances Directive (RoHS). RoHS prohibits companies from selling products that contain certain hazardous materials in EU member states. In addition, the EU’s Registration, Evaluation, Authorization, and Restriction of Chemicals Directive also restricts substances of very high concern in products. Compliance with such regulations may be costly and, therefore, we may incur significant costs to comply with these laws and regulations.
70
In addition, new environmental laws may further affect how we manufacture our products, how we use, generate or dispose of hazardous materials and waste, or further affect what materials can be used in our products. Any required changes to our operations or products may increase our manufacturing costs, detrimentally impact the performance of our products, add greater testing lead-times for product introductions or have other similar effects.
In connection with our research and manufacturing activities, we use, and our employees may be exposed to, materials that are hazardous to human health, safety or the environment. The risk of accidental injury to our employees or contamination from these materials cannot be eliminated, and we could be held liable for any resulting damages, the related liability for which could exceed our reserves. We do not specifically insure against environmental liabilities. If an enforcement action were to occur, our reputation and our business and financial condition may be harmed, even if we were to prevail or settle the action on terms favorable to us.
We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cybersecurity incidents, could harm our ability to operate our business effectively.
Increased global cybersecurity vulnerabilities, cybersecurity threats and sophisticated and targeted cybersecurity attacks pose a risk to the security of our systems and networks, including the confidentiality, availability and integrity of any underlying information and data, and those of our customers, partners, suppliers and third-party service providers. Our ability to effectively manage and maintain our internal business information, and to ship products to customers and invoice them on a timely basis, depends significantly on our enterprise resource planning system and other information systems.
Portions of our information technology systems may experience interruptions, delays or cessations of service or produce errors in connection with ongoing systems implementation work. In addition, interfaces between our products and our customers’ computer networks could provide additional opportunities for cybersecurity attacks on us and our customers. The techniques used to attack computer systems are sophisticated, change frequently and may originate from less regulated and remote areas of the world. Cybersecurity attacks in particular are evolving and include, but are not limited to: threats, malicious software, ransomware, attempts to gain unauthorized access to data and other electronic security breaches that could lead to disruptions in systems, misappropriation of confidential or otherwise protected information and corruption of data. As a result, there can be no assurance that our protective measures will prevent or detect security breaches that could have a significant impact on our business, reputation, financial condition and results of operations.
The failure of these systems to operate or integrate effectively with other internal, customer, supplier or third-party service provider systems and to protect the underlying information technology system and data integrity, including from cyber-attacks, intrusions or other breaches or unauthorized access of these systems, or any failure by us to remediate any such attacks or breaches, may also result in damage to our reputation or competitiveness, delays in product fulfillment and reduced efficiency of our operations, and could require significant capital investments to remediate any such failure, problem or breach, all of which could adversely affect our business, financial condition and results of operations.
Discontinuation, reform or replacement of LIBOR and other benchmark rates, or uncertainty related to the potential for any of the foregoing, may adversely affect our business.
The U.K. Financial Conduct Authority announced in 2017 that it intends to phase out the London Inter-Bank Offered Rate (LIBOR) by the end of 2023. In addition, other regulators have suggested reforming or replacing other benchmark rates. The discontinuation, reform or replacement of LIBOR or any other benchmark rates may have an unpredictable impact on contractual mechanics in the credit markets or cause disruption to the broader financial markets. Uncertainty as to the nature of such potential discontinuation, reform or replacement may also negatively impact interest expense related to borrowings under our Credit Facility. Borrowings under our Credit Facility bear interest, at our election, either at the Alternate Base Rate (as defined in the Credit Facility), or at the Adjusted LIBO Rate (as defined in the Credit Facility), which is derived from LIBOR. We may in the future pursue amendments to our Credit Facility to provide for a transition mechanism or other reference rate in anticipation of LIBOR’s discontinuation, but we may not be able to reach agreement with our Lenders on any such amendments. As a result, additional financing to replace any then-outstanding LIBOR-based debt may be unavailable, more expensive or restricted by the terms of such outstanding indebtedness.
Our stock price may be volatile, and your investment in our stock could suffer a decline in value.
There has been and could continue to be significant volatility in the market price and trading volume of our equity securities. For example, our closing stock price ranged from $208.49 to $285.24 per share from January 3, 2021 to October 2, 2021. Factors contributing to our stock price volatility may include our financial performance, as well as broader economic, political and market factors, including the COVID-19 pandemic. In addition to the other risk factors previously discussed in this Quarterly Report on Form 10-Q, there are many other factors that we may not be able to control that could have a significant effect on our stock price. These include, but are not limited to:
71
•actual or anticipated fluctuations in our operating results or future prospects;
•our announcements or our competitors’ announcements of new products;
•the public’s reaction to our press releases, our other public announcements and our filings with the SEC;
•strategic actions by us or our competitors, such as acquisitions or restructurings;
•new laws or regulations or new interpretations of existing laws or regulations applicable to our business;
•changes in accounting standards, policies, guidance, interpretations or principles;
•changes in our growth rates or our competitors’ growth rates;
•developments regarding our patents or proprietary rights or those of our competitors;
•ongoing legal proceedings;
•our inability to raise additional capital as needed;
•concerns or allegations as to the safety or efficacy of our products;
•changes in financial markets or general economic conditions, including the effects of recession or slow economic growth in the U.S. and abroad;
•effects of public health crises, epidemics and pandemics, such as the COVID-19 pandemic;
•sales of stock by us or members of our management team, our Board or certain institutional stockholders; and
•changes in stock market analyst recommendations or earnings estimates regarding our stock, other comparable companies or our industry generally.
Therefore, you may not be able to resell your shares at or above the price you paid for them.
Our investors could experience substantial dilution of their investments as a result of subsequent exercises of our outstanding options, vesting of outstanding restricted stock units (RSUs) and performance stock units (PSUs), or the grant of future equity awards by us.
As of October 2, 2021, approximately 10.7 million shares of our common stock were reserved for issuance under our equity incentive plans, of which approximately 3.1 million shares were subject to options outstanding at such date at a weighted-average exercise price of $80.55 per share, approximately 2.9 million shares were subject to outstanding RSUs, approximately 0.3 million shares were subject to outstanding PSUs and approximately 4.4 million shares were available for future awards under our 2017 Equity Incentive Plan. Over the past 36 months, we have experienced higher rates of stock option exercises compared to many earlier periods, and this trend may continue. To the extent outstanding options are exercised or outstanding RSUs or PSUs vest, our existing stockholders may incur dilution.
We rely on equity awards to motivate current employees and to attract new employees. The grant of future equity awards by us to our employees and other service providers may further dilute our stockholders.
Future resales of our stock, including those by our insiders and a few investment funds, may cause our stock price to decline.
A significant portion of our outstanding shares are held by our directors, our executive officers and a few investment funds. Resales by these stockholders of a substantial number of such shares, announcements of any proposed resale of substantial amounts of our stock or the perception that substantial resales may be made, could significantly reduce the market price of our stock. Some of our directors and executive officers have entered into Rule 10b5-1 trading plans pursuant to which they have arranged to sell shares of our stock from time to time in the future. Generally, these sales require public filings. Actual or potential sales by these insiders, including those under a pre-arranged Rule 10b5-1 trading plan, could be interpreted by the market as an indication that the insider has lost confidence in our stock and reduce the market price of our stock.
We have registered and expect to continue to register shares reserved under our equity plans pursuant to Registration Statements on Form S-8. All shares issued pursuant to a Registration Statement on Form S-8 can be freely sold in the public market upon issuance, subject to restrictions on our affiliates under Rule 144. If a large number of these shares are sold in the public market, the sales could reduce the trading price of our stock.
72
We may elect not to declare cash dividends on our stock, may elect to only pay dividends on an infrequent or irregular basis, or may elect not to make any additional stock repurchases. As a result, any return on your investment may be limited to the value of our stock. In addition, the payment of any future dividends or the repurchase of our stock might limit our ability to pursue other growth opportunities.
Our Board may from time to time declare, and we may pay, dividends on our outstanding shares in the manner and upon the terms and conditions permitted under applicable law. However, we may elect to retain all future earnings for the operation and expansion of our business, rather than paying cash dividends on our stock. In addition, under certain circumstances, our Credit Facility may limit our ability to pay cash dividends, repurchase our common stock or make other distributions to stockholders. Any payment of cash dividends on our stock will be at the discretion of our Board and will depend upon our results of operations, earnings, capital requirements, financial condition, business prospects, contractual restrictions and other factors deemed relevant by our Board. In the event our Board declares any dividends, there is no assurance with respect to the amount, timing or frequency of any such dividends.
Any repurchase of our common stock under the stock repurchase plan authorized by our Board in October 2021 (2021 Repurchase Program) will be at the discretion of a committee comprised of our CEO and Chief Financial Officer, and will depend on several factors, including, but not limited to, results of operations, capital requirements, financial conditions, available capital from operations or other sources and the market price of our common stock. Therefore, there is no assurance with respect to the amount, price or timing of any such repurchases. We may elect to retain all future earnings for the operation and expansion of our business, rather than repurchasing additional outstanding shares. For additional information related to our 2021 Repurchase Program, please see Note 17 to our accompanying condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.
In the event we pay dividends, or make any stock repurchases in the future, our ability to finance any material expansion of our business, including through acquisitions, investments or increased capital spending, or to fund our operations, may be limited. In addition, any repurchases we may make in the future may not prove to be at optimal prices. Our Board may modify or amend the 2021 Repurchase Program, or adopt a new stock repurchase program, at any time at its discretion without stockholder approval.
73
Item 6. Exhibits
EXHIBIT INDEX
Exhibit
Number
Description of Document
3.1(1)
3.2(2)
4.1(1)
4.2(1)
4.3#(3)
31.1*
31.2*
32.1*
101.INS*XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.
101.SCH*XBRL Taxonomy Extension Schema Document
101.CAL*XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*XBRL Taxonomy Extension Label Linkbase Document
101.PRE*XBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
Attached as Exhibit 101 to this report are the following formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets as of October 2, 2021 and January 2, 2021, (ii) Condensed Consolidated Statements of Income for the three and nine months ended October 2, 2021 and September 26, 2020, respectively, (iii) Condensed Consolidated Statements of Comprehensive Income for the three and nine months ended October 2, 2021 and September 26, 2020, respectively, (iv) Condensed Consolidated Statements of Cash Flows for the nine months ended October 2, 2021 and September 26, 2020, respectively, and (v) Notes to Condensed Consolidated Financial Statements.
 _____________________________
(1)    Incorporated by reference to the exhibits to the Company’s Registration Statement on Form S-1 (No. 333-142171), originally filed on April 17, 2007. The number given in parentheses indicates the corresponding exhibit number in such Form S-1, as amended.
(2)    Incorporated by reference to the exhibit to the Company’s Current Report on Form 8-K filed on October 30, 2019. The number given in parentheses indicates the corresponding exhibit number in such Form 8-K.
(3)    Incorporated by reference to the exhibit to the Company’s Registration Statement on Form S-8 filed on February 11, 2008. The number given in parentheses indicates the corresponding exhibit number in such Form S-8.
#     Indicates management or compensatory plan.
*     Filed herewith.
74
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
MASIMO CORPORATION
Date: October 26, 2021By:
/s/ JOE KIANI
Joe Kiani
Chief Executive Officer and Chairman
Date: October 26, 2021By:
/s/ MICAH YOUNG
Micah Young
Executive Vice President and Chief Financial Officer
75
 EX-31.1 2 masi-20211002x10qex311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
I, Joe Kiani, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of Masimo Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
/s/ JOE KIANI
Date: October 26, 2021Joe Kiani
Chairman of the Board and Chief Executive Officer
(Principal Executive Officer)


 EX-31.2 3 masi-20211002x10qex312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER
I, Micah Young, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of Masimo Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
/s/ MICAH YOUNG
Date: October 26, 2021Micah Young
Executive Vice President and Chief Financial Officer
(Principal Financial Officer)


 EX-32.1 4 masi-20211002x10qex321.htm EX-32.1 Document

Exhibit 32.1

CERTIFICATIONS OF
CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, Joe Kiani, Chief Executive Officer of Masimo Corporation (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that to my knowledge:
1. The Quarterly Report on Form 10-Q of the Company for the period ended October 2, 2021 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ JOE KIANI
Date: October 26, 2021Joe Kiani
Chairman of the Board and Chief Executive Officer
(Principal Executive Officer)
I, Micah Young, Executive Vice President and Chief Financial Officer of Masimo Corporation (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that to my knowledge:
1. The Quarterly Report on Form 10-Q of the Company for the period ended October 2, 2021 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ MICAH YOUNG
Date: October 26, 2021Micah Young
Executive Vice President and Chief Financial Officer
(Principal Financial Officer)
A signed original of these certifications has been provided to Masimo Corporation and will be retained by Masimo Corporation and furnished to the Securities and Exchange Commission or its staff upon request.
These certifications are being furnished solely to accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350, and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 and are not to be incorporated by reference into any filing of Masimo Corporation, whether made before or after the date hereof, regardless of any general incorporation language in such filing.


EX-101.SCH 5 masi-20211002.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Condensed Consolidated Statements of Operations Condensed Consolidated Statement of Operations link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Consolidated Statement of Stockholders' Equity Consolidated Statement of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Description of the Company link:presentationLink link:calculationLink link:definitionLink 2102102 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2203201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 2405401 - Disclosure - Summary of Significant Accounting Policies - Revenue, Performance Obligation (Details) link:presentationLink link:calculationLink link:definitionLink 2405401 - Disclosure - Summary of Significant Accounting Policies - Revenue, Performance Obligation (Details) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Summary of Significant Accounting Policies - Changes in Product Warranty Accrual (Detail) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Basic and Diluted Net Income Per Share (Detail) link:presentationLink link:calculationLink link:definitionLink 2408404 - Disclosure - Summary of Significant Accounting Policies - Supplemental Cash Flow Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2409405 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2110103 - Disclosure - Related Party Disclosures link:presentationLink link:calculationLink link:definitionLink 2411406 - Disclosure - Related Party Transactions Related Party Transactions - (Details) link:presentationLink link:calculationLink link:definitionLink 2112104 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2313302 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2414407 - Disclosure - Inventories - Components of Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 2115105 - Disclosure - Other Current Assets link:presentationLink link:calculationLink link:definitionLink 2316303 - Disclosure - Other Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2417408 - Disclosure - Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2118106 - Disclosure - Lease Receivable link:presentationLink link:calculationLink link:definitionLink 2319304 - Disclosure - Lease Receivable (Tables) link:presentationLink link:calculationLink link:definitionLink 2420409 - Disclosure - Lease Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 2421410 - Disclosure - Lease Receivable Sales-Type (Details) link:presentationLink link:calculationLink link:definitionLink 2422411 - Disclosure - Lease Receivable Sales-type Lease, Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 2123107 - Disclosure - Deferred Costs and Other Contract Assets link:presentationLink link:calculationLink link:definitionLink 2324305 - Disclosure - Deferred Costs and Other Contract Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2425412 - Disclosure - Deferred Costs and Other Contract Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2126108 - Disclosure - Property and Equipment, net link:presentationLink link:calculationLink link:definitionLink 2327306 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 2428413 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2129109 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 2330307 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2431414 - Disclosure - Intangible Assets - Schedule of Finite-Lived Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2432415 - Disclosure - Intangible Assets - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2433416 - Disclosure - Intangible Assets - Future Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2134110 - Disclosure - Goodwill link:presentationLink link:calculationLink link:definitionLink 2335308 - Disclosure - Goodwill (Table) link:presentationLink link:calculationLink link:definitionLink 2436417 - Disclosure - Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2137111 - Disclosure - Lessee ROU Assets and Lease Liabilities link:presentationLink link:calculationLink link:definitionLink 2338309 - Disclosure - Lessee ROU Assets and Lease Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2439418 - Disclosure - Lessee ROU Assets and Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2440419 - Disclosure - Lessee ROU Assets and Lease Liabilities Lessee Operating Lease Balance Sheet Classification (Details) link:presentationLink link:calculationLink link:definitionLink 2441420 - Disclosure - Lessee ROU Assets and Lease Liabilities Future Maturities Operating Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2142112 - Disclosure - Other Non-Current Assets link:presentationLink link:calculationLink link:definitionLink 2343310 - Disclosure - Other Non-Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2444421 - Disclosure - Other Non-Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2145113 - Disclosure - Deferred Revenue and Other Contract Liabilities link:presentationLink link:calculationLink link:definitionLink 2346311 - Disclosure - Deferred Revenue and Other Contract Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2447422 - Disclosure - Deferred Revenue and Other Contract Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2447422 - Disclosure - Deferred Revenue and Other Contract Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2448423 - Disclosure - Deferred Revenue and Other Contract Liabilities - Changes in Deferred Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2149114 - Disclosure - Other Current Liabilities link:presentationLink link:calculationLink link:definitionLink 2350312 - Disclosure - Other Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2451424 - Disclosure - Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2152115 - Disclosure - Credit Facility link:presentationLink link:calculationLink link:definitionLink 2353313 - Disclosure - Credit Facility Tables) link:presentationLink link:calculationLink link:definitionLink 2454425 - Disclosure - Credit Facility (Details) link:presentationLink link:calculationLink link:definitionLink 2155116 - Disclosure - Other Non-Current Liabilities link:presentationLink link:calculationLink link:definitionLink 2356314 - Disclosure - Other Non-Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2457426 - Disclosure - Other Non-Current Liabilities - (Detail) link:presentationLink link:calculationLink link:definitionLink 2158117 - Disclosure - Stock Repurchase Program link:presentationLink link:calculationLink link:definitionLink 2359315 - Disclosure - Stock Repurchase Program (Tables) link:presentationLink link:calculationLink link:definitionLink 2460427 - Disclosure - Stock Repurchase Program - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2161118 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2362316 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2463428 - Disclosure - Stock-Based Compensation - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2464429 - Disclosure - Stock-Based Compensation - Number and Weighted Average Exercise Price of Options Issued and Outstanding under all Stock Option Plans (Detail) link:presentationLink link:calculationLink link:definitionLink 2465430 - Disclosure - Stock-Based Compensation Stock-Based Compensation - Summary of Unvested RSU Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2466431 - Disclosure - Stock-Based Compensation - Range of Assumptions Used and Resulting Weighted-Average Fair Value of Options Granted at Date of Grant (Detail) link:presentationLink link:calculationLink link:definitionLink 2167119 - Disclosure - Non-operating income link:presentationLink link:calculationLink link:definitionLink 2368317 - Disclosure - Non-operating income (Tables) link:presentationLink link:calculationLink link:definitionLink 2469432 - Disclosure - Non-operating income (Detail) link:presentationLink link:calculationLink link:definitionLink 2170120 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2471433 - Disclosure - Income Taxes - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2172121 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2373318 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 2474434 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2475435 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments Under Operating and Capital Leases (Detail) link:presentationLink link:calculationLink link:definitionLink 2176122 - Disclosure - Segment Information and Enterprise Reporting link:presentationLink link:calculationLink link:definitionLink 2377319 - Disclosure - Segment Information and Enterprise Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 2478436 - Disclosure - Segment Information and Enterprise Reporting - Analysis of Product Revenues Based upon Geographic Area Shipped (Detail) link:presentationLink link:calculationLink link:definitionLink 2479437 - Disclosure - Segment Information and Enterprise Reporting Long-lived assets by geographic area (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 masi-20211002_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 masi-20211002_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 masi-20211002_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Customer [Domain] Customer [Domain] Litigation Costs and Contingencies Legal Matters and Contingencies [Text Block] Net Income Per Share Earnings Per Share, Policy [Policy Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Leasehold improvements Leasehold Improvements [Member] Emerging Growth Company Entity Emerging Growth Company Lessee ROU assets, net Operating Lease, Right-of-Use Asset Preferred stock, shares outstanding Preferred Stock, Shares Outstanding Accrued compensation Employee-related Liabilities, Current Goodwill Goodwill Disclosure [Text Block] Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Statistical Measurement [Domain] Statistical Measurement [Domain] Entity Address, Address Line One Entity Address, Address Line One Other Other Intangible Assets [Member] Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block] Related Party Transaction, Due from (to) Related Party Related Party Transaction, Due from (to) Related Party Segment Information Segment Reporting, Policy [Policy Text Block] Europe, Middle East and Africa EMEA [Member] EMEA [Member] Percentage of Accounts Receivable Balance Percentage of Accounts Receivable Balance Percentage of Accounts Receivable Balance Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Contract with Customer, Asset and Liability Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Entity Filer Category Entity Filer Category Canceled Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Net income attributable to stockholders of Masimo Corporation: Earnings Per Share Reconciliation [Abstract] Operating Lease, Weighted Average Remaining Lease Term Operating Lease, Weighted Average Remaining Lease Term Indirect taxes receivable Value Added Tax Receivable, Current Other non-current assets Other Assets, Noncurrent Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Segments [Axis] Segments [Axis] Expected dividends Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Options available for grant, end of period Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Deferred costs and other contract assets Deferred Costs, Noncurrent Share-based compensation arrangement by share-based payment award, range of percentage payout Share-based compensation arrangement by share-based payment award, range of percentage payout Share-based compensation arrangement by share-based payment award, range of percentage payout Schedule of Other Nonoperating Income (Expense) Schedule of Other Nonoperating Income (Expense) [Table Text Block] Share-based Compensation Expense APIC, Share-based Payment Arrangement, Increase for Cost Recognition Related Party Transaction, Expenses from Transactions with Related Party Related Party Transaction, Expenses from Transactions with Related Party Decrease in income tax payable Increase (Decrease) in Income Taxes Payable Aggregate intrinsic value of options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Interest income Interest Income, Other Document Fiscal Year Focus Document Fiscal Year Focus Subsequent Event Type [Domain] Subsequent Event Type [Domain] Other comprehensive income, net of tax: Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent [Abstract] Litigation Settlement, Expense Litigation Settlement, Expense Revenue Recognition and Deferred Revenue [Abstract] Revenue Recognition and Deferred Revenue [Abstract] Amortization of Intangible Assets Amortization of Intangible Assets Schedule of Revenue by Major Customers, by Reporting Segments [Table] Schedule of Revenue by Major Customers, by Reporting Segments [Table] Preferred Stock, Value, Outstanding Preferred Stock, Value, Outstanding Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Acquired Finite-lived Intangible Assets, Weighted Average Useful Life 2017 Equity Incentive Plan [Domain] 2017 Equity Incentive Plan [Domain] 2017 Equity Incentive Plan [Domain] Operating Lease, Weighted Average Discount Rate, Percent Operating Lease, Weighted Average Discount Rate, Percent Components of Inventory Schedule of Inventory, Current [Table Text Block] Options to purchase of shares of common stock Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Prepaid income taxes Prepaid Taxes Employment Agreement, Severance Terms Employment Agreement, Severance Terms Employment Agreement, Severance Terms Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Business Acquisition [Axis] Business Acquisition [Axis] Employment Agreement, Severance Benefits, Special Payment, Qualifying Termination Employment Agreement, Severance Benefits, Special Payment, Qualifying Termination Employment Agreement, Severance Benefits, Special Payment, Qualifying Termination Revenue from External Customer [Line Items] Revenue from External Customer [Line Items] Title of Individual [Domain] Title of Individual [Domain] Award Type [Domain] Award Type [Domain] Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights Share Repurchase Program [Domain] Share Repurchase Program [Domain] Credit Facility [Domain] Credit Facility [Domain] ASSETS Assets [Abstract] Subsegments [Axis] Subsegments [Axis] Related Party Transactions [Abstract] Related Party Transactions [Abstract] Options exercisable, end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Land Land [Member] Settlements made Product Warranty Expense Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expired in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expired in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expired in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Concentration Risk, Percentage Concentration Risk, Percentage Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Concentration Risk, Long-lived Asset Geographic Area, Percentage Concentration Risk, Long-lived Asset Geographic Area, Percentage Concentration Risk, Long-lived Asset Geographic Area, Percentage 2018 Repurchase Program 2018 Repurchase Program [Member] 2018 Repurchase Program Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Options outstanding, beginning of period Options outstanding, end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Entity Address, City or Town Entity Address, City or Town Loss Contingency, Damages Awarded, Value Loss Contingency, Damages Awarded, Value Retained Earnings Retained Earnings [Member] Debt Instrument [Axis] Debt Instrument [Axis] Deferred Revenue Arrangement, by Type [Table] Deferred Revenue Arrangement, by Type [Table] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Related Party [Axis] Related Party [Axis] Schedule of Long-lived Assets by Geographic Areas Long-lived Assets by Geographic Areas [Table Text Block] Increase in accounts receivable Increase (Decrease) in Accounts Receivable 2024 Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Four Unpaid purchases of property and equipment Capital Expenditures Incurred but Not yet Paid ROU assets obtained in exchange for lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Shares paid for tax withholding, shares Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Decrease (increase) in other current assets Increase (Decrease) in Other Current Assets Entity Interactive Data Current Entity Interactive Data Current Other Tax Expense (Benefit) Other Tax Expense (Benefit) Accrued donations Accrued Donations, Current Accrued Donations, Current Increase in deferred revenue and other contract-related liabilities Increase (Decrease) in Deferred Revenue Basic Net income per basic share Earnings Per Share, Basic Other Non-Current Assets Other Assets Disclosure [Text Block] Cercacor Laboratories Cercacor Laboratories [Member] Cercacor Laboratories [Member] 2023 Lessee, Operating Lease, Liability, to be Paid, Year Three Deferred Revenue and Other Contract Liabilities Revenue from Contract with Customer [Text Block] Sublease Income Sublease Income Thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Five Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Document Type Document Type Not for Profit Organization Not for Profit Organization [Member] Not for Profit Organization [Member] Interest Expense, Debt Interest Expense, Debt Prepaid expenses Prepaid Expense, Current Reporting Unit [Domain] Reporting Unit [Domain] Geographic Concentration Risk Geographic Concentration Risk [Member] Entity Current Reporting Status Entity Current Reporting Status Machinery, equipment and tooling Machinery and Equipment [Member] Shares paid for tax withholding, value Share-based Payment Arrangement, Decrease for Tax Withholding Obligation Deferred tax liabilities Deferred Tax Liabilities, Net Operating lease liabilities Operating Lease, Payments Allowance for credit loss Sales-type lease, Allowance for Credit Loss Sales-type lease, Allowance for Credit Loss Accrued customer reimbursements Accounts Payable, Other Provision for credit losses Accounts Receivable, Credit Loss Expense (Reversal) Reporting Unit [Axis] Reporting Unit [Axis] Plan Name [Axis] Plan Name [Axis] Accrual for warranties issued Standard and Extended Product Warranty Accrual, Period Increase (Decrease) Settlement of promissory note receivable in connection with business combination Settlement of promissory note in connection with acquisition option exercise Settlement of promissory note in connection with acquisition option exercise Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Document Transition Report Document Transition Report Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Accrued Liabilities [Abstract] Accrued Liabilities [Abstract] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Total liabilities and equity Liabilities and Equity Other current liabilities Other Accrued Liabilities, Current Accrued legal fees Accrued Professional Fees Sale-Type Lease Receivable Sale-Type Lease Receivable [Table Text Block] Sale-Type Lease Receivable [Table Text Block] Lease receivable, noncurrent Net Investment in Lease, before Allowance for Credit Loss, Noncurrent North and South America (excluding the U.S.) Americas [Member] 2025 Lessee, Operating Lease, Liability, to be Paid, Year Five Exercised Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Restricted cash Restricted Cash Additional paid-in capital Additional Paid in Capital Payments for Royalties Payments for Royalties Like Minded Labs Like Minded Labs [Member] Like Minded Labs [Member] LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Unrecognized tax benefit that would affect effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate 2023 Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Three (Decrease) increase in accounts payable Increase (Decrease) in Accounts Payable Line of Credit Facility, Maximum Sublimit Line of Credit Facility, Maximum Sublimit Line of Credit Facility, Maximum Sublimit Repurchases of common stock, value Value of shares repurchased Treasury Stock, Value, Acquired, Cost Method Treasury Stock Acquired, Average Cost Per Share Treasury Stock Acquired, Average Cost Per Share 2024 Finite-Lived Intangible Asset, Expected Amortization, Year Four Stock options exercised, value Stock Issued During Period, Value, Stock Options Exercised Equipment leased to customers, net Equipment leased to customers Equipment leased to customers Minimum Minimum Minimum [Member] Deferred Costs and Other Contract Assets Deferred Costs and Other Contract Assets [Text Block] Deferred Costs and Other Contract Assets [Text Block] 2007 Stock Incentive Plan [Domain] 2007 Stock Incentive Plan [Domain] 2007 Stock Incentive Plan [Domain] Gross profit Gross Profit 2022 Lessee, Operating Lease, Liability, to be Paid, Year Two Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Selling, general and administrative Selling, General and Administrative Expense Other Assets, Longterm [Abstract] Other Assets, Longterm [Abstract] Other Assets, Longterm [Abstract] Reclassifications Reclassification, Comparability Adjustment [Policy Text Block] Preferred stock, shares authorized Preferred Stock, Shares Authorized Gross unrecognized tax benefit Unrecognized Tax Benefits Thereafter Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, after Year Five Property Plant and Equipment, Occupied Square Feet Property Plant and Equipment, Occupied Square Feet The amount of square feet occupied. Trading Symbol Trading Symbol Deferred tax assets Deferred Income Tax Assets, Net Current liabilities Liabilities, Current [Abstract] Revenue Recognition, and Deferred Revenue and Other Contract Liabilities Revenue [Policy Text Block] Other Liabilities, Long Term [Abstract] Other Liabilities, Long Term [Abstract] Other Liabilities, Long Term [Abstract] Business combinations, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Credit Facility Debt Disclosure [Text Block] Options exercisable, end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Subleased Property Subleased Property [Domain] Subleased Property [Domain] Share-Based Compensation Share-based Payment Arrangement [Text Block] Prepaid rebates and royalties, current Prepaid Royalties Inventories Inventory Disclosure [Text Block] Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward] Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward] Accounting Policies [Abstract] Accounting Policies [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Finite-Lived License Agreements, Gross Finite-Lived License Agreements, Gross Letters of Credit Outstanding, Amount Letters of Credit Outstanding, Amount Present value Operating Lease, Liability Realized and unrealized foreign currency (losses) gains Foreign Currency Transaction Gain (Loss), before Tax Non-operating (loss) income Nonoperating Income (Expense) Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Performance Shares Performance Shares [Member] Commitments and contingencies - (Note 21) Commitments and Contingencies Lessee, ROU Assets and Lease Liabilities Lessee, Operating Leases [Text Block] Vantrix Corp Vantrix Corp [Member] Vantrix Corp [Member] Deposit to acquire noncontrolling interest(2) Deposit Assets Accounts receivable, allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Demonstration units Demonstration units Demonstration Units [Member] Demonstration units. Non-operating income Other Nonoperating Income and Expense [Text Block] Schedule of Range of Assumptions Used and Resulting Weighted-Average Fair Value of Options Granted at Date of Grant Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Options Held Options Held [Member] Payment for Administrative Fees Payment for Administrative Fees Income tax payable, non-current Income Tax Payable, Noncurrent Income Tax Payable, Noncurrent Like Minded Media Ventures Like Minded Entertainment [Member] Like Minded Entertainment [Member] Document Period End Date Document Period End Date Foreign Line of Credit [Member] Foreign Line of Credit [Member] Customer notes receivable Nontrade Receivables, Current 2021 Repurchase Program 2021 Repurchase Program [Member] 2021 Repurchase Program Cumulative effect of adoption of ASU 2016-13 Accounting Standards Update 2016-13 [Member] Diluted share equivalent: stock options, RSUs and PSUs Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Revenues from External Customers and Long-Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Goodwill [Line Items] Goodwill [Line Items] Class of Stock [Axis] Class of Stock [Axis] Entity Registrant Name Entity Registrant Name Diluted net income per share: Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Treasury Stock, Shares Treasury Stock, Shares Imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Building and building improvements Land, Buildings and Improvements [Member] Furniture and office equipment Furniture and Office Equipment [Member] Furniture and Office Equipment [Member] Work-in-process Inventory, Work in Process, Net of Reserves Recognition of revenue deferred in prior periods Deferred Revenue, Revenue Recognized Lease receivable, current Less: current portion of lease receivable Net Investment in Lease, before Allowance for Credit Loss, Current Accrued expenses Accrued Liabilities, Current Finished goods Inventory, Finished Goods, Net of Reserves Basic net income per share: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Employee Stock Option Share-based Payment Arrangement, Option [Member] Equity [Abstract] Equity [Abstract] Consolidation Items [Domain] Consolidation Items [Domain] Comprehensive Income Comprehensive Income, Policy [Policy Text Block] Schedule of Acquired Indefinite-lived Intangible Assets by Major Class [Table] Schedule of Acquired Indefinite-lived Intangible Assets by Major Class [Table] Product Warranty Standard Product Warranty, Policy [Policy Text Block] Effect of foreign currency exchange rates on cash Effect of Exchange Rate on Cash and Cash Equivalents Common Stock Common Stock [Member] Segment Information and Enterprise Reporting Segment Reporting Disclosure [Text Block] Operating income Operating Income (Loss) Company's contribution to employee retirement savings plan Defined Contribution Plan, Employer Discretionary Contribution Amount Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Other strategic investing activities Payments to Acquire Long-term Investments Stock Repurchase Program, Period Stock Repurchase Program, Period in Force Lessee lease liabilities, current Operating Lease, Liability, Current 2022 Finite-Lived Intangible Asset, Expected Amortization, Year Two Accumulated other comprehensive (loss) income Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Stock-based compensation Share-based Payment Arrangement, Noncash Expense Additional Paid-in Capital Additional Paid-in Capital [Member] Cash and cash equivalents Cash, cash equivalents and restricted cash at end of period Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Depreciation Depreciation Related Party Transaction, Amounts of Transaction Related Party Transaction, Amounts of Transaction Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Treasury Stock Treasury Stock [Member] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Sales Revenue, Product Line Revenue, Product and Service Benchmark [Member] Goodwill [Abstract] Goodwill [Abstract] Goodwill [Abstract] Changes in Product Warranty Accrual Schedule of Product Warranty Liability [Table Text Block] (Decrease) increase in accrued liabilities Increase (Decrease) in Accrued Liabilities Schedule of Share-based Compensation, Restricted Stock Units Award Activity Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Income taxes Income Taxes Paid Other Other Nonoperating Income (Expense) Increase in other non-current liabilities Increase (Decrease) in Other Operating Liabilities Purchases of property and equipment, net Payments to Acquire Property, Plant, and Equipment Other Non-Current Liabilities Other Liabilities Disclosure [Text Block] Maximum Maximum Maximum [Member] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Total liabilities Liabilities Raw materials Inventory, Raw Materials, Net of Reserves Masimo vs. Physicians Healthsource, Inc. Masimo vs. Physicians Healthsource, Inc. [Member] Masimo vs. Physicians Healthsource, Inc. [Member] Legal Entity [Axis] Legal Entity [Axis] Schedule Other Current Liabilities Schedule of Accrued Liabilities [Table Text Block] 2021 (balance of year) Finite-Lived Intangible Asset, Expected Amortization, Year One Award Type [Axis] Award Type [Axis] Granted Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Aggregate intrinsic value of options outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Share-based Payment Arrangement, Expensed and Capitalized, Amount Share-based Payment Arrangement, Expensed and Capitalized, Amount Lessee, Operating Lease, Liability, Maturity Lessee, Operating Lease, Liability, Maturity [Table Text Block] Consolidation Items [Axis] Consolidation Items [Axis] Stockholders' Equity Attributable to Parent Stockholders' Equity Attributable to Parent Preferred stock, shares issued Preferred Stock, Shares Issued Supplemental Cash Flow Information Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Noncontrolling interest(1) Minority Interest - Current Liabilities Minority Interest - Current Liabilities Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expired, Weighed Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expired, Weighed Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expired, Weighed Average Grant Date Fair Value Intangible Assets Intangible Assets Disclosure [Text Block] Repurchases of common stock Payments for Repurchase of Common Stock Property, Plant and Equipment, Useful Life Property, Plant and Equipment, Useful Life Other non-current liabilities Total other non-current liabilities Deferred Credits and Other Liabilities Subsegments Consolidation Items [Domain] Subsegments Consolidation Items [Domain] Risk-free interest rate, minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Increase in deferred costs and other contract assets Increase (Decrease) in Deferred Charges Lessee non-current lease liabilities Operating Lease, Liability, Noncurrent 2021 (balance of year) Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year One Adjustments for New Accounting Pronouncements [Axis] Accounting Standards Update [Axis] Interest expense Interest Expense Licenses-related party Licensing Agreements [Member] (Decrease) increase in accrued compensation Increase (Decrease) in Employee Related Liabilities Estimated volatility, maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Changes in pre-existing warranties (including changes in estimates) Standard and Extended Product Warranty Accrual, Increase (Decrease) for Preexisting Warranties City Area Code City Area Code Retained earnings Retained Earnings (Accumulated Deficit) Acquired technologies Acquired Technology [Member] Acquired Technology [Member] Increase in lease receivable, net Proceeds from Lease Payment, Operating Activity Litigation Case [Domain] Litigation Case [Domain] Accrued indirect taxes payable Accrual for Taxes Other than Income Taxes, Current Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Operating Lease, Variable Lease Income Operating Lease, Variable Lease Income Share Repurchase Program [Axis] Share Repurchase Program [Axis] Strategic investments Equity Method Investments Income Statement [Abstract] Income Statement [Abstract] Amendment Flag Amendment Flag Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Operating Lease, Right-of-Use Asset, Accumulated Amortization Operating Lease, Right-of-Use Asset, Accumulated Amortization Operating Lease, Right-of-Use Asset, Accumulated Amortization Unsettled common stock proceeds from option exercises Proceeds from stock options exercised, unsettled at period end Proceeds from stock options exercised, unsettled at period end Proceeds from issuance of common stock Proceeds from Stock Options Exercised Related Party Transaction [Axis] Related Party Transaction [Axis] Restricted/Performance stock units vested Stock Issued During Period, Shares, Restricted Stock Award, Gross Canceled Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Provision for income taxes Income Tax Expense (Benefit) Purchase Commitment Purchase Commitment [Member] Trade accounts receivable, net of allowance for credit losses Accounts Receivable, after Allowance for Credit Loss, Current Asia and Australia Asia Pacific [Member] Asia Pacific [Member] Supplemental Unemployment Benefits, Severance Benefits, Required Notice of Resignation Supplemental Unemployment Benefits, Severance Benefits, Required Notice of Resignation Supplemental Unemployment Benefits, Severance Benefits, Required Notice of Resignation Equity Components [Axis] Equity Components [Axis] Related Party Transaction, Date Related Party Transaction, Date Total current assets Assets, Current Accounts Receivable Accounts Receivable [Member] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Total Lessee, Operating Lease, Liability, to be Paid Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Inventories Total inventories Inventory, Net Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Entity File Number Entity File Number Analysis of Product Revenues Based upon the Geographic Area Shipped Segment Reporting Information, Revenue for Reportable Segment [Abstract] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Thereafter(1) Lessee, Operating Lease, Liability, to be Paid, after Year Five Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Reimbursement Fee Reimbursement Fee [Member] Reimbursement Fee [Member] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Smaller Reporting Company Entity Small Business Preferred stock, par value Preferred Stock, Par or Stated Value Per Share Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Revenue Benchmark Revenue Benchmark [Member] Chief Executive Officer Chief Executive Officer Chief Executive Officer [Member] Weighted-average fair value of options granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Equity Component [Domain] Equity Component [Domain] 2021 (balance of year) Lessee, Operating Lease, Liability, to be Paid, Year One Unrealized (losses) gains from foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Bank balance covered by Federal Deposit Insurance Corporation limit Cash, FDIC Insured Amount Bank Balances Bank Balances Finite-Lived Intangible Assets, Cost Incurred to Renew or Extend Finite-Lived Intangible Assets, Cost Incurred to Renew or Extend Statement [Line Items] Statement [Line Items] Litigation Case [Axis] Litigation Case [Axis] Long-term Line of Credit, Noncurrent Long-term Line of Credit, Noncurrent Weighted-Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Unrecognized contract revenue Revenue, Remaining Performance Obligation, Amount 2022 Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Two Other Commitment Other Commitment Related Party Transaction, Purchases from Related Party Related Party Transaction, Purchases from Related Party 2024 Lessee, Operating Lease, Liability, to be Paid, Year Four Patents And Trademarks Patents And Trademarks [Member] Patents and Trademarks. Maturities of short-term investments Payments for (Proceeds from) Short-term Investments Debt Disclosure [Abstract] Debt Disclosure [Abstract] Entity Address, State or Province Entity Address, State or Province Income before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Type of Adoption [Domain] Accounting Standards Update [Domain] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Transfer to Investments Other Significant Noncash Transaction, Consideration Given Accrued rebates and allowances Accrued rebates and allowances Accrued rebates and allowances Segment Reporting [Abstract] Segment Reporting [Abstract] Entity [Domain] Entity [Domain] Unrecognized tax benefits Unrecognized Tax Benefits Liabilities Noncurrent Unrecognized tax benefits liabilities noncurrent. Revenue from External Customers by Products and Services [Table] Revenue from External Customers by Products and Services [Table] Finite-Lived Intangible Asset, Useful Life Finite-Lived Intangible Asset, Useful Life Lease receivable Sales-type and Direct Financing Leases, Lease Receivable, Payments to be Received Customer [Axis] Customer [Axis] Use of Estimates Use of Estimates, Policy [Policy Text Block] Reconciliation of Basic and Diluted Net Income Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Entity Shell Company Entity Shell Company Local Phone Number Local Phone Number Vesting [Axis] Vesting [Axis] Less: Non-current portion of deferred revenue Deferred Revenue, Noncurrent Total assets Assets Litigation awards Gain (Loss) Related to Litigation Settlement Plan Name [Domain] Plan Name [Domain] Common stock, shares authorized Common Stock, Shares Authorized Severance plan participation agreements Severance Plan Participation Agreements Severance plan participation agreements. Interest expense Interest Paid, Excluding Capitalized Interest, Operating Activities Geographical [Domain] Geographical [Domain] Title of Individual [Axis] Title of Individual [Axis] Research and development Research and Development Expense Lessee, Operating Lease, Renewal Term Lessee, Operating Lease, Renewal Term Shipping and Handling Costs and Fees Shipping and Handling costs and Fees [Policy Text Block] Shipping and Handling costs and Fees [Policy Text Block] Loss contingency, damages sought Loss Contingency, Damages Sought, Value Per Violation Loss Contingency, Damages Sought, Value Per Violation Weighted average number of years until the next renewal Finite-Lived Intangible Asset, Weighted Average Period before Next Renewal or Extension Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Revolving Credit Facility [Member] Revolving Credit Facility [Member] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Transportation, vehicles and other Transportation, vehicles and other Transportation Equipment [Member] Furniture and office equipment Furniture and Fixtures [Member] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Entity Tax Identification Number Entity Tax Identification Number Other current assets Other Assets, Miscellaneous, Current Fair value of common stock received for payment of stock option exercise price Fair value of common stock received for payment of stock option exercise price Fair value of common stock received for payment of stock option exercise price Geographical [Axis] Geographical [Axis] Deferred costs and other contract assets Deferred Costs and Other Assets Other current liabilities Total other current liabilities Accrued Liabilities and Other Liabilities Basic Weighted-average shares outstanding - basic Weighted Average Number of Shares Outstanding, Basic Diluted Net income per diluted share Earnings Per Share, Diluted Segments [Domain] Segments [Domain] Related party payables Due to Related Parties, Current Vesting [Domain] Vesting [Domain] Sales Sales [Member] Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Intangible Assets Intangible Assets, Finite-Lived, Policy [Policy Text Block] International Non-US [Member] Unbilled contract receivables Unbilled Contracts Receivable Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Schedule of Components Of Other Liabilities Long Term Table Components Of Other Liabilities Long Term Table [Table Text Block] This element may be used as a single block of text to encapsulate the entire disclosure for other liabilities including data and tables. Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Treasury Stock, Value Treasury Stock, Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Related Party Transaction [Line Items] Related Party Transaction [Line Items] Prepaid contract allowances Prepaid Discount Prepaid Discount Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Leased Property Leased Property [Member] Leased Property [Member] Subsegments [Domain] Subsegments [Domain] Accounts payable Accounts Payable, Current Taxes Collected From Customers And Remitted To Governmental Authorities Taxes Collected From Customers And Remitted To Governmental Authorities Policy [Policy Text Block] Disclosure of accounting policy for taxes collected from customers and remitted to government authorities. Concentration Risk Type [Axis] Concentration Risk Type [Axis] Depreciation and amortization Depreciation, Depletion and Amortization Revenue, Major Customer [Line Items] Revenue, Major Customer [Line Items] 2023 Finite-Lived Intangible Asset, Expected Amortization, Year Three Number of Sources of Product Revenue Number of Sources of Product Revenue Number of Sources of Product Revenue Business Combinations Business Combinations Policy [Policy Text Block] Accumulated Other Comprehensive Income (loss) AOCI Attributable to Parent [Member] Lease receivable, net Total Sales-type Lease, Lease Receivable Decrease (increase) in inventories Increase (Decrease) in Inventories Percentage of Revenue - Customer Concentration Percentage of Revenue - Customer Concentration Percentage of Revenue - Customer Concentration Common Stock, Shares, Outstanding Common Stock, Shares, Outstanding Warranty accrual, beginning of period Warranty accrual, end of period Standard and Extended Product Warranty Accrual Cost of goods sold Cost of Goods and Services Sold Accrued warranty Product Warranty Accrual, Current Increase in intangible assets Payments to Acquire Intangible Assets Deposit release to acquire noncontrolling interest(1) Payments to Acquire Additional Interest in Subsidiaries Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Number of common shares authorized to be repurchased under new stock repurchase program Stock Repurchase Program, Number of Shares Authorized to be Repurchased Movement in Deferred Revenue [Roll Forward] Movement in Deferred Revenue [Roll Forward] Lessee Operating Lease Balance Sheet Classification Lessee Operating Lease Balance Sheet Classification [Table Text Block] [Table Text Block] for Lessee Operating Lease Balance Sheet Classification [Table] Deferred commissions Deferred Sales Commissions Deferred Sales Commissions Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Acquired Indefinite-lived Intangible Assets [Line Items] Acquired Indefinite-lived Intangible Assets [Line Items] Award Date [Domain] Award Date [Domain] Property, Plant and Equipment Schedule of Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Stockholders’ equity Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Customer relationships Customer Relationships [Member] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Property and Equipment, net Property, Plant and Equipment Disclosure [Text Block] Total operating expenses Operating Expenses Other Other Liabilities, Noncurrent Schedule of Finite-Lived Intangible Assets, Future Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Fiscal Periods Fiscal Period, Policy [Policy Text Block] Repurchases of common stock, shares Treasury Stock, Shares, Acquired Treasury Stock, Shares, Acquired Debt Instrument [Line Items] Debt Instrument [Line Items] Income Tax Effects Allocated Directly to Equity, Cumulative Effect of Change in Accounting Principle Income Tax Effects Allocated Directly to Equity, Cumulative Effect of Change in Accounting Principle Total property and equipment Property, Plant and Equipment, Gross Other Current Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Related Party Transaction [Domain] Related Party Transaction [Domain] Document Quarterly Report Document Quarterly Report Product revenue Revenues Current Borrowing Capacity Line of Credit Facility, Current Borrowing Capacity Trademarks Trademarks [Member] Options outstanding, beginning of period Options outstanding, end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Impairment of Goodwill, Intangible Assets and Other Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] Patents Patents [Member] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Share-based Compensation Expense Share-based Payment Arrangement, Expense Revenue Recognition, Multiple-deliverable Arrangements [Line Items] Revenue Recognition, Multiple-deliverable Arrangements [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Estimated volatility, minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Document Fiscal Period Focus Document Fiscal Period Focus Net income Net income Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Restricted cash(1) Restricted Cash, Current Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Aggregate intrinsic value of options exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Concentration Risk, Just-in-time Distributors Concentration Risk, Just-in-time Distributors Concentration Risk, Just-in-time Distributors Construction-in-progress (CIP) Construction in Progress [Member] Loss on disposal of equipment, intangibles and other assets Gain (Loss) on Disposition of Property Plant Equipment Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Shares, Issued, Beginning Balance Shares, Issued, Ending Balance Shares, Issued United States (U.S.) UNITED STATES Common stock, par value Common Stock, Par or Stated Value Per Share 2025 Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Five Risk-free interest rate, maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Accrued property taxes Taxes Payable, Current Current assets Assets, Current [Abstract] Total intangible assets Finite-Lived Intangible Assets, Gross Common Stock, Capital Shares Reserved for Future Issuance Common Stock, Capital Shares Reserved for Future Issuance Award Date [Axis] Award Date [Axis] Leases [Abstract] Leases [Abstract] Entity Central Index Key Entity Central Index Key Schedule of Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Percentage Of Revenue Two Customer Percentage Of Revenue Two Customer Percentage of revenue two customer. Deferred revenue and other contract liabilities, current Deferred revenue and other contract liabilities - current Deferred Revenue, Current Security Exchange Name Security Exchange Name Schedule of Nonvested Performance-based Units Activity Schedule of Nonvested Performance-based Units Activity [Table Text Block] Stock options exercised, shares Exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Diluted Weighted-average shares outstanding - diluted Weighted Average Number of Shares Outstanding, Diluted Income Taxes Income Tax Disclosure [Text Block] Lease Receivable Lessor, Sales-type Leases [Text Block] Contingencies And Commitments [Line Items] Contingencies And Commitments [Line Items] Contingencies And Commitments [Line Items] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Related Party [Domain] Related Party [Domain] Current Fiscal Year End Date Current Fiscal Year End Date Schedule of Number and Weighted Average Exercise Price of Options Issued and Outstanding under all Stock Option Plans Share-based Payment Arrangement, Option, Activity [Table Text Block] Stock Repurchase Program Stockholders' Equity Note Disclosure [Text Block] 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Five Other Current Assets Other Current Assets [Text Block] Fair Value of Measurements Fair Value of Financial Instruments, Policy [Policy Text Block] Nonoperating Income (Expense) [Abstract] Nonoperating Income (Expense) [Abstract] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Class of Stock [Line Items] Class of Stock [Line Items] Credit Facility [Axis] Credit Facility [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Building and building improvements Building and Building Improvements [Member] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Schedule of Deferred Costs and Other Contract Assets Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Subsegments Consolidation Items [Axis] Subsegments Consolidation Items [Axis] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Purchase Commitment, Remaining Minimum Amount Committed Purchase Commitment, Remaining Minimum Amount Committed Expected term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Total current liabilities Liabilities, Current Class of Stock [Domain] Class of Stock [Domain] Payroll tax withholdings on behalf of employees for vested equity awards Payment, Tax Withholding, Share-based Payment Arrangement Sales-type Lease, Lease Receivable, Maturity Sales-type and Direct Financing Leases, Lease Receivable, Maturity [Table Text Block] 2021 PSU Grant [Domain] 2021 PSU Grant [Domain] 2021 PSU Grant Contingencies And Commitments [Table] Contingencies And Commitments [Table] Contingencies And Commitments [Table] Line of Credit Facility, Maximum Borrowing Capacity Line of Credit Facility, Maximum Borrowing Capacity Foreign currency translation adjustment Goodwill, Foreign Currency Translation Gain (Loss) Product revenue Product Revenue from Contract with Customer, Including Assessed Tax Entity Address, Postal Zip Code Entity Address, Postal Zip Code Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Title of 12(b) Security Title of 12(b) Security Long-Lived Assets Long-Lived Assets Cash Distribution Cash Distribution [Member] Statement [Table] Statement [Table] Other current assets Total other current assets Other Assets, Current Recently Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Increase in other non-current assets Increase (Decrease) in Other Noncurrent Assets Range of assumptions used and resulting weighted-average fair value of options granted at the date of grant Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Statistical Measurement [Axis] Statistical Measurement [Axis] Accounts Receivable and Allowance for Credit Losses Accounts Receivable [Policy Text Block] Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document and Entity Information [Abstract] Masimo vs Former Agency Tender Masimo vs Former Agency Tender [Member] Masimo vs Former Agency Tender [Domain] Subsequent Event Subsequent Event [Member] Prepaid deposits and other Deposits Assets, Noncurrent Schedule of Other Non-Current Assets Schedule of Other Non-Current Assets Schedule of Other Assets [Table Text Block] Percentage Of Revenue One Customer Percentage Of Revenue One Customer Percentage of the Company's total revenue that is from one customer. Intangible assets, net Finite-Lived Intangible Assets, Net Goodwill Goodwill Deferred revenue Deferred revenue, beginning of the period Deferred revenue, end of the period Deferred Revenue Income tax payable Accrued Income Taxes, Current Deferred Costs and Other Contract Assets Deferred Costs and Other Contract Assets [Policy Text Block] Deferred Costs and Other Contract Assets [Policy Text Block] Inventory Inventory, Policy [Policy Text Block] Proceeds from Legal Settlements Proceeds from Legal Settlements Schedule of Goodwill Schedule of Goodwill [Table Text Block] Description of the Company Nature of Operations [Text Block] Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Warranty period for defects in material and workmanship Warranty Period For Defects In Material And Workmanship Warranty period for defects in material and workmanship. Subsequent Event Type [Axis] Subsequent Event Type [Axis] Common Stock, Value, Outstanding Common Stock, Value, Outstanding Operating lease costs Operating Lease, Cost Computer equipment and software Computer Equipment [Member] Revenue deferred during the period Deferred Revenue, Additions Total deferred revenue and other contract liabilities Other Liabilities and Deferred Revenue, Noncurrent Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Related Party Transactions Disclosure Related Party Transactions Disclosure [Text Block] Reportable Geographical Components Reportable Geographical Components [Member] Concentration Risk, AR Balance One Customer ConcentrationRiskARCustomer Concentration Risk, Customer, Percentage of Receivable Balance Company contribution percentage based on employee contribution of up to 3% of employee's compensation Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Provision for deferred income taxes Deferred Income Tax Expense (Benefit) EX-101.PRE 9 masi-20211002_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 10 masi-20211002_g1.jpg GRAPHIC begin 644 masi-20211002_g1.jpg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end XML 11 masi-20211002_htm.xml IDEA: XBRL DOCUMENT 0000937556 2021-01-03 2021-10-02 0000937556 2021-10-02 0000937556 2021-01-02 0000937556 2021-07-04 2021-10-02 0000937556 2020-06-28 2020-09-26 0000937556 2019-12-29 2020-09-26 0000937556 us-gaap:CommonStockMember 2021-01-02 0000937556 us-gaap:TreasuryStockMember 2021-01-02 0000937556 us-gaap:AdditionalPaidInCapitalMember 2021-01-02 0000937556 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-02 0000937556 us-gaap:RetainedEarningsMember 2021-01-02 0000937556 us-gaap:CommonStockMember 2021-01-03 2021-04-03 0000937556 us-gaap:AdditionalPaidInCapitalMember 2021-01-03 2021-04-03 0000937556 2021-01-03 2021-04-03 0000937556 us-gaap:TreasuryStockMember 2021-01-03 2021-04-03 0000937556 us-gaap:RetainedEarningsMember 2021-01-03 2021-04-03 0000937556 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-03 2021-04-03 0000937556 us-gaap:CommonStockMember 2021-04-03 0000937556 us-gaap:TreasuryStockMember 2021-04-03 0000937556 us-gaap:AdditionalPaidInCapitalMember 2021-04-03 0000937556 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-03 0000937556 us-gaap:RetainedEarningsMember 2021-04-03 0000937556 2021-04-03 0000937556 us-gaap:CommonStockMember 2021-04-04 2021-07-03 0000937556 us-gaap:AdditionalPaidInCapitalMember 2021-04-04 2021-07-03 0000937556 2021-04-04 2021-07-03 0000937556 us-gaap:RetainedEarningsMember 2021-04-04 2021-07-03 0000937556 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-04 2021-07-03 0000937556 us-gaap:CommonStockMember 2021-07-03 0000937556 us-gaap:TreasuryStockMember 2021-07-03 0000937556 us-gaap:AdditionalPaidInCapitalMember 2021-07-03 0000937556 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-03 0000937556 us-gaap:RetainedEarningsMember 2021-07-03 0000937556 2021-07-03 0000937556 us-gaap:CommonStockMember 2021-07-04 2021-10-02 0000937556 us-gaap:AdditionalPaidInCapitalMember 2021-07-04 2021-10-02 0000937556 us-gaap:RetainedEarningsMember 2021-07-04 2021-10-02 0000937556 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-04 2021-10-02 0000937556 us-gaap:CommonStockMember 2021-10-02 0000937556 us-gaap:TreasuryStockMember 2021-10-02 0000937556 us-gaap:AdditionalPaidInCapitalMember 2021-10-02 0000937556 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-10-02 0000937556 us-gaap:RetainedEarningsMember 2021-10-02 0000937556 us-gaap:CommonStockMember 2019-12-28 0000937556 us-gaap:TreasuryStockMember 2019-12-28 0000937556 us-gaap:AdditionalPaidInCapitalMember 2019-12-28 0000937556 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-28 0000937556 us-gaap:RetainedEarningsMember 2019-12-28 0000937556 2019-12-28 0000937556 us-gaap:CommonStockMember 2019-12-29 2020-03-28 0000937556 us-gaap:AdditionalPaidInCapitalMember 2019-12-29 2020-03-28 0000937556 2019-12-29 2020-03-28 0000937556 us-gaap:TreasuryStockMember 2019-12-29 2020-03-28 0000937556 us-gaap:AccountingStandardsUpdate201613Member us-gaap:RetainedEarningsMember 2019-12-29 2020-03-28 0000937556 us-gaap:RetainedEarningsMember 2019-12-29 2020-03-28 0000937556 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-29 2020-03-28 0000937556 us-gaap:CommonStockMember 2020-03-28 0000937556 us-gaap:TreasuryStockMember 2020-03-28 0000937556 us-gaap:AdditionalPaidInCapitalMember 2020-03-28 0000937556 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-28 0000937556 us-gaap:RetainedEarningsMember 2020-03-28 0000937556 2020-03-28 0000937556 us-gaap:CommonStockMember 2020-03-29 2020-06-27 0000937556 us-gaap:AdditionalPaidInCapitalMember 2020-03-29 2020-06-27 0000937556 2020-03-29 2020-06-27 0000937556 us-gaap:TreasuryStockMember 2020-03-29 2020-06-27 0000937556 us-gaap:RetainedEarningsMember 2020-03-29 2020-06-27 0000937556 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-29 2020-06-27 0000937556 us-gaap:CommonStockMember 2020-06-27 0000937556 us-gaap:TreasuryStockMember 2020-06-27 0000937556 us-gaap:AdditionalPaidInCapitalMember 2020-06-27 0000937556 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-27 0000937556 us-gaap:RetainedEarningsMember 2020-06-27 0000937556 2020-06-27 0000937556 us-gaap:CommonStockMember 2020-06-28 2020-09-26 0000937556 us-gaap:AdditionalPaidInCapitalMember 2020-06-28 2020-09-26 0000937556 us-gaap:RetainedEarningsMember 2020-06-28 2020-09-26 0000937556 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-28 2020-09-26 0000937556 us-gaap:CommonStockMember 2020-09-26 0000937556 us-gaap:TreasuryStockMember 2020-09-26 0000937556 us-gaap:AdditionalPaidInCapitalMember 2020-09-26 0000937556 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-26 0000937556 us-gaap:RetainedEarningsMember 2020-09-26 0000937556 2020-09-26 0000937556 srt:MinimumMember us-gaap:LandBuildingsAndImprovementsMember 2021-01-03 2021-10-02 0000937556 srt:MaximumMember us-gaap:LandBuildingsAndImprovementsMember 2021-01-03 2021-10-02 0000937556 srt:MinimumMember us-gaap:ComputerEquipmentMember 2021-01-03 2021-10-02 0000937556 srt:MaximumMember us-gaap:ComputerEquipmentMember 2021-01-03 2021-10-02 0000937556 masi:DemonstrationUnitsMember 2021-01-03 2021-10-02 0000937556 srt:MinimumMember masi:FurnitureandOfficeEquipmentMember 2021-01-03 2021-10-02 0000937556 srt:MaximumMember masi:FurnitureandOfficeEquipmentMember 2021-01-03 2021-10-02 0000937556 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2021-01-03 2021-10-02 0000937556 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2021-01-03 2021-10-02 0000937556 srt:MinimumMember us-gaap:TransportationEquipmentMember 2021-01-03 2021-10-02 0000937556 srt:MaximumMember us-gaap:TransportationEquipmentMember 2021-01-03 2021-10-02 0000937556 us-gaap:PatentsMember 2021-01-03 2021-10-02 0000937556 us-gaap:TrademarksMember 2021-01-03 2021-10-02 0000937556 srt:MinimumMember 2024-07-03 2021-10-02 0000937556 srt:MaximumMember 2027-07-03 2021-10-02 0000937556 srt:MinimumMember 2021-01-03 2021-10-02 0000937556 srt:MaximumMember 2021-01-03 2021-10-02 0000937556 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember 2019-12-29 2020-09-26 0000937556 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember 2021-01-03 2021-10-02 0000937556 masi:CercacorLaboratoriesMember 2021-07-04 2021-10-02 0000937556 masi:CercacorLaboratoriesMember 2020-06-28 2020-09-26 0000937556 masi:CercacorLaboratoriesMember 2021-01-03 2021-10-02 0000937556 masi:CercacorLaboratoriesMember 2019-12-29 2020-09-26 0000937556 masi:LeasedPropertyMember 2021-01-03 2021-10-02 0000937556 masi:SubleasedPropertyDomain 2021-01-03 2021-10-02 0000937556 masi:CercacorLaboratoriesMember 2021-10-02 0000937556 masi:CercacorLaboratoriesMember 2021-01-02 0000937556 masi:NotforProfitOrganizationMember 2020-06-28 2020-09-26 0000937556 masi:NotforProfitOrganizationMember 2021-07-04 2021-10-02 0000937556 masi:NotforProfitOrganizationMember 2021-01-03 2021-10-02 0000937556 masi:NotforProfitOrganizationMember 2019-12-29 2020-09-26 0000937556 masi:LikeMindedEntertainmentMember 2021-07-04 2021-10-02 0000937556 masi:LikeMindedEntertainmentMember 2021-01-03 2021-10-02 0000937556 masi:LikeMindedEntertainmentMember 2020-06-28 2020-09-26 0000937556 masi:LikeMindedEntertainmentMember 2019-12-29 2020-09-26 0000937556 masi:LikeMindedEntertainmentMember 2021-01-02 0000937556 masi:LikeMindedEntertainmentMember 2021-10-02 0000937556 masi:LikeMindedLabsMember 2021-10-02 0000937556 masi:VantrixCorpMember us-gaap:PurchaseCommitmentMember 2021-07-08 2021-07-08 0000937556 masi:VantrixCorpMember us-gaap:OptionMember 2021-07-08 2021-07-08 0000937556 masi:ReimbursementFeeMember 2021-01-03 2021-10-02 0000937556 masi:ReimbursementFeeMember 2020-06-28 2020-09-26 0000937556 masi:ReimbursementFeeMember 2019-12-29 2020-09-26 0000937556 masi:ReimbursementFeeMember 2021-07-04 2021-10-02 0000937556 us-gaap:BuildingAndBuildingImprovementsMember 2021-10-02 0000937556 us-gaap:BuildingAndBuildingImprovementsMember 2021-01-02 0000937556 us-gaap:MachineryAndEquipmentMember 2021-10-02 0000937556 us-gaap:MachineryAndEquipmentMember 2021-01-02 0000937556 us-gaap:LandMember 2021-10-02 0000937556 us-gaap:LandMember 2021-01-02 0000937556 us-gaap:TransportationEquipmentMember 2021-10-02 0000937556 us-gaap:TransportationEquipmentMember 2021-01-02 0000937556 us-gaap:ComputerEquipmentMember 2021-10-02 0000937556 us-gaap:ComputerEquipmentMember 2021-01-02 0000937556 us-gaap:LeaseholdImprovementsMember 2021-10-02 0000937556 us-gaap:LeaseholdImprovementsMember 2021-01-02 0000937556 us-gaap:FurnitureAndFixturesMember 2021-10-02 0000937556 us-gaap:FurnitureAndFixturesMember 2021-01-02 0000937556 masi:DemonstrationUnitsMember 2021-10-02 0000937556 masi:DemonstrationUnitsMember 2021-01-02 0000937556 us-gaap:ConstructionInProgressMember 2021-10-02 0000937556 us-gaap:ConstructionInProgressMember 2021-01-02 0000937556 us-gaap:PatentsMember 2021-10-02 0000937556 us-gaap:PatentsMember 2021-01-02 0000937556 masi:AcquiredTechnologyMember 2021-10-02 0000937556 masi:AcquiredTechnologyMember 2021-01-02 0000937556 us-gaap:CustomerRelationshipsMember 2021-10-02 0000937556 us-gaap:CustomerRelationshipsMember 2021-01-02 0000937556 us-gaap:TrademarksMember 2021-10-02 0000937556 us-gaap:TrademarksMember 2021-01-02 0000937556 us-gaap:LicensingAgreementsMember 2021-10-02 0000937556 us-gaap:LicensingAgreementsMember 2021-01-02 0000937556 us-gaap:LicensingAgreementsMember masi:CercacorLaboratoriesMember 2021-10-02 0000937556 us-gaap:LicensingAgreementsMember masi:CercacorLaboratoriesMember 2021-01-02 0000937556 us-gaap:OtherIntangibleAssetsMember 2021-10-02 0000937556 us-gaap:OtherIntangibleAssetsMember 2021-01-02 0000937556 masi:PatentsAndTrademarksMember 2021-07-04 2021-10-02 0000937556 masi:PatentsAndTrademarksMember 2020-06-28 2020-09-26 0000937556 masi:PatentsAndTrademarksMember 2021-01-03 2021-10-02 0000937556 masi:PatentsAndTrademarksMember 2019-12-29 2020-09-26 0000937556 2026-10-01 2021-10-02 0000937556 2022-10-01 2021-10-02 0000937556 us-gaap:RevolvingCreditFacilityMember 2018-12-17 0000937556 us-gaap:RevolvingCreditFacilityMember 2018-12-17 0000937556 us-gaap:ForeignLineOfCreditMember 2018-12-17 0000937556 us-gaap:RevolvingCreditFacilityMember 2021-10-02 0000937556 us-gaap:RevolvingCreditFacilityMember 2021-01-02 0000937556 us-gaap:RevolvingCreditFacilityMember 2020-06-28 2020-09-26 0000937556 us-gaap:RevolvingCreditFacilityMember 2021-07-04 2021-10-02 0000937556 us-gaap:RevolvingCreditFacilityMember 2019-12-29 2020-09-26 0000937556 us-gaap:RevolvingCreditFacilityMember 2021-01-03 2021-10-02 0000937556 masi:A2021RepurchaseProgramMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2021-10-29 0000937556 masi:A2021RepurchaseProgramMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2021-10-29 2024-10-29 0000937556 masi:A2018RepurchaseProgramMember us-gaap:CommonStockMember 2018-07-01 0000937556 masi:A2018RepurchaseProgramMember us-gaap:CommonStockMember 2018-09-11 2021-09-11 0000937556 srt:MinimumMember masi:A2017EquityIncentivePlanDomain 2021-10-02 0000937556 masi:A2017EquityIncentivePlanDomain 2021-07-04 2021-10-02 0000937556 srt:MaximumMember masi:A2017EquityIncentivePlanDomain 2021-10-02 0000937556 srt:MaximumMember masi:A2007StockIncentivePlanDomain 2021-10-02 0000937556 us-gaap:EmployeeStockOptionMember 2021-07-04 2021-10-02 0000937556 us-gaap:EmployeeStockOptionMember 2020-06-28 2020-09-26 0000937556 us-gaap:EmployeeStockOptionMember 2021-01-03 2021-10-02 0000937556 us-gaap:EmployeeStockOptionMember 2019-12-29 2020-09-26 0000937556 us-gaap:EmployeeStockOptionMember 2021-10-02 0000937556 us-gaap:RestrictedStockUnitsRSUMember 2021-01-02 0000937556 us-gaap:RestrictedStockUnitsRSUMember 2021-01-03 2021-10-02 0000937556 us-gaap:RestrictedStockUnitsRSUMember 2021-10-02 0000937556 us-gaap:RestrictedStockUnitsRSUMember 2021-07-04 2021-10-02 0000937556 us-gaap:RestrictedStockUnitsRSUMember 2020-06-28 2020-09-26 0000937556 us-gaap:RestrictedStockUnitsRSUMember 2019-12-29 2020-09-26 0000937556 us-gaap:PerformanceSharesMember 2021-01-02 0000937556 srt:MinimumMember us-gaap:PerformanceSharesMember 2021-01-03 2021-10-02 0000937556 us-gaap:PerformanceSharesMember 2021-01-03 2021-10-02 0000937556 us-gaap:PerformanceSharesMember 2021-10-02 0000937556 srt:MinimumMember masi:A2021PSUGrantDomain us-gaap:PerformanceSharesMember 2021-01-03 2021-10-02 0000937556 srt:MinimumMember masi:A2021PSUGrantDomain us-gaap:PerformanceSharesMember 2021-10-02 0000937556 srt:MaximumMember masi:A2021PSUGrantDomain us-gaap:PerformanceSharesMember 2021-10-02 0000937556 srt:MaximumMember masi:A2021PSUGrantDomain us-gaap:PerformanceSharesMember 2021-01-03 2021-10-02 0000937556 us-gaap:PerformanceSharesMember 2021-07-04 2021-10-02 0000937556 us-gaap:PerformanceSharesMember 2020-06-28 2020-09-26 0000937556 us-gaap:PerformanceSharesMember 2019-12-29 2020-09-26 0000937556 srt:ChiefExecutiveOfficerMember us-gaap:CashDistributionMember 2017-07-27 2017-07-27 0000937556 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember 2017-07-27 2017-07-27 0000937556 srt:ChiefExecutiveOfficerMember 2021-01-03 2021-10-02 0000937556 us-gaap:SalesRevenueProductLineMember 2021-07-04 2021-10-02 0000937556 us-gaap:SalesRevenueProductLineMember 2020-06-28 2020-09-26 0000937556 us-gaap:SalesRevenueProductLineMember 2021-01-03 2021-10-02 0000937556 us-gaap:SalesRevenueProductLineMember 2019-12-29 2020-09-26 0000937556 us-gaap:SalesMember 2021-07-04 2021-10-02 0000937556 us-gaap:SalesMember 2020-06-28 2020-09-26 0000937556 us-gaap:SalesMember 2021-01-03 2021-10-02 0000937556 us-gaap:SalesMember 2019-12-29 2020-09-26 0000937556 us-gaap:AccountsReceivableMember 2021-10-02 0000937556 us-gaap:AccountsReceivableMember 2021-01-02 0000937556 masi:MasimovsFormerAgencyTenderMember 2018-04-01 2018-06-30 0000937556 masi:MasimovsFormerAgencyTenderMember 2019-12-29 2020-06-27 0000937556 2019-07-08 2019-07-08 0000937556 masi:Masimovs.PhysiciansHealthsourceInc.Member 2014-01-02 2014-01-03 0000937556 srt:ReportableGeographicalComponentsMember country:US 2021-07-04 2021-10-02 0000937556 country:US us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-07-04 2021-10-02 0000937556 srt:ReportableGeographicalComponentsMember country:US 2020-06-28 2020-09-26 0000937556 country:US us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-06-28 2020-09-26 0000937556 srt:ReportableGeographicalComponentsMember country:US 2021-01-03 2021-10-02 0000937556 country:US us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-01-03 2021-10-02 0000937556 srt:ReportableGeographicalComponentsMember country:US 2019-12-29 2020-09-26 0000937556 country:US us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-12-29 2020-09-26 0000937556 srt:ReportableGeographicalComponentsMember us-gaap:EMEAMember 2021-07-04 2021-10-02 0000937556 us-gaap:EMEAMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-07-04 2021-10-02 0000937556 srt:ReportableGeographicalComponentsMember us-gaap:EMEAMember 2020-06-28 2020-09-26 0000937556 us-gaap:EMEAMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-06-28 2020-09-26 0000937556 srt:ReportableGeographicalComponentsMember us-gaap:EMEAMember 2021-01-03 2021-10-02 0000937556 us-gaap:EMEAMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-01-03 2021-10-02 0000937556 srt:ReportableGeographicalComponentsMember us-gaap:EMEAMember 2019-12-29 2020-09-26 0000937556 us-gaap:EMEAMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-12-29 2020-09-26 0000937556 srt:ReportableGeographicalComponentsMember srt:AsiaPacificMember 2021-07-04 2021-10-02 0000937556 srt:AsiaPacificMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-07-04 2021-10-02 0000937556 srt:ReportableGeographicalComponentsMember srt:AsiaPacificMember 2020-06-28 2020-09-26 0000937556 srt:AsiaPacificMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-06-28 2020-09-26 0000937556 srt:ReportableGeographicalComponentsMember srt:AsiaPacificMember 2021-01-03 2021-10-02 0000937556 srt:AsiaPacificMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-01-03 2021-10-02 0000937556 srt:ReportableGeographicalComponentsMember srt:AsiaPacificMember 2019-12-29 2020-09-26 0000937556 srt:AsiaPacificMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-12-29 2020-09-26 0000937556 srt:ReportableGeographicalComponentsMember srt:AmericasMember 2021-07-04 2021-10-02 0000937556 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-07-04 2021-10-02 0000937556 srt:ReportableGeographicalComponentsMember srt:AmericasMember 2020-06-28 2020-09-26 0000937556 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-06-28 2020-09-26 0000937556 srt:ReportableGeographicalComponentsMember srt:AmericasMember 2021-01-03 2021-10-02 0000937556 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-01-03 2021-10-02 0000937556 srt:ReportableGeographicalComponentsMember srt:AmericasMember 2019-12-29 2020-09-26 0000937556 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-12-29 2020-09-26 0000937556 srt:ReportableGeographicalComponentsMember country:US 2021-10-02 0000937556 srt:ReportableGeographicalComponentsMember country:US 2021-01-02 0000937556 srt:ReportableGeographicalComponentsMember us-gaap:NonUsMember 2021-10-02 0000937556 srt:ReportableGeographicalComponentsMember us-gaap:NonUsMember 2021-01-02 shares iso4217:USD iso4217:USD shares masi:segment utr:sqft pure masi:Agreement masi:distributor masi:Customer false 2021 Q3 0000937556 --01-01 10-Q true 2021-10-02 false 001-33642 MASIMO CORP DE 33-0368882 52 Discovery Irvine, CA 92618 (949) 297-7000 Common Stock, $0.001 par value MASI NASDAQ Yes Yes Large Accelerated Filer false false false 55221689 652354000 641447000 2081000 1603000 191332000 141350000 202328000 215952000 91772000 102416000 1137786000 1101165000 66955000 57666000 22599000 20076000 274929000 272511000 74089000 73923000 101242000 103206000 39294000 39363000 49886000 44642000 1766780000 1712552000 60710000 64061000 69785000 71601000 46641000 44935000 51118000 53239000 228254000 233836000 70377000 71076000 298631000 304912000 1.000 1.000 5000000 5000000 0 0 0 0 0 0 1.000 1.000 100000000 100000000 55222000 55251000 55000 55000 16540000 15993000 767653000 638736000 736575000 703693000 -3432000 1413000 1502604000 1341215000 1468149000 1407640000 1766780000 1712552000 307414000 278112000 911575000 848690000 103750000 99186000 318124000 292551000 203664000 178926000 593451000 556139000 100647000 90376000 291180000 278714000 35406000 28852000 103860000 86971000 0 0 0 474000 136053000 119228000 395040000 365211000 67611000 59698000 198411000 190928000 -78000 1357000 -735000 6108000 67533000 61055000 197676000 197036000 9762000 11650000 36287000 27403000 57771000 49405000 161389000 169633000 1.05 0.90 2.93 3.11 1.00 0.85 2.80 2.92 55143000 54997000 55125000 54543000 57664000 58280000 57651000 58033000 57771000 49405000 161389000 169633000 -3165000 2653000 -4845000 1504000 54606000 52058000 156544000 171137000 55251000 55000 15993000 -638736000 703693000 1413000 1341215000 1407640000 61000 0 2886000 2886000 303000 -68000 16691000 16691000 12708000 12708000 547000 547000 128917000 128917000 53383000 53383000 -2884000 -2884000 55000000 55000 16540000 -767653000 702596000 -1471000 1394598000 1328125000 52000 0 3442000 3442000 4000 1000 33000 33000 8262000 8262000 50235000 50235000 1204000 1204000 55057000 55000 16540000 -767653000 714267000 -267000 1444833000 1391235000 165000 0 9748000 9748000 12560000 12560000 57771000 57771000 -3165000 -3165000 55222000 55000 16540000 -767653000 736575000 -3432000 1502604000 1468149000 53696000 54000 15530000 -526580000 600624000 -6718000 1100494000 1167874000 384000 0 13495000 13495000 46000 -8000 1424000 1424000 11272000 11272000 3000 3000 371000 371000 439000 439000 64456000 64456000 -2463000 -2463000 54115000 54000 15533000 -526951000 623967000 -9181000 1165389000 1253278000 825000 1000 21212000 21213000 9000 13188000 13188000 1000 1000 220000 220000 55772000 55772000 1314000 1314000 54948000 55000 15534000 -527171000 658367000 -7867000 1221161000 1344545000 107000 0 6314000 6314000 1000 -1000 25000 25000 11912000 11912000 49405000 49405000 2653000 2653000 55055000 55000 15534000 -527171000 676568000 -5214000 1270566000 1414804000 161389000 169633000 26449000 21200000 33530000 36372000 -371000 -202000 647000 5000 0 136000 50967000 9459000 -12329000 86815000 -4433000 23461000 -9312000 -6279000 2573000 1964000 144000 775000 -4290000 31793000 -1298000 3654000 -3969000 4691000 -1456000 -2756000 1378000 9973000 634000 395000 167151000 146545000 0 -70000000 20680000 60017000 8185000 5763000 0 78310000 2600000 6750000 -31465000 -80840000 18975000 40994000 16724000 1449000 128917000 591000 -126666000 38954000 -89000 -294000 8931000 104365000 645004000 568075000 653935000 672440000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. Description of the Company </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Masimo Corporation (the Company) is a global medical technology company that develops, manufactures and markets a variety of noninvasive patient monitoring technologies, hospital automation solutions, home monitoring devices and consumer products. The Company’s mission is to improve patient outcomes, reduce the cost of care and take noninvasive monitoring to new sites and applications. The Company’s patient monitoring solutions generally incorporate a monitor or circuit board, proprietary single-patient use or reusable sensors, software and/or cables. The Company primarily sells its products to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, long-term care facilities, and consumers through its direct sales force, distributors and original equipment manufacturer (OEM) partners.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Masimo’s core measurement technologies are based on Measure-through Motion and Low Perfusion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> pulse oximetry, known as Masimo Signal Extraction Technology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (SET</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) pulse oximetry, and advanced rainbow</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pulse CO-Oximetry parameters such as noninvasive hemoglobin (SpHb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), alongside many other modalities, including brain function monitoring, hemodynamic monitoring, regional oximetry, acoustic respiration rate monitoring, capnography, nasal high-flow respiratory support therapy, patient position and activity tracking and neuromodulation technology for the reduction of symptoms associated with opioid withdrawal. Masimo’s measurement technologies are available on many types of devices, from bedside hospital monitors like the Root</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patient Monitoring and Connectivity Hub, to various handheld and portable devices, and to the tetherless Masimo SafetyNet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> remote patient surveillance solution. The Masimo Hospital Automation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Platform facilitates data integration, connectivity, and interoperability through solutions like Patient SafetyNet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Replica</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and UniView</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to facilitate more efficient clinical workflows and to help clinicians provide the best possible care, both in-person and remotely. Leveraging the Company’s expertise in hospital-grade technologies, the Company has also expanded its suite of products intended for use outside the hospital to products for consumers, including Sleep</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a sleep quality solution and the Radius Tº</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> wireless, wearable continuous thermometer.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The use of the trademark Patient SafetyNet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> is under license from the University HealthSystem Consortium.</span></div> <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. Summary of Significant Accounting Policies </span></div><div style="margin-top:4.5pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) have been condensed or omitted pursuant to such rules and regulations. The accompanying condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, including normal recurring accruals, necessary to present fairly the Company’s condensed consolidated financial statements. The accompanying condensed consolidated balance sheet as of January 2, 2021 was derived from the Company’s audited consolidated financial statements at that date. The accompanying condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes contained in the Company’s Annual Report on Form 10-K for the fiscal year ended January 2, 2021 (fiscal year 2020), filed with the SEC on February 23, 2021. The results for the three and nine months ended October 2, 2021 are not necessarily indicative of the results to be expected for the fiscal year ending January 1, 2022 (fiscal year 2021) or for any other interim period or for any future year.</span></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fiscal Periods</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows a conventional 52/53 week fiscal year. Under a conventional 52/53 week fiscal year, a 52 week fiscal year includes four quarters of 13 weeks while a 53 week fiscal year includes three 13 week fiscal quarters and one 14 week fiscal quarter. The Company’s last 53 week fiscal year was fiscal year 2020. Fiscal year 2021 is a 52 week fiscal year ending January 1, 2022. All references to years in these notes to condensed consolidated financial statements are fiscal years unless otherwise noted.</span></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts in the accompanying condensed consolidated financial statements have been reclassified to conform to the current period presentation.</span></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company prepares its financial statements in conformity with GAAP, which requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates include the determination of standalone selling prices, variable consideration, total consideration allocated to each performance obligation within a contract, inventory valuation, valuation of the Company’s equity awards, valuation of identifiable assets and liabilities connected with business combinations, deferred taxes and any associated valuation allowances, deferred revenue, uncertain income tax positions, and litigation costs and related accruals. Actual results could differ from such estimates.</span></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for business combinations using the acquisition method of accounting, which requires that once control is obtained, all the assets acquired, liabilities assumed and noncontrolling interests in the acquired entity, if applicable, are recorded at their respective fair values at the date of acquisition. The excess of the purchase price over the fair values of identifiable assets, liabilities and noncontrolling interests in the acquired entity, if applicable, is recorded as goodwill. The Company finalizes the purchase price allocation within one year from the acquisition date.</span></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Authoritative guidance describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">●    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1—Quoted prices in active markets for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">identical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> assets or liabilities.</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">●    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">similar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> assets or liabilities, quoted prices in markets that are not active; or other inputs that can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">●    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to current authoritative guidance, entities are allowed an irrevocable option to elect the fair value for the initial and subsequent measurement for specified financial assets and liabilities on a contract-by-contract basis. The Company did not elect to apply the fair value option under this guidance to specific assets or liabilities on a contract-by-contract basis. There were no transfers between Level 1, Level 2 and Level 3 inputs during either the nine months ended October 2, 2021 or September 26, 2020. The Company carries cash and cash equivalents, at cost, which approximates fair value. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For certain other financial assets and liabilities, including restricted cash, accounts receivable, accounts payable and other current assets and liabilities, the carrying amounts approximate their fair value primarily due to the relatively short maturity of these balances. The Company also measures certain non-financial assets at fair value on a non-recurring basis, primarily goodwill, intangible assets and operating lease right-of-use assets, in connection with periodic evaluations for potential impairment.</span></div><div style="margin-top:13pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity from date of purchase of three months or less, or highly liquid investments that are readily convertible into known amounts of cash, to be cash equivalents.</span></div><div style="margin-top:13pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Credit Losses</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable consist of trade receivables recorded at the time of invoicing of product sales, reduced by reserves for estimated bad debts and returns. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Credit is extended based on an evaluation of the customer’s financial condition. Collateral is generally not required. The Company records an allowance for credit losses that it does not expect to collect based on relevant information, including historical experience, current conditions, and reasonable and supportable forecasts. Accounts are charged off against the allowance when the Company believes they are uncollectible.</span></div><div style="margin-top:13pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value. Cost is determined using a standard cost method, which approximates the first in, first out method, and includes material, labor and overhead costs. Inventory valuation adjustments are recorded for inventory items that have become excess or obsolete or are no longer used in current production and for inventory items that have a market price less than carrying value in inventory. The Company generally determines inventory valuation adjustments based on an evaluation of the expected future use of its inventory on an item by item basis and applies historical obsolescence rates to estimate the loss on inventory expected to have a recovery value below cost. The Company also records other specific inventory valuation adjustments when it becomes aware of unique events or circumstances that result in an expected recovery value below cost. For inventory items that have been written down, the reduced value becomes the new cost basis.</span></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost. Depreciation is calculated using the straight-line method over estimated useful lives as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.064%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Useful Lives</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building improvements</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 to 39 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 12 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Demonstration units</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 6 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of useful life or term of lease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery, equipment and tooling</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 10 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transportation, vehicles and other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 to 20 years</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Land is not depreciated and construction-in-progress is not depreciated until placed in service. Normal repair and maintenance costs are expensed as incurred, whereas significant improvements that materially increase values or extend useful lives are capitalized and depreciated over the remaining estimated useful lives of the related assets. Upon sale or retirement of depreciable assets, the related cost and accumulated depreciation or amortization are removed from the accounts and any gain or loss on the sale or retirement is recognized in income.</span></div><div style="margin-top:13pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consist primarily of patents, trademarks, software development costs, customer relationships and acquired technology. Costs related to patents and trademarks, which include legal and application fees, are capitalized and amortized over the estimated useful lives using the straight-line method. Patent and trademark amortization commences once final approval of the patent or trademark has been obtained. Patent costs are amortized over the lesser of 10 years or the patent’s remaining legal life, which assumes renewals, and trademark costs are amortized over 17 years, and their associated amortization cost is included in selling, general and administrative expense in the accompanying condensed consolidated statements of operations. For intangibles purchased in an asset acquisition or business combination, which mainly include patents, trademarks, customer relationships and acquired technologies, the useful life is determined largely by valuation estimates of remaining economic life. The Company’s policy is to renew its patents and trademarks. Costs to renew patents and trademarks are capitalized and amortized over the remaining useful life of the intangible asset. The Company periodically evaluates the amortization period and carrying basis of patents, trademarks and other intangible assets to determine whether any events or circumstances warrant a revised estimated useful life or reduction in value. Capitalized application costs are charged to operations when it is determined that the patent or trademark will not be obtained or is abandoned.</span></div><div style="margin-top:13pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Goodwill, Intangible Assets and Other Long-Lived Assets</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is recorded as the difference, if any, between the aggregate consideration paid for an acquisition and the fair value of the acquired net tangible and intangible assets. Goodwill is not amortized, but instead is tested annually for impairment, or more frequently when events or changes in circumstances indicate that goodwill might be impaired. In assessing goodwill impairment, the Company has the option to first assess the qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. The Company’s qualitative assessment of the recoverability of goodwill considers various macroeconomic, industry-specific and Company-specific factors, including: (i) severe adverse industry or economic trends; (ii) significant Company-specific actions; (iii) current, historical or projected deterioration of the Company’s financial performance; or (iv) a sustained decrease in the Company’s market capitalization below its net book value. If, after assessing the totality of events or circumstances, the Company determines it is unlikely that the fair value of a reporting unit is less than its carrying amount, then a quantitative analysis is unnecessary. However, if the Company concludes otherwise, or if the Company elects to bypass the qualitative analysis, then the Company must perform a quantitative analysis that compares the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill is not considered impaired; otherwise, a goodwill impairment loss is recognized for the lesser of: (a) the amount that the carrying amount of a reporting unit exceeds its fair value; or (b) the amount of the goodwill allocated to that reporting unit. The annual impairment test is performed during the fourth fiscal quarter.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews long-lived assets and identifiable intangibles for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted operating cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair value of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less costs to sell.</span></div><div style="margin-top:13pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition, Deferred Revenue and Other Contract Liabilities</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company derives the majority of its product revenue from four primary sources: (i) direct sales under deferred equipment agreements with end-user hospitals where the Company provides up-front monitoring equipment at no up-front charge in exchange for a multi-year sensor purchase commitment; (ii) other direct sales of noninvasive monitoring solutions to end-user hospitals, emergency medical response organizations and other direct customers; (iii) sales of noninvasive monitoring solutions to distributors who then typically resell to end-user hospitals, emergency medical response organizations and other customers; and (iv) sales of integrated circuit boards to OEM customers who incorporate the Company’s embedded software technology into their multiparameter monitoring devices. Subject to customer credit considerations, the majority of such sales are made on open account using industry standard payment terms based on the geography within which the specific customer is located.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally recognizes revenue following a single, principles-based five-step model to be applied to all contracts with customers and generally provides for the recognition of revenue in an amount that reflects the consideration to which the Company expects to be entitled, net of allowances for estimated returns, discounts or sales incentives, as well as taxes collected from customers that are remitted to government authorities, when control over the promised goods or services are transferred to the customer. Revenue related to equipment supplied under sales-type lease arrangements is recognized once control over the equipment is transferred to the customer, while revenue related to equipment supplied under operating-type lease arrangements is generally recognized on a straight-line basis over the term of the lease. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the majority of the Company’s revenue contracts and transactions contain standard business terms and conditions, there are some transactions that contain non-standard business terms and conditions. As a result, contract interpretation, judgment and analysis is required to determine the appropriate accounting, including: (i) the amount of the total consideration, as well as variable consideration, (ii) whether the arrangement contains an embedded lease, and if so, whether such embedded lease is a sales-type lease or an operating lease, (iii) the identification of the distinct performance obligations contained within the arrangement, (iv) how the arrangement consideration should be allocated to each performance obligation when multiple performance obligations exist, including the determination of standalone selling price, and (v) when to recognize revenue on the performance obligations. Changes in judgments on these assumptions and estimates could materially impact the timing of revenue recognition.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements to sell its monitoring solutions and services, sometimes as a part of arrangements with multiple performance obligations that include various combinations of product sales, equipment leases and services. In the case of contracts with multiple performance obligations, the authoritative guidance provides that the total consideration be allocated to each performance obligation on the basis of relative standalone selling prices. When a standalone selling price is not readily observable, the Company estimates the standalone selling price by considering multiple factors including, but not limited to, features and functionality of the product, geographies, type of customer, contractual prices pursuant to Group Purchasing Organization (GPO) contracts, the Company’s pricing and discount practices, and other market conditions.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales under deferred equipment agreements are generally structured such that the Company agrees to provide certain monitoring-related equipment, software, installation, training and/or warranty support at no up-front charge in exchange for the customer’s commitment to purchase sensors over the term of the agreement, which generally ranges from three years to six years. The Company allocates contract consideration under deferred equipment agreements containing fixed annual sensor purchase commitments to the underlying lease and non-lease components at contract inception. In determining whether any underlying lease components are related to a sales-type lease or an operating lease, the Company evaluates the customer’s rights and ability to control the use of the underlying equipment throughout the contract term, including any equipment substitution rights retained by the Company, as well as the Company’s expectations surrounding potential contract/lease extensions or renewals and the customer’s likelihood to exercise any purchase options. Revenue allocable to non-lease performance obligations is generally recognized as such non-lease performance obligations are satisfied. Revenue allocable to lease components under sales-type lease arrangements is generally recognized when control over the equipment is transferred to the customer. Revenue allocable to lease components under operating lease arrangements is generally recognized over the term of the operating lease. The Company generally does not expect to derive any significant value in excess of such asset’s unamortized book value from equipment underlying its operating lease arrangements after the end of the agreement. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from the sale of products to end-user hospitals, emergency medical response organizations, other direct customers, distributors and OEM customers, is recognized by the Company when control of such products transfer to the customer based upon the terms of the contract or underlying purchase order.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue related to OEM rainbow</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> parameter software licenses is recognized by the Company upon the OEM’s shipment of its product to its customer, as reported to the Company by the OEM.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides certain customers with various sales incentives that may take the form of discounts or rebates. The Company records estimates related to these programs as a reduction to revenue at the time of sale. In general, customers do not have a right of return for credit or refund. However, the Company allows returns under certain circumstances. At the end of each period, the Company estimates and accrues for these returns as a reduction to revenue. The Company estimates the revenue constraints related to these forms of variable consideration based on various factors, including expected purchasing volumes, prior sales and returns history, and specific contractual terms and limitations.</span></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shipping and Handling Costs and Fees</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All shipping and handling costs are expensed as incurred and are recorded as a component of cost of goods sold in the accompanying condensed consolidated statements of operations. Charges for shipping and handling billed to customers are included as a component of product revenue.</span></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Taxes Collected From Customers and Remitted to Governmental Authorities</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s policy is to present revenue net of taxes collected from customers and remitted to governmental authorities.</span></div><div style="margin-top:13pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Costs and Other Contract Assets</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The costs of monitoring-related equipment provided to customers under operating lease arrangements within the Company’s deferred equipment agreements are generally deferred and amortized to cost of goods sold over the life of the underlying contracts. Some of the Company’s deferred equipment agreements also contain provisions for certain allowances to be made directly to the end-user hospital customer at the inception of the arrangement. These allowances are generally allocated to the lease and non-lease components and recognized as a reduction to revenue as the underlying performance obligations are satisfied.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally invoices its customers under deferred equipment agreements as sensors are provided to the customer. However, the Company may recognize revenue for certain non-lease performance obligations under deferred equipment agreements with fixed annual commitments at the time such performance obligations are satisfied and prior to the customer being invoiced. When this occurs, the Company records an unbilled contract receivable related to such revenue until the customer has been invoiced pursuant to the terms of the underlying deferred equipment agreement.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The incremental costs of obtaining a contract with a customer are capitalized and deferred if the Company expects such costs to be recoverable over the life of the contract and the contract term is greater than one year. Such deferred costs generally relate to certain incentive sales commissions earned by the Company’s internal sales team in connection with the execution of deferred equipment agreements and are amortized to expense over the expected term of the underlying contract.</span></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Warranty</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally provides a warranty against defects in material and workmanship for a period ranging from six months to forty-eight months, depending on the product type. In traditional sales activities, including direct and OEM sales, the Company establishes an accrued liability for the estimated warranty costs at the time of revenue recognition, with a corresponding provision to cost of goods sold. Customers may also purchase extended warranty coverage or service level upgrades separately or as part of a deferred equipment agreement. Revenue related to extended warranty coverage and service level upgrades is generally recognized over the life of the contract, which reasonably approximates the period over which such services will be provided. The related extended warranty and service level upgrade costs are expensed as incurred.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the product warranty accrual were as follows (in thousands):</span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">September 26,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warranty accrual, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,740 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,395 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrual for warranties issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,442 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in pre-existing warranties (including changes in estimates)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,347)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements made</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(891)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(883)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warranty accrual, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,944 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,843 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation Costs and Contingencies</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records a charge equal to at least the minimum estimated liability for a loss contingency or litigation settlement when both of the following conditions are met: (i) information available prior to issuance of the financial statements indicates that it is probable that a liability had been incurred at the date of the financial statements, and (ii) the range of loss can be reasonably estimated. The determination of whether a loss contingency or litigation settlement is probable or reasonably possible involves a significant amount of management judgment, as does the estimation of the range of loss given the nature of contingencies. Liabilities related to litigation settlements with multiple elements are recorded based on the fair value of each element. Legal and other litigation related expenses are recognized as the services are provided. The Company records insurance and other indemnity recoveries for litigation expenses when both of the following conditions are met: (a) the recovery is probable, and (b) collectability is reasonably assured. Insurance recoveries are only recorded to the extent the litigation costs to which they relate have been incurred and recognized in the financial statements.</span></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income includes foreign currency translation adjustments and any related tax benefits that have been excluded from net income and reflected in stockholders’ equity.</span></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income Per Share</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A computation of basic and diluted net income per share is as follows (in thousands, except per share data):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">September 26,<br/>2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">September 26,<br/>2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,771 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,405 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,389 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,633 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic net income per share:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,143 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,997 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,125 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,543 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per basic share</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.05</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.93</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted net income per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,543 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted share equivalent: stock options, RSUs and PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,283 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,526 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,490 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,664 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,280 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,651 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,033 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per diluted share</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.00</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.85</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.80</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.92</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per share is computed by dividing net income by the weighted-average number of shares outstanding during the period. Net income per diluted share is computed by dividing the net income by the weighted-average number of shares and potential shares outstanding during the period, if the effect of potential shares is dilutive. Potential shares include incremental shares of stock issuable upon the exercise of stock options and the vesting of both restricted share units (RSUs) and performance share units (PSUs). For each of the three months ended October 2, 2021 and September 26, 2020, weighted options to purchase 0.1 million shares of common stock were outstanding but not included in the computation of diluted net income per share because the effect of including such shares would have been antidilutive in the applicable period. For the nine months ended October 2, 2021 and September 26, 2020, weighted options to purchase 0.2 million and 0.3 million shares of common stock, respectively, were outstanding but not included in the computation of diluted net i</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ncome per share because the effect of including such shares would have been antidilutive in the applicable period. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain RSUs are considered contingently issuable shares as their vesting is contingent upon the occurrence of certain future events. Since such events had not occurred and were not considered probable of occurring as of each of October 2, 2021 and September 26, 2020, 2.7 million weighted-average shares related to such RSUs have been excluded from the calculation of potential shares for each of the three and nine month periods then ended.</span></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Supplemental Cash Flow Information</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information includes the following (in thousands):</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">September 26,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid during the year for:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,898 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,961 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,699 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-cash operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease liabilities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,917 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-cash investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid purchases of property and equipment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,182 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,988 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">       Settlement of promissory note receivable in connection with business combination</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid strategic investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposit release to acquire noncontrolling interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,374 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-cash financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">       Unsettled common stock proceeds from option exercises</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">       Fair value of common stock received for payment of stock option exercise price</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reconciliation of cash, cash equivalents and restricted cash:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652,354 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">669,056 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,581 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,384 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653,935 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672,440 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">     See Note 5.</span></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the “management approach” in determining reportable business segments. The management approach designates the internal organization used by management for making operating decisions and assessing performance as the source for determining the Company’s reportable segments. Based on this assessment, management has determined it operates in one reportable business segment, which is comprised of patient monitoring and related products.</span></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASU 2019-12). The standard simplifies the accounting for income taxes by removing exceptions to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income or a gain from other items, to the requirement to recognize a deferred tax liability for equity method investments when a foreign subsidiary becomes an equity method investment, to the ability not to recognize a deferred tax liability for a foreign subsidiary when a foreign equity method investment becomes a subsidiary, and to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. In addition, the standard requires that an entity recognize a franchise tax that is partially based on income as an income-based tax and account for any incremental amount incurred as a non-income-based tax, evaluate when a step up in the tax basis of goodwill should be considered part of the business combination in which the book goodwill was originally recognized and when it should be considered a separate transaction, reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date, and specifies that an entity is not required to allocate the consolidated amount of current and deferred tax expense to a legal entity that is not subject to tax in its separate financial statements; however, an entity may elect to do so (on an entity-by-entity basis) for a legal entity that is both not subject to tax and disregarded by the taxing authority. The Company’s adoption of this standard, effective as of January 3, 2021, did not have a material impact on its consolidated financial statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the FASB issued ASU No. 2020-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The standard provides updates for technical corrections, clarifications to guidance, simplifications to wording or structure of guidance, and other minor improvements across various areas of accounting within GAAP. ASU No. 2020-10 is effective after December 15, 2020 on a retrospective basis. Early adoption is permitted. The Company’s adoption of this standard, effective as of January 3, 2021, did not have a material impact on its consolidated financial statements.</span></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU No. 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (ASU 2020-04)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The new standard provides temporary optional expedients and exceptions to the guidance in GAAP on contract modifications and hedge accounting to ease the financial reporting burdens related to the expected market transition from the London Interbank Offered Rate (LIBOR) and other interbank offered rates to alternative reference rates, such as the Secured Overnight Financing Rate (SOFR). Entities can make a one-time election to sell and/or reclassify held-to-maturity debt securities that reference an interest rate affected by reference rate reform. ASU 2020-04 is effective beginning on March 12, 2020, and the Company may elect to apply this standard prospectively through December 31, 2022. The relief is temporary and generally cannot be applied to contract modifications that occur after December 31, 2022 or hedging relationships entered into or evaluated after that date. However, certain optional expedients can be applied to hedging relationships evaluated in periods after December 31, 2022. The Company is currently evaluating the expected impact of this standard, but does not expect it to have a material impact on its consolidated financial statements upon adoption.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the FASB issued ASU No. 2021-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Scope (ASU 2021-01)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The new standard clarified the scope and application of the original guidance. ASU No. 2021-01 is effective as of March 12, 2020 through December 31, 2022 and may be applied to contract modifications and hedging relationships from the beginning of an interim period that includes or is subsequent to March 12, 2020. The Company is currently evaluating the expected impact of this standard, but does not expect it to have a material impact on its consolidated financial statements upon adoption.</span></div> <div style="margin-top:4.5pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) have been condensed or omitted pursuant to such rules and regulations. The accompanying condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, including normal recurring accruals, necessary to present fairly the Company’s condensed consolidated financial statements. The accompanying condensed consolidated balance sheet as of January 2, 2021 was derived from the Company’s audited consolidated financial statements at that date. The accompanying condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes contained in the Company’s Annual Report on Form 10-K for the fiscal year ended January 2, 2021 (fiscal year 2020), filed with the SEC on February 23, 2021. The results for the three and nine months ended October 2, 2021 are not necessarily indicative of the results to be expected for the fiscal year ending January 1, 2022 (fiscal year 2021) or for any other interim period or for any future year.</span></div> <div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fiscal Periods</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows a conventional 52/53 week fiscal year. Under a conventional 52/53 week fiscal year, a 52 week fiscal year includes four quarters of 13 weeks while a 53 week fiscal year includes three 13 week fiscal quarters and one 14 week fiscal quarter. The Company’s last 53 week fiscal year was fiscal year 2020. Fiscal year 2021 is a 52 week fiscal year ending January 1, 2022. All references to years in these notes to condensed consolidated financial statements are fiscal years unless otherwise noted.</span></div> <div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts in the accompanying condensed consolidated financial statements have been reclassified to conform to the current period presentation.</span></div> <div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company prepares its financial statements in conformity with GAAP, which requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates include the determination of standalone selling prices, variable consideration, total consideration allocated to each performance obligation within a contract, inventory valuation, valuation of the Company’s equity awards, valuation of identifiable assets and liabilities connected with business combinations, deferred taxes and any associated valuation allowances, deferred revenue, uncertain income tax positions, and litigation costs and related accruals. Actual results could differ from such estimates.</span></div> <div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for business combinations using the acquisition method of accounting, which requires that once control is obtained, all the assets acquired, liabilities assumed and noncontrolling interests in the acquired entity, if applicable, are recorded at their respective fair values at the date of acquisition. The excess of the purchase price over the fair values of identifiable assets, liabilities and noncontrolling interests in the acquired entity, if applicable, is recorded as goodwill. The Company finalizes the purchase price allocation within one year from the acquisition date.</span></div> <div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Authoritative guidance describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">●    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1—Quoted prices in active markets for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">identical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> assets or liabilities.</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">●    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">similar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> assets or liabilities, quoted prices in markets that are not active; or other inputs that can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">●    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to current authoritative guidance, entities are allowed an irrevocable option to elect the fair value for the initial and subsequent measurement for specified financial assets and liabilities on a contract-by-contract basis. The Company did not elect to apply the fair value option under this guidance to specific assets or liabilities on a contract-by-contract basis. There were no transfers between Level 1, Level 2 and Level 3 inputs during either the nine months ended October 2, 2021 or September 26, 2020. The Company carries cash and cash equivalents, at cost, which approximates fair value. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For certain other financial assets and liabilities, including restricted cash, accounts receivable, accounts payable and other current assets and liabilities, the carrying amounts approximate their fair value primarily due to the relatively short maturity of these balances. The Company also measures certain non-financial assets at fair value on a non-recurring basis, primarily goodwill, intangible assets and operating lease right-of-use assets, in connection with periodic evaluations for potential impairment.</span></div> <div style="margin-top:13pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity from date of purchase of three months or less, or highly liquid investments that are readily convertible into known amounts of cash, to be cash equivalents.</span></div> <div style="margin-top:13pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Credit Losses</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable consist of trade receivables recorded at the time of invoicing of product sales, reduced by reserves for estimated bad debts and returns. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Credit is extended based on an evaluation of the customer’s financial condition. Collateral is generally not required. The Company records an allowance for credit losses that it does not expect to collect based on relevant information, including historical experience, current conditions, and reasonable and supportable forecasts. Accounts are charged off against the allowance when the Company believes they are uncollectible.</span></div> <div style="margin-top:13pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value. Cost is determined using a standard cost method, which approximates the first in, first out method, and includes material, labor and overhead costs. Inventory valuation adjustments are recorded for inventory items that have become excess or obsolete or are no longer used in current production and for inventory items that have a market price less than carrying value in inventory. The Company generally determines inventory valuation adjustments based on an evaluation of the expected future use of its inventory on an item by item basis and applies historical obsolescence rates to estimate the loss on inventory expected to have a recovery value below cost. The Company also records other specific inventory valuation adjustments when it becomes aware of unique events or circumstances that result in an expected recovery value below cost. For inventory items that have been written down, the reduced value becomes the new cost basis.</span></div> <div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost. Depreciation is calculated using the straight-line method over estimated useful lives as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.064%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Useful Lives</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building improvements</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 to 39 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 12 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Demonstration units</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 6 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of useful life or term of lease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery, equipment and tooling</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 10 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transportation, vehicles and other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 to 20 years</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Land is not depreciated and construction-in-progress is not depreciated until placed in service. Normal repair and maintenance costs are expensed as incurred, whereas significant improvements that materially increase values or extend useful lives are capitalized and depreciated over the remaining estimated useful lives of the related assets. Upon sale or retirement of depreciable assets, the related cost and accumulated depreciation or amortization are removed from the accounts and any gain or loss on the sale or retirement is recognized in income.</span></div> <div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost. Depreciation is calculated using the straight-line method over estimated useful lives as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.064%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Useful Lives</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building improvements</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 to 39 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 12 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Demonstration units</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 6 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of useful life or term of lease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery, equipment and tooling</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 10 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transportation, vehicles and other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 to 20 years</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, consists of the following (in thousands):</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">January 2,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,990 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,310 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery, equipment and tooling</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,833 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,843 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,938 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,151 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transportation, vehicles and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,114 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,175 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,131 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,693 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,885 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,295 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,186 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,567 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Demonstration units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,049 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,024 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-progress (CIP)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,955 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,589 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,081 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406,647 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(151,152)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134,136)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,929 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,511 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> P7Y P39Y P2Y P12Y P3Y P2Y P6Y P3Y P10Y P4Y P20Y <div style="margin-top:13pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consist primarily of patents, trademarks, software development costs, customer relationships and acquired technology. Costs related to patents and trademarks, which include legal and application fees, are capitalized and amortized over the estimated useful lives using the straight-line method. Patent and trademark amortization commences once final approval of the patent or trademark has been obtained. Patent costs are amortized over the lesser of 10 years or the patent’s remaining legal life, which assumes renewals, and trademark costs are amortized over 17 years, and their associated amortization cost is included in selling, general and administrative expense in the accompanying condensed consolidated statements of operations. For intangibles purchased in an asset acquisition or business combination, which mainly include patents, trademarks, customer relationships and acquired technologies, the useful life is determined largely by valuation estimates of remaining economic life. The Company’s policy is to renew its patents and trademarks. Costs to renew patents and trademarks are capitalized and amortized over the remaining useful life of the intangible asset. The Company periodically evaluates the amortization period and carrying basis of patents, trademarks and other intangible assets to determine whether any events or circumstances warrant a revised estimated useful life or reduction in value. Capitalized application costs are charged to operations when it is determined that the patent or trademark will not be obtained or is abandoned.</span></div> P10Y P17Y <div style="margin-top:13pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Goodwill, Intangible Assets and Other Long-Lived Assets</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is recorded as the difference, if any, between the aggregate consideration paid for an acquisition and the fair value of the acquired net tangible and intangible assets. Goodwill is not amortized, but instead is tested annually for impairment, or more frequently when events or changes in circumstances indicate that goodwill might be impaired. In assessing goodwill impairment, the Company has the option to first assess the qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. The Company’s qualitative assessment of the recoverability of goodwill considers various macroeconomic, industry-specific and Company-specific factors, including: (i) severe adverse industry or economic trends; (ii) significant Company-specific actions; (iii) current, historical or projected deterioration of the Company’s financial performance; or (iv) a sustained decrease in the Company’s market capitalization below its net book value. If, after assessing the totality of events or circumstances, the Company determines it is unlikely that the fair value of a reporting unit is less than its carrying amount, then a quantitative analysis is unnecessary. However, if the Company concludes otherwise, or if the Company elects to bypass the qualitative analysis, then the Company must perform a quantitative analysis that compares the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill is not considered impaired; otherwise, a goodwill impairment loss is recognized for the lesser of: (a) the amount that the carrying amount of a reporting unit exceeds its fair value; or (b) the amount of the goodwill allocated to that reporting unit. The annual impairment test is performed during the fourth fiscal quarter.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews long-lived assets and identifiable intangibles for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted operating cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair value of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less costs to sell.</span></div> <div style="margin-top:13pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition, Deferred Revenue and Other Contract Liabilities</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company derives the majority of its product revenue from four primary sources: (i) direct sales under deferred equipment agreements with end-user hospitals where the Company provides up-front monitoring equipment at no up-front charge in exchange for a multi-year sensor purchase commitment; (ii) other direct sales of noninvasive monitoring solutions to end-user hospitals, emergency medical response organizations and other direct customers; (iii) sales of noninvasive monitoring solutions to distributors who then typically resell to end-user hospitals, emergency medical response organizations and other customers; and (iv) sales of integrated circuit boards to OEM customers who incorporate the Company’s embedded software technology into their multiparameter monitoring devices. Subject to customer credit considerations, the majority of such sales are made on open account using industry standard payment terms based on the geography within which the specific customer is located.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally recognizes revenue following a single, principles-based five-step model to be applied to all contracts with customers and generally provides for the recognition of revenue in an amount that reflects the consideration to which the Company expects to be entitled, net of allowances for estimated returns, discounts or sales incentives, as well as taxes collected from customers that are remitted to government authorities, when control over the promised goods or services are transferred to the customer. Revenue related to equipment supplied under sales-type lease arrangements is recognized once control over the equipment is transferred to the customer, while revenue related to equipment supplied under operating-type lease arrangements is generally recognized on a straight-line basis over the term of the lease. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the majority of the Company’s revenue contracts and transactions contain standard business terms and conditions, there are some transactions that contain non-standard business terms and conditions. As a result, contract interpretation, judgment and analysis is required to determine the appropriate accounting, including: (i) the amount of the total consideration, as well as variable consideration, (ii) whether the arrangement contains an embedded lease, and if so, whether such embedded lease is a sales-type lease or an operating lease, (iii) the identification of the distinct performance obligations contained within the arrangement, (iv) how the arrangement consideration should be allocated to each performance obligation when multiple performance obligations exist, including the determination of standalone selling price, and (v) when to recognize revenue on the performance obligations. Changes in judgments on these assumptions and estimates could materially impact the timing of revenue recognition.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements to sell its monitoring solutions and services, sometimes as a part of arrangements with multiple performance obligations that include various combinations of product sales, equipment leases and services. In the case of contracts with multiple performance obligations, the authoritative guidance provides that the total consideration be allocated to each performance obligation on the basis of relative standalone selling prices. When a standalone selling price is not readily observable, the Company estimates the standalone selling price by considering multiple factors including, but not limited to, features and functionality of the product, geographies, type of customer, contractual prices pursuant to Group Purchasing Organization (GPO) contracts, the Company’s pricing and discount practices, and other market conditions.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales under deferred equipment agreements are generally structured such that the Company agrees to provide certain monitoring-related equipment, software, installation, training and/or warranty support at no up-front charge in exchange for the customer’s commitment to purchase sensors over the term of the agreement, which generally ranges from three years to six years. The Company allocates contract consideration under deferred equipment agreements containing fixed annual sensor purchase commitments to the underlying lease and non-lease components at contract inception. In determining whether any underlying lease components are related to a sales-type lease or an operating lease, the Company evaluates the customer’s rights and ability to control the use of the underlying equipment throughout the contract term, including any equipment substitution rights retained by the Company, as well as the Company’s expectations surrounding potential contract/lease extensions or renewals and the customer’s likelihood to exercise any purchase options. Revenue allocable to non-lease performance obligations is generally recognized as such non-lease performance obligations are satisfied. Revenue allocable to lease components under sales-type lease arrangements is generally recognized when control over the equipment is transferred to the customer. Revenue allocable to lease components under operating lease arrangements is generally recognized over the term of the operating lease. The Company generally does not expect to derive any significant value in excess of such asset’s unamortized book value from equipment underlying its operating lease arrangements after the end of the agreement. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from the sale of products to end-user hospitals, emergency medical response organizations, other direct customers, distributors and OEM customers, is recognized by the Company when control of such products transfer to the customer based upon the terms of the contract or underlying purchase order.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue related to OEM rainbow</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> parameter software licenses is recognized by the Company upon the OEM’s shipment of its product to its customer, as reported to the Company by the OEM.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides certain customers with various sales incentives that may take the form of discounts or rebates. The Company records estimates related to these programs as a reduction to revenue at the time of sale. In general, customers do not have a right of return for credit or refund. However, the Company allows returns under certain circumstances. At the end of each period, the Company estimates and accrues for these returns as a reduction to revenue. The Company estimates the revenue constraints related to these forms of variable consideration based on various factors, including expected purchasing volumes, prior sales and returns history, and specific contractual terms and limitations.</span></div> 4 P3Y P6Y <div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shipping and Handling Costs and Fees</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All shipping and handling costs are expensed as incurred and are recorded as a component of cost of goods sold in the accompanying condensed consolidated statements of operations. Charges for shipping and handling billed to customers are included as a component of product revenue.</span></div> <div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Taxes Collected From Customers and Remitted to Governmental Authorities</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s policy is to present revenue net of taxes collected from customers and remitted to governmental authorities.</span></div> <div style="margin-top:13pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Costs and Other Contract Assets</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The costs of monitoring-related equipment provided to customers under operating lease arrangements within the Company’s deferred equipment agreements are generally deferred and amortized to cost of goods sold over the life of the underlying contracts. Some of the Company’s deferred equipment agreements also contain provisions for certain allowances to be made directly to the end-user hospital customer at the inception of the arrangement. These allowances are generally allocated to the lease and non-lease components and recognized as a reduction to revenue as the underlying performance obligations are satisfied.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally invoices its customers under deferred equipment agreements as sensors are provided to the customer. However, the Company may recognize revenue for certain non-lease performance obligations under deferred equipment agreements with fixed annual commitments at the time such performance obligations are satisfied and prior to the customer being invoiced. When this occurs, the Company records an unbilled contract receivable related to such revenue until the customer has been invoiced pursuant to the terms of the underlying deferred equipment agreement.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The incremental costs of obtaining a contract with a customer are capitalized and deferred if the Company expects such costs to be recoverable over the life of the contract and the contract term is greater than one year. Such deferred costs generally relate to certain incentive sales commissions earned by the Company’s internal sales team in connection with the execution of deferred equipment agreements and are amortized to expense over the expected term of the underlying contract.</span></div> <div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Warranty</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally provides a warranty against defects in material and workmanship for a period ranging from six months to forty-eight months, depending on the product type. In traditional sales activities, including direct and OEM sales, the Company establishes an accrued liability for the estimated warranty costs at the time of revenue recognition, with a corresponding provision to cost of goods sold. Customers may also purchase extended warranty coverage or service level upgrades separately or as part of a deferred equipment agreement. Revenue related to extended warranty coverage and service level upgrades is generally recognized over the life of the contract, which reasonably approximates the period over which such services will be provided. The related extended warranty and service level upgrade costs are expensed as incurred.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the product warranty accrual were as follows (in thousands):</span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">September 26,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warranty accrual, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,740 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,395 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrual for warranties issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,442 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in pre-existing warranties (including changes in estimates)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,347)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements made</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(891)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(883)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warranty accrual, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,944 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,843 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> P6M P48M <div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the product warranty accrual were as follows (in thousands):</span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">September 26,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warranty accrual, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,740 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,395 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrual for warranties issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,442 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in pre-existing warranties (including changes in estimates)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,347)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements made</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(891)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(883)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warranty accrual, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,944 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,843 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2740000 3395000 3442000 428000 -2347000 -97000 891000 883000 2944000 2843000 <div style="margin-top:13pt;text-indent:11.25pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation Costs and Contingencies</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records a charge equal to at least the minimum estimated liability for a loss contingency or litigation settlement when both of the following conditions are met: (i) information available prior to issuance of the financial statements indicates that it is probable that a liability had been incurred at the date of the financial statements, and (ii) the range of loss can be reasonably estimated. The determination of whether a loss contingency or litigation settlement is probable or reasonably possible involves a significant amount of management judgment, as does the estimation of the range of loss given the nature of contingencies. Liabilities related to litigation settlements with multiple elements are recorded based on the fair value of each element. Legal and other litigation related expenses are recognized as the services are provided. The Company records insurance and other indemnity recoveries for litigation expenses when both of the following conditions are met: (a) the recovery is probable, and (b) collectability is reasonably assured. Insurance recoveries are only recorded to the extent the litigation costs to which they relate have been incurred and recognized in the financial statements.</span></div> <div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income includes foreign currency translation adjustments and any related tax benefits that have been excluded from net income and reflected in stockholders’ equity.</span></div> <div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income Per Share</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A computation of basic and diluted net income per share is as follows (in thousands, except per share data):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">September 26,<br/>2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">September 26,<br/>2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,771 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,405 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,389 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,633 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic net income per share:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,143 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,997 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,125 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,543 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per basic share</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.05</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.93</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted net income per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,543 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted share equivalent: stock options, RSUs and PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,283 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,526 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,490 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,664 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,280 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,651 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,033 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per diluted share</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.00</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.85</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.80</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.92</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per share is computed by dividing net income by the weighted-average number of shares outstanding during the period. Net income per diluted share is computed by dividing the net income by the weighted-average number of shares and potential shares outstanding during the period, if the effect of potential shares is dilutive. Potential shares include incremental shares of stock issuable upon the exercise of stock options and the vesting of both restricted share units (RSUs) and performance share units (PSUs). For each of the three months ended October 2, 2021 and September 26, 2020, weighted options to purchase 0.1 million shares of common stock were outstanding but not included in the computation of diluted net income per share because the effect of including such shares would have been antidilutive in the applicable period. For the nine months ended October 2, 2021 and September 26, 2020, weighted options to purchase 0.2 million and 0.3 million shares of common stock, respectively, were outstanding but not included in the computation of diluted net i</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ncome per share because the effect of including such shares would have been antidilutive in the applicable period. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain RSUs are considered contingently issuable shares as their vesting is contingent upon the occurrence of certain future events. Since such events had not occurred and were not considered probable of occurring as of each of October 2, 2021 and September 26, 2020, 2.7 million weighted-average shares related to such RSUs have been excluded from the calculation of potential shares for each of the three and nine month periods then ended.</span></div> <div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A computation of basic and diluted net income per share is as follows (in thousands, except per share data):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">September 26,<br/>2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">September 26,<br/>2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,771 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,405 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,389 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,633 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic net income per share:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,143 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,997 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,125 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,543 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per basic share</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.05</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.93</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted net income per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,543 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted share equivalent: stock options, RSUs and PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,283 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,526 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,490 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,664 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,280 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,651 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,033 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per diluted share</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.00</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.85</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.80</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.92</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 57771000 49405000 161389000 169633000 55143000 54997000 55125000 54543000 1.05 0.90 2.93 3.11 55143000 54997000 55125000 54543000 2521000 3283000 2526000 3490000 57664000 58280000 57651000 58033000 1.00 0.85 2.80 2.92 100000 100000 200000 300000 2700000 2700000 <div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information includes the following (in thousands):</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">September 26,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid during the year for:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,898 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,961 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,699 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-cash operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease liabilities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,917 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-cash investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid purchases of property and equipment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,182 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,988 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">       Settlement of promissory note receivable in connection with business combination</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid strategic investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposit release to acquire noncontrolling interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,374 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-cash financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">       Unsettled common stock proceeds from option exercises</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">       Fair value of common stock received for payment of stock option exercise price</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reconciliation of cash, cash equivalents and restricted cash:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652,354 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">669,056 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,581 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,384 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653,935 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672,440 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 202000 194000 36898000 35961000 5567000 4699000 4917000 9900000 3182000 3988000 0 5100000 3,400 3374000 0 112000 27000 0 220000 652354000 669056000 1581000 3384000 653935000 672440000 <div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the “management approach” in determining reportable business segments. The management approach designates the internal organization used by management for making operating decisions and assessing performance as the source for determining the Company’s reportable segments. Based on this assessment, management has determined it operates in one reportable business segment, which is comprised of patient monitoring and related products.</span></div> <div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASU 2019-12). The standard simplifies the accounting for income taxes by removing exceptions to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income or a gain from other items, to the requirement to recognize a deferred tax liability for equity method investments when a foreign subsidiary becomes an equity method investment, to the ability not to recognize a deferred tax liability for a foreign subsidiary when a foreign equity method investment becomes a subsidiary, and to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. In addition, the standard requires that an entity recognize a franchise tax that is partially based on income as an income-based tax and account for any incremental amount incurred as a non-income-based tax, evaluate when a step up in the tax basis of goodwill should be considered part of the business combination in which the book goodwill was originally recognized and when it should be considered a separate transaction, reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date, and specifies that an entity is not required to allocate the consolidated amount of current and deferred tax expense to a legal entity that is not subject to tax in its separate financial statements; however, an entity may elect to do so (on an entity-by-entity basis) for a legal entity that is both not subject to tax and disregarded by the taxing authority. The Company’s adoption of this standard, effective as of January 3, 2021, did not have a material impact on its consolidated financial statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the FASB issued ASU No. 2020-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The standard provides updates for technical corrections, clarifications to guidance, simplifications to wording or structure of guidance, and other minor improvements across various areas of accounting within GAAP. ASU No. 2020-10 is effective after December 15, 2020 on a retrospective basis. Early adoption is permitted. The Company’s adoption of this standard, effective as of January 3, 2021, did not have a material impact on its consolidated financial statements.</span></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU No. 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (ASU 2020-04)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The new standard provides temporary optional expedients and exceptions to the guidance in GAAP on contract modifications and hedge accounting to ease the financial reporting burdens related to the expected market transition from the London Interbank Offered Rate (LIBOR) and other interbank offered rates to alternative reference rates, such as the Secured Overnight Financing Rate (SOFR). Entities can make a one-time election to sell and/or reclassify held-to-maturity debt securities that reference an interest rate affected by reference rate reform. ASU 2020-04 is effective beginning on March 12, 2020, and the Company may elect to apply this standard prospectively through December 31, 2022. The relief is temporary and generally cannot be applied to contract modifications that occur after December 31, 2022 or hedging relationships entered into or evaluated after that date. However, certain optional expedients can be applied to hedging relationships evaluated in periods after December 31, 2022. The Company is currently evaluating the expected impact of this standard, but does not expect it to have a material impact on its consolidated financial statements upon adoption.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the FASB issued ASU No. 2021-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Scope (ASU 2021-01)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The new standard clarified the scope and application of the original guidance. ASU No. 2021-01 is effective as of March 12, 2020 through December 31, 2022 and may be applied to contract modifications and hedging relationships from the beginning of an interim period that includes or is subsequent to March 12, 2020. The Company is currently evaluating the expected impact of this standard, but does not expect it to have a material impact on its consolidated financial statements upon adoption.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued ASU No. 2021-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share (Topic 260), Debt - Modifications and Extinguishments (Subtopic 470-50), Compensation - Stock Compensation (Topic 718), and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (ASU 2021-04)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The new standard addresses modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another topic. ASU No. 2021-04 is effective after December 15, 2021 on a prospective basis, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period and should be applied as of the beginning of the fiscal year that includes the interim period. The Company is currently evaluating the expected impact of this standard, but does not expect it to have a material impact on its consolidated financial statements upon adoption.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the FASB issued ASU No. 2021-05, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842), Lessors - Certain Leases with Variable Lease Payments (ASU 2021-05)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This new standard amends the original ASU No. 2016-02 lease standard by requiring lessors to classify leases as operating leases if they have variable lease payments that do not depend on an index or rate and would have selling losses at lease commencement if they were classified as sales-type. ASU 2021-05 is effective for annual reporting periods beginning after December 15, 2021, and for interim periods within those years, and may be adopted either prospectively or on a retrospective basis for leases that commenced or were modified after the date of initial adoption of ASC 842. Early adoption is permitt</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ed. The Company is currently evaluating the expected impact of this standard on its consolidated financial statements upon adoption, but anticipates that, among other things, the classification of certain leases for which the Company is the lessor will change from sales-type leases to operating leases under this new standard, resulting in the initial deferral and subsequent expensing of equipment costs over time under certain leases that are currently recognized immediately upon lease commencement. Similarly, any revenue that is currently recognized for these leases on the date of lease commencement will now be recognized over the term of the operating lease upon adoption of this new standard. The Company currently expects to complete its assessment of the full financial impact of this new standard during the next three to six months.</span> <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. Related Party Transactions </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s Chairman and Chief Executive Officer (CEO) is also the Chairman and CEO of Cercacor Laboratories, Inc. (Cercacor). The Company is a party to the following agreements with Cercacor:</span></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Cross-Licensing Agreement - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Cercacor are parties to a cross-licensing agreement (Cross-Licensing Agreement), which governs each party’s rights to certain intellectual property held by the two companies. The Company is subject to certain annual minimum aggregate royalty obligations for use of the rainbow</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> licensed technology. The current annual minimum royalty obligation is $5.0 million. Aggregate liabilities payable to Cercacor arising under the Cross-Licensing Agreement were $2.9 million and $3.5 million for the three months ended October 2, 2021 and September 26, 2020, respectively. Aggregate liabilities payable to Cercacor arising under the Cross-Licensing Agreement were $9.6 million and $9.7 million for the nine months ended October 2, 2021 and September 26, 2020, respectively.</span></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Administrative Services Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The Company is a party to an administrative services agreement with Cercacor (G&amp;A Services Agreement), which governs certain general and administrative services that the Company provides to Cercacor. Amounts charged by the Company pursuant to the G&amp;A Services Agreement were less than $0.1 million for each of the three months ended October 2, 2021 and September 26, 2020. Amounts charged by the Company pursuant to the G&amp;A Services Agreement were $0.2 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for each of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended October 2, 2021 and September 26, 2020.</span></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Lease and Sublease Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Effective December 2019, the Company entered into a lease agreement with Cercacor for approximately 34,000 square feet of office, research and development space at one of the Company’s owned facilities in Irvine (Cercacor Lease). The term of the Cercacor Lease expires on December 31, 2024. In March 2016, the Company entered into a sublease agreement with Cercacor for approximately 16,830 square feet of excess office and laboratory space located at 40 Parker, Irvine, California (Cercacor Sublease). The Cercacor Sublease began on May 1, 2016 and expired on December 15, 2019. The Company recognized approximately $0.3 million of lease income for each of the three months ended October 2, 2021 and September 26, 2020. The Company recognized approximately $0.9 million and $0.8 million of lease income for the nine months ended October 2, 2021 and September 26, 2020, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net amounts due to Cercacor at October 2, 2021 and January 2, 2021 were approximately $3.3 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.6 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s CEO is also the Chairman of the Masimo Foundation for Ethics, Innovation and Competition in Healthcare (Masimo Foundation), a non-profit organization that was founded in 2010 to provide a platform for encouraging ethics, innovation and competition in healthcare. In addition, the Company’s Executive Vice President (EVP), Chief Financial Officer (CFO) serves as the Treasurer of the Masimo Foundation and the Company’s EVP, General Counsel and Corporate Secretary serves as the Secretary for the Masimo Foundation. During the three months ended October 2, 2021 and September 26, 2020, the Company made no cash contributions to the Masimo Foundation. During the nine months ended October 2, 2021, the Company made no contributions to the Masimo Foundation. During the nine months ended September 26, 2020, the Company made cash contributions of approximately $1.5 million to the Masimo Foundation. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended October 2, 2021 and September 26, 2020, the Company made various in-kind contributions to the Masimo Foundation, mainly in the form of donated administrative services.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s CEO is also a co-founder and a member of the board of directors of Like Minded Media Ventures (LMMV), a team of storytellers that create content focused in the areas of true stories, social causes and science</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LMMV creates stories with a multi-platform strategy, bridging the gap between film, television, digital and social media. The Company entered into a marketing service agreement with LMMV for audiovisual production services promoting brand awareness, including television commercials and digital advertising, during the second quarter of 2020. During the three and nine months ended October 2, 2021, the Company incurred no marketing expenses to LMMV under the marketing service agreement. During the three and nine months ended September 26, 2020, the Company incurred $0.2 million and $3.5 million, respectively, in marketing expenses to LMMV under the marketing service agreement. At October 2, 2021 and January 2, 2021, there was no amo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unt due to LMMV for services rendered.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a software license and professional services agreement with Like Minded Labs (LML), a subsidiary of LMMV, during the second quarter of 2021. Pursuant to the software license agreement, LML granted the Company a perpetual, non-exclusive and fully paid-up right and license to integrate LML’s software into the Company’s products in exchange for a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> one-time license fee. Pursuant to the professional services agreement, LML will provide professional services to the Company, including the development of custom software intended to support the integration of the licensed software into the Company’s products, as well as future support services upon the Company’s acceptance of deliverables.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> entered into a patent purchase and option agreement with Vantrix Corporation (Vantrix), an acquiree of LML, for certain patents for $0.5 million, and the right to purchase two pools of additional patents from Vantrix for an exercise fee of up to $1.1 million. The </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreements with LML and Vantrix include sublicensing provisions whereby the software and patents are licensed back to LML or Vantrix, respectively, for further advancement of the technologies.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains an aircraft time share agreement, pursuant to which the Company has agreed from time to time to make its aircraft available to the Company’s CEO for lease on a time-sharing basis. The Company charges the Company’s CEO for personal use based on agreed upon reimbursement rates. For each of the three and nine months ended October 2, 2021 and September 26, 2020, the Company charged the Company’s CEO less than $0.1 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to such disbursements.</span></div> <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. Related Party Transactions </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s Chairman and Chief Executive Officer (CEO) is also the Chairman and CEO of Cercacor Laboratories, Inc. (Cercacor). The Company is a party to the following agreements with Cercacor:</span></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Cross-Licensing Agreement - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Cercacor are parties to a cross-licensing agreement (Cross-Licensing Agreement), which governs each party’s rights to certain intellectual property held by the two companies. The Company is subject to certain annual minimum aggregate royalty obligations for use of the rainbow</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> licensed technology. The current annual minimum royalty obligation is $5.0 million. Aggregate liabilities payable to Cercacor arising under the Cross-Licensing Agreement were $2.9 million and $3.5 million for the three months ended October 2, 2021 and September 26, 2020, respectively. Aggregate liabilities payable to Cercacor arising under the Cross-Licensing Agreement were $9.6 million and $9.7 million for the nine months ended October 2, 2021 and September 26, 2020, respectively.</span></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Administrative Services Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The Company is a party to an administrative services agreement with Cercacor (G&amp;A Services Agreement), which governs certain general and administrative services that the Company provides to Cercacor. Amounts charged by the Company pursuant to the G&amp;A Services Agreement were less than $0.1 million for each of the three months ended October 2, 2021 and September 26, 2020. Amounts charged by the Company pursuant to the G&amp;A Services Agreement were $0.2 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for each of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended October 2, 2021 and September 26, 2020.</span></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Lease and Sublease Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Effective December 2019, the Company entered into a lease agreement with Cercacor for approximately 34,000 square feet of office, research and development space at one of the Company’s owned facilities in Irvine (Cercacor Lease). The term of the Cercacor Lease expires on December 31, 2024. In March 2016, the Company entered into a sublease agreement with Cercacor for approximately 16,830 square feet of excess office and laboratory space located at 40 Parker, Irvine, California (Cercacor Sublease). The Cercacor Sublease began on May 1, 2016 and expired on December 15, 2019. The Company recognized approximately $0.3 million of lease income for each of the three months ended October 2, 2021 and September 26, 2020. The Company recognized approximately $0.9 million and $0.8 million of lease income for the nine months ended October 2, 2021 and September 26, 2020, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net amounts due to Cercacor at October 2, 2021 and January 2, 2021 were approximately $3.3 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.6 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s CEO is also the Chairman of the Masimo Foundation for Ethics, Innovation and Competition in Healthcare (Masimo Foundation), a non-profit organization that was founded in 2010 to provide a platform for encouraging ethics, innovation and competition in healthcare. In addition, the Company’s Executive Vice President (EVP), Chief Financial Officer (CFO) serves as the Treasurer of the Masimo Foundation and the Company’s EVP, General Counsel and Corporate Secretary serves as the Secretary for the Masimo Foundation. During the three months ended October 2, 2021 and September 26, 2020, the Company made no cash contributions to the Masimo Foundation. During the nine months ended October 2, 2021, the Company made no contributions to the Masimo Foundation. During the nine months ended September 26, 2020, the Company made cash contributions of approximately $1.5 million to the Masimo Foundation. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended October 2, 2021 and September 26, 2020, the Company made various in-kind contributions to the Masimo Foundation, mainly in the form of donated administrative services.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s CEO is also a co-founder and a member of the board of directors of Like Minded Media Ventures (LMMV), a team of storytellers that create content focused in the areas of true stories, social causes and science</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LMMV creates stories with a multi-platform strategy, bridging the gap between film, television, digital and social media. The Company entered into a marketing service agreement with LMMV for audiovisual production services promoting brand awareness, including television commercials and digital advertising, during the second quarter of 2020. During the three and nine months ended October 2, 2021, the Company incurred no marketing expenses to LMMV under the marketing service agreement. During the three and nine months ended September 26, 2020, the Company incurred $0.2 million and $3.5 million, respectively, in marketing expenses to LMMV under the marketing service agreement. At October 2, 2021 and January 2, 2021, there was no amo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unt due to LMMV for services rendered.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a software license and professional services agreement with Like Minded Labs (LML), a subsidiary of LMMV, during the second quarter of 2021. Pursuant to the software license agreement, LML granted the Company a perpetual, non-exclusive and fully paid-up right and license to integrate LML’s software into the Company’s products in exchange for a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> one-time license fee. Pursuant to the professional services agreement, LML will provide professional services to the Company, including the development of custom software intended to support the integration of the licensed software into the Company’s products, as well as future support services upon the Company’s acceptance of deliverables.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> entered into a patent purchase and option agreement with Vantrix Corporation (Vantrix), an acquiree of LML, for certain patents for $0.5 million, and the right to purchase two pools of additional patents from Vantrix for an exercise fee of up to $1.1 million. The </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreements with LML and Vantrix include sublicensing provisions whereby the software and patents are licensed back to LML or Vantrix, respectively, for further advancement of the technologies.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains an aircraft time share agreement, pursuant to which the Company has agreed from time to time to make its aircraft available to the Company’s CEO for lease on a time-sharing basis. The Company charges the Company’s CEO for personal use based on agreed upon reimbursement rates. For each of the three and nine months ended October 2, 2021 and September 26, 2020, the Company charged the Company’s CEO less than $0.1 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to such disbursements.</span></div> <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. Related Party Transactions </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s Chairman and Chief Executive Officer (CEO) is also the Chairman and CEO of Cercacor Laboratories, Inc. (Cercacor). The Company is a party to the following agreements with Cercacor:</span></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Cross-Licensing Agreement - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Cercacor are parties to a cross-licensing agreement (Cross-Licensing Agreement), which governs each party’s rights to certain intellectual property held by the two companies. The Company is subject to certain annual minimum aggregate royalty obligations for use of the rainbow</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> licensed technology. The current annual minimum royalty obligation is $5.0 million. Aggregate liabilities payable to Cercacor arising under the Cross-Licensing Agreement were $2.9 million and $3.5 million for the three months ended October 2, 2021 and September 26, 2020, respectively. Aggregate liabilities payable to Cercacor arising under the Cross-Licensing Agreement were $9.6 million and $9.7 million for the nine months ended October 2, 2021 and September 26, 2020, respectively.</span></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Administrative Services Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The Company is a party to an administrative services agreement with Cercacor (G&amp;A Services Agreement), which governs certain general and administrative services that the Company provides to Cercacor. Amounts charged by the Company pursuant to the G&amp;A Services Agreement were less than $0.1 million for each of the three months ended October 2, 2021 and September 26, 2020. Amounts charged by the Company pursuant to the G&amp;A Services Agreement were $0.2 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for each of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended October 2, 2021 and September 26, 2020.</span></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Lease and Sublease Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Effective December 2019, the Company entered into a lease agreement with Cercacor for approximately 34,000 square feet of office, research and development space at one of the Company’s owned facilities in Irvine (Cercacor Lease). The term of the Cercacor Lease expires on December 31, 2024. In March 2016, the Company entered into a sublease agreement with Cercacor for approximately 16,830 square feet of excess office and laboratory space located at 40 Parker, Irvine, California (Cercacor Sublease). The Cercacor Sublease began on May 1, 2016 and expired on December 15, 2019. The Company recognized approximately $0.3 million of lease income for each of the three months ended October 2, 2021 and September 26, 2020. The Company recognized approximately $0.9 million and $0.8 million of lease income for the nine months ended October 2, 2021 and September 26, 2020, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net amounts due to Cercacor at October 2, 2021 and January 2, 2021 were approximately $3.3 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.6 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s CEO is also the Chairman of the Masimo Foundation for Ethics, Innovation and Competition in Healthcare (Masimo Foundation), a non-profit organization that was founded in 2010 to provide a platform for encouraging ethics, innovation and competition in healthcare. In addition, the Company’s Executive Vice President (EVP), Chief Financial Officer (CFO) serves as the Treasurer of the Masimo Foundation and the Company’s EVP, General Counsel and Corporate Secretary serves as the Secretary for the Masimo Foundation. During the three months ended October 2, 2021 and September 26, 2020, the Company made no cash contributions to the Masimo Foundation. During the nine months ended October 2, 2021, the Company made no contributions to the Masimo Foundation. During the nine months ended September 26, 2020, the Company made cash contributions of approximately $1.5 million to the Masimo Foundation. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended October 2, 2021 and September 26, 2020, the Company made various in-kind contributions to the Masimo Foundation, mainly in the form of donated administrative services.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s CEO is also a co-founder and a member of the board of directors of Like Minded Media Ventures (LMMV), a team of storytellers that create content focused in the areas of true stories, social causes and science</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LMMV creates stories with a multi-platform strategy, bridging the gap between film, television, digital and social media. The Company entered into a marketing service agreement with LMMV for audiovisual production services promoting brand awareness, including television commercials and digital advertising, during the second quarter of 2020. During the three and nine months ended October 2, 2021, the Company incurred no marketing expenses to LMMV under the marketing service agreement. During the three and nine months ended September 26, 2020, the Company incurred $0.2 million and $3.5 million, respectively, in marketing expenses to LMMV under the marketing service agreement. At October 2, 2021 and January 2, 2021, there was no amo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unt due to LMMV for services rendered.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a software license and professional services agreement with Like Minded Labs (LML), a subsidiary of LMMV, during the second quarter of 2021. Pursuant to the software license agreement, LML granted the Company a perpetual, non-exclusive and fully paid-up right and license to integrate LML’s software into the Company’s products in exchange for a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> one-time license fee. Pursuant to the professional services agreement, LML will provide professional services to the Company, including the development of custom software intended to support the integration of the licensed software into the Company’s products, as well as future support services upon the Company’s acceptance of deliverables.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> entered into a patent purchase and option agreement with Vantrix Corporation (Vantrix), an acquiree of LML, for certain patents for $0.5 million, and the right to purchase two pools of additional patents from Vantrix for an exercise fee of up to $1.1 million. The </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreements with LML and Vantrix include sublicensing provisions whereby the software and patents are licensed back to LML or Vantrix, respectively, for further advancement of the technologies.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains an aircraft time share agreement, pursuant to which the Company has agreed from time to time to make its aircraft available to the Company’s CEO for lease on a time-sharing basis. The Company charges the Company’s CEO for personal use based on agreed upon reimbursement rates. For each of the three and nine months ended October 2, 2021 and September 26, 2020, the Company charged the Company’s CEO less than $0.1 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to such disbursements.</span></div> 5000000 2900000 3500000 9600000 9700000 100000 100000 200000 200000 34000 2024-12-31 16830 300000 300000 900000 800000 -3300000 -3600000 0 0 0 1500000 0 0 200000 3500000 0 0 3000000 500000 1100000 100000 100000 100000 100000 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. Inventories </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of the following (in thousands):</span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">January 2,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,593 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,098 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,383 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,985 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,352 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,869 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,328 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,952 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of the following (in thousands):</span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">January 2,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,593 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,098 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,383 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,985 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,352 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,869 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,328 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,952 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 121593000 133098000 14383000 15985000 66352000 66869000 202328000 215952000 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. Other Current Assets </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets consist of the following (in thousands): </span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">January 2,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,351 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,235 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease receivable, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,685 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,206 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,501 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,782 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indirect taxes receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,715 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,545 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid rebates and royalties, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,066 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,081 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,496 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,397 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer notes receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,283 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposit to acquire noncontrolling interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,599 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,513 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,772 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,416 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">     Restricted cash includes funds received from the Bill and Melinda Gates Foundation. As the Company incurs costs associated with research and development related to this project, on a quarterly basis, the Company reclasses amounts from the grant to offset costs incurred.</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">     During the year ended January 2, 2021, the Company obtained a controlling interest in a provider of advanced hemodynamic monitoring solutions. The Company made a deposit to acquire the noncontrolling interest of the acquiree. During the first quarter of 2021, the Company acquired the remaining noncontrolling interest. The impact of the noncontrolling interest is immaterial in all periods presented.</span></div> <div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets consist of the following (in thousands): </span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">January 2,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,351 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,235 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease receivable, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,685 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,206 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,501 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,782 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indirect taxes receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,715 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,545 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid rebates and royalties, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,066 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,081 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,496 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,397 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer notes receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,283 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposit to acquire noncontrolling interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,599 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,513 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,772 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,416 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">     Restricted cash includes funds received from the Bill and Melinda Gates Foundation. As the Company incurs costs associated with research and development related to this project, on a quarterly basis, the Company reclasses amounts from the grant to offset costs incurred.</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">     During the year ended January 2, 2021, the Company obtained a controlling interest in a provider of advanced hemodynamic monitoring solutions. The Company made a deposit to acquire the noncontrolling interest of the acquiree. During the first quarter of 2021, the Company acquired the remaining noncontrolling interest. The impact of the noncontrolling interest is immaterial in all periods presented.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-current assets consist of the following (in thousands):</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">January 2,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lessee ROU assets, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,561 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,324 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strategic investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,928 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,002 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid deposits and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,397 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,316 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other non-current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,886 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,642 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 30351000 30235000 26685000 23206000 15501000 14782000 10715000 14545000 3066000 3081000 1496000 3397000 1359000 2283000 0 3374000 2599000 7513000 91772000 102416000 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. Lease Receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue and costs, as well as a lease receivable, at the time the lease commences pursuant to deferred equipment agreements containing embedded sales-type leases. Lease revenue related to both operating-type and sales-type leases for the three months ended October 2, 2021 and September 26, 2020 was approximately $12.0 million and $13.0 million, respectively, and is included within product revenue in the accompanying condensed consolidated statements of operations. Lease revenue related to both operating-type and sales-type leases for the nine months ended October 2, 2021 and September 26, 2020 was approximately $40.0 million and $31.0 million, respectively, and is included within product revenue in the accompanying condensed consolidated statements of operations. Costs related to embedded leases within the Company’s deferred equipment agreements are included in cost of goods sold in the accompanying condensed consolidated statements of operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease receivable consists of the following (in thousands):</span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">January 2,<br/>2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,879 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,074 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for credit loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(239)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Lease receivable, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,640 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,872 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of lease receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,685)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Lease receivable, noncurrent</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,955 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,666 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 2, 2021, estimated future maturities of customer sales-type lease receivables for each of the following fiscal years are as follows (in thousands):</span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.789%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%;text-decoration:underline">Fiscal year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (balance of year)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,888 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,995 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,371 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,349 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,535 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,502 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,640 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated future operating lease payments expected to be received from customers under deferred equipment agreements are not material as of October 2, 2021.</span></div> 12000000 13000000 40000000 31000000 <div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease receivable consists of the following (in thousands):</span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">January 2,<br/>2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,879 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,074 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for credit loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(239)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Lease receivable, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,640 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,872 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of lease receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,685)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Lease receivable, noncurrent</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,955 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,666 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 93879000 81074000 239000 202000 93640000 80872000 26685000 23206000 66955000 57666000 <div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 2, 2021, estimated future maturities of customer sales-type lease receivables for each of the following fiscal years are as follows (in thousands):</span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.789%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%;text-decoration:underline">Fiscal year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (balance of year)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,888 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,995 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,371 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,349 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,535 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,502 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,640 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 6888000 25995000 21371000 17349000 11535000 10502000 93640000 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. Deferred Costs and Other Contract Assets </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred costs and other contract assets consist of the following (in thousands):</span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">January 2,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred commissions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,976 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,477 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid contract allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,336 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unbilled contract receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,317 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,925 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment leased to customers, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,486 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,338 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Deferred costs and other contract assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,599 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,076 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred costs and other contract assets consist of the following (in thousands):</span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">January 2,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred commissions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,976 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,477 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid contract allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,336 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unbilled contract receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,317 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,925 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment leased to customers, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,486 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,338 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Deferred costs and other contract assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,599 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,076 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 9976000 7477000 6820000 7336000 4317000 3925000 1486000 1338000 22599000 20076000 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. Property and Equipment, net </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, consists of the following (in thousands):</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">January 2,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,990 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,310 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery, equipment and tooling</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,833 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,843 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,938 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,151 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transportation, vehicles and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,114 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,175 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,131 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,693 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,885 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,295 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,186 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,567 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Demonstration units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,049 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,024 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-progress (CIP)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,955 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,589 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,081 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406,647 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(151,152)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134,136)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,929 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,511 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended October 2, 2021 and September 26, 2020, depreciation expense of property and equipment was $6.5 million and $5.8 million, respectively. For the nine months ended October 2, 2021 and September 26, 2020, depreciation expense of property and equipment was $18.8 million and $16.0 million, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance in CIP at October 2, 2021 related primarily to</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the capitalized implementation costs related to a new enterprise resource planning software system and costs related to equipment and other facility improvements, the underlying assets for which have not been completed or placed into service. The decrease in CIP balance from January 2, 2021 primarily relates to the Company’s European headquarters building in Switzerland being placed into service along with a</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> phase of the new enterprise resource planning software system for certain subsidiaries being placed into service. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance in CIP at January 2, 2021 related primarily to acquisition and improvement costs for a portion of the Company’s European headquarters building in Switzerland, capitalized implementation costs related to a new enterprise resource planning software system and costs related to manufacturing equipment and other facility improvements, the underlying assets for which had not been placed into service.</span></div> 141990000 122310000 101833000 90843000 56938000 57151000 33114000 33175000 32131000 24693000 20885000 19295000 14186000 13567000 1049000 1024000 23955000 44589000 426081000 406647000 151152000 134136000 274929000 272511000 6500000 5800000 18800000 16000000 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. Intangible Assets, net </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net, consist of the following (in thousands):</span></div><div style="margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">January 2,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,528 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,875 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired technologies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,039 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,636 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,666 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,080 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,708 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,108 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,108 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses-related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,257 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,693 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,676 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,589 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,587)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,666)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Intangible assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,089 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,923 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets have a weighted-average amortization period of twelve years. Total amortization expense for the three months ended October 2, 2021 and September 26, 2020 was $2.7 million and $1.6 million, respectively. Total amortization expense for the nine months ended October 2, 2021 and September 26, 2020 was $7.6 million and $5.2 million, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total renewal costs for patents and trademarks for the three months ended October 2, 2021 and September 26, 2020 were $0.9 million and $0.6 million, respectively. Total renewal costs for patents and trademarks for the nine months ended October 2, 2021 and September 26, 2020 were $1.3 million and $1.2 million, respectively. As of October 2, 2021, the weighted-average number of years until the next renewal was two years for patents and four years for trademarks.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense for each of the next fiscal years is as follows (in thousands):</span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.789%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%;text-decoration:underline">Fiscal year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (balance of year)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,211 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,377 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,964 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,352 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,274 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,911 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,089 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net, consist of the following (in thousands):</span></div><div style="margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">January 2,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,528 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,875 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired technologies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,039 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,636 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,666 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,080 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,708 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,108 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,108 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses-related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,257 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,693 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,676 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,589 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,587)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,666)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Intangible assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,089 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,923 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 30528000 26875000 28567000 29039000 24636000 24666000 12080000 11708000 8108000 5108000 7500000 7500000 6257000 5693000 117676000 110589000 43587000 36666000 74089000 73923000 P12Y 2700000 1600000 7600000 5200000 900000 600000 1300000 1200000 P2Y P4Y <div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense for each of the next fiscal years is as follows (in thousands):</span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.789%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%;text-decoration:underline">Fiscal year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (balance of year)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,211 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,377 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,964 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,352 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,274 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,911 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,089 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 9211000 8377000 7964000 7352000 6274000 34911000 74089000 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. Goodwill </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in goodwill were as follows (in thousands):</span></div><div style="margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.789%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Nine Months Ended <br/>October 2, <br/>2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,206 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,964)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,242 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> <div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in goodwill were as follows (in thousands):</span></div><div style="margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.789%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Nine Months Ended <br/>October 2, <br/>2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,206 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,964)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,242 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 103206000 -1964000 101242000 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. Lessee ROU Assets and Lease Liabilities </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain facilities in North and South America, Europe, the Middle East and Asia-Pacific regions under operating lease agreements expiring at various dates through January 2032. In addition, the Company leases equipment in the U.S. and Europe, and these leases are classified as operating leases and expire at various dates through August 2026. The majority of these leases are non-cancellable and generally do not contain any material restrictive covenants, material residual value guarantees or other material guarantees. The Company recognizes lease costs under these agreements using a straight-line method based on total lease payments. Certain facility leases contain predetermined price escalations and in some cases renewal options, the longest of which is for five years.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally estimates the applicabl</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e discount rate used to determine the net present value of lease payments based on available information at the lease commencement date. As of October 2, 2021, the weighted-average discount rate used by the Company for all operating leases was approximately 2.6%.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance sheet classifications for amounts related to the Company’s operating leases for which it is the lessee are as follows (in thousands):</span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.793%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance sheet classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">January 2,<br/>2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lessee ROU assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,561 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,324 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lessee current lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,147 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,975 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lessee non-current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,471 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,373 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,618 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,348 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 2, 2021 and January 2, 2021, accumulated amortization for lessee ROU assets was $13.0 million and $9.2 million, respectively. The weighted-average remaining lease term for the Company’s operating leases was 6.7 years as of October 2, 2021.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 2, 2021, estimated future operating lease payments for each of the following fiscal years were as follows (in thousands):</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.789%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%;text-decoration:underline">Fiscal year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (balance of year)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,509 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,093 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,649 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,998 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,689 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,071)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Present value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,618 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">     Includes optional renewal period for certain leases.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended October 2, 2021 and September 26, 2020, operating lease costs were approximately $2.1 million and $1.8 million, respectively. During the nine months ended October 2, 2021 and September 26, 2020, operating lease costs were approximately $6.2 million and $5.2 million, respectively.</span></div> P5Y 0.026 <div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance sheet classifications for amounts related to the Company’s operating leases for which it is the lessee are as follows (in thousands):</span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.793%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance sheet classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">January 2,<br/>2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lessee ROU assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,561 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,324 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lessee current lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,147 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,975 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lessee non-current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,471 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,373 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,618 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,348 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 31561000 32324000 6147000 5975000 27471000 28373000 33618000 34348000 13000000 9200000 P6Y8M12D <div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 2, 2021, estimated future operating lease payments for each of the following fiscal years were as follows (in thousands):</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.789%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%;text-decoration:underline">Fiscal year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (balance of year)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,509 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,093 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,649 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,998 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,689 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,071)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Present value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,618 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">     Includes optional renewal period for certain leases.</span></div> 1509000 7093000 6649000 5123000 3998000 12317000 36689000 3071000 33618000 2100000 1800000 6200000 5200000 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. Other Non-Current Assets </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-current assets consist of the following (in thousands):</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">January 2,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lessee ROU assets, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,561 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,324 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strategic investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,928 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,002 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid deposits and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,397 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,316 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other non-current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,886 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,642 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 31561000 32324000 13928000 8002000 4397000 4316000 49886000 44642000 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. Deferred Revenue and Other Contract Liabilities, Current</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue and other contract liabilities consist of the following (in thousands):</span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">January 2,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,392 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,221 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates and allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,322 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued customer reimbursements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,744 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,829 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total deferred revenue and other contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,458 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,177 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Non-current portion of deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,817)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,242)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Deferred revenue and other contract liabilities - current</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,641 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,935 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue relates to contracted amounts that have been invoiced to customers for which remaining performance obligations must be completed before the Company can recognize the revenue. These amounts primarily relate to undelivered equipment, sensors and services under deferred equipment agreements, extended warranty agreements and maintenance agreements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in deferred revenue were as follows (in thousands):</span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.789%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Nine Months Ended <br/>October 2, <br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,221 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Revenue deferred during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Recognition of revenue deferred in prior periods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,254)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Deferred revenue, end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,392 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected revenue from remaining contractual performance obligations (Unrecognized Contract Revenue) includes deferred revenue, as well as other amounts that will be invoiced and recognized as revenue in future periods, when the Company completes its performance obligations. While Unrecognized Contract Revenue is similar in concept to backlog, Unrecognized Contract Revenue excludes revenue allocable to monitoring-related equipment that is effectively leased to customers under deferred equipment agreements and other contractual obligations for which neither party has performed. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 2, 2021, the Company had approximately $987.3 million of Unrecognized Contract Revenue related to executed contracts with an original duration of one year or more. The Company expects to recognize approximately $272.7 million of this amount as revenue within the next twelve months and the remaining balance thereafter.</span></div>The estimated timing of this revenue is based, in part, on management’s estimates and assumptions about when its performance obligations will be completed. As a result, the actual timing of this revenue in future periods may vary, possibly materially <div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue and other contract liabilities consist of the following (in thousands):</span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">January 2,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,392 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,221 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates and allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,322 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued customer reimbursements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,744 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,829 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total deferred revenue and other contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,458 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,177 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Non-current portion of deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,817)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,242)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Deferred revenue and other contract liabilities - current</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,641 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,935 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in deferred revenue were as follows (in thousands):</span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.789%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Nine Months Ended <br/>October 2, <br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,221 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Revenue deferred during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Recognition of revenue deferred in prior periods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,254)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Deferred revenue, end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,392 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 34392000 33221000 11322000 12127000 4744000 3829000 50458000 49177000 3817000 4242000 46641000 44935000 33221000 23425000 22254000 34392000 987300000 P1Y 272700000 P12M <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. Other Current Liabilities </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities consist of the following (in thousands):</span></div><div style="margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">January 2,<br/>2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued indirect taxes payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,081 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,365 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,794 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lessee lease liabilities, current </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,147 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,975 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,443 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,910 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,947 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,058 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related party payables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,446 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,655 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued warranty</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,944 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,740 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued property taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,686 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,682 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued donations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,071 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,096 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,469 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,118 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,239 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">During the year ended January 2, 2021, the Company obtained a controlling interest in a provider of advanced hemodynamic monitoring solutions. The noncontrolling interest of the acquiree was recorded within other current liabilities as of January 2, 2021, as the noncontrolling interest shares were mandatorily redeemable. During the first quarter of 2021, the Company acquired the remaining noncontrolling interest. The impact of the noncontrolling interest is immaterial in all periods presented.</span></div> <div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities consist of the following (in thousands):</span></div><div style="margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">January 2,<br/>2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued indirect taxes payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,081 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,365 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,794 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lessee lease liabilities, current </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,147 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,975 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,443 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,910 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,947 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,058 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related party payables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,446 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,655 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued warranty</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,944 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,740 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued property taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,686 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,682 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued donations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,071 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,096 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,469 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,118 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,239 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">During the year ended January 2, 2021, the Company obtained a controlling interest in a provider of advanced hemodynamic monitoring solutions. The noncontrolling interest of the acquiree was recorded within other current liabilities as of January 2, 2021, as the noncontrolling interest shares were mandatorily redeemable. During the first quarter of 2021, the Company acquired the remaining noncontrolling interest. The impact of the noncontrolling interest is immaterial in all periods presented.</span></div> 12081000 14365000 12046000 6794000 6147000 5975000 4443000 5910000 3947000 4058000 3446000 3655000 2944000 2740000 1686000 1682000 1307000 495000 3071000 4096000 0 3469000 51118000 53239000 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. Credit Facility </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently maintains a credit facility with various lenders that provides for up to $150.0 million of unsecured borrowings, with an option, subject to certain conditions, for the Company to increase the aggregate borrowing capacity up to $550.0 million in the future with such lenders and additional lenders, as required. The credit facility also provides for a sublimit of up to $25.0 million for the issuance of letters of credit and a sublimit of $75.0 million for borrowings in specified foreign currencies. All unpaid principal under the credit facility will become due and payable on December 17, 2023. Proceeds from the credit facility are expected to be used for general corporate, capital investment and working capital needs. As of October 2, 2021 and January 2, 2021, the credit facility had no outstanding draws and $2.4 million and $1.7 million of outstanding letters of credit, respectively. The Company was in compliance with all covenants under the credit facility as of October 2, 2021 and January 2, 2021.</span></div>For each of the three months ended October 2, 2021 and September 26, 2020, the Company incurred total interest expense of $0.1 million under the credit facility. 150000000 550000000 25000000 75000000 0 0 2400000 1700000 100000 100000 200000 200000 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. Other Non-Current Liabilities </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-current liabilities consist of the following (in thousands):</span></div><div style="margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">January 2,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lessee non-current lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,471 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,373 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax payable, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,980 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,245 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,352 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,777 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,063 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,247 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,511 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,434 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total other non-current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,377 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,076 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized tax benefits relate to the Company’s long-term portion of tax liability associated with uncertain tax positions. Authoritative guidance prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. See Note 20 to these condensed consolidated financial statements for further details.</span></div> <div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-current liabilities consist of the following (in thousands):</span></div><div style="margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">January 2,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lessee non-current lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,471 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,373 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax payable, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,980 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,245 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,352 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,777 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,063 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,247 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,511 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,434 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total other non-current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,377 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,076 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 27471000 28373000 16980000 19245000 15352000 11777000 6063000 6247000 4511000 5434000 70377000 71076000 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17. Stock Repurchase Program </span></div><div style="margin-top:4.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company’s Board of Directors (Board) approved a stock repurchase program, authorizing the Company to purchase up to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares of its common stock over a period of up to three years (2021 Repurchase Program). The Company expects to fund the 2021 Repurchase Program through its available cash, cash expected to be generated from future operations, the credit facility and other potential sources of capital. The 2021 Repurchase Program can be carried out at the discretion of a committee comprised of the CEO and CFO through open market purchases, one or more Rule 10b5-1 trading plans, block trades and privately negotiated transactions.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, the Company’s Board approved a stock repurchase program, authorizing the Company to purchase up to 5.0 million additional shares of its common stock over a period of up to three years (2018 Repurchase Program). During the third quarter of 2021, the 2018 Repurchase Program expired.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the Company’s stock repurchase activities (in thousands, except per share amounts):</span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">September 26,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">September 26,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares repurchased</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average cost per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235.88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value of shares repurchased</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,917 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">     Excludes shares withheld from the shares of its common stock actually issued in connection with the vesting of PSU or RSU awards to satisfy certain U.S. federal and state tax withholding obligations.</span></div> 3000000 P3Y 5000000 P3Y 0 0 547000 4000 0 0 235.88 164.44 0 0 128917000 591000 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18. Stock-Based Compensation </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense for the three months ended October 2, 2021 and September 26, 2020 was $12.6 million and $11.9 million, respectively. Total stock-based compensation expense for the nine months ended October 2, 2021 and September 26, 2020 was $33.5 million and $36.4 million, respectively. As of October 2, 2021, an aggregate of 10.7 million shares of common stock were reserved for future issuance under the Company’s equity plans, of which 4.4 million shares were available for future grant under the Masimo Corporation 2017 Equity Incentive Plan (2017 Equity Plan). Additional information related to the Company’s current equity incentive plans, stock-based award activity and valuation of stock-based awards is included below.</span></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Incentive Plans</span></div><div style="margin-top:4.5pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Equity Incentive Plan</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2017, the Company’s stockholders ratified and approved the 2017 Equity Plan. The 2017 Equity Plan permits the grant of stock options, restricted stock, RSUs, stock appreciation rights, PSUs, performance shares, performance bonus awards and other stock or cash awards to employees, directors and consultants of the Company and employees and consultants of any parent or subsidiary of the Company. Upon its effectiveness, an aggregate of 5.0 million shares were available for issuance under the 2017 Equity Plan. In May 2020, the Company’s stockholders approved an increase of 2.5 million shares to the 2017 Equity Plan. The aggregate number of shares that may be awarded under the 2017 Equity Plan is 7.5 million shares. The 2017 Equity Plan provides that at least 95% of the equity awards issued under the 2017 Equity Plan must vest over a period of not less than one year following the date of grant. The exercise price per share of each option granted under the 2017 Equity Plan may not be less than the fair market value of a share of the Company’s common stock on the date of grant, which is generally equal to the closing price of the Company’s common stock on the Nasdaq Global Select Market on the grant date.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2007 Stock Incentive Plan</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective June 1, 2017, upon the approval and ratification of the 2017 Equity Plan, the Company’s 2007 Stock Incentive Plan (2007 Equity Plan) terminated, provided that awards outstanding under the 2007 Equity Plan will continue to be governed by the terms of that plan. In addition, upon the effectiveness of the 2017 Equity Plan, an aggregate of 5.0 million shares of the Company’s common stock registered under prior registration statements for issuance pursuant to the 2007 Equity Plan were deregistered and concurrently registered under the 2017 Equity Plan. </span></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Award Activity</span></div><div style="margin-top:4.5pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number and weighted-average exercise price of options issued and outstanding under all of the Company’s equity plans are as follows (in thousands, except for weighted-average exercise prices):</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Nine Months Ended <br/>October 2, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,448 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.44 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146.62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(278)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, end of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,105 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.55 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable, end of period</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,255 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.57 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock option expense for the three months ended October 2, 2021 and September 26, 2020 was $3.2 million and $3.8 million, respectively. Total stock option expense for the nine months ended October 2, 2021 and September 26, 2020 was $9.9 million and $11.9 million, respectively. As of October 2, 2021, the Company had $30.7 million of unrecognized compensation cost related to non-vested stock options that are expected to vest over a weighted-average period of approximately 2.6 years. The weighted-average remaining contractual term of options outstanding with an exercise price less than the closing price of the Company’s common stock as of October 2, 2021 was 5.3 years. The weighted-average remaining contractual term of options exercisable, with an exercise price less than the closing price of the Company’s common stock as of October 2, 2021, was 4.4 years.</span></div><div style="margin-top:13pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RSUs</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of RSUs issued and outstanding under all of the Company’s equity plans are as follows (in thousands, except for weighted-average grant date fair value amounts):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Nine Months Ended <br/>October 2, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Units</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Weighted-Average Grant<br/> Date Fair Value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,862 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.66 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248.57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199.02 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding, end of period</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,900 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.88 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total RSU expense for the three months ended October 2, 2021 and September 26, 2020 was $2.4 million and $1.5 million, respectively. Total RSU expense for the nine months ended October 2, 2021 and September 26, 2020 was $6.7 million and $4.0 million, respectively. As of October 2, 2021, the Company had $34.7 million of unrecognized compensation cost related to non-vested RSU awards expected to be recognized and vest over a weighted-average period of approximately 3.6 years.</span></div><div style="margin-top:13pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PSUs</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of PSUs outstanding under all of the Company’s equity plans are as follows (in thousands, except for weighted-average grant date fair value amounts):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Nine Months Ended <br/>October 2, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Units</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Weighted-Average Grant<br/> Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs outstanding, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.28 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.99 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166.84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(273)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs outstanding, end of period</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168.68 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">     On February 22, 2021, the Audit Committee approved the weighted payout percentage for the 2018 PSU awards (three-year performance period), which were based upon the actual fiscal 2020 performance against pre-established performance objectives. Included in the granted amount are those additional PSUs earned based on actual performance achieved. These PSUs were originally awarded at target.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2021, the Company awarded 68,600 PSUs that will vest three years from the award date, based on the achievement of certain 2024 performance criteria approved by the Board. If earned, the PSUs granted will vest upon achievement of the performance criteria after the year in which the performance achievement level has been determined. The number of shares that may be earned can range from 0% to 200% of the target amount; therefore, the maximum number of shares that can be issued under these awards is twice the original award of 68,600 PSUs, or 137,200 shares. Based on management’s estimate of the number of units expected to vest, total PSU expense for the three months ended October 2, 2021 and September 26, 2020 was $7.0 million and $6.6 million, respectively. Based on management’s estimate of the number of units expected to vest, total PSU expense for the nine months ended October 2, 2021 and September 26, 2020 was $16.9 million and $20.5 million, respectively. As of October 2, 2021, the Company had $41.1 million of unrecognized compensation cost related to non-vested PSU awards expected to be recognized and vest over a weighted-average period of approximately 1.1 years.</span></div><div style="margin-top:13pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation of Stock-Based Award Activity</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each RSU and PSU is determined based on the closing price of the Company’s common stock on the grant date.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option pricing model is used to estimate the fair value of options granted under the Company’s stock-based compensation plans. The range of assumptions used and the resulting weighted-average fair value of options granted at the date of grant were as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2, </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">September 26,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">September 26,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2% to 0.3%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3% to 0.9%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2% to 1.7%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.7% to 33.6%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.9% to 34.7%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.9% to 35.5%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividends</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value of options granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$66.24</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$75.72</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$50.39</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">No stock options were granted during the three months ended October 2, 2021.</span></div>The aggregate intrinsic value of options is calculated as the positive difference, if any, between the market value of the Company’s common stock on the date of exercise or the respective period end, as appropriate, and the exercise price of the options. The aggregate intrinsic value of options outstanding with an exercise price less than the closing price of the Company’s common stock as of October 2, 2021 was $589.6 million. The aggregate intrinsic value of options exercisable with an exercise price less than the closing price of the Company’s common stock as of October 2, 2021 was $484.5 million. The aggregate intrinsic value of options exercised during the three months ended October 2, 2021 was $35.4 million. 12600000 11900000 33500000 36400000 10700000 4400000 5000000 2500000 7500000 5000000 <div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number and weighted-average exercise price of options issued and outstanding under all of the Company’s equity plans are as follows (in thousands, except for weighted-average exercise prices):</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Nine Months Ended <br/>October 2, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,448 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.44 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146.62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(278)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, end of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,105 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.55 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable, end of period</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,255 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.57 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3448000 77.44 85000 250.15 150000 146.62 278000 57.88 3105000 80.55 2255000 55.57 3200000 3800000 9900000 11900000 30700000 P2Y7M6D P5Y3M18D P4Y4M24D <div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of RSUs issued and outstanding under all of the Company’s equity plans are as follows (in thousands, except for weighted-average grant date fair value amounts):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Nine Months Ended <br/>October 2, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Units</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Weighted-Average Grant<br/> Date Fair Value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,862 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.66 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248.57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199.02 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding, end of period</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,900 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.88 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 2862000 99.66 89000 248.57 17000 199.02 0 0 34000 163.57 2900000 102.88 2400000 1500000 6700000 4000000 34700000 P3Y7M6D <div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of PSUs outstanding under all of the Company’s equity plans are as follows (in thousands, except for weighted-average grant date fair value amounts):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Nine Months Ended <br/>October 2, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Units</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Weighted-Average Grant<br/> Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs outstanding, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.28 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.99 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166.84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(273)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs outstanding, end of period</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168.68 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">     On February 22, 2021, the Audit Committee approved the weighted payout percentage for the 2018 PSU awards (three-year performance period), which were based upon the actual fiscal 2020 performance against pre-established performance objectives. Included in the granted amount are those additional PSUs earned based on actual performance achieved. These PSUs were originally awarded at target.</span></div> 444000 120.28 148000 162.99 17000 166.84 0 0 273000 86.95 302000 168.68 68600 three years 0 2 68600 137200 7000000 6600000 16900000 20500000 41100000 P1Y1M6D The range of assumptions used and the resulting weighted-average fair value of options granted at the date of grant were as follows:<div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2, </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">September 26,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">September 26,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2% to 0.3%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3% to 0.9%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2% to 1.7%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.7% to 33.6%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.9% to 34.7%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.9% to 35.5%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividends</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value of options granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$66.24</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$75.72</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$50.39</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">No stock options were granted during the three months ended October 2, 2021.</span></div> 0 0.002 0.003 0.003 0.009 0.002 0.017 P0Y P5Y1M6D P5Y7M6D P5Y1M6D 0 0.327 0.336 0.309 0.347 0.269 0.355 0 0 0 0 0 66.24 75.72 50.39 589600000 484500000 35400000 56900000 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19. Non-operating (loss) income</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-operating (loss) income consists of the following (in thousands): </span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">September 26,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">September 26,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">677 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,120 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(259)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized and unrealized foreign currency (losses) gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,153)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,357 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(735)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,108 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-operating (loss) income consists of the following (in thousands): </span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">September 26,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">September 26,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">677 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,120 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(259)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized and unrealized foreign currency (losses) gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,153)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,357 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(735)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,108 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 242000 797000 677000 5120000 87000 84000 259000 250000 -233000 647000 -1153000 1246000 0 3000 0 8000 -78000 1357000 -735000 6108000 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20. Income Taxes </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has provided for income taxes in fiscal year 2021 interim periods based on the estimated effective income tax rate for the complete fiscal year, as adjusted for discrete tax events, including excess tax benefits or deficiencies related to stock-based compensation, in the period such events occur. The estimated annual effective tax rate is computed based on the expected annual pretax income of the consolidated entities located within each taxing jurisdiction based on legislation enacted as of the balance sheet date. For the three months ended October 2, 2021 and September 26, 2020, the Company recorded discrete tax benefits of approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$6.4 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $3.1 million, respectively, related to excess tax benefits realized from stock-based compensation. For the nine months ended October 2, 2021 and September 26, 2020, the Company recorded discrete tax benefits of approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$12.0 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $20.2 million, respectively, related to excess tax benefits realized from stock-based compensation.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assets and liabilities are determined based on the future tax consequences associated with temporary differences between income and expenses reported for accounting and tax purposes. A valuation allowance for deferred tax assets is recorded to the extent that the Company cannot determine that the ultimate realization of the net deferred tax assets is more likely than not. Realization of deferred tax assets is principally dependent upon the achievement of future taxable income, the estimation of which requires significant judgment by the Company’s management. The judgment of the Company’s management regarding future profitability may change due to many factors, including future market conditions and the Company’s ability to successfully execute its business plans or tax planning strategies. These changes, if any, may require material adjustments to these deferred tax asset balances.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 2, 2021, the liability for income taxes associated with uncertain tax positions was approximately $21.6 million. If fully recognized, approximately $19.6 million (net of federal benefit on state taxes) would impact the Company’s effective tax rate. It is reasonably possible that the amount of unrecognized tax benefits in various jurisdictions may change in the next twelve months due to the expiration of statutes of limitation and audit settlements. However, due to the uncertainty surrounding the timing of these events, an estimate of the change within the next twelve months cannot currently be made.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducts business in multiple jurisdictions and, as a result, one or more of the Company’s subsidiaries files income tax returns in U.S. federal, various state, local and foreign jurisdictions. The Company has concluded all U.S. federal income tax matters through fiscal year 2016. All material state, local and foreign income tax matters have been concluded through fiscal year 2012. The Company does not believe that the results of any tax authority examination would have a significant impact on its consolidated financial statements.</span></div> 6400000 3100000 12000000 20200000 21600000 19600000 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">21. Commitments and Contingencies </span></div><div style="margin-top:4.5pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Retirement Savings Plan</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors a qualified defined contribution plan or 401(k) plan, the Masimo Retirement Savings Plan (MRSP), covering the Company’s full-time U.S. employees who meet certain eligibility requirements. In general, the Company matches an employee’s contribution up to 3% of the employee’s compensation, subject to a maximum amount. The Company may also contribute to the MRSP on a discretionary basis. The Company contributed $0.9 million and $0.8 million to the MRSP for the three months ended October 2, 2021 and September 26, 2020, respectively, all in the form of matching contributions. The Company contributed $2.8 million and $2.4 million to the MRSP for the nine months ended October 2, 2021 and September 26, 2020, respectively, all in the form of matching contributions. In addition, the Company sponsors various defined contribution plans in certain locations outside of the United States, the contributions to which were not material for any period.</span></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employment and Severance Agreements</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2017, the Company entered into the First Amendment to the certain Amended and Restated Employment Agreement entered into between the Company and Mr. Kiani on November 4, 2015 (as amended, the Amended Employment Agreement). Pursuant to the terms of the Amended Employment Agreement, upon a “Qualifying Termination” (as defined in the Amended Employment Agreement), Mr. Kiani will be entitled to receive a cash severance benefit equal to two times the sum of his then-current base salary and the average annual bonus paid to Mr. Kiani during the immediately preceding three years, the full amount of the “Award Shares” (as defined in the Amended Employment Agreement) and the full amount of the “Cash Payment” (as defined in the Amended Employment Agreement). In addition, in the event of a “Change in Control” (as defined in the Amended Employment Agreement) prior to a Qualifying Termination, on each of the first and second anniversaries of the Change in Control, 50% of the Cash Payment and 50% of the Award Shares will vest, subject in each case to Mr. Kiani’s continuous employment through each such anniversary date; however, in the event of a Qualifying Termination or a termination of Mr. Kiani’s employment due to death or disability prior to either of such anniversaries, any unvested amount of the Cash Payment and all of the unvested Award Shares shall vest and be paid in full. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in the event of a Change in Control prior to a Qualifying Termination, Mr. Kiani’s stock options and any other equity awards will vest in accordance with their terms, but in no event later than in two equal installments on each of the one year and two year anniversaries of the Change in Control, subject in each case to Mr. Kiani’s continuous employment through each such anniversary date. As of October 2, 2021, the expense related to the Award Shares and Cash Payment that would be recognized in the Company’s consolidated financial statements upon the occurrence of a Qualifying Termination under the Restated Employment Agreement was approximately $292.9 million.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 2, 2021, the Company had severance plan participation agreements wit</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h five exe</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cutive officers. The participation agreements (the Agreements) are governed by the terms and conditions of the Company’s 2007 Severance Protection Plan (the Severance Plan), which became effective on July 19, 2007 and which was amended effective December 31, 2008. Under each of the Agreements, the applicable executive officer may be entitled to receive certain salary, equity, medical and life insurance benefits if he is terminated by the Company without cause or if he terminates his employment for good reason under certain circumstances. The executive officers are also required to give the Company six months’ advance notice of their resignation under certain circumstances.</span></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to contractual obligations with vendors, the Company had $155.9 million of purchase commitments as of October 2, 2021 that are expected to be purchased within one year. These purchase commitments have been made for certain inventory items in order to secure sufficient levels of those items, other critical inventory and manufacturing supplies, and to achieve better pricing. </span></div><div style="margin-top:13pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Contractual Commitments</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company may provide bank guarantees to support government hospital tenders in certain foreign jurisdictions. As of October 2, 2021, the Company had approximately $3.4 million in outstanding unsecured bank guarantees. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain circumstances, the Company also provides limited indemnification within its various customer contracts whereby the Company indemnifies the parties to whom it sells its products with respect to potential infringement of intellectual property, and against bodily injury caused by a defective Company product. It is not possible to predict the maximum potential amount of future payments under these or similar agreements, due to the conditional nature of the Company’s obligations and the unique facts and circumstances involved. As of October 2, 2021, the Company had not incurred any significant costs related to contractual indemnification of its customers.</span></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Risk</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to credit loss for the amount of its cash deposits with financial institutions in excess of federally insured limits. The Company invests a portion of its excess cash with major financial institutions. As of October 2, 2021, the Company had $652.4 million of bank balances, of which $5.0 million was covered by either the U.S. Federal Deposit Insurance Corporation limit or foreign countries’ deposit insurance organizations. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s ability to sell its products to U.S. hospitals depends in part on its relationships with GPOs. Many existing and potential customers for the Company’s products become members of GPOs. GPOs negotiate pricing arrangements and contracts, sometimes exclusively, with medical supply manufacturers and distributors, and these negotiated prices are made available to a GPO’s affiliated hospitals and other members. During the three months ended October 2, 2021 and September 26, 2020, revenue from the sale of the Company’s products to customers that are members of GPOs approximated 55.0% and 48.1% of product revenue, respectively. During the nine months ended October 2, 2021 and September 26, 2020, revenue from the sale of the Company’s products to customers that are members of GPOs approximated 51.8% and 49.6% of product revenue, r</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">espectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended October 2, 2021, the Company had sales through two just-in-time distributors that represented 15.0% and 10.4% of product revenue, respectively. For the three months ended September 26, 2020, the Company had sales through the same two just-in-time distributors that represented 11.0% and 9.3% of product revenue, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended October 2, 2021, the Company had sales through two just-in-time distributors that represented 14.6% and 10.4% of product revenue, respectively. For the nine months ended September 26, 2020, the Company had sales through the same two just-in-time distributors that represented 11.2% and 10.0% of product revenue, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 2, 2021 and January 2, 2021, one customer represented 9.4% and 9.1%, respectively, of the Company’s accounts receivable balance. The receivable balance related to such customer is fully secured by a letter of credit.</span></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of fiscal year 2017, the Company became aware that certain amounts had been paid by a foreign government customer to the Company’s former appointed foreign agent in connection with a foreign government tender, but had not been remitted by such agent to the Company in accordance with the agency agreement. On December 28, 2017, the Company initiated arbitration proceedings against this foreign agent after unsuccessful attempts to recover such remittances. As a result, the Company recorded a net charge of approximately $10.5 million during the fourth quarter of fiscal year 2017 in connection with this dispute, of which $2.0 million was recovered during the year ended December 28, 2019. An arbitration hearing was held on February 11, 2019. On July 8, 2019, the arbitrator awarded the Company $10.5 million in damages, fees and costs. On January 12, 2020, the Company received notice that bankruptcy restructuring proceedings had been initiated for the foreign agent. The Company filed its claim with the bankruptcy trustee on January 16, 2020. In July 2020, the Company was notified that a bankruptcy reorganization proposal had been submitted for voting by creditors in August 2020. The reorganization proposal was rejected by a vote of the creditors on August 26, 2020. On October 22, 2020, the Company filed a petition seeking to enforce the arbitration award. Although the Company intends to vigorously pursue the collection of the arbitration award, there is no guarantee that the Company will be successful in these efforts. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 2, 2014, a putative class action complaint was filed against the Company in the U.S. District Court for the Central District of California (District Court) by Physicians Healthsource, Inc. The complaint alleges that the Company sent unsolicited facsimile advertisements in violation of the Junk Fax Protection Act of 2005 and related regulations. The complaint seeks $500 for each alleged violation, treble damages if the District Court finds the alleged violations to be knowing, plus interest, costs and injunctive relief. On March 26, 2019, an amended complaint was filed adding Radha Geismann, M.D. PC as an additional named plaintiff. On June 17, 2019, the plaintiffs filed their motion for class certification. On September 10, 2019, the parties filed motions for summary judgment. On September 30, 2019, the Company filed its opposition to the motion for class certification, and the plaintiffs filed their reply on October 7, 2019. On November 21, 2019, the District Court issued an order denying the plaintiffs’ motion for class certification and granting in part and denying in part the Company’s motion for summary judgment, and deferring ruling on the plaintiffs’ motion for summary judgment. On December 5, 2019, the plaintiffs filed a petition for permission to appeal the order denying class certification, which was denied on January 24, 2020. Trial of the individual plaintiffs’ claims was scheduled for June 2, 2020, but on April 1, 2020, the District Court vacated the trial date and directed the parties to conduct an in-person mediation. The mediation has not occurred and no new trial date has been set. On July 13, 2020, the District Court issued an order granting in part and denying in part the plaintiffs’ motion for summary judgment. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes it has good and substantial defenses to the claims, but there is no guarantee that the Company will prevail. The Company is unable to determine whether any loss will ultimately occur or to estimate the range of such loss; therefore, no amount of loss has been accrued by the Company in the accompanying condensed consolidated financial statements. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 9, 2020, the Company filed a complaint against Apple Inc. (Apple) in the District Court for infringement of a number of patents, for trade secret misappropriation, and for ownership and correction of inventorship of a number of Apple patents listing one of its former employees as an inventor. Apple filed petitions for Inter Partes review of the asserted patents in the U.S. Patent and Trademark Office (PTO). The PTO has instituted Inter Partes review of the asserted patents. On October 13, 2020, the District Court stayed the patent infringement claims pending completion of the Inter Partes review proceedings. On February 5, 2021, the Company filed a fourth amended complaint. On February 26, 2021, Apple filed a partial motion to dismiss the trade secrets claim in the fourth amended complaint. On April 21, 2021, the District Court issued an order granting in part and denying in part the motion to dismiss. On May 5, 2021, Apple filed its answer to the fourth amended complaint. The Company is seeking damages, injunctive relief, and declaratory judgment regarding ownership of the Apple patents. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 30, 2021, the Company filed a complaint with the U.S. International Trade Commission (ITC) against Apple for infringement of a number of other patents. The Company filed an amended complaint on July 12, 2021. On August 13, 2021, the ITC issued a Notice of Institution of Investigation on the asserted patents. An evidentiary hearing is scheduled for June 6-10, 2022, and the target date for completion of the ITC investigation is January 16, 2023. The Company is seeking an exclusion order and a permanent cease and desist order. Although the Company intends to vigorously pursue all of its legal remedies, there is no guarantee that the Company will be successful in these efforts.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be involved in other litigation and investigations relating to claims and matters arising out of its operations in the normal course of business. The Company believes that it currently is not a party to any other legal proceedings which, individually or in the aggregate, would have a material adverse effect on its consolidated financial position, results of operations or cash flows.</span></div> 0.03 900000 800000 2800000 2400000 0.50 0.50 292900000 5 P6M 155900000 3400000 652400000 5000000 0.550 0.481 0.518 0.496 2 0.150 0.104 2 0.110 0.093 2 0.146 0.104 2 0.112 0.100 1 0.094 0.091 10500000 2000000 10500000 500 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">22. Segment Information and Enterprise Reporting </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in one segment based upon the Company’s organizational structure and the way in which the Company’s chief operating decision maker, the CEO, reviews financial information presented on a consolidated basis, accompanied by disaggregated information about revenues by geographic region, for purposes of making operating decisions and assessing financial performance. In addition, the Company’s assets are primarily located in the U.S. The Company does not produce reports for, or measure the performance of, its geographic regions on any asset-based metrics. Therefore, geographic information is presented only for revenues and long-lived assets. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following schedule presents an analysis of the Company’s product revenues based upon the geographic area to which the product was shipped (in thousands, except percentages):</span></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.096%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">September 26,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">September 26,<br/>2020</span></td></tr><tr><td colspan="48" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Geographic area by destination:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States (U.S.)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,060 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,919 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613,197 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571,158 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,223 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,257 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,053 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,781 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia and Australia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,878 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,583 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">North and South America (excluding the U.S.)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,252 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,353 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,190 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,596 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Product revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,413 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,112 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911,574 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848,690 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s consolidated long-lived assets (tangible non-current assets) by geographic area are (in thousands, except percentages):</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">January 2,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-lived assets by geographic area:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,435 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,094 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,980 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,755 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total long-lived assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276,415 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,849 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> <div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following schedule presents an analysis of the Company’s product revenues based upon the geographic area to which the product was shipped (in thousands, except percentages):</span></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.096%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">September 26,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">September 26,<br/>2020</span></td></tr><tr><td colspan="48" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Geographic area by destination:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States (U.S.)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,060 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,919 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613,197 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571,158 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,223 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,257 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,053 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,781 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia and Australia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,878 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,583 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">North and South America (excluding the U.S.)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,252 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,353 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,190 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,596 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Product revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,413 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,112 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911,574 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848,690 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 207060000 0.674 186919000 0.672 613197000 0.673 571158000 0.673 56223000 0.183 54257000 0.195 177053000 0.194 176781000 0.208 34878000 0.113 27583000 0.099 94134000 0.103 73155000 0.086 9252000 0.030 9353000 0.034 27190000 0.030 27596000 0.033 307413000 1.000 278112000 1.000 911574000 1.000 848690000 1.000 <div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s consolidated long-lived assets (tangible non-current assets) by geographic area are (in thousands, except percentages):</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">October 2,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">January 2,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-lived assets by geographic area:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,435 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,094 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,980 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,755 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total long-lived assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276,415 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,849 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 239435000 0.866 238094000 0.869 36980000 0.134 35755000 0.131 276415000 1.000 273849000 1.000 XML 12 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
 9 Months Ended
Oct. 02, 2021
shares
Document And Entity Information [Abstract]  
Document Type 10-Q
Document Quarterly Report true
Document Period End Date Oct. 02, 2021
Document Transition Report false
Entity File Number 001-33642
Entity Registrant Name MASIMO CORP
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 33-0368882
Entity Address, Address Line One 52 Discovery
Entity Address, City or Town Irvine,
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92618
City Area Code (949)
Local Phone Number 297-7000
Title of 12(b) Security Common Stock, $0.001 par value
Trading Symbol MASI
Security Exchange Name NASDAQ
Entity Current Reporting Status Yes
Entity Interactive Data Current Yes
Entity Filer Category Large Accelerated Filer
Smaller Reporting Company false
Emerging Growth Company false
Entity Shell Company false
Entity Common Stock, Shares Outstanding 55,221,689
Amendment Flag false
Document Fiscal Year Focus 2021
Document Fiscal Period Focus Q3
Entity Central Index Key 0000937556
Current Fiscal Year End Date --01-01
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets - USD ($)
Oct. 02, 2021
Jan. 02, 2021
Current assets    
Cash and cash equivalents $ 652,354,000 $ 641,447,000
Trade accounts receivable, net of allowance for credit losses 191,332,000 141,350,000
Inventories 202,328,000 215,952,000
Other current assets 91,772,000 102,416,000
Total current assets 1,137,786,000 1,101,165,000
Lease receivable, noncurrent 66,955,000 57,666,000
Deferred costs and other contract assets 22,599,000 20,076,000
Property and equipment, net 274,929,000 272,511,000
Intangible assets, net 74,089,000 73,923,000
Goodwill 101,242,000 103,206,000
Deferred tax assets 39,294,000 39,363,000
Other non-current assets 49,886,000 44,642,000
Total assets 1,766,780,000 1,712,552,000
Current liabilities    
Accounts payable 60,710,000 64,061,000
Accrued compensation 69,785,000 71,601,000
Deferred revenue and other contract liabilities, current 46,641,000 44,935,000
Other current liabilities 51,118,000 53,239,000
Total current liabilities 228,254,000 233,836,000
Other non-current liabilities 70,377,000 71,076,000
Total liabilities 298,631,000 304,912,000
Commitments and contingencies - (Note 21)
Stockholders’ equity    
Preferred Stock, Value, Outstanding 0 0
Common Stock, Value, Outstanding 55,000 55,000
Treasury Stock, Value (767,653,000) (638,736,000)
Additional paid-in capital 736,575,000 703,693,000
Accumulated other comprehensive (loss) income (3,432,000) 1,413,000
Retained earnings 1,502,604,000 1,341,215,000
Stockholders' Equity Attributable to Parent 1,468,149,000 1,407,640,000
Total liabilities and equity $ 1,766,780,000 $ 1,712,552,000
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Oct. 02, 2021
Jan. 02, 2021
Statement of Financial Position [Abstract]    
Accounts receivable, allowance for doubtful accounts $ 2,081 $ 1,603
Preferred stock, par value $ 1.000 $ 1.000
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 1.000 $ 1.000
Common stock, shares authorized 100,000,000 100,000,000
Common Stock, Shares, Outstanding 55,222,000 55,251,000
Treasury Stock, Shares 16,540,000 15,993,000
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Operations Condensed Consolidated Statement of Operations - USD ($)
shares in Thousands
 3 Months Ended 9 Months Ended
Oct. 02, 2021
Sep. 26, 2020
Oct. 02, 2021
Sep. 26, 2020
Income Statement [Abstract]        
Product revenue $ 307,414,000 $ 278,112,000 $ 911,575,000 $ 848,690,000
Cost of goods sold 103,750,000 99,186,000 318,124,000 292,551,000
Gross profit 203,664,000 178,926,000 593,451,000 556,139,000
Selling, general and administrative 100,647,000 90,376,000 291,180,000 278,714,000
Research and development 35,406,000 28,852,000 103,860,000 86,971,000
Litigation awards 0 0 0 (474,000)
Total operating expenses 136,053,000 119,228,000 395,040,000 365,211,000
Operating income 67,611,000 59,698,000 198,411,000 190,928,000
Non-operating (loss) income (78,000) 1,357,000 (735,000) 6,108,000
Income before provision for income taxes 67,533,000 61,055,000 197,676,000 197,036,000
Provision for income taxes 9,762,000 11,650,000 36,287,000 27,403,000
Net income $ 57,771,000 $ 49,405,000 $ 161,389,000 $ 169,633,000
Basic $ 1.05 $ 0.90 $ 2.93 $ 3.11
Diluted $ 1.00 $ 0.85 $ 2.80 $ 2.92
Basic 55,143 54,997 55,125 54,543
Diluted 57,664 58,280 57,651 58,033
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Comprehensive Income - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Oct. 02, 2021
Sep. 26, 2020
Oct. 02, 2021
Sep. 26, 2020
Income Statement [Abstract]        
Net income $ 57,771 $ 49,405 $ 161,389 $ 169,633
Other comprehensive income, net of tax:        
Unrealized (losses) gains from foreign currency translation adjustments (3,165) 2,653 (4,845) 1,504
Comprehensive income $ 54,606 $ 52,058 $ 156,544 $ 171,137
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Statement of Stockholders' Equity Consolidated Statement of Stockholders' Equity - USD ($)
shares in Thousands
Total
Common Stock
Treasury Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income (loss)
Retained Earnings
Shares, Issued, Beginning Balance at Dec. 28, 2019   53,696 15,530      
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Dec. 28, 2019 $ 1,167,874,000 $ 54,000 $ (526,580,000) $ 600,624,000 $ (6,718,000) $ 1,100,494,000
Stock options exercised, shares   384        
Stock options exercised, value 13,495,000 $ 0   13,495,000    
Restricted/Performance stock units vested   46        
Shares paid for tax withholding, shares   (8)        
Shares paid for tax withholding, value (1,424,000)     (1,424,000)    
Share-based Compensation Expense       11,272,000    
Share-based Compensation Expense 11,272,000          
Repurchases of common stock, shares   (3) (3)      
Repurchases of common stock, value (371,000)   $ (371,000)      
Income Tax Effects Allocated Directly to Equity, Cumulative Effect of Change in Accounting Principle 439,000          
Income Tax Effects Allocated Directly to Equity, Cumulative Effect of Change in Accounting Principle | Cumulative effect of adoption of ASU 2016-13           439,000
Net income 64,456,000         64,456,000
Unrealized (losses) gains from foreign currency translation adjustments (2,463,000)       (2,463,000)  
Shares, Issued, Ending Balance at Mar. 28, 2020   54,115 15,533      
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Mar. 28, 2020 1,253,278,000 $ 54,000 $ (526,951,000) 623,967,000 (9,181,000) 1,165,389,000
Shares, Issued, Beginning Balance at Dec. 28, 2019   53,696 15,530      
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Dec. 28, 2019 $ 1,167,874,000 $ 54,000 $ (526,580,000) 600,624,000 (6,718,000) 1,100,494,000
Repurchases of common stock, shares (4)          
Repurchases of common stock, value $ (591,000)          
Net income 169,633,000          
Unrealized (losses) gains from foreign currency translation adjustments 1,504,000          
Shares, Issued, Ending Balance at Sep. 26, 2020   55,055 15,534      
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Sep. 26, 2020 1,414,804,000 $ 55,000 $ (527,171,000) 676,568,000 (5,214,000) 1,270,566,000
Shares, Issued, Beginning Balance at Mar. 28, 2020   54,115 15,533      
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Mar. 28, 2020 1,253,278,000 $ 54,000 $ (526,951,000) 623,967,000 (9,181,000) 1,165,389,000
Stock options exercised, shares   825        
Stock options exercised, value 21,213,000 $ 1,000   21,212,000    
Restricted/Performance stock units vested   9        
Share-based Compensation Expense       13,188,000    
Share-based Compensation Expense 13,188,000          
Repurchases of common stock, shares   (1) (1)      
Repurchases of common stock, value (220,000)   $ (220,000)      
Net income 55,772,000         55,772,000
Unrealized (losses) gains from foreign currency translation adjustments 1,314,000       1,314,000  
Shares, Issued, Ending Balance at Jun. 27, 2020   54,948 15,534      
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Jun. 27, 2020 1,344,545,000 $ 55,000 $ (527,171,000) 658,367,000 (7,867,000) 1,221,161,000
Stock options exercised, shares   107        
Stock options exercised, value 6,314,000 $ 0   6,314,000    
Restricted/Performance stock units vested   1        
Shares paid for tax withholding, shares   (1)        
Shares paid for tax withholding, value (25,000)     (25,000)    
Share-based Compensation Expense       11,912,000    
Share-based Compensation Expense $ 11,912,000          
Repurchases of common stock, shares 0          
Repurchases of common stock, value $ 0          
Net income 49,405,000         49,405,000
Unrealized (losses) gains from foreign currency translation adjustments 2,653,000       2,653,000  
Shares, Issued, Ending Balance at Sep. 26, 2020   55,055 15,534      
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Sep. 26, 2020 1,414,804,000 $ 55,000 $ (527,171,000) 676,568,000 (5,214,000) 1,270,566,000
Shares, Issued, Beginning Balance at Jan. 02, 2021   55,251 15,993      
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Jan. 02, 2021 1,407,640,000 $ 55,000 $ (638,736,000) 703,693,000 1,413,000 1,341,215,000
Stock options exercised, shares   61        
Stock options exercised, value 2,886,000 $ 0   2,886,000    
Restricted/Performance stock units vested   303        
Shares paid for tax withholding, shares   (68)        
Shares paid for tax withholding, value (16,691,000)     (16,691,000)    
Share-based Compensation Expense       12,708,000    
Share-based Compensation Expense 12,708,000          
Repurchases of common stock, shares   (547) (547)      
Repurchases of common stock, value (128,917,000)   $ (128,917,000)      
Net income 53,383,000         53,383,000
Unrealized (losses) gains from foreign currency translation adjustments (2,884,000)       (2,884,000)  
Shares, Issued, Ending Balance at Apr. 03, 2021   55,000 16,540      
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Apr. 03, 2021 1,328,125,000 $ 55,000 $ (767,653,000) 702,596,000 (1,471,000) 1,394,598,000
Shares, Issued, Beginning Balance at Jan. 02, 2021   55,251 15,993      
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Jan. 02, 2021 $ 1,407,640,000 $ 55,000 $ (638,736,000) 703,693,000 1,413,000 1,341,215,000
Stock options exercised, shares 278          
Repurchases of common stock, shares (547)          
Repurchases of common stock, value $ (128,917,000)          
Net income 161,389,000          
Unrealized (losses) gains from foreign currency translation adjustments (4,845,000)          
Shares, Issued, Ending Balance at Oct. 02, 2021   55,222 16,540      
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Oct. 02, 2021 1,468,149,000 $ 55,000 $ (767,653,000) 736,575,000 (3,432,000) 1,502,604,000
Shares, Issued, Beginning Balance at Apr. 03, 2021   55,000 16,540      
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Apr. 03, 2021 1,328,125,000 $ 55,000 $ (767,653,000) 702,596,000 (1,471,000) 1,394,598,000
Stock options exercised, shares   52        
Stock options exercised, value 3,442,000 $ 0   3,442,000    
Restricted/Performance stock units vested   4        
Shares paid for tax withholding, shares   1        
Shares paid for tax withholding, value (33,000)     (33,000)    
Share-based Compensation Expense       8,262,000    
Share-based Compensation Expense 8,262,000          
Net income 50,235,000         50,235,000
Unrealized (losses) gains from foreign currency translation adjustments 1,204,000       1,204,000  
Shares, Issued, Ending Balance at Jul. 03, 2021   55,057 16,540      
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Jul. 03, 2021 1,391,235,000 $ 55,000 $ (767,653,000) 714,267,000 (267,000) 1,444,833,000
Stock options exercised, shares   165        
Stock options exercised, value 9,748,000 $ 0   9,748,000    
Share-based Compensation Expense       12,560,000    
Share-based Compensation Expense $ 12,560,000          
Repurchases of common stock, shares 0          
Repurchases of common stock, value $ 0          
Net income 57,771,000         57,771,000
Unrealized (losses) gains from foreign currency translation adjustments (3,165,000)       (3,165,000)  
Shares, Issued, Ending Balance at Oct. 02, 2021   55,222 16,540      
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Oct. 02, 2021 $ 1,468,149,000 $ 55,000 $ (767,653,000) $ 736,575,000 $ (3,432,000) $ 1,502,604,000
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Cash Flows - USD ($)
 9 Months Ended
Oct. 02, 2021
Sep. 26, 2020
Cash flows from operating activities:    
Net income $ 161,389,000 $ 169,633,000
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 26,449,000 21,200,000
Stock-based compensation 33,530,000 36,372,000
Loss on disposal of equipment, intangibles and other assets 371,000 202,000
Provision for credit losses 647,000 5,000
Provision for deferred income taxes 0 136,000
Changes in operating assets and liabilities:    
Increase in accounts receivable (50,967,000) (9,459,000)
Decrease (increase) in inventories 12,329,000 (86,815,000)
Decrease (increase) in other current assets 4,433,000 (23,461,000)
Increase in lease receivable, net (9,312,000) (6,279,000)
Increase in deferred costs and other contract assets (2,573,000) (1,964,000)
Increase in other non-current assets (144,000) (775,000)
(Decrease) increase in accounts payable (4,290,000) 31,793,000
(Decrease) increase in accrued compensation (1,298,000) 3,654,000
(Decrease) increase in accrued liabilities (3,969,000) 4,691,000
Decrease in income tax payable (1,456,000) (2,756,000)
Increase in deferred revenue and other contract-related liabilities 1,378,000 9,973,000
Increase in other non-current liabilities 634,000 395,000
Net cash provided by operating activities 167,151,000 146,545,000
Cash flows from investing activities:    
Maturities of short-term investments 0 (70,000,000)
Purchases of property and equipment, net (20,680,000) (60,017,000)
Increase in intangible assets (8,185,000) (5,763,000)
Business combinations, net of cash acquired 0 78,310,000
Other strategic investing activities (2,600,000) (6,750,000)
Net cash used in investing activities (31,465,000) (80,840,000)
Cash flows from financing activities:    
Proceeds from issuance of common stock 18,975,000 40,994,000
Payroll tax withholdings on behalf of employees for vested equity awards (16,724,000) (1,449,000)
Repurchases of common stock (128,917,000) (591,000)
Net cash (used in) provided by financing activities (126,666,000) 38,954,000
Effect of foreign currency exchange rates on cash (89,000) (294,000)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 8,931,000 104,365,000
Cash, cash equivalents and restricted cash at end of period 652,354,000 669,056,000
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $ 653,935,000 $ 672,440,000
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.21.2
Description of the Company
 9 Months Ended
Oct. 02, 2021
Accounting Policies [Abstract]  
Description of the Company
1. Description of the Company
Masimo Corporation (the Company) is a global medical technology company that develops, manufactures and markets a variety of noninvasive patient monitoring technologies, hospital automation solutions, home monitoring devices and consumer products. The Company’s mission is to improve patient outcomes, reduce the cost of care and take noninvasive monitoring to new sites and applications. The Company’s patient monitoring solutions generally incorporate a monitor or circuit board, proprietary single-patient use or reusable sensors, software and/or cables. The Company primarily sells its products to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, long-term care facilities, and consumers through its direct sales force, distributors and original equipment manufacturer (OEM) partners.
Masimo’s core measurement technologies are based on Measure-through Motion and Low Perfusion™ pulse oximetry, known as Masimo Signal Extraction Technology® (SET®) pulse oximetry, and advanced rainbow® Pulse CO-Oximetry parameters such as noninvasive hemoglobin (SpHb®), alongside many other modalities, including brain function monitoring, hemodynamic monitoring, regional oximetry, acoustic respiration rate monitoring, capnography, nasal high-flow respiratory support therapy, patient position and activity tracking and neuromodulation technology for the reduction of symptoms associated with opioid withdrawal. Masimo’s measurement technologies are available on many types of devices, from bedside hospital monitors like the Root® Patient Monitoring and Connectivity Hub, to various handheld and portable devices, and to the tetherless Masimo SafetyNet™ remote patient surveillance solution. The Masimo Hospital Automation™ Platform facilitates data integration, connectivity, and interoperability through solutions like Patient SafetyNet™(1), Replica®, and UniView™ to facilitate more efficient clinical workflows and to help clinicians provide the best possible care, both in-person and remotely. Leveraging the Company’s expertise in hospital-grade technologies, the Company has also expanded its suite of products intended for use outside the hospital to products for consumers, including Sleep™, a sleep quality solution and the Radius Tº™ wireless, wearable continuous thermometer.
______________
(1)    The use of the trademark Patient SafetyNet™ is under license from the University HealthSystem Consortium.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies
 9 Months Ended
Oct. 02, 2021
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
2. Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) have been condensed or omitted pursuant to such rules and regulations. The accompanying condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, including normal recurring accruals, necessary to present fairly the Company’s condensed consolidated financial statements. The accompanying condensed consolidated balance sheet as of January 2, 2021 was derived from the Company’s audited consolidated financial statements at that date. The accompanying condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes contained in the Company’s Annual Report on Form 10-K for the fiscal year ended January 2, 2021 (fiscal year 2020), filed with the SEC on February 23, 2021. The results for the three and nine months ended October 2, 2021 are not necessarily indicative of the results to be expected for the fiscal year ending January 1, 2022 (fiscal year 2021) or for any other interim period or for any future year.
Fiscal Periods
The Company follows a conventional 52/53 week fiscal year. Under a conventional 52/53 week fiscal year, a 52 week fiscal year includes four quarters of 13 weeks while a 53 week fiscal year includes three 13 week fiscal quarters and one 14 week fiscal quarter. The Company’s last 53 week fiscal year was fiscal year 2020. Fiscal year 2021 is a 52 week fiscal year ending January 1, 2022. All references to years in these notes to condensed consolidated financial statements are fiscal years unless otherwise noted.
Reclassifications
Certain amounts in the accompanying condensed consolidated financial statements have been reclassified to conform to the current period presentation.
Use of Estimates
The Company prepares its financial statements in conformity with GAAP, which requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates include the determination of standalone selling prices, variable consideration, total consideration allocated to each performance obligation within a contract, inventory valuation, valuation of the Company’s equity awards, valuation of identifiable assets and liabilities connected with business combinations, deferred taxes and any associated valuation allowances, deferred revenue, uncertain income tax positions, and litigation costs and related accruals. Actual results could differ from such estimates.
Business Combinations
The Company accounts for business combinations using the acquisition method of accounting, which requires that once control is obtained, all the assets acquired, liabilities assumed and noncontrolling interests in the acquired entity, if applicable, are recorded at their respective fair values at the date of acquisition. The excess of the purchase price over the fair values of identifiable assets, liabilities and noncontrolling interests in the acquired entity, if applicable, is recorded as goodwill. The Company finalizes the purchase price allocation within one year from the acquisition date.
Fair Value Measurements
Authoritative guidance describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:
●    Level 1—Quoted prices in active markets for identical assets or liabilities.
●    Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active; or other inputs that can be corroborated by observable market data for substantially the full term of the assets or liabilities.
●    Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
Pursuant to current authoritative guidance, entities are allowed an irrevocable option to elect the fair value for the initial and subsequent measurement for specified financial assets and liabilities on a contract-by-contract basis. The Company did not elect to apply the fair value option under this guidance to specific assets or liabilities on a contract-by-contract basis. There were no transfers between Level 1, Level 2 and Level 3 inputs during either the nine months ended October 2, 2021 or September 26, 2020. The Company carries cash and cash equivalents, at cost, which approximates fair value.
For certain other financial assets and liabilities, including restricted cash, accounts receivable, accounts payable and other current assets and liabilities, the carrying amounts approximate their fair value primarily due to the relatively short maturity of these balances. The Company also measures certain non-financial assets at fair value on a non-recurring basis, primarily goodwill, intangible assets and operating lease right-of-use assets, in connection with periodic evaluations for potential impairment.
Cash and Cash Equivalents
The Company considers all highly liquid investments with an original maturity from date of purchase of three months or less, or highly liquid investments that are readily convertible into known amounts of cash, to be cash equivalents.
Accounts Receivable and Allowance for Credit Losses
Accounts receivable consist of trade receivables recorded at the time of invoicing of product sales, reduced by reserves for estimated bad debts and returns. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Credit is extended based on an evaluation of the customer’s financial condition. Collateral is generally not required. The Company records an allowance for credit losses that it does not expect to collect based on relevant information, including historical experience, current conditions, and reasonable and supportable forecasts. Accounts are charged off against the allowance when the Company believes they are uncollectible.
Inventory
Inventories are stated at the lower of cost or net realizable value. Cost is determined using a standard cost method, which approximates the first in, first out method, and includes material, labor and overhead costs. Inventory valuation adjustments are recorded for inventory items that have become excess or obsolete or are no longer used in current production and for inventory items that have a market price less than carrying value in inventory. The Company generally determines inventory valuation adjustments based on an evaluation of the expected future use of its inventory on an item by item basis and applies historical obsolescence rates to estimate the loss on inventory expected to have a recovery value below cost. The Company also records other specific inventory valuation adjustments when it becomes aware of unique events or circumstances that result in an expected recovery value below cost. For inventory items that have been written down, the reduced value becomes the new cost basis.
Property and Equipment
Property and equipment are stated at cost. Depreciation is calculated using the straight-line method over estimated useful lives as follows:
Useful Lives
Building and building improvements
7 to 39 years
Computer equipment and software
2 to 12 years
Demonstration units3 years
Furniture and office equipment
2 to 6 years
Leasehold improvementsLesser of useful life or term of lease
Machinery, equipment and tooling
3 to 10 years
Transportation, vehicles and other
4 to 20 years
Land is not depreciated and construction-in-progress is not depreciated until placed in service. Normal repair and maintenance costs are expensed as incurred, whereas significant improvements that materially increase values or extend useful lives are capitalized and depreciated over the remaining estimated useful lives of the related assets. Upon sale or retirement of depreciable assets, the related cost and accumulated depreciation or amortization are removed from the accounts and any gain or loss on the sale or retirement is recognized in income.
Intangible Assets
Intangible assets consist primarily of patents, trademarks, software development costs, customer relationships and acquired technology. Costs related to patents and trademarks, which include legal and application fees, are capitalized and amortized over the estimated useful lives using the straight-line method. Patent and trademark amortization commences once final approval of the patent or trademark has been obtained. Patent costs are amortized over the lesser of 10 years or the patent’s remaining legal life, which assumes renewals, and trademark costs are amortized over 17 years, and their associated amortization cost is included in selling, general and administrative expense in the accompanying condensed consolidated statements of operations. For intangibles purchased in an asset acquisition or business combination, which mainly include patents, trademarks, customer relationships and acquired technologies, the useful life is determined largely by valuation estimates of remaining economic life. The Company’s policy is to renew its patents and trademarks. Costs to renew patents and trademarks are capitalized and amortized over the remaining useful life of the intangible asset. The Company periodically evaluates the amortization period and carrying basis of patents, trademarks and other intangible assets to determine whether any events or circumstances warrant a revised estimated useful life or reduction in value. Capitalized application costs are charged to operations when it is determined that the patent or trademark will not be obtained or is abandoned.
Impairment of Goodwill, Intangible Assets and Other Long-Lived Assets
Goodwill is recorded as the difference, if any, between the aggregate consideration paid for an acquisition and the fair value of the acquired net tangible and intangible assets. Goodwill is not amortized, but instead is tested annually for impairment, or more frequently when events or changes in circumstances indicate that goodwill might be impaired. In assessing goodwill impairment, the Company has the option to first assess the qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. The Company’s qualitative assessment of the recoverability of goodwill considers various macroeconomic, industry-specific and Company-specific factors, including: (i) severe adverse industry or economic trends; (ii) significant Company-specific actions; (iii) current, historical or projected deterioration of the Company’s financial performance; or (iv) a sustained decrease in the Company’s market capitalization below its net book value. If, after assessing the totality of events or circumstances, the Company determines it is unlikely that the fair value of a reporting unit is less than its carrying amount, then a quantitative analysis is unnecessary. However, if the Company concludes otherwise, or if the Company elects to bypass the qualitative analysis, then the Company must perform a quantitative analysis that compares the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill is not considered impaired; otherwise, a goodwill impairment loss is recognized for the lesser of: (a) the amount that the carrying amount of a reporting unit exceeds its fair value; or (b) the amount of the goodwill allocated to that reporting unit. The annual impairment test is performed during the fourth fiscal quarter.
The Company reviews long-lived assets and identifiable intangibles for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted operating cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair value of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less costs to sell.
Revenue Recognition, Deferred Revenue and Other Contract Liabilities
The Company derives the majority of its product revenue from four primary sources: (i) direct sales under deferred equipment agreements with end-user hospitals where the Company provides up-front monitoring equipment at no up-front charge in exchange for a multi-year sensor purchase commitment; (ii) other direct sales of noninvasive monitoring solutions to end-user hospitals, emergency medical response organizations and other direct customers; (iii) sales of noninvasive monitoring solutions to distributors who then typically resell to end-user hospitals, emergency medical response organizations and other customers; and (iv) sales of integrated circuit boards to OEM customers who incorporate the Company’s embedded software technology into their multiparameter monitoring devices. Subject to customer credit considerations, the majority of such sales are made on open account using industry standard payment terms based on the geography within which the specific customer is located.
The Company generally recognizes revenue following a single, principles-based five-step model to be applied to all contracts with customers and generally provides for the recognition of revenue in an amount that reflects the consideration to which the Company expects to be entitled, net of allowances for estimated returns, discounts or sales incentives, as well as taxes collected from customers that are remitted to government authorities, when control over the promised goods or services are transferred to the customer. Revenue related to equipment supplied under sales-type lease arrangements is recognized once control over the equipment is transferred to the customer, while revenue related to equipment supplied under operating-type lease arrangements is generally recognized on a straight-line basis over the term of the lease.
While the majority of the Company’s revenue contracts and transactions contain standard business terms and conditions, there are some transactions that contain non-standard business terms and conditions. As a result, contract interpretation, judgment and analysis is required to determine the appropriate accounting, including: (i) the amount of the total consideration, as well as variable consideration, (ii) whether the arrangement contains an embedded lease, and if so, whether such embedded lease is a sales-type lease or an operating lease, (iii) the identification of the distinct performance obligations contained within the arrangement, (iv) how the arrangement consideration should be allocated to each performance obligation when multiple performance obligations exist, including the determination of standalone selling price, and (v) when to recognize revenue on the performance obligations. Changes in judgments on these assumptions and estimates could materially impact the timing of revenue recognition.
The Company enters into agreements to sell its monitoring solutions and services, sometimes as a part of arrangements with multiple performance obligations that include various combinations of product sales, equipment leases and services. In the case of contracts with multiple performance obligations, the authoritative guidance provides that the total consideration be allocated to each performance obligation on the basis of relative standalone selling prices. When a standalone selling price is not readily observable, the Company estimates the standalone selling price by considering multiple factors including, but not limited to, features and functionality of the product, geographies, type of customer, contractual prices pursuant to Group Purchasing Organization (GPO) contracts, the Company’s pricing and discount practices, and other market conditions.
Sales under deferred equipment agreements are generally structured such that the Company agrees to provide certain monitoring-related equipment, software, installation, training and/or warranty support at no up-front charge in exchange for the customer’s commitment to purchase sensors over the term of the agreement, which generally ranges from three years to six years. The Company allocates contract consideration under deferred equipment agreements containing fixed annual sensor purchase commitments to the underlying lease and non-lease components at contract inception. In determining whether any underlying lease components are related to a sales-type lease or an operating lease, the Company evaluates the customer’s rights and ability to control the use of the underlying equipment throughout the contract term, including any equipment substitution rights retained by the Company, as well as the Company’s expectations surrounding potential contract/lease extensions or renewals and the customer’s likelihood to exercise any purchase options. Revenue allocable to non-lease performance obligations is generally recognized as such non-lease performance obligations are satisfied. Revenue allocable to lease components under sales-type lease arrangements is generally recognized when control over the equipment is transferred to the customer. Revenue allocable to lease components under operating lease arrangements is generally recognized over the term of the operating lease. The Company generally does not expect to derive any significant value in excess of such asset’s unamortized book value from equipment underlying its operating lease arrangements after the end of the agreement.
Revenue from the sale of products to end-user hospitals, emergency medical response organizations, other direct customers, distributors and OEM customers, is recognized by the Company when control of such products transfer to the customer based upon the terms of the contract or underlying purchase order.
Revenue related to OEM rainbow® parameter software licenses is recognized by the Company upon the OEM’s shipment of its product to its customer, as reported to the Company by the OEM.
The Company provides certain customers with various sales incentives that may take the form of discounts or rebates. The Company records estimates related to these programs as a reduction to revenue at the time of sale. In general, customers do not have a right of return for credit or refund. However, the Company allows returns under certain circumstances. At the end of each period, the Company estimates and accrues for these returns as a reduction to revenue. The Company estimates the revenue constraints related to these forms of variable consideration based on various factors, including expected purchasing volumes, prior sales and returns history, and specific contractual terms and limitations.
Shipping and Handling Costs and Fees
All shipping and handling costs are expensed as incurred and are recorded as a component of cost of goods sold in the accompanying condensed consolidated statements of operations. Charges for shipping and handling billed to customers are included as a component of product revenue.
Taxes Collected From Customers and Remitted to Governmental Authorities
The Company’s policy is to present revenue net of taxes collected from customers and remitted to governmental authorities.
Deferred Costs and Other Contract Assets
The costs of monitoring-related equipment provided to customers under operating lease arrangements within the Company’s deferred equipment agreements are generally deferred and amortized to cost of goods sold over the life of the underlying contracts. Some of the Company’s deferred equipment agreements also contain provisions for certain allowances to be made directly to the end-user hospital customer at the inception of the arrangement. These allowances are generally allocated to the lease and non-lease components and recognized as a reduction to revenue as the underlying performance obligations are satisfied.
The Company generally invoices its customers under deferred equipment agreements as sensors are provided to the customer. However, the Company may recognize revenue for certain non-lease performance obligations under deferred equipment agreements with fixed annual commitments at the time such performance obligations are satisfied and prior to the customer being invoiced. When this occurs, the Company records an unbilled contract receivable related to such revenue until the customer has been invoiced pursuant to the terms of the underlying deferred equipment agreement.
The incremental costs of obtaining a contract with a customer are capitalized and deferred if the Company expects such costs to be recoverable over the life of the contract and the contract term is greater than one year. Such deferred costs generally relate to certain incentive sales commissions earned by the Company’s internal sales team in connection with the execution of deferred equipment agreements and are amortized to expense over the expected term of the underlying contract.
Product Warranty
The Company generally provides a warranty against defects in material and workmanship for a period ranging from six months to forty-eight months, depending on the product type. In traditional sales activities, including direct and OEM sales, the Company establishes an accrued liability for the estimated warranty costs at the time of revenue recognition, with a corresponding provision to cost of goods sold. Customers may also purchase extended warranty coverage or service level upgrades separately or as part of a deferred equipment agreement. Revenue related to extended warranty coverage and service level upgrades is generally recognized over the life of the contract, which reasonably approximates the period over which such services will be provided. The related extended warranty and service level upgrade costs are expensed as incurred.
Changes in the product warranty accrual were as follows (in thousands):
Nine Months Ended
October 2,
2021		September 26,
2020
Warranty accrual, beginning of period$2,740 $3,395 
Accrual for warranties issued3,442 428 
Changes in pre-existing warranties (including changes in estimates)(2,347)(97)
Settlements made(891)(883)
Warranty accrual, end of period$2,944 $2,843 
Litigation Costs and Contingencies
The Company records a charge equal to at least the minimum estimated liability for a loss contingency or litigation settlement when both of the following conditions are met: (i) information available prior to issuance of the financial statements indicates that it is probable that a liability had been incurred at the date of the financial statements, and (ii) the range of loss can be reasonably estimated. The determination of whether a loss contingency or litigation settlement is probable or reasonably possible involves a significant amount of management judgment, as does the estimation of the range of loss given the nature of contingencies. Liabilities related to litigation settlements with multiple elements are recorded based on the fair value of each element. Legal and other litigation related expenses are recognized as the services are provided. The Company records insurance and other indemnity recoveries for litigation expenses when both of the following conditions are met: (a) the recovery is probable, and (b) collectability is reasonably assured. Insurance recoveries are only recorded to the extent the litigation costs to which they relate have been incurred and recognized in the financial statements.
Comprehensive Income
Comprehensive income includes foreign currency translation adjustments and any related tax benefits that have been excluded from net income and reflected in stockholders’ equity.
Net Income Per Share
A computation of basic and diluted net income per share is as follows (in thousands, except per share data):
Three Months EndedNine Months Ended
October 2,
2021		September 26,
2020		October 2,
2021		September 26,
2020
Net income$57,771 $49,405 $161,389 $169,633 
Basic net income per share:
Weighted-average shares outstanding - basic55,143 54,997 55,125 54,543 
Net income per basic share$1.05 $0.90 $2.93 $3.11 
Diluted net income per share:
Weighted-average shares outstanding - basic55,143 54,997 55,125 54,543 
Diluted share equivalent: stock options, RSUs and PSUs2,521 3,283 2,526 3,490 
Weighted-average shares outstanding - diluted57,664 58,280 57,651 58,033 
Net income per diluted share$1.00 $0.85 $2.80 $2.92 
Basic net income per share is computed by dividing net income by the weighted-average number of shares outstanding during the period. Net income per diluted share is computed by dividing the net income by the weighted-average number of shares and potential shares outstanding during the period, if the effect of potential shares is dilutive. Potential shares include incremental shares of stock issuable upon the exercise of stock options and the vesting of both restricted share units (RSUs) and performance share units (PSUs). For each of the three months ended October 2, 2021 and September 26, 2020, weighted options to purchase 0.1 million shares of common stock were outstanding but not included in the computation of diluted net income per share because the effect of including such shares would have been antidilutive in the applicable period. For the nine months ended October 2, 2021 and September 26, 2020, weighted options to purchase 0.2 million and 0.3 million shares of common stock, respectively, were outstanding but not included in the computation of diluted net income per share because the effect of including such shares would have been antidilutive in the applicable period. Certain RSUs are considered contingently issuable shares as their vesting is contingent upon the occurrence of certain future events. Since such events had not occurred and were not considered probable of occurring as of each of October 2, 2021 and September 26, 2020, 2.7 million weighted-average shares related to such RSUs have been excluded from the calculation of potential shares for each of the three and nine month periods then ended.
Supplemental Cash Flow Information
Supplemental cash flow information includes the following (in thousands):
Nine Months Ended
October 2,
2021		September 26,
2020
Cash paid during the year for:
Interest expense
$202 $194 
Income taxes
36,898 35,961 
Operating lease liabilities
5,567 4,699 
Non-cash operating activities:
ROU assets obtained in exchange for lease liabilities
$4,917 $9,900 
Non-cash investing activities:
Unpaid purchases of property and equipment$3,182 $3,988 
       Settlement of promissory note receivable in connection with business combination— 5,100 
Unpaid strategic investments3,400 — 
Deposit release to acquire noncontrolling interest(1)
3,374 — 
Non-cash financing activities:
       Unsettled common stock proceeds from option exercises$112 $27 
       Fair value of common stock received for payment of stock option exercise price— 220 
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents
$652,354 $669,056 
Restricted cash
1,581 3,384 
Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows$653,935 $672,440 
______________
(1)     See Note 5.
Segment Information
The Company uses the “management approach” in determining reportable business segments. The management approach designates the internal organization used by management for making operating decisions and assessing performance as the source for determining the Company’s reportable segments. Based on this assessment, management has determined it operates in one reportable business segment, which is comprised of patient monitoring and related products.
Recently Adopted Accounting Pronouncements
In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12). The standard simplifies the accounting for income taxes by removing exceptions to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income or a gain from other items, to the requirement to recognize a deferred tax liability for equity method investments when a foreign subsidiary becomes an equity method investment, to the ability not to recognize a deferred tax liability for a foreign subsidiary when a foreign equity method investment becomes a subsidiary, and to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. In addition, the standard requires that an entity recognize a franchise tax that is partially based on income as an income-based tax and account for any incremental amount incurred as a non-income-based tax, evaluate when a step up in the tax basis of goodwill should be considered part of the business combination in which the book goodwill was originally recognized and when it should be considered a separate transaction, reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date, and specifies that an entity is not required to allocate the consolidated amount of current and deferred tax expense to a legal entity that is not subject to tax in its separate financial statements; however, an entity may elect to do so (on an entity-by-entity basis) for a legal entity that is both not subject to tax and disregarded by the taxing authority. The Company’s adoption of this standard, effective as of January 3, 2021, did not have a material impact on its consolidated financial statements.
In October 2020, the FASB issued ASU No. 2020-10, Codification Improvements. The standard provides updates for technical corrections, clarifications to guidance, simplifications to wording or structure of guidance, and other minor improvements across various areas of accounting within GAAP. ASU No. 2020-10 is effective after December 15, 2020 on a retrospective basis. Early adoption is permitted. The Company’s adoption of this standard, effective as of January 3, 2021, did not have a material impact on its consolidated financial statements.
Recently Issued Accounting Pronouncements
In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (ASU 2020-04). The new standard provides temporary optional expedients and exceptions to the guidance in GAAP on contract modifications and hedge accounting to ease the financial reporting burdens related to the expected market transition from the London Interbank Offered Rate (LIBOR) and other interbank offered rates to alternative reference rates, such as the Secured Overnight Financing Rate (SOFR). Entities can make a one-time election to sell and/or reclassify held-to-maturity debt securities that reference an interest rate affected by reference rate reform. ASU 2020-04 is effective beginning on March 12, 2020, and the Company may elect to apply this standard prospectively through December 31, 2022. The relief is temporary and generally cannot be applied to contract modifications that occur after December 31, 2022 or hedging relationships entered into or evaluated after that date. However, certain optional expedients can be applied to hedging relationships evaluated in periods after December 31, 2022. The Company is currently evaluating the expected impact of this standard, but does not expect it to have a material impact on its consolidated financial statements upon adoption.
In January 2021, the FASB issued ASU No. 2021-01, Reference Rate Reform (Topic 848): Scope (ASU 2021-01). The new standard clarified the scope and application of the original guidance. ASU No. 2021-01 is effective as of March 12, 2020 through December 31, 2022 and may be applied to contract modifications and hedging relationships from the beginning of an interim period that includes or is subsequent to March 12, 2020. The Company is currently evaluating the expected impact of this standard, but does not expect it to have a material impact on its consolidated financial statements upon adoption.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.21.2
Related Party Disclosures
 9 Months Ended
Oct. 02, 2021
Related Party Transactions [Abstract]  
Related Party Transactions Disclosure
3. Related Party Transactions
The Company’s Chairman and Chief Executive Officer (CEO) is also the Chairman and CEO of Cercacor Laboratories, Inc. (Cercacor). The Company is a party to the following agreements with Cercacor:
•Cross-Licensing Agreement - The Company and Cercacor are parties to a cross-licensing agreement (Cross-Licensing Agreement), which governs each party’s rights to certain intellectual property held by the two companies. The Company is subject to certain annual minimum aggregate royalty obligations for use of the rainbow® licensed technology. The current annual minimum royalty obligation is $5.0 million. Aggregate liabilities payable to Cercacor arising under the Cross-Licensing Agreement were $2.9 million and $3.5 million for the three months ended October 2, 2021 and September 26, 2020, respectively. Aggregate liabilities payable to Cercacor arising under the Cross-Licensing Agreement were $9.6 million and $9.7 million for the nine months ended October 2, 2021 and September 26, 2020, respectively.
•Administrative Services Agreement - The Company is a party to an administrative services agreement with Cercacor (G&A Services Agreement), which governs certain general and administrative services that the Company provides to Cercacor. Amounts charged by the Company pursuant to the G&A Services Agreement were less than $0.1 million for each of the three months ended October 2, 2021 and September 26, 2020. Amounts charged by the Company pursuant to the G&A Services Agreement were $0.2 million for each of the nine months ended October 2, 2021 and September 26, 2020.
•Lease and Sublease Agreements - Effective December 2019, the Company entered into a lease agreement with Cercacor for approximately 34,000 square feet of office, research and development space at one of the Company’s owned facilities in Irvine (Cercacor Lease). The term of the Cercacor Lease expires on December 31, 2024. In March 2016, the Company entered into a sublease agreement with Cercacor for approximately 16,830 square feet of excess office and laboratory space located at 40 Parker, Irvine, California (Cercacor Sublease). The Cercacor Sublease began on May 1, 2016 and expired on December 15, 2019. The Company recognized approximately $0.3 million of lease income for each of the three months ended October 2, 2021 and September 26, 2020. The Company recognized approximately $0.9 million and $0.8 million of lease income for the nine months ended October 2, 2021 and September 26, 2020, respectively.
Net amounts due to Cercacor at October 2, 2021 and January 2, 2021 were approximately $3.3 million and $3.6 million, respectively.
The Company’s CEO is also the Chairman of the Masimo Foundation for Ethics, Innovation and Competition in Healthcare (Masimo Foundation), a non-profit organization that was founded in 2010 to provide a platform for encouraging ethics, innovation and competition in healthcare. In addition, the Company’s Executive Vice President (EVP), Chief Financial Officer (CFO) serves as the Treasurer of the Masimo Foundation and the Company’s EVP, General Counsel and Corporate Secretary serves as the Secretary for the Masimo Foundation. During the three months ended October 2, 2021 and September 26, 2020, the Company made no cash contributions to the Masimo Foundation. During the nine months ended October 2, 2021, the Company made no contributions to the Masimo Foundation. During the nine months ended September 26, 2020, the Company made cash contributions of approximately $1.5 million to the Masimo Foundation.
During the three and nine months ended October 2, 2021 and September 26, 2020, the Company made various in-kind contributions to the Masimo Foundation, mainly in the form of donated administrative services.
The Company’s CEO is also a co-founder and a member of the board of directors of Like Minded Media Ventures (LMMV), a team of storytellers that create content focused in the areas of true stories, social causes and science. LMMV creates stories with a multi-platform strategy, bridging the gap between film, television, digital and social media. The Company entered into a marketing service agreement with LMMV for audiovisual production services promoting brand awareness, including television commercials and digital advertising, during the second quarter of 2020. During the three and nine months ended October 2, 2021, the Company incurred no marketing expenses to LMMV under the marketing service agreement. During the three and nine months ended September 26, 2020, the Company incurred $0.2 million and $3.5 million, respectively, in marketing expenses to LMMV under the marketing service agreement. At October 2, 2021 and January 2, 2021, there was no amount due to LMMV for services rendered.
The Company entered into a software license and professional services agreement with Like Minded Labs (LML), a subsidiary of LMMV, during the second quarter of 2021. Pursuant to the software license agreement, LML granted the Company a perpetual, non-exclusive and fully paid-up right and license to integrate LML’s software into the Company’s products in exchange for a $3.0 million one-time license fee. Pursuant to the professional services agreement, LML will provide professional services to the Company, including the development of custom software intended to support the integration of the licensed software into the Company’s products, as well as future support services upon the Company’s acceptance of deliverables.
In July 2021, the Company entered into a patent purchase and option agreement with Vantrix Corporation (Vantrix), an acquiree of LML, for certain patents for $0.5 million, and the right to purchase two pools of additional patents from Vantrix for an exercise fee of up to $1.1 million. The agreements with LML and Vantrix include sublicensing provisions whereby the software and patents are licensed back to LML or Vantrix, respectively, for further advancement of the technologies.
The Company maintains an aircraft time share agreement, pursuant to which the Company has agreed from time to time to make its aircraft available to the Company’s CEO for lease on a time-sharing basis. The Company charges the Company’s CEO for personal use based on agreed upon reimbursement rates. For each of the three and nine months ended October 2, 2021 and September 26, 2020, the Company charged the Company’s CEO less than $0.1 million related to such disbursements.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.21.2
Inventories
 9 Months Ended
Oct. 02, 2021
Inventory Disclosure [Abstract]  
Inventories
4. Inventories
Inventories consist of the following (in thousands):
October 2,
2021		January 2,
2021
Raw materials$121,593 $133,098 
Work-in-process14,383 15,985 
Finished goods66,352 66,869 
     Total inventories$202,328 $215,952 
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.21.2
Other Current Assets
 9 Months Ended
Oct. 02, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Other Current Assets
5. Other Current Assets
Other current assets consist of the following (in thousands):
October 2,
2021		January 2,
2021
Prepaid expenses$30,351 $30,235 
Lease receivable, current26,685 23,206 
Prepaid income taxes15,501 14,782 
Indirect taxes receivable10,715 14,545 
Prepaid rebates and royalties, current3,066 3,081 
Restricted cash(1)
1,496 3,397 
Customer notes receivable1,359 2,283 
Deposit to acquire noncontrolling interest(2)
— 3,374 
Other current assets2,599 7,513 
     Total other current assets$91,772 $102,416 
______________
(1)     Restricted cash includes funds received from the Bill and Melinda Gates Foundation. As the Company incurs costs associated with research and development related to this project, on a quarterly basis, the Company reclasses amounts from the grant to offset costs incurred.
(2)     During the year ended January 2, 2021, the Company obtained a controlling interest in a provider of advanced hemodynamic monitoring solutions. The Company made a deposit to acquire the noncontrolling interest of the acquiree. During the first quarter of 2021, the Company acquired the remaining noncontrolling interest. The impact of the noncontrolling interest is immaterial in all periods presented.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.21.2
Lease Receivable
 9 Months Ended
Oct. 02, 2021
Leases [Abstract]  
Lease Receivable
6. Lease Receivable
The Company recognizes revenue and costs, as well as a lease receivable, at the time the lease commences pursuant to deferred equipment agreements containing embedded sales-type leases. Lease revenue related to both operating-type and sales-type leases for the three months ended October 2, 2021 and September 26, 2020 was approximately $12.0 million and $13.0 million, respectively, and is included within product revenue in the accompanying condensed consolidated statements of operations. Lease revenue related to both operating-type and sales-type leases for the nine months ended October 2, 2021 and September 26, 2020 was approximately $40.0 million and $31.0 million, respectively, and is included within product revenue in the accompanying condensed consolidated statements of operations. Costs related to embedded leases within the Company’s deferred equipment agreements are included in cost of goods sold in the accompanying condensed consolidated statements of operations.
Lease receivable consists of the following (in thousands):
October 2,
2021		January 2,
2021
Lease receivable$93,879 $81,074 
Allowance for credit loss(239)(202)
     Lease receivable, net93,640 80,872 
Less: current portion of lease receivable(26,685)(23,206)
     Lease receivable, noncurrent$66,955 $57,666 
As of October 2, 2021, estimated future maturities of customer sales-type lease receivables for each of the following fiscal years are as follows (in thousands):
Fiscal yearAmount
2021 (balance of year)$6,888 
202225,995 
202321,371 
202417,349 
202511,535 
Thereafter10,502 
    Total$93,640 
Estimated future operating lease payments expected to be received from customers under deferred equipment agreements are not material as of October 2, 2021.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.21.2
Deferred Costs and Other Contract Assets
 9 Months Ended
Oct. 02, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Deferred Costs and Other Contract Assets
7. Deferred Costs and Other Contract Assets
Deferred costs and other contract assets consist of the following (in thousands):
October 2,
2021		January 2,
2021
Deferred commissions$9,976 $7,477 
Prepaid contract allowances6,820 7,336 
Unbilled contract receivables4,317 3,925 
Equipment leased to customers, net1,486 1,338 
     Deferred costs and other contract assets$22,599 $20,076 
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.21.2
Property and Equipment, net
 9 Months Ended
Oct. 02, 2021
Property, Plant and Equipment [Abstract]  
Property and Equipment, net
8. Property and Equipment, net
Property and equipment, net, consists of the following (in thousands):
October 2,
2021		January 2,
2021
Building and building improvements$141,990 $122,310 
Machinery, equipment and tooling101,833 90,843 
Land56,938 57,151 
Transportation, vehicles and other33,114 33,175 
Computer equipment and software32,131 24,693 
Leasehold improvements20,885 19,295 
Furniture and office equipment14,186 13,567 
Demonstration units1,049 1,024 
Construction-in-progress (CIP)23,955 44,589 
     Total property and equipment426,081 406,647 
Accumulated depreciation(151,152)(134,136)
     Property and equipment, net$274,929 $272,511 
For the three months ended October 2, 2021 and September 26, 2020, depreciation expense of property and equipment was $6.5 million and $5.8 million, respectively. For the nine months ended October 2, 2021 and September 26, 2020, depreciation expense of property and equipment was $18.8 million and $16.0 million, respectively.
The balance in CIP at October 2, 2021 related primarily to the capitalized implementation costs related to a new enterprise resource planning software system and costs related to equipment and other facility improvements, the underlying assets for which have not been completed or placed into service. The decrease in CIP balance from January 2, 2021 primarily relates to the Company’s European headquarters building in Switzerland being placed into service along with a phase of the new enterprise resource planning software system for certain subsidiaries being placed into service.
The balance in CIP at January 2, 2021 related primarily to acquisition and improvement costs for a portion of the Company’s European headquarters building in Switzerland, capitalized implementation costs related to a new enterprise resource planning software system and costs related to manufacturing equipment and other facility improvements, the underlying assets for which had not been placed into service.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.21.2
Intangible Assets
 9 Months Ended
Oct. 02, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets
9. Intangible Assets, net
Intangible assets, net, consist of the following (in thousands):
October 2,
2021		January 2,
2021
Patents$30,528 $26,875 
Acquired technologies28,567 29,039 
Customer relationships24,636 24,666 
Trademarks12,080 11,708 
Licenses8,108 5,108 
Licenses-related party7,500 7,500 
Other6,257 5,693 
     Total intangible assets117,676 110,589 
Accumulated amortization(43,587)(36,666)
     Intangible assets, net$74,089 $73,923 
Intangible assets have a weighted-average amortization period of twelve years. Total amortization expense for the three months ended October 2, 2021 and September 26, 2020 was $2.7 million and $1.6 million, respectively. Total amortization expense for the nine months ended October 2, 2021 and September 26, 2020 was $7.6 million and $5.2 million, respectively.
Total renewal costs for patents and trademarks for the three months ended October 2, 2021 and September 26, 2020 were $0.9 million and $0.6 million, respectively. Total renewal costs for patents and trademarks for the nine months ended October 2, 2021 and September 26, 2020 were $1.3 million and $1.2 million, respectively. As of October 2, 2021, the weighted-average number of years until the next renewal was two years for patents and four years for trademarks.
Estimated amortization expense for each of the next fiscal years is as follows (in thousands):
Fiscal yearAmount
2021 (balance of year)$9,211 
20228,377 
20237,964 
20247,352 
20256,274 
Thereafter34,911 
     Total$74,089 
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.21.2
Goodwill
 9 Months Ended
Oct. 02, 2021
Goodwill [Abstract]  
Goodwill
10. Goodwill
Changes in goodwill were as follows (in thousands):
Nine Months Ended
October 2,
2021
Goodwill, beginning of period$103,206 
Foreign currency translation adjustment(1,964)
Goodwill, end of period$101,242 
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.21.2
Lessee ROU Assets and Lease Liabilities
 9 Months Ended
Oct. 02, 2021
Leases [Abstract]  
Lessee, ROU Assets and Lease Liabilities
11. Lessee ROU Assets and Lease Liabilities
The Company leases certain facilities in North and South America, Europe, the Middle East and Asia-Pacific regions under operating lease agreements expiring at various dates through January 2032. In addition, the Company leases equipment in the U.S. and Europe, and these leases are classified as operating leases and expire at various dates through August 2026. The majority of these leases are non-cancellable and generally do not contain any material restrictive covenants, material residual value guarantees or other material guarantees. The Company recognizes lease costs under these agreements using a straight-line method based on total lease payments. Certain facility leases contain predetermined price escalations and in some cases renewal options, the longest of which is for five years.
The Company generally estimates the applicable discount rate used to determine the net present value of lease payments based on available information at the lease commencement date. As of October 2, 2021, the weighted-average discount rate used by the Company for all operating leases was approximately 2.6%.
The balance sheet classifications for amounts related to the Company’s operating leases for which it is the lessee are as follows (in thousands):
Balance sheet classificationOctober 2,
2021		January 2,
2021
Lessee ROU assetsOther non-current assets$31,561 $32,324 
Lessee current lease liabilitiesOther current liabilities6,147 5,975 
Lessee non-current lease liabilitiesOther non-current liabilities27,471 28,373 
     Total operating lease liabilities$33,618 $34,348 
As of October 2, 2021 and January 2, 2021, accumulated amortization for lessee ROU assets was $13.0 million and $9.2 million, respectively. The weighted-average remaining lease term for the Company’s operating leases was 6.7 years as of October 2, 2021.
As of October 2, 2021, estimated future operating lease payments for each of the following fiscal years were as follows (in thousands):
Fiscal yearAmount
2021 (balance of year)$1,509 
20227,093 
20236,649 
20245,123 
20253,998 
Thereafter(1)
12,317 
   Total36,689 
   Imputed interest(3,071)
   Present value$33,618 
______________
(1)     Includes optional renewal period for certain leases.
During the three months ended October 2, 2021 and September 26, 2020, operating lease costs were approximately $2.1 million and $1.8 million, respectively. During the nine months ended October 2, 2021 and September 26, 2020, operating lease costs were approximately $6.2 million and $5.2 million, respectively.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.21.2
Other Non-Current Assets
 9 Months Ended
Oct. 02, 2021
Other Assets, Longterm [Abstract]  
Other Non-Current Assets
12. Other Non-Current Assets
Other non-current assets consist of the following (in thousands):
October 2,
2021		January 2,
2021
Lessee ROU assets, net$31,561 $32,324 
Strategic investments13,928 8,002 
Prepaid deposits and other4,397 4,316 
Total other non-current assets$49,886 $44,642 
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.21.2
Deferred Revenue and Other Contract Liabilities
 9 Months Ended
Oct. 02, 2021
Revenue Recognition and Deferred Revenue [Abstract]  
Deferred Revenue and Other Contract Liabilities
13. Deferred Revenue and Other Contract Liabilities, Current
Deferred revenue and other contract liabilities consist of the following (in thousands):
October 2,
2021		January 2,
2021
Deferred revenue$34,392 $33,221 
Accrued rebates and allowances11,322 12,127 
Accrued customer reimbursements4,744 3,829 
     Total deferred revenue and other contract liabilities50,458 49,177 
Less: Non-current portion of deferred revenue(3,817)(4,242)
     Deferred revenue and other contract liabilities - current$46,641 $44,935 
Deferred revenue relates to contracted amounts that have been invoiced to customers for which remaining performance obligations must be completed before the Company can recognize the revenue. These amounts primarily relate to undelivered equipment, sensors and services under deferred equipment agreements, extended warranty agreements and maintenance agreements.
Changes in deferred revenue were as follows (in thousands):
Nine Months Ended
October 2,
2021
Deferred revenue, beginning of the period$33,221 
  Revenue deferred during the period23,425 
  Recognition of revenue deferred in prior periods(22,254)
     Deferred revenue, end of the period$34,392 
Expected revenue from remaining contractual performance obligations (Unrecognized Contract Revenue) includes deferred revenue, as well as other amounts that will be invoiced and recognized as revenue in future periods, when the Company completes its performance obligations. While Unrecognized Contract Revenue is similar in concept to backlog, Unrecognized Contract Revenue excludes revenue allocable to monitoring-related equipment that is effectively leased to customers under deferred equipment agreements and other contractual obligations for which neither party has performed.
As of October 2, 2021, the Company had approximately $987.3 million of Unrecognized Contract Revenue related to executed contracts with an original duration of one year or more. The Company expects to recognize approximately $272.7 million of this amount as revenue within the next twelve months and the remaining balance thereafter.
The estimated timing of this revenue is based, in part, on management’s estimates and assumptions about when its performance obligations will be completed. As a result, the actual timing of this revenue in future periods may vary, possibly materially
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Other Current Liabilities
 9 Months Ended
Oct. 02, 2021
Accrued Liabilities [Abstract]  
Other Current Liabilities
14. Other Current Liabilities
Other current liabilities consist of the following (in thousands):
October 2,
2021		January 2,
2021
Accrued indirect taxes payable$12,081 $14,365 
Accrued expenses12,046 6,794 
Lessee lease liabilities, current 6,147 5,975 
Income tax payable4,443 5,910 
Accrued legal fees3,947 4,058 
Related party payables3,446 3,655 
Accrued warranty2,944 2,740 
Accrued property taxes1,686 1,682 
Accrued donations1,307 495 
Other current liabilities3,071 4,096 
Noncontrolling interest(1)
— 3,469 
     Total other current liabilities$51,118 $53,239 
______________
(1)During the year ended January 2, 2021, the Company obtained a controlling interest in a provider of advanced hemodynamic monitoring solutions. The noncontrolling interest of the acquiree was recorded within other current liabilities as of January 2, 2021, as the noncontrolling interest shares were mandatorily redeemable. During the first quarter of 2021, the Company acquired the remaining noncontrolling interest. The impact of the noncontrolling interest is immaterial in all periods presented.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.21.2
Credit Facility
 9 Months Ended
Oct. 02, 2021
Debt Disclosure [Abstract]  
Credit Facility
15. Credit Facility
The Company currently maintains a credit facility with various lenders that provides for up to $150.0 million of unsecured borrowings, with an option, subject to certain conditions, for the Company to increase the aggregate borrowing capacity up to $550.0 million in the future with such lenders and additional lenders, as required. The credit facility also provides for a sublimit of up to $25.0 million for the issuance of letters of credit and a sublimit of $75.0 million for borrowings in specified foreign currencies. All unpaid principal under the credit facility will become due and payable on December 17, 2023. Proceeds from the credit facility are expected to be used for general corporate, capital investment and working capital needs. As of October 2, 2021 and January 2, 2021, the credit facility had no outstanding draws and $2.4 million and $1.7 million of outstanding letters of credit, respectively. The Company was in compliance with all covenants under the credit facility as of October 2, 2021 and January 2, 2021.
For each of the three months ended October 2, 2021 and September 26, 2020, the Company incurred total interest expense of $0.1 million under the credit facility.
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.21.2
Other Non-Current Liabilities
 9 Months Ended
Oct. 02, 2021
Other Liabilities, Long Term [Abstract]  
Other Non-Current Liabilities
16. Other Non-Current Liabilities
Other non-current liabilities consist of the following (in thousands):
October 2,
2021		January 2,
2021
Lessee non-current lease liabilities$27,471 $28,373 
Income tax payable, non-current16,980 19,245 
Unrecognized tax benefits15,352 11,777 
Deferred tax liabilities6,063 6,247 
Other4,511 5,434 
     Total other non-current liabilities$70,377 $71,076 
Unrecognized tax benefits relate to the Company’s long-term portion of tax liability associated with uncertain tax positions. Authoritative guidance prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. See Note 20 to these condensed consolidated financial statements for further details.
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.21.2
Stock Repurchase Program
 9 Months Ended
Oct. 02, 2021
Equity [Abstract]  
Stock Repurchase Program
17. Stock Repurchase Program
In October 2021, the Company’s Board of Directors (Board) approved a stock repurchase program, authorizing the Company to purchase up to 3.0 million shares of its common stock over a period of up to three years (2021 Repurchase Program). The Company expects to fund the 2021 Repurchase Program through its available cash, cash expected to be generated from future operations, the credit facility and other potential sources of capital. The 2021 Repurchase Program can be carried out at the discretion of a committee comprised of the CEO and CFO through open market purchases, one or more Rule 10b5-1 trading plans, block trades and privately negotiated transactions.
In July 2018, the Company’s Board approved a stock repurchase program, authorizing the Company to purchase up to 5.0 million additional shares of its common stock over a period of up to three years (2018 Repurchase Program). During the third quarter of 2021, the 2018 Repurchase Program expired.
The following table provides a summary of the Company’s stock repurchase activities (in thousands, except per share amounts):
Three Months EndedNine Months Ended
October 2,
2021		September 26,
2020		October 2,
2021		September 26,
2020
Shares repurchased(1)
— — 547 4 
Average cost per share$— $— $235.88 $164.44 
Value of shares repurchased$— $— $128,917 $591 
______________
(1)     Excludes shares withheld from the shares of its common stock actually issued in connection with the vesting of PSU or RSU awards to satisfy certain U.S. federal and state tax withholding obligations.
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-Based Compensation
 9 Months Ended
Oct. 02, 2021
Share-based Payment Arrangement [Abstract]  
Share-Based Compensation
18. Stock-Based Compensation
Total stock-based compensation expense for the three months ended October 2, 2021 and September 26, 2020 was $12.6 million and $11.9 million, respectively. Total stock-based compensation expense for the nine months ended October 2, 2021 and September 26, 2020 was $33.5 million and $36.4 million, respectively. As of October 2, 2021, an aggregate of 10.7 million shares of common stock were reserved for future issuance under the Company’s equity plans, of which 4.4 million shares were available for future grant under the Masimo Corporation 2017 Equity Incentive Plan (2017 Equity Plan). Additional information related to the Company’s current equity incentive plans, stock-based award activity and valuation of stock-based awards is included below.
Equity Incentive Plans
2017 Equity Incentive Plan
On June 1, 2017, the Company’s stockholders ratified and approved the 2017 Equity Plan. The 2017 Equity Plan permits the grant of stock options, restricted stock, RSUs, stock appreciation rights, PSUs, performance shares, performance bonus awards and other stock or cash awards to employees, directors and consultants of the Company and employees and consultants of any parent or subsidiary of the Company. Upon its effectiveness, an aggregate of 5.0 million shares were available for issuance under the 2017 Equity Plan. In May 2020, the Company’s stockholders approved an increase of 2.5 million shares to the 2017 Equity Plan. The aggregate number of shares that may be awarded under the 2017 Equity Plan is 7.5 million shares. The 2017 Equity Plan provides that at least 95% of the equity awards issued under the 2017 Equity Plan must vest over a period of not less than one year following the date of grant. The exercise price per share of each option granted under the 2017 Equity Plan may not be less than the fair market value of a share of the Company’s common stock on the date of grant, which is generally equal to the closing price of the Company’s common stock on the Nasdaq Global Select Market on the grant date.
2007 Stock Incentive Plan
Effective June 1, 2017, upon the approval and ratification of the 2017 Equity Plan, the Company’s 2007 Stock Incentive Plan (2007 Equity Plan) terminated, provided that awards outstanding under the 2007 Equity Plan will continue to be governed by the terms of that plan. In addition, upon the effectiveness of the 2017 Equity Plan, an aggregate of 5.0 million shares of the Company’s common stock registered under prior registration statements for issuance pursuant to the 2007 Equity Plan were deregistered and concurrently registered under the 2017 Equity Plan.
Stock-Based Award Activity
Stock Options
The number and weighted-average exercise price of options issued and outstanding under all of the Company’s equity plans are as follows (in thousands, except for weighted-average exercise prices):
Nine Months Ended
October 2, 2021
SharesWeighted-Average
Exercise Price
Options outstanding, beginning of period3,448 $77.44 
Granted85 250.15 
Canceled(150)146.62 
Exercised(278)57.88 
Options outstanding, end of period3,105 $80.55 
Options exercisable, end of period2,255 $55.57 
Total stock option expense for the three months ended October 2, 2021 and September 26, 2020 was $3.2 million and $3.8 million, respectively. Total stock option expense for the nine months ended October 2, 2021 and September 26, 2020 was $9.9 million and $11.9 million, respectively. As of October 2, 2021, the Company had $30.7 million of unrecognized compensation cost related to non-vested stock options that are expected to vest over a weighted-average period of approximately 2.6 years. The weighted-average remaining contractual term of options outstanding with an exercise price less than the closing price of the Company’s common stock as of October 2, 2021 was 5.3 years. The weighted-average remaining contractual term of options exercisable, with an exercise price less than the closing price of the Company’s common stock as of October 2, 2021, was 4.4 years.
RSUs
The number of RSUs issued and outstanding under all of the Company’s equity plans are as follows (in thousands, except for weighted-average grant date fair value amounts):
Nine Months Ended
October 2, 2021
UnitsWeighted-Average Grant
 Date Fair Value
RSUs outstanding, beginning of period2,862 $99.66 
Granted89 248.57 
Canceled(17)199.02 
Expired— — 
Vested(34)163.57 
RSUs outstanding, end of period2,900 $102.88 
Total RSU expense for the three months ended October 2, 2021 and September 26, 2020 was $2.4 million and $1.5 million, respectively. Total RSU expense for the nine months ended October 2, 2021 and September 26, 2020 was $6.7 million and $4.0 million, respectively. As of October 2, 2021, the Company had $34.7 million of unrecognized compensation cost related to non-vested RSU awards expected to be recognized and vest over a weighted-average period of approximately 3.6 years.
PSUs
The number of PSUs outstanding under all of the Company’s equity plans are as follows (in thousands, except for weighted-average grant date fair value amounts):
Nine Months Ended
October 2, 2021
UnitsWeighted-Average Grant
 Date Fair Value
PSUs outstanding, beginning of period444 $120.28 
Granted(1)
148 162.99 
Canceled(17)166.84 
Expired— — 
Vested(273)86.95 
PSUs outstanding, end of period302 $168.68 
______________
(1)     On February 22, 2021, the Audit Committee approved the weighted payout percentage for the 2018 PSU awards (three-year performance period), which were based upon the actual fiscal 2020 performance against pre-established performance objectives. Included in the granted amount are those additional PSUs earned based on actual performance achieved. These PSUs were originally awarded at target.
During the first quarter of 2021, the Company awarded 68,600 PSUs that will vest three years from the award date, based on the achievement of certain 2024 performance criteria approved by the Board. If earned, the PSUs granted will vest upon achievement of the performance criteria after the year in which the performance achievement level has been determined. The number of shares that may be earned can range from 0% to 200% of the target amount; therefore, the maximum number of shares that can be issued under these awards is twice the original award of 68,600 PSUs, or 137,200 shares. Based on management’s estimate of the number of units expected to vest, total PSU expense for the three months ended October 2, 2021 and September 26, 2020 was $7.0 million and $6.6 million, respectively. Based on management’s estimate of the number of units expected to vest, total PSU expense for the nine months ended October 2, 2021 and September 26, 2020 was $16.9 million and $20.5 million, respectively. As of October 2, 2021, the Company had $41.1 million of unrecognized compensation cost related to non-vested PSU awards expected to be recognized and vest over a weighted-average period of approximately 1.1 years.
Valuation of Stock-Based Award Activity
The fair value of each RSU and PSU is determined based on the closing price of the Company’s common stock on the grant date.
The Black-Scholes option pricing model is used to estimate the fair value of options granted under the Company’s stock-based compensation plans. The range of assumptions used and the resulting weighted-average fair value of options granted at the date of grant were as follows:
Three Months EndedNine Months Ended
October 2,
2021(1)
September 26,
2020		October 2,
2021		September 26,
2020
Risk-free interest rate
—%
0.2% to 0.3%
0.3% to 0.9%
0.2% to 1.7%
Expected term (in years)0.05.15.65.1
Estimated volatility
—%
32.7% to 33.6%
30.9% to 34.7%
26.9% to 35.5%
Expected dividends0%0%0%0%
Weighted-average fair value of options granted$—$66.24$75.72$50.39
__________________
(1)    No stock options were granted during the three months ended October 2, 2021.
The aggregate intrinsic value of options is calculated as the positive difference, if any, between the market value of the Company’s common stock on the date of exercise or the respective period end, as appropriate, and the exercise price of the options. The aggregate intrinsic value of options outstanding with an exercise price less than the closing price of the Company’s common stock as of October 2, 2021 was $589.6 million. The aggregate intrinsic value of options exercisable with an exercise price less than the closing price of the Company’s common stock as of October 2, 2021 was $484.5 million. The aggregate intrinsic value of options exercised during the three months ended October 2, 2021 was $35.4 million.
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Non-operating income
 9 Months Ended
Oct. 02, 2021
Nonoperating Income (Expense) [Abstract]  
Non-operating income
19. Non-operating (loss) income
Non-operating (loss) income consists of the following (in thousands):
Three Months EndedNine Months Ended
October 2,
2021		September 26,
2020		October 2,
2021		September 26,
2020
Interest income$242 $797 $677 $5,120 
Interest expense(87)(84)(259)(250)
Realized and unrealized foreign currency (losses) gains(233)647 (1,153)1,246 
Other — (3)— (8)
Total
$(78)$1,357 $(735)$6,108 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.21.2
Income Taxes
 9 Months Ended
Oct. 02, 2021
Income Tax Disclosure [Abstract]  
Income Taxes
20. Income Taxes
The Company has provided for income taxes in fiscal year 2021 interim periods based on the estimated effective income tax rate for the complete fiscal year, as adjusted for discrete tax events, including excess tax benefits or deficiencies related to stock-based compensation, in the period such events occur. The estimated annual effective tax rate is computed based on the expected annual pretax income of the consolidated entities located within each taxing jurisdiction based on legislation enacted as of the balance sheet date. For the three months ended October 2, 2021 and September 26, 2020, the Company recorded discrete tax benefits of approximately $6.4 million and $3.1 million, respectively, related to excess tax benefits realized from stock-based compensation. For the nine months ended October 2, 2021 and September 26, 2020, the Company recorded discrete tax benefits of approximately $12.0 million and $20.2 million, respectively, related to excess tax benefits realized from stock-based compensation.
Deferred tax assets and liabilities are determined based on the future tax consequences associated with temporary differences between income and expenses reported for accounting and tax purposes. A valuation allowance for deferred tax assets is recorded to the extent that the Company cannot determine that the ultimate realization of the net deferred tax assets is more likely than not. Realization of deferred tax assets is principally dependent upon the achievement of future taxable income, the estimation of which requires significant judgment by the Company’s management. The judgment of the Company’s management regarding future profitability may change due to many factors, including future market conditions and the Company’s ability to successfully execute its business plans or tax planning strategies. These changes, if any, may require material adjustments to these deferred tax asset balances.
As of October 2, 2021, the liability for income taxes associated with uncertain tax positions was approximately $21.6 million. If fully recognized, approximately $19.6 million (net of federal benefit on state taxes) would impact the Company’s effective tax rate. It is reasonably possible that the amount of unrecognized tax benefits in various jurisdictions may change in the next twelve months due to the expiration of statutes of limitation and audit settlements. However, due to the uncertainty surrounding the timing of these events, an estimate of the change within the next twelve months cannot currently be made.
The Company conducts business in multiple jurisdictions and, as a result, one or more of the Company’s subsidiaries files income tax returns in U.S. federal, various state, local and foreign jurisdictions. The Company has concluded all U.S. federal income tax matters through fiscal year 2016. All material state, local and foreign income tax matters have been concluded through fiscal year 2012. The Company does not believe that the results of any tax authority examination would have a significant impact on its consolidated financial statements.
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies
 9 Months Ended
Oct. 02, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
21. Commitments and Contingencies
Employee Retirement Savings Plan
The Company sponsors a qualified defined contribution plan or 401(k) plan, the Masimo Retirement Savings Plan (MRSP), covering the Company’s full-time U.S. employees who meet certain eligibility requirements. In general, the Company matches an employee’s contribution up to 3% of the employee’s compensation, subject to a maximum amount. The Company may also contribute to the MRSP on a discretionary basis. The Company contributed $0.9 million and $0.8 million to the MRSP for the three months ended October 2, 2021 and September 26, 2020, respectively, all in the form of matching contributions. The Company contributed $2.8 million and $2.4 million to the MRSP for the nine months ended October 2, 2021 and September 26, 2020, respectively, all in the form of matching contributions. In addition, the Company sponsors various defined contribution plans in certain locations outside of the United States, the contributions to which were not material for any period.
Employment and Severance Agreements
In July 2017, the Company entered into the First Amendment to the certain Amended and Restated Employment Agreement entered into between the Company and Mr. Kiani on November 4, 2015 (as amended, the Amended Employment Agreement). Pursuant to the terms of the Amended Employment Agreement, upon a “Qualifying Termination” (as defined in the Amended Employment Agreement), Mr. Kiani will be entitled to receive a cash severance benefit equal to two times the sum of his then-current base salary and the average annual bonus paid to Mr. Kiani during the immediately preceding three years, the full amount of the “Award Shares” (as defined in the Amended Employment Agreement) and the full amount of the “Cash Payment” (as defined in the Amended Employment Agreement). In addition, in the event of a “Change in Control” (as defined in the Amended Employment Agreement) prior to a Qualifying Termination, on each of the first and second anniversaries of the Change in Control, 50% of the Cash Payment and 50% of the Award Shares will vest, subject in each case to Mr. Kiani’s continuous employment through each such anniversary date; however, in the event of a Qualifying Termination or a termination of Mr. Kiani’s employment due to death or disability prior to either of such anniversaries, any unvested amount of the Cash Payment and all of the unvested Award Shares shall vest and be paid in full.
Additionally, in the event of a Change in Control prior to a Qualifying Termination, Mr. Kiani’s stock options and any other equity awards will vest in accordance with their terms, but in no event later than in two equal installments on each of the one year and two year anniversaries of the Change in Control, subject in each case to Mr. Kiani’s continuous employment through each such anniversary date. As of October 2, 2021, the expense related to the Award Shares and Cash Payment that would be recognized in the Company’s consolidated financial statements upon the occurrence of a Qualifying Termination under the Restated Employment Agreement was approximately $292.9 million.
As of October 2, 2021, the Company had severance plan participation agreements with five executive officers. The participation agreements (the Agreements) are governed by the terms and conditions of the Company’s 2007 Severance Protection Plan (the Severance Plan), which became effective on July 19, 2007 and which was amended effective December 31, 2008. Under each of the Agreements, the applicable executive officer may be entitled to receive certain salary, equity, medical and life insurance benefits if he is terminated by the Company without cause or if he terminates his employment for good reason under certain circumstances. The executive officers are also required to give the Company six months’ advance notice of their resignation under certain circumstances.
Purchase Commitments
Pursuant to contractual obligations with vendors, the Company had $155.9 million of purchase commitments as of October 2, 2021 that are expected to be purchased within one year. These purchase commitments have been made for certain inventory items in order to secure sufficient levels of those items, other critical inventory and manufacturing supplies, and to achieve better pricing.
Other Contractual Commitments
In the normal course of business, the Company may provide bank guarantees to support government hospital tenders in certain foreign jurisdictions. As of October 2, 2021, the Company had approximately $3.4 million in outstanding unsecured bank guarantees.
In certain circumstances, the Company also provides limited indemnification within its various customer contracts whereby the Company indemnifies the parties to whom it sells its products with respect to potential infringement of intellectual property, and against bodily injury caused by a defective Company product. It is not possible to predict the maximum potential amount of future payments under these or similar agreements, due to the conditional nature of the Company’s obligations and the unique facts and circumstances involved. As of October 2, 2021, the Company had not incurred any significant costs related to contractual indemnification of its customers.
Concentrations of Risk
The Company is exposed to credit loss for the amount of its cash deposits with financial institutions in excess of federally insured limits. The Company invests a portion of its excess cash with major financial institutions. As of October 2, 2021, the Company had $652.4 million of bank balances, of which $5.0 million was covered by either the U.S. Federal Deposit Insurance Corporation limit or foreign countries’ deposit insurance organizations.
The Company’s ability to sell its products to U.S. hospitals depends in part on its relationships with GPOs. Many existing and potential customers for the Company’s products become members of GPOs. GPOs negotiate pricing arrangements and contracts, sometimes exclusively, with medical supply manufacturers and distributors, and these negotiated prices are made available to a GPO’s affiliated hospitals and other members. During the three months ended October 2, 2021 and September 26, 2020, revenue from the sale of the Company’s products to customers that are members of GPOs approximated 55.0% and 48.1% of product revenue, respectively. During the nine months ended October 2, 2021 and September 26, 2020, revenue from the sale of the Company’s products to customers that are members of GPOs approximated 51.8% and 49.6% of product revenue, respectively.
For the three months ended October 2, 2021, the Company had sales through two just-in-time distributors that represented 15.0% and 10.4% of product revenue, respectively. For the three months ended September 26, 2020, the Company had sales through the same two just-in-time distributors that represented 11.0% and 9.3% of product revenue, respectively.
For the nine months ended October 2, 2021, the Company had sales through two just-in-time distributors that represented 14.6% and 10.4% of product revenue, respectively. For the nine months ended September 26, 2020, the Company had sales through the same two just-in-time distributors that represented 11.2% and 10.0% of product revenue, respectively.
As of October 2, 2021 and January 2, 2021, one customer represented 9.4% and 9.1%, respectively, of the Company’s accounts receivable balance. The receivable balance related to such customer is fully secured by a letter of credit.
Litigation
During the third quarter of fiscal year 2017, the Company became aware that certain amounts had been paid by a foreign government customer to the Company’s former appointed foreign agent in connection with a foreign government tender, but had not been remitted by such agent to the Company in accordance with the agency agreement. On December 28, 2017, the Company initiated arbitration proceedings against this foreign agent after unsuccessful attempts to recover such remittances. As a result, the Company recorded a net charge of approximately $10.5 million during the fourth quarter of fiscal year 2017 in connection with this dispute, of which $2.0 million was recovered during the year ended December 28, 2019. An arbitration hearing was held on February 11, 2019. On July 8, 2019, the arbitrator awarded the Company $10.5 million in damages, fees and costs. On January 12, 2020, the Company received notice that bankruptcy restructuring proceedings had been initiated for the foreign agent. The Company filed its claim with the bankruptcy trustee on January 16, 2020. In July 2020, the Company was notified that a bankruptcy reorganization proposal had been submitted for voting by creditors in August 2020. The reorganization proposal was rejected by a vote of the creditors on August 26, 2020. On October 22, 2020, the Company filed a petition seeking to enforce the arbitration award. Although the Company intends to vigorously pursue the collection of the arbitration award, there is no guarantee that the Company will be successful in these efforts.
On January 2, 2014, a putative class action complaint was filed against the Company in the U.S. District Court for the Central District of California (District Court) by Physicians Healthsource, Inc. The complaint alleges that the Company sent unsolicited facsimile advertisements in violation of the Junk Fax Protection Act of 2005 and related regulations. The complaint seeks $500 for each alleged violation, treble damages if the District Court finds the alleged violations to be knowing, plus interest, costs and injunctive relief. On March 26, 2019, an amended complaint was filed adding Radha Geismann, M.D. PC as an additional named plaintiff. On June 17, 2019, the plaintiffs filed their motion for class certification. On September 10, 2019, the parties filed motions for summary judgment. On September 30, 2019, the Company filed its opposition to the motion for class certification, and the plaintiffs filed their reply on October 7, 2019. On November 21, 2019, the District Court issued an order denying the plaintiffs’ motion for class certification and granting in part and denying in part the Company’s motion for summary judgment, and deferring ruling on the plaintiffs’ motion for summary judgment. On December 5, 2019, the plaintiffs filed a petition for permission to appeal the order denying class certification, which was denied on January 24, 2020. Trial of the individual plaintiffs’ claims was scheduled for June 2, 2020, but on April 1, 2020, the District Court vacated the trial date and directed the parties to conduct an in-person mediation. The mediation has not occurred and no new trial date has been set. On July 13, 2020, the District Court issued an order granting in part and denying in part the plaintiffs’ motion for summary judgment.
The Company believes it has good and substantial defenses to the claims, but there is no guarantee that the Company will prevail. The Company is unable to determine whether any loss will ultimately occur or to estimate the range of such loss; therefore, no amount of loss has been accrued by the Company in the accompanying condensed consolidated financial statements.
On January 9, 2020, the Company filed a complaint against Apple Inc. (Apple) in the District Court for infringement of a number of patents, for trade secret misappropriation, and for ownership and correction of inventorship of a number of Apple patents listing one of its former employees as an inventor. Apple filed petitions for Inter Partes review of the asserted patents in the U.S. Patent and Trademark Office (PTO). The PTO has instituted Inter Partes review of the asserted patents. On October 13, 2020, the District Court stayed the patent infringement claims pending completion of the Inter Partes review proceedings. On February 5, 2021, the Company filed a fourth amended complaint. On February 26, 2021, Apple filed a partial motion to dismiss the trade secrets claim in the fourth amended complaint. On April 21, 2021, the District Court issued an order granting in part and denying in part the motion to dismiss. On May 5, 2021, Apple filed its answer to the fourth amended complaint. The Company is seeking damages, injunctive relief, and declaratory judgment regarding ownership of the Apple patents.
On June 30, 2021, the Company filed a complaint with the U.S. International Trade Commission (ITC) against Apple for infringement of a number of other patents. The Company filed an amended complaint on July 12, 2021. On August 13, 2021, the ITC issued a Notice of Institution of Investigation on the asserted patents. An evidentiary hearing is scheduled for June 6-10, 2022, and the target date for completion of the ITC investigation is January 16, 2023. The Company is seeking an exclusion order and a permanent cease and desist order. Although the Company intends to vigorously pursue all of its legal remedies, there is no guarantee that the Company will be successful in these efforts.
From time to time, the Company may be involved in other litigation and investigations relating to claims and matters arising out of its operations in the normal course of business. The Company believes that it currently is not a party to any other legal proceedings which, individually or in the aggregate, would have a material adverse effect on its consolidated financial position, results of operations or cash flows.
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.21.2
Segment Information and Enterprise Reporting
 9 Months Ended
Oct. 02, 2021
Segment Reporting [Abstract]  
Segment Information and Enterprise Reporting
22. Segment Information and Enterprise Reporting
The Company operates in one segment based upon the Company’s organizational structure and the way in which the Company’s chief operating decision maker, the CEO, reviews financial information presented on a consolidated basis, accompanied by disaggregated information about revenues by geographic region, for purposes of making operating decisions and assessing financial performance. In addition, the Company’s assets are primarily located in the U.S. The Company does not produce reports for, or measure the performance of, its geographic regions on any asset-based metrics. Therefore, geographic information is presented only for revenues and long-lived assets.
The following schedule presents an analysis of the Company’s product revenues based upon the geographic area to which the product was shipped (in thousands, except percentages):
Three Months EndedNine Months Ended
October 2,
2021		September 26,
2020		October 2,
2021		September 26,
2020
Geographic area by destination:
United States (U.S.)$207,060 67.4 %$186,919 67.2 %$613,197 67.3 %$571,158 67.3 %
Europe, Middle East and Africa56,223 18.3 54,257 19.5 177,053 19.4 176,781 20.8 
Asia and Australia34,878 11.3 27,583 9.9 94,134 10.3 73,155 8.6 
North and South America (excluding the U.S.)9,252 3.0 9,353 3.4 27,190 3.0 27,596 3.3 
     Product revenue$307,413 100.0 %$278,112 100.0 %$911,574 100.0 %$848,690 100.0 %
The Company’s consolidated long-lived assets (tangible non-current assets) by geographic area are (in thousands, except percentages):
October 2,
2021		January 2,
2021
Long-lived assets by geographic area:
United States$239,435 86.6 %$238,094 86.9 %
International36,980 13.4 35,755 13.1 
     Total long-lived assets$276,415 100.0 %$273,849 100.0 %
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Oct. 02, 2021
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) have been condensed or omitted pursuant to such rules and regulations. The accompanying condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, including normal recurring accruals, necessary to present fairly the Company’s condensed consolidated financial statements. The accompanying condensed consolidated balance sheet as of January 2, 2021 was derived from the Company’s audited consolidated financial statements at that date. The accompanying condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes contained in the Company’s Annual Report on Form 10-K for the fiscal year ended January 2, 2021 (fiscal year 2020), filed with the SEC on February 23, 2021. The results for the three and nine months ended October 2, 2021 are not necessarily indicative of the results to be expected for the fiscal year ending January 1, 2022 (fiscal year 2021) or for any other interim period or for any future year.
Fiscal Periods
Fiscal Periods
The Company follows a conventional 52/53 week fiscal year. Under a conventional 52/53 week fiscal year, a 52 week fiscal year includes four quarters of 13 weeks while a 53 week fiscal year includes three 13 week fiscal quarters and one 14 week fiscal quarter. The Company’s last 53 week fiscal year was fiscal year 2020. Fiscal year 2021 is a 52 week fiscal year ending January 1, 2022. All references to years in these notes to condensed consolidated financial statements are fiscal years unless otherwise noted.
Reclassifications
Reclassifications
Certain amounts in the accompanying condensed consolidated financial statements have been reclassified to conform to the current period presentation.
Use of Estimates
Use of Estimates
The Company prepares its financial statements in conformity with GAAP, which requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates include the determination of standalone selling prices, variable consideration, total consideration allocated to each performance obligation within a contract, inventory valuation, valuation of the Company’s equity awards, valuation of identifiable assets and liabilities connected with business combinations, deferred taxes and any associated valuation allowances, deferred revenue, uncertain income tax positions, and litigation costs and related accruals. Actual results could differ from such estimates.
Business Combinations
Business Combinations
The Company accounts for business combinations using the acquisition method of accounting, which requires that once control is obtained, all the assets acquired, liabilities assumed and noncontrolling interests in the acquired entity, if applicable, are recorded at their respective fair values at the date of acquisition. The excess of the purchase price over the fair values of identifiable assets, liabilities and noncontrolling interests in the acquired entity, if applicable, is recorded as goodwill. The Company finalizes the purchase price allocation within one year from the acquisition date.
Fair Value of Measurements
Fair Value Measurements
Authoritative guidance describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:
●    Level 1—Quoted prices in active markets for identical assets or liabilities.
●    Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active; or other inputs that can be corroborated by observable market data for substantially the full term of the assets or liabilities.
●    Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
Pursuant to current authoritative guidance, entities are allowed an irrevocable option to elect the fair value for the initial and subsequent measurement for specified financial assets and liabilities on a contract-by-contract basis. The Company did not elect to apply the fair value option under this guidance to specific assets or liabilities on a contract-by-contract basis. There were no transfers between Level 1, Level 2 and Level 3 inputs during either the nine months ended October 2, 2021 or September 26, 2020. The Company carries cash and cash equivalents, at cost, which approximates fair value.
For certain other financial assets and liabilities, including restricted cash, accounts receivable, accounts payable and other current assets and liabilities, the carrying amounts approximate their fair value primarily due to the relatively short maturity of these balances. The Company also measures certain non-financial assets at fair value on a non-recurring basis, primarily goodwill, intangible assets and operating lease right-of-use assets, in connection with periodic evaluations for potential impairment.
Cash and Cash Equivalents
Cash and Cash Equivalents
The Company considers all highly liquid investments with an original maturity from date of purchase of three months or less, or highly liquid investments that are readily convertible into known amounts of cash, to be cash equivalents.
Accounts Receivable and Allowance for Credit Losses
Accounts Receivable and Allowance for Credit Losses
Accounts receivable consist of trade receivables recorded at the time of invoicing of product sales, reduced by reserves for estimated bad debts and returns. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Credit is extended based on an evaluation of the customer’s financial condition. Collateral is generally not required. The Company records an allowance for credit losses that it does not expect to collect based on relevant information, including historical experience, current conditions, and reasonable and supportable forecasts. Accounts are charged off against the allowance when the Company believes they are uncollectible.
Inventory
Inventory
Inventories are stated at the lower of cost or net realizable value. Cost is determined using a standard cost method, which approximates the first in, first out method, and includes material, labor and overhead costs. Inventory valuation adjustments are recorded for inventory items that have become excess or obsolete or are no longer used in current production and for inventory items that have a market price less than carrying value in inventory. The Company generally determines inventory valuation adjustments based on an evaluation of the expected future use of its inventory on an item by item basis and applies historical obsolescence rates to estimate the loss on inventory expected to have a recovery value below cost. The Company also records other specific inventory valuation adjustments when it becomes aware of unique events or circumstances that result in an expected recovery value below cost. For inventory items that have been written down, the reduced value becomes the new cost basis.
Property and Equipment
Property and Equipment
Property and equipment are stated at cost. Depreciation is calculated using the straight-line method over estimated useful lives as follows:
Useful Lives
Building and building improvements
7 to 39 years
Computer equipment and software
2 to 12 years
Demonstration units3 years
Furniture and office equipment
2 to 6 years
Leasehold improvementsLesser of useful life or term of lease
Machinery, equipment and tooling
3 to 10 years
Transportation, vehicles and other
4 to 20 years
Land is not depreciated and construction-in-progress is not depreciated until placed in service. Normal repair and maintenance costs are expensed as incurred, whereas significant improvements that materially increase values or extend useful lives are capitalized and depreciated over the remaining estimated useful lives of the related assets. Upon sale or retirement of depreciable assets, the related cost and accumulated depreciation or amortization are removed from the accounts and any gain or loss on the sale or retirement is recognized in income.
Intangible Assets
Intangible Assets
Intangible assets consist primarily of patents, trademarks, software development costs, customer relationships and acquired technology. Costs related to patents and trademarks, which include legal and application fees, are capitalized and amortized over the estimated useful lives using the straight-line method. Patent and trademark amortization commences once final approval of the patent or trademark has been obtained. Patent costs are amortized over the lesser of 10 years or the patent’s remaining legal life, which assumes renewals, and trademark costs are amortized over 17 years, and their associated amortization cost is included in selling, general and administrative expense in the accompanying condensed consolidated statements of operations. For intangibles purchased in an asset acquisition or business combination, which mainly include patents, trademarks, customer relationships and acquired technologies, the useful life is determined largely by valuation estimates of remaining economic life. The Company’s policy is to renew its patents and trademarks. Costs to renew patents and trademarks are capitalized and amortized over the remaining useful life of the intangible asset. The Company periodically evaluates the amortization period and carrying basis of patents, trademarks and other intangible assets to determine whether any events or circumstances warrant a revised estimated useful life or reduction in value. Capitalized application costs are charged to operations when it is determined that the patent or trademark will not be obtained or is abandoned.
Impairment of Goodwill, Intangible Assets and Other Long-Lived Assets
Impairment of Goodwill, Intangible Assets and Other Long-Lived Assets
Goodwill is recorded as the difference, if any, between the aggregate consideration paid for an acquisition and the fair value of the acquired net tangible and intangible assets. Goodwill is not amortized, but instead is tested annually for impairment, or more frequently when events or changes in circumstances indicate that goodwill might be impaired. In assessing goodwill impairment, the Company has the option to first assess the qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. The Company’s qualitative assessment of the recoverability of goodwill considers various macroeconomic, industry-specific and Company-specific factors, including: (i) severe adverse industry or economic trends; (ii) significant Company-specific actions; (iii) current, historical or projected deterioration of the Company’s financial performance; or (iv) a sustained decrease in the Company’s market capitalization below its net book value. If, after assessing the totality of events or circumstances, the Company determines it is unlikely that the fair value of a reporting unit is less than its carrying amount, then a quantitative analysis is unnecessary. However, if the Company concludes otherwise, or if the Company elects to bypass the qualitative analysis, then the Company must perform a quantitative analysis that compares the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill is not considered impaired; otherwise, a goodwill impairment loss is recognized for the lesser of: (a) the amount that the carrying amount of a reporting unit exceeds its fair value; or (b) the amount of the goodwill allocated to that reporting unit. The annual impairment test is performed during the fourth fiscal quarter.
The Company reviews long-lived assets and identifiable intangibles for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted operating cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair value of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less costs to sell.
Revenue Recognition, and Deferred Revenue and Other Contract Liabilities
Revenue Recognition, Deferred Revenue and Other Contract Liabilities
The Company derives the majority of its product revenue from four primary sources: (i) direct sales under deferred equipment agreements with end-user hospitals where the Company provides up-front monitoring equipment at no up-front charge in exchange for a multi-year sensor purchase commitment; (ii) other direct sales of noninvasive monitoring solutions to end-user hospitals, emergency medical response organizations and other direct customers; (iii) sales of noninvasive monitoring solutions to distributors who then typically resell to end-user hospitals, emergency medical response organizations and other customers; and (iv) sales of integrated circuit boards to OEM customers who incorporate the Company’s embedded software technology into their multiparameter monitoring devices. Subject to customer credit considerations, the majority of such sales are made on open account using industry standard payment terms based on the geography within which the specific customer is located.
The Company generally recognizes revenue following a single, principles-based five-step model to be applied to all contracts with customers and generally provides for the recognition of revenue in an amount that reflects the consideration to which the Company expects to be entitled, net of allowances for estimated returns, discounts or sales incentives, as well as taxes collected from customers that are remitted to government authorities, when control over the promised goods or services are transferred to the customer. Revenue related to equipment supplied under sales-type lease arrangements is recognized once control over the equipment is transferred to the customer, while revenue related to equipment supplied under operating-type lease arrangements is generally recognized on a straight-line basis over the term of the lease.
While the majority of the Company’s revenue contracts and transactions contain standard business terms and conditions, there are some transactions that contain non-standard business terms and conditions. As a result, contract interpretation, judgment and analysis is required to determine the appropriate accounting, including: (i) the amount of the total consideration, as well as variable consideration, (ii) whether the arrangement contains an embedded lease, and if so, whether such embedded lease is a sales-type lease or an operating lease, (iii) the identification of the distinct performance obligations contained within the arrangement, (iv) how the arrangement consideration should be allocated to each performance obligation when multiple performance obligations exist, including the determination of standalone selling price, and (v) when to recognize revenue on the performance obligations. Changes in judgments on these assumptions and estimates could materially impact the timing of revenue recognition.
The Company enters into agreements to sell its monitoring solutions and services, sometimes as a part of arrangements with multiple performance obligations that include various combinations of product sales, equipment leases and services. In the case of contracts with multiple performance obligations, the authoritative guidance provides that the total consideration be allocated to each performance obligation on the basis of relative standalone selling prices. When a standalone selling price is not readily observable, the Company estimates the standalone selling price by considering multiple factors including, but not limited to, features and functionality of the product, geographies, type of customer, contractual prices pursuant to Group Purchasing Organization (GPO) contracts, the Company’s pricing and discount practices, and other market conditions.
Sales under deferred equipment agreements are generally structured such that the Company agrees to provide certain monitoring-related equipment, software, installation, training and/or warranty support at no up-front charge in exchange for the customer’s commitment to purchase sensors over the term of the agreement, which generally ranges from three years to six years. The Company allocates contract consideration under deferred equipment agreements containing fixed annual sensor purchase commitments to the underlying lease and non-lease components at contract inception. In determining whether any underlying lease components are related to a sales-type lease or an operating lease, the Company evaluates the customer’s rights and ability to control the use of the underlying equipment throughout the contract term, including any equipment substitution rights retained by the Company, as well as the Company’s expectations surrounding potential contract/lease extensions or renewals and the customer’s likelihood to exercise any purchase options. Revenue allocable to non-lease performance obligations is generally recognized as such non-lease performance obligations are satisfied. Revenue allocable to lease components under sales-type lease arrangements is generally recognized when control over the equipment is transferred to the customer. Revenue allocable to lease components under operating lease arrangements is generally recognized over the term of the operating lease. The Company generally does not expect to derive any significant value in excess of such asset’s unamortized book value from equipment underlying its operating lease arrangements after the end of the agreement.
Revenue from the sale of products to end-user hospitals, emergency medical response organizations, other direct customers, distributors and OEM customers, is recognized by the Company when control of such products transfer to the customer based upon the terms of the contract or underlying purchase order.
Revenue related to OEM rainbow® parameter software licenses is recognized by the Company upon the OEM’s shipment of its product to its customer, as reported to the Company by the OEM.
The Company provides certain customers with various sales incentives that may take the form of discounts or rebates. The Company records estimates related to these programs as a reduction to revenue at the time of sale. In general, customers do not have a right of return for credit or refund. However, the Company allows returns under certain circumstances. At the end of each period, the Company estimates and accrues for these returns as a reduction to revenue. The Company estimates the revenue constraints related to these forms of variable consideration based on various factors, including expected purchasing volumes, prior sales and returns history, and specific contractual terms and limitations.
Shipping and Handling Costs and Fees
Shipping and Handling Costs and Fees
All shipping and handling costs are expensed as incurred and are recorded as a component of cost of goods sold in the accompanying condensed consolidated statements of operations. Charges for shipping and handling billed to customers are included as a component of product revenue.
Taxes Collected From Customers And Remitted To Governmental Authorities
Taxes Collected From Customers and Remitted to Governmental Authorities
The Company’s policy is to present revenue net of taxes collected from customers and remitted to governmental authorities.
Deferred Costs and Other Contract Assets
Deferred Costs and Other Contract Assets
The costs of monitoring-related equipment provided to customers under operating lease arrangements within the Company’s deferred equipment agreements are generally deferred and amortized to cost of goods sold over the life of the underlying contracts. Some of the Company’s deferred equipment agreements also contain provisions for certain allowances to be made directly to the end-user hospital customer at the inception of the arrangement. These allowances are generally allocated to the lease and non-lease components and recognized as a reduction to revenue as the underlying performance obligations are satisfied.
The Company generally invoices its customers under deferred equipment agreements as sensors are provided to the customer. However, the Company may recognize revenue for certain non-lease performance obligations under deferred equipment agreements with fixed annual commitments at the time such performance obligations are satisfied and prior to the customer being invoiced. When this occurs, the Company records an unbilled contract receivable related to such revenue until the customer has been invoiced pursuant to the terms of the underlying deferred equipment agreement.
The incremental costs of obtaining a contract with a customer are capitalized and deferred if the Company expects such costs to be recoverable over the life of the contract and the contract term is greater than one year. Such deferred costs generally relate to certain incentive sales commissions earned by the Company’s internal sales team in connection with the execution of deferred equipment agreements and are amortized to expense over the expected term of the underlying contract.
Product Warranty
Product Warranty
The Company generally provides a warranty against defects in material and workmanship for a period ranging from six months to forty-eight months, depending on the product type. In traditional sales activities, including direct and OEM sales, the Company establishes an accrued liability for the estimated warranty costs at the time of revenue recognition, with a corresponding provision to cost of goods sold. Customers may also purchase extended warranty coverage or service level upgrades separately or as part of a deferred equipment agreement. Revenue related to extended warranty coverage and service level upgrades is generally recognized over the life of the contract, which reasonably approximates the period over which such services will be provided. The related extended warranty and service level upgrade costs are expensed as incurred.
Changes in the product warranty accrual were as follows (in thousands):
Nine Months Ended
October 2,
2021		September 26,
2020
Warranty accrual, beginning of period$2,740 $3,395 
Accrual for warranties issued3,442 428 
Changes in pre-existing warranties (including changes in estimates)(2,347)(97)
Settlements made(891)(883)
Warranty accrual, end of period$2,944 $2,843 
Litigation Costs and Contingencies
Litigation Costs and Contingencies
The Company records a charge equal to at least the minimum estimated liability for a loss contingency or litigation settlement when both of the following conditions are met: (i) information available prior to issuance of the financial statements indicates that it is probable that a liability had been incurred at the date of the financial statements, and (ii) the range of loss can be reasonably estimated. The determination of whether a loss contingency or litigation settlement is probable or reasonably possible involves a significant amount of management judgment, as does the estimation of the range of loss given the nature of contingencies. Liabilities related to litigation settlements with multiple elements are recorded based on the fair value of each element. Legal and other litigation related expenses are recognized as the services are provided. The Company records insurance and other indemnity recoveries for litigation expenses when both of the following conditions are met: (a) the recovery is probable, and (b) collectability is reasonably assured. Insurance recoveries are only recorded to the extent the litigation costs to which they relate have been incurred and recognized in the financial statements.
Comprehensive Income
Comprehensive Income
Comprehensive income includes foreign currency translation adjustments and any related tax benefits that have been excluded from net income and reflected in stockholders’ equity.
Net Income Per Share
Net Income Per Share
A computation of basic and diluted net income per share is as follows (in thousands, except per share data):
Three Months EndedNine Months Ended
October 2,
2021		September 26,
2020		October 2,
2021		September 26,
2020
Net income$57,771 $49,405 $161,389 $169,633 
Basic net income per share:
Weighted-average shares outstanding - basic55,143 54,997 55,125 54,543 
Net income per basic share$1.05 $0.90 $2.93 $3.11 
Diluted net income per share:
Weighted-average shares outstanding - basic55,143 54,997 55,125 54,543 
Diluted share equivalent: stock options, RSUs and PSUs2,521 3,283 2,526 3,490 
Weighted-average shares outstanding - diluted57,664 58,280 57,651 58,033 
Net income per diluted share$1.00 $0.85 $2.80 $2.92 
Basic net income per share is computed by dividing net income by the weighted-average number of shares outstanding during the period. Net income per diluted share is computed by dividing the net income by the weighted-average number of shares and potential shares outstanding during the period, if the effect of potential shares is dilutive. Potential shares include incremental shares of stock issuable upon the exercise of stock options and the vesting of both restricted share units (RSUs) and performance share units (PSUs). For each of the three months ended October 2, 2021 and September 26, 2020, weighted options to purchase 0.1 million shares of common stock were outstanding but not included in the computation of diluted net income per share because the effect of including such shares would have been antidilutive in the applicable period. For the nine months ended October 2, 2021 and September 26, 2020, weighted options to purchase 0.2 million and 0.3 million shares of common stock, respectively, were outstanding but not included in the computation of diluted net income per share because the effect of including such shares would have been antidilutive in the applicable period. Certain RSUs are considered contingently issuable shares as their vesting is contingent upon the occurrence of certain future events. Since such events had not occurred and were not considered probable of occurring as of each of October 2, 2021 and September 26, 2020, 2.7 million weighted-average shares related to such RSUs have been excluded from the calculation of potential shares for each of the three and nine month periods then ended.
Segment Information
Segment Information
The Company uses the “management approach” in determining reportable business segments. The management approach designates the internal organization used by management for making operating decisions and assessing performance as the source for determining the Company’s reportable segments. Based on this assessment, management has determined it operates in one reportable business segment, which is comprised of patient monitoring and related products.
Recently Issued Accounting Pronouncements
Recently Adopted Accounting Pronouncements
In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12). The standard simplifies the accounting for income taxes by removing exceptions to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income or a gain from other items, to the requirement to recognize a deferred tax liability for equity method investments when a foreign subsidiary becomes an equity method investment, to the ability not to recognize a deferred tax liability for a foreign subsidiary when a foreign equity method investment becomes a subsidiary, and to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. In addition, the standard requires that an entity recognize a franchise tax that is partially based on income as an income-based tax and account for any incremental amount incurred as a non-income-based tax, evaluate when a step up in the tax basis of goodwill should be considered part of the business combination in which the book goodwill was originally recognized and when it should be considered a separate transaction, reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date, and specifies that an entity is not required to allocate the consolidated amount of current and deferred tax expense to a legal entity that is not subject to tax in its separate financial statements; however, an entity may elect to do so (on an entity-by-entity basis) for a legal entity that is both not subject to tax and disregarded by the taxing authority. The Company’s adoption of this standard, effective as of January 3, 2021, did not have a material impact on its consolidated financial statements.
In October 2020, the FASB issued ASU No. 2020-10, Codification Improvements. The standard provides updates for technical corrections, clarifications to guidance, simplifications to wording or structure of guidance, and other minor improvements across various areas of accounting within GAAP. ASU No. 2020-10 is effective after December 15, 2020 on a retrospective basis. Early adoption is permitted. The Company’s adoption of this standard, effective as of January 3, 2021, did not have a material impact on its consolidated financial statements.
Recently Issued Accounting Pronouncements
In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (ASU 2020-04). The new standard provides temporary optional expedients and exceptions to the guidance in GAAP on contract modifications and hedge accounting to ease the financial reporting burdens related to the expected market transition from the London Interbank Offered Rate (LIBOR) and other interbank offered rates to alternative reference rates, such as the Secured Overnight Financing Rate (SOFR). Entities can make a one-time election to sell and/or reclassify held-to-maturity debt securities that reference an interest rate affected by reference rate reform. ASU 2020-04 is effective beginning on March 12, 2020, and the Company may elect to apply this standard prospectively through December 31, 2022. The relief is temporary and generally cannot be applied to contract modifications that occur after December 31, 2022 or hedging relationships entered into or evaluated after that date. However, certain optional expedients can be applied to hedging relationships evaluated in periods after December 31, 2022. The Company is currently evaluating the expected impact of this standard, but does not expect it to have a material impact on its consolidated financial statements upon adoption.
In January 2021, the FASB issued ASU No. 2021-01, Reference Rate Reform (Topic 848): Scope (ASU 2021-01). The new standard clarified the scope and application of the original guidance. ASU No. 2021-01 is effective as of March 12, 2020 through December 31, 2022 and may be applied to contract modifications and hedging relationships from the beginning of an interim period that includes or is subsequent to March 12, 2020. The Company is currently evaluating the expected impact of this standard, but does not expect it to have a material impact on its consolidated financial statements upon adoption.
In May 2021, the FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt - Modifications and Extinguishments (Subtopic 470-50), Compensation - Stock Compensation (Topic 718), and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (ASU 2021-04). The new standard addresses modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another topic. ASU No. 2021-04 is effective after December 15, 2021 on a prospective basis, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period and should be applied as of the beginning of the fiscal year that includes the interim period. The Company is currently evaluating the expected impact of this standard, but does not expect it to have a material impact on its consolidated financial statements upon adoption.
In July 2021, the FASB issued ASU No. 2021-05, Leases (Topic 842), Lessors - Certain Leases with Variable Lease Payments (ASU 2021-05). This new standard amends the original ASU No. 2016-02 lease standard by requiring lessors to classify leases as operating leases if they have variable lease payments that do not depend on an index or rate and would have selling losses at lease commencement if they were classified as sales-type. ASU 2021-05 is effective for annual reporting periods beginning after December 15, 2021, and for interim periods within those years, and may be adopted either prospectively or on a retrospective basis for leases that commenced or were modified after the date of initial adoption of ASC 842. Early adoption is permitted. The Company is currently evaluating the expected impact of this standard on its consolidated financial statements upon adoption, but anticipates that, among other things, the classification of certain leases for which the Company is the lessor will change from sales-type leases to operating leases under this new standard, resulting in the initial deferral and subsequent expensing of equipment costs over time under certain leases that are currently recognized immediately upon lease commencement. Similarly, any revenue that is currently recognized for these leases on the date of lease commencement will now be recognized over the term of the operating lease upon adoption of this new standard. The Company currently expects to complete its assessment of the full financial impact of this new standard during the next three to six months.
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies (Tables)
 9 Months Ended
Oct. 02, 2021
Accounting Policies [Abstract]  
Property, Plant and Equipment
Property and equipment are stated at cost. Depreciation is calculated using the straight-line method over estimated useful lives as follows:
Useful Lives
Building and building improvements
7 to 39 years
Computer equipment and software
2 to 12 years
Demonstration units3 years
Furniture and office equipment
2 to 6 years
Leasehold improvementsLesser of useful life or term of lease
Machinery, equipment and tooling
3 to 10 years
Transportation, vehicles and other
4 to 20 years
Property and equipment, net, consists of the following (in thousands):
October 2,
2021		January 2,
2021
Building and building improvements$141,990 $122,310 
Machinery, equipment and tooling101,833 90,843 
Land56,938 57,151 
Transportation, vehicles and other33,114 33,175 
Computer equipment and software32,131 24,693 
Leasehold improvements20,885 19,295 
Furniture and office equipment14,186 13,567 
Demonstration units1,049 1,024 
Construction-in-progress (CIP)23,955 44,589 
     Total property and equipment426,081 406,647 
Accumulated depreciation(151,152)(134,136)
     Property and equipment, net$274,929 $272,511 
Changes in Product Warranty Accrual
Changes in the product warranty accrual were as follows (in thousands):
Nine Months Ended
October 2,
2021		September 26,
2020
Warranty accrual, beginning of period$2,740 $3,395 
Accrual for warranties issued3,442 428 
Changes in pre-existing warranties (including changes in estimates)(2,347)(97)
Settlements made(891)(883)
Warranty accrual, end of period$2,944 $2,843 
Reconciliation of Basic and Diluted Net Income Per Share
A computation of basic and diluted net income per share is as follows (in thousands, except per share data):
Three Months EndedNine Months Ended
October 2,
2021		September 26,
2020		October 2,
2021		September 26,
2020
Net income$57,771 $49,405 $161,389 $169,633 
Basic net income per share:
Weighted-average shares outstanding - basic55,143 54,997 55,125 54,543 
Net income per basic share$1.05 $0.90 $2.93 $3.11 
Diluted net income per share:
Weighted-average shares outstanding - basic55,143 54,997 55,125 54,543 
Diluted share equivalent: stock options, RSUs and PSUs2,521 3,283 2,526 3,490 
Weighted-average shares outstanding - diluted57,664 58,280 57,651 58,033 
Net income per diluted share$1.00 $0.85 $2.80 $2.92 
Supplemental Cash Flow Information
Supplemental cash flow information includes the following (in thousands):
Nine Months Ended
October 2,
2021		September 26,
2020
Cash paid during the year for:
Interest expense
$202 $194 
Income taxes
36,898 35,961 
Operating lease liabilities
5,567 4,699 
Non-cash operating activities:
ROU assets obtained in exchange for lease liabilities
$4,917 $9,900 
Non-cash investing activities:
Unpaid purchases of property and equipment$3,182 $3,988 
       Settlement of promissory note receivable in connection with business combination— 5,100 
Unpaid strategic investments3,400 — 
Deposit release to acquire noncontrolling interest(1)
3,374 — 
Non-cash financing activities:
       Unsettled common stock proceeds from option exercises$112 $27 
       Fair value of common stock received for payment of stock option exercise price— 220 
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents
$652,354 $669,056 
Restricted cash
1,581 3,384 
Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows$653,935 $672,440 
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.21.2
Inventories (Tables)
 9 Months Ended
Oct. 02, 2021
Inventory Disclosure [Abstract]  
Components of Inventory
Inventories consist of the following (in thousands):
October 2,
2021		January 2,
2021
Raw materials$121,593 $133,098 
Work-in-process14,383 15,985 
Finished goods66,352 66,869 
     Total inventories$202,328 $215,952 
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.21.2
Other Current Assets (Tables)
 9 Months Ended
Oct. 02, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Schedule of Other Non-Current Assets
Other current assets consist of the following (in thousands):
October 2,
2021		January 2,
2021
Prepaid expenses$30,351 $30,235 
Lease receivable, current26,685 23,206 
Prepaid income taxes15,501 14,782 
Indirect taxes receivable10,715 14,545 
Prepaid rebates and royalties, current3,066 3,081 
Restricted cash(1)
1,496 3,397 
Customer notes receivable1,359 2,283 
Deposit to acquire noncontrolling interest(2)
— 3,374 
Other current assets2,599 7,513 
     Total other current assets$91,772 $102,416 
______________
(1)     Restricted cash includes funds received from the Bill and Melinda Gates Foundation. As the Company incurs costs associated with research and development related to this project, on a quarterly basis, the Company reclasses amounts from the grant to offset costs incurred.
(2)     During the year ended January 2, 2021, the Company obtained a controlling interest in a provider of advanced hemodynamic monitoring solutions. The Company made a deposit to acquire the noncontrolling interest of the acquiree. During the first quarter of 2021, the Company acquired the remaining noncontrolling interest. The impact of the noncontrolling interest is immaterial in all periods presented.
Other non-current assets consist of the following (in thousands):
October 2,
2021		January 2,
2021
Lessee ROU assets, net$31,561 $32,324 
Strategic investments13,928 8,002 
Prepaid deposits and other4,397 4,316 
Total other non-current assets$49,886 $44,642 
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.21.2
Lease Receivable (Tables)
 9 Months Ended
Oct. 02, 2021
Leases [Abstract]  
Sale-Type Lease Receivable
Lease receivable consists of the following (in thousands):
October 2,
2021		January 2,
2021
Lease receivable$93,879 $81,074 
Allowance for credit loss(239)(202)
     Lease receivable, net93,640 80,872 
Less: current portion of lease receivable(26,685)(23,206)
     Lease receivable, noncurrent$66,955 $57,666 
Sales-type Lease, Lease Receivable, Maturity
As of October 2, 2021, estimated future maturities of customer sales-type lease receivables for each of the following fiscal years are as follows (in thousands):
Fiscal yearAmount
2021 (balance of year)$6,888 
202225,995 
202321,371 
202417,349 
202511,535 
Thereafter10,502 
    Total$93,640 
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.21.2
Deferred Costs and Other Contract Assets (Tables)
 9 Months Ended
Oct. 02, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Schedule of Deferred Costs and Other Contract Assets
Deferred costs and other contract assets consist of the following (in thousands):
October 2,
2021		January 2,
2021
Deferred commissions$9,976 $7,477 
Prepaid contract allowances6,820 7,336 
Unbilled contract receivables4,317 3,925 
Equipment leased to customers, net1,486 1,338 
     Deferred costs and other contract assets$22,599 $20,076 
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.21.2
Property and Equipment (Tables)
 9 Months Ended
Oct. 02, 2021
Property, Plant and Equipment [Abstract]  
Schedule of Property, Plant and Equipment
Property and equipment are stated at cost. Depreciation is calculated using the straight-line method over estimated useful lives as follows:
Useful Lives
Building and building improvements
7 to 39 years
Computer equipment and software
2 to 12 years
Demonstration units3 years
Furniture and office equipment
2 to 6 years
Leasehold improvementsLesser of useful life or term of lease
Machinery, equipment and tooling
3 to 10 years
Transportation, vehicles and other
4 to 20 years
Property and equipment, net, consists of the following (in thousands):
October 2,
2021		January 2,
2021
Building and building improvements$141,990 $122,310 
Machinery, equipment and tooling101,833 90,843 
Land56,938 57,151 
Transportation, vehicles and other33,114 33,175 
Computer equipment and software32,131 24,693 
Leasehold improvements20,885 19,295 
Furniture and office equipment14,186 13,567 
Demonstration units1,049 1,024 
Construction-in-progress (CIP)23,955 44,589 
     Total property and equipment426,081 406,647 
Accumulated depreciation(151,152)(134,136)
     Property and equipment, net$274,929 $272,511 
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.21.2
Intangible Assets (Tables)
 9 Months Ended
Oct. 02, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Finite-Lived Intangible Assets
Intangible assets, net, consist of the following (in thousands):
October 2,
2021		January 2,
2021
Patents$30,528 $26,875 
Acquired technologies28,567 29,039 
Customer relationships24,636 24,666 
Trademarks12,080 11,708 
Licenses8,108 5,108 
Licenses-related party7,500 7,500 
Other6,257 5,693 
     Total intangible assets117,676 110,589 
Accumulated amortization(43,587)(36,666)
     Intangible assets, net$74,089 $73,923 
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense
Estimated amortization expense for each of the next fiscal years is as follows (in thousands):
Fiscal yearAmount
2021 (balance of year)$9,211 
20228,377 
20237,964 
20247,352 
20256,274 
Thereafter34,911 
     Total$74,089 
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.21.2
Goodwill (Table)
 9 Months Ended
Oct. 02, 2021
Goodwill [Abstract]  
Schedule of Goodwill
Changes in goodwill were as follows (in thousands):
Nine Months Ended
October 2,
2021
Goodwill, beginning of period$103,206 
Foreign currency translation adjustment(1,964)
Goodwill, end of period$101,242 
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.21.2
Lessee ROU Assets and Lease Liabilities (Tables)
 9 Months Ended
Oct. 02, 2021
Leases [Abstract]  
Lessee Operating Lease Balance Sheet Classification
The balance sheet classifications for amounts related to the Company’s operating leases for which it is the lessee are as follows (in thousands):
Balance sheet classificationOctober 2,
2021		January 2,
2021
Lessee ROU assetsOther non-current assets$31,561 $32,324 
Lessee current lease liabilitiesOther current liabilities6,147 5,975 
Lessee non-current lease liabilitiesOther non-current liabilities27,471 28,373 
     Total operating lease liabilities$33,618 $34,348 
Lessee, Operating Lease, Liability, Maturity
As of October 2, 2021, estimated future operating lease payments for each of the following fiscal years were as follows (in thousands):
Fiscal yearAmount
2021 (balance of year)$1,509 
20227,093 
20236,649 
20245,123 
20253,998 
Thereafter(1)
12,317 
   Total36,689 
   Imputed interest(3,071)
   Present value$33,618 
______________
(1)     Includes optional renewal period for certain leases.
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.21.2
Other Non-Current Assets (Tables)
 9 Months Ended
Oct. 02, 2021
Other Assets, Longterm [Abstract]  
Schedule of Other Non-Current Assets
Other current assets consist of the following (in thousands):
October 2,
2021		January 2,
2021
Prepaid expenses$30,351 $30,235 
Lease receivable, current26,685 23,206 
Prepaid income taxes15,501 14,782 
Indirect taxes receivable10,715 14,545 
Prepaid rebates and royalties, current3,066 3,081 
Restricted cash(1)
1,496 3,397 
Customer notes receivable1,359 2,283 
Deposit to acquire noncontrolling interest(2)
— 3,374 
Other current assets2,599 7,513 
     Total other current assets$91,772 $102,416 
______________
(1)     Restricted cash includes funds received from the Bill and Melinda Gates Foundation. As the Company incurs costs associated with research and development related to this project, on a quarterly basis, the Company reclasses amounts from the grant to offset costs incurred.
(2)     During the year ended January 2, 2021, the Company obtained a controlling interest in a provider of advanced hemodynamic monitoring solutions. The Company made a deposit to acquire the noncontrolling interest of the acquiree. During the first quarter of 2021, the Company acquired the remaining noncontrolling interest. The impact of the noncontrolling interest is immaterial in all periods presented.
Other non-current assets consist of the following (in thousands):
October 2,
2021		January 2,
2021
Lessee ROU assets, net$31,561 $32,324 
Strategic investments13,928 8,002 
Prepaid deposits and other4,397 4,316 
Total other non-current assets$49,886 $44,642 
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.21.2
Deferred Revenue and Other Contract Liabilities (Tables)
 9 Months Ended
Oct. 02, 2021
Revenue Recognition and Deferred Revenue [Abstract]  
Contract with Customer, Asset and Liability
Deferred revenue and other contract liabilities consist of the following (in thousands):
October 2,
2021		January 2,
2021
Deferred revenue$34,392 $33,221 
Accrued rebates and allowances11,322 12,127 
Accrued customer reimbursements4,744 3,829 
     Total deferred revenue and other contract liabilities50,458 49,177 
Less: Non-current portion of deferred revenue(3,817)(4,242)
     Deferred revenue and other contract liabilities - current$46,641 $44,935 
Changes in deferred revenue were as follows (in thousands):
Nine Months Ended
October 2,
2021
Deferred revenue, beginning of the period$33,221 
  Revenue deferred during the period23,425 
  Recognition of revenue deferred in prior periods(22,254)
     Deferred revenue, end of the period$34,392 
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.21.2
Other Current Liabilities (Tables)
 9 Months Ended
Oct. 02, 2021
Accrued Liabilities [Abstract]  
Schedule Other Current Liabilities
Other current liabilities consist of the following (in thousands):
October 2,
2021		January 2,
2021
Accrued indirect taxes payable$12,081 $14,365 
Accrued expenses12,046 6,794 
Lessee lease liabilities, current 6,147 5,975 
Income tax payable4,443 5,910 
Accrued legal fees3,947 4,058 
Related party payables3,446 3,655 
Accrued warranty2,944 2,740 
Accrued property taxes1,686 1,682 
Accrued donations1,307 495 
Other current liabilities3,071 4,096 
Noncontrolling interest(1)
— 3,469 
     Total other current liabilities$51,118 $53,239 
______________
(1)During the year ended January 2, 2021, the Company obtained a controlling interest in a provider of advanced hemodynamic monitoring solutions. The noncontrolling interest of the acquiree was recorded within other current liabilities as of January 2, 2021, as the noncontrolling interest shares were mandatorily redeemable. During the first quarter of 2021, the Company acquired the remaining noncontrolling interest. The impact of the noncontrolling interest is immaterial in all periods presented.
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.21.2
Other Non-Current Liabilities (Tables)
 9 Months Ended
Oct. 02, 2021
Other Liabilities, Long Term [Abstract]  
Schedule of Components Of Other Liabilities Long Term Table
Other non-current liabilities consist of the following (in thousands):
October 2,
2021		January 2,
2021
Lessee non-current lease liabilities$27,471 $28,373 
Income tax payable, non-current16,980 19,245 
Unrecognized tax benefits15,352 11,777 
Deferred tax liabilities6,063 6,247 
Other4,511 5,434 
     Total other non-current liabilities$70,377 $71,076 
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-Based Compensation (Tables)
 9 Months Ended
Oct. 02, 2021
Share-based Payment Arrangement [Abstract]  
Schedule of Number and Weighted Average Exercise Price of Options Issued and Outstanding under all Stock Option Plans
The number and weighted-average exercise price of options issued and outstanding under all of the Company’s equity plans are as follows (in thousands, except for weighted-average exercise prices):
Nine Months Ended
October 2, 2021
SharesWeighted-Average
Exercise Price
Options outstanding, beginning of period3,448 $77.44 
Granted85 250.15 
Canceled(150)146.62 
Exercised(278)57.88 
Options outstanding, end of period3,105 $80.55 
Options exercisable, end of period2,255 $55.57 
Schedule of Share-based Compensation, Restricted Stock Units Award Activity
The number of RSUs issued and outstanding under all of the Company’s equity plans are as follows (in thousands, except for weighted-average grant date fair value amounts):
Nine Months Ended
October 2, 2021
UnitsWeighted-Average Grant
 Date Fair Value
RSUs outstanding, beginning of period2,862 $99.66 
Granted89 248.57 
Canceled(17)199.02 
Expired— — 
Vested(34)163.57 
RSUs outstanding, end of period2,900 $102.88 
Schedule of Nonvested Performance-based Units Activity
The number of PSUs outstanding under all of the Company’s equity plans are as follows (in thousands, except for weighted-average grant date fair value amounts):
Nine Months Ended
October 2, 2021
UnitsWeighted-Average Grant
 Date Fair Value
PSUs outstanding, beginning of period444 $120.28 
Granted(1)
148 162.99 
Canceled(17)166.84 
Expired— — 
Vested(273)86.95 
PSUs outstanding, end of period302 $168.68 
______________
(1)     On February 22, 2021, the Audit Committee approved the weighted payout percentage for the 2018 PSU awards (three-year performance period), which were based upon the actual fiscal 2020 performance against pre-established performance objectives. Included in the granted amount are those additional PSUs earned based on actual performance achieved. These PSUs were originally awarded at target.
Schedule of Range of Assumptions Used and Resulting Weighted-Average Fair Value of Options Granted at Date of Grant The range of assumptions used and the resulting weighted-average fair value of options granted at the date of grant were as follows:
Three Months EndedNine Months Ended
October 2,
2021(1)
September 26,
2020		October 2,
2021		September 26,
2020
Risk-free interest rate
—%
0.2% to 0.3%
0.3% to 0.9%
0.2% to 1.7%
Expected term (in years)0.05.15.65.1
Estimated volatility
—%
32.7% to 33.6%
30.9% to 34.7%
26.9% to 35.5%
Expected dividends0%0%0%0%
Weighted-average fair value of options granted$—$66.24$75.72$50.39
__________________
(1)    No stock options were granted during the three months ended October 2, 2021.
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.21.2
Non-operating income (Tables)
 9 Months Ended
Oct. 02, 2021
Nonoperating Income (Expense) [Abstract]  
Schedule of Other Nonoperating Income (Expense)
Non-operating (loss) income consists of the following (in thousands):
Three Months EndedNine Months Ended
October 2,
2021		September 26,
2020		October 2,
2021		September 26,
2020
Interest income$242 $797 $677 $5,120 
Interest expense(87)(84)(259)(250)
Realized and unrealized foreign currency (losses) gains(233)647 (1,153)1,246 
Other — (3)— (8)
Total
$(78)$1,357 $(735)$6,108 
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.21.2
Segment Information and Enterprise Reporting (Tables)
 9 Months Ended
Oct. 02, 2021
Segment Reporting [Abstract]  
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area
The following schedule presents an analysis of the Company’s product revenues based upon the geographic area to which the product was shipped (in thousands, except percentages):
Three Months EndedNine Months Ended
October 2,
2021		September 26,
2020		October 2,
2021		September 26,
2020
Geographic area by destination:
United States (U.S.)$207,060 67.4 %$186,919 67.2 %$613,197 67.3 %$571,158 67.3 %
Europe, Middle East and Africa56,223 18.3 54,257 19.5 177,053 19.4 176,781 20.8 
Asia and Australia34,878 11.3 27,583 9.9 94,134 10.3 73,155 8.6 
North and South America (excluding the U.S.)9,252 3.0 9,353 3.4 27,190 3.0 27,596 3.3 
     Product revenue$307,413 100.0 %$278,112 100.0 %$911,574 100.0 %$848,690 100.0 %
Schedule of Long-lived Assets by Geographic Areas
The Company’s consolidated long-lived assets (tangible non-current assets) by geographic area are (in thousands, except percentages):
October 2,
2021		January 2,
2021
Long-lived assets by geographic area:
United States$239,435 86.6 %$238,094 86.9 %
International36,980 13.4 35,755 13.1 
     Total long-lived assets$276,415 100.0 %$273,849 100.0 %
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies - Revenue, Performance Obligation (Details)
Oct. 02, 2021
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01  
Summary Of Significant Accounting Policies [Line Items]  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period 12 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-07-03 | Minimum  
Summary Of Significant Accounting Policies [Line Items]  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period 3 years
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-10-01  
Summary Of Significant Accounting Policies [Line Items]  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period 1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-07-03 | Maximum  
Summary Of Significant Accounting Policies [Line Items]  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period 6 years
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies - Changes in Product Warranty Accrual (Detail) - USD ($)
$ in Thousands
 9 Months Ended
Oct. 02, 2021
Sep. 26, 2020
Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]    
Warranty accrual, beginning of period $ 2,740 $ 3,395
Accrual for warranties issued 3,442 428
Changes in pre-existing warranties (including changes in estimates) (2,347) (97)
Settlements made (891) (883)
Warranty accrual, end of period $ 2,944 $ 2,843
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies - Reconciliation of Basic and Diluted Net Income Per Share (Detail) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Oct. 02, 2021
Jul. 03, 2021
Apr. 03, 2021
Sep. 26, 2020
Jun. 27, 2020
Mar. 28, 2020
Oct. 02, 2021
Sep. 26, 2020
Net income attributable to stockholders of Masimo Corporation:                
Net income $ 57,771 $ 50,235 $ 53,383 $ 49,405 $ 55,772 $ 64,456 $ 161,389 $ 169,633
Basic net income per share:                
Weighted-average shares outstanding - basic 55,143     54,997     55,125 54,543
Net income per basic share $ 1.05     $ 0.90     $ 2.93 $ 3.11
Diluted net income per share:                
Weighted-average shares outstanding - basic 55,143     54,997     55,125 54,543
Diluted share equivalent: stock options, RSUs and PSUs 2,521     3,283     2,526 3,490
Weighted-average shares outstanding - diluted 57,664     58,280     57,651 58,033
Net income per diluted share $ 1.00     $ 0.85     $ 2.80 $ 2.92
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies - Supplemental Cash Flow Information (Detail) - USD ($)
 9 Months Ended
Oct. 02, 2021
Sep. 26, 2020
Jan. 02, 2021
Dec. 28, 2019
Accounting Policies [Abstract]        
Interest expense $ 202,000 $ 194,000    
Income taxes 36,898,000 35,961,000    
Operating lease liabilities 5,567,000 4,699,000    
ROU assets obtained in exchange for lease liabilities 4,917,000 9,900,000    
Unpaid purchases of property and equipment 3,182,000 3,988,000    
Settlement of promissory note receivable in connection with business combination $ 0 5,100,000    
Transfer to Investments 3,400      
Deposit release to acquire noncontrolling interest(1) $ 3,374,000 0    
Unsettled common stock proceeds from option exercises 112,000 27,000    
Fair value of common stock received for payment of stock option exercise price 0 220,000    
Cash and cash equivalents 652,354,000 669,056,000 $ 641,447,000  
Restricted cash 1,581,000 3,384,000    
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $ 653,935,000 $ 672,440,000 $ 645,004,000 $ 568,075,000
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies - Additional Information (Detail)
shares in Thousands
 3 Months Ended 9 Months Ended
Oct. 02, 2021
shares
Sep. 26, 2020
shares
Oct. 02, 2021
segment
shares
Sep. 26, 2020
shares
Summary Of Significant Accounting Policies [Line Items]        
Number of Sources of Product Revenue | segment     4  
Options to purchase of shares of common stock 100 100 200 300
Patents        
Summary Of Significant Accounting Policies [Line Items]        
Finite-Lived Intangible Asset, Useful Life     10 years  
Trademarks        
Summary Of Significant Accounting Policies [Line Items]        
Finite-Lived Intangible Asset, Useful Life     17 years  
Demonstration units        
Summary Of Significant Accounting Policies [Line Items]        
Property, Plant and Equipment, Useful Life     3 years  
Restricted Stock Units (RSUs)        
Summary Of Significant Accounting Policies [Line Items]        
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period     89  
Restricted Stock Units (RSUs) | Chief Executive Officer        
Summary Of Significant Accounting Policies [Line Items]        
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period     2,700 2,700
Minimum        
Summary Of Significant Accounting Policies [Line Items]        
Warranty period for defects in material and workmanship     6 months  
Minimum | Building and building improvements        
Summary Of Significant Accounting Policies [Line Items]        
Property, Plant and Equipment, Useful Life     7 years  
Minimum | Computer equipment and software        
Summary Of Significant Accounting Policies [Line Items]        
Property, Plant and Equipment, Useful Life     2 years  
Minimum | Furniture and office equipment        
Summary Of Significant Accounting Policies [Line Items]        
Property, Plant and Equipment, Useful Life     2 years  
Minimum | Machinery, equipment and tooling        
Summary Of Significant Accounting Policies [Line Items]        
Property, Plant and Equipment, Useful Life     3 years  
Minimum | Transportation, vehicles and other        
Summary Of Significant Accounting Policies [Line Items]        
Property, Plant and Equipment, Useful Life     4 years  
Maximum        
Summary Of Significant Accounting Policies [Line Items]        
Warranty period for defects in material and workmanship     48 months  
Maximum | Building and building improvements        
Summary Of Significant Accounting Policies [Line Items]        
Property, Plant and Equipment, Useful Life     39 years  
Maximum | Computer equipment and software        
Summary Of Significant Accounting Policies [Line Items]        
Property, Plant and Equipment, Useful Life     12 years  
Maximum | Furniture and office equipment        
Summary Of Significant Accounting Policies [Line Items]        
Property, Plant and Equipment, Useful Life     6 years  
Maximum | Machinery, equipment and tooling        
Summary Of Significant Accounting Policies [Line Items]        
Property, Plant and Equipment, Useful Life     10 years  
Maximum | Transportation, vehicles and other        
Summary Of Significant Accounting Policies [Line Items]        
Property, Plant and Equipment, Useful Life     20 years  
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.21.2
Related Party Transactions Related Party Transactions - (Details)
 3 Months Ended 9 Months Ended
Jul. 08, 2021
USD ($)
Oct. 02, 2021
USD ($)
Sep. 26, 2020
USD ($)
Oct. 02, 2021
USD ($)
ft²
Sep. 26, 2020
USD ($)
Jan. 02, 2021
USD ($)
Related Party Transaction [Line Items]            
Related Party Transactions Disclosure      
3. Related Party Transactions
The Company’s Chairman and Chief Executive Officer (CEO) is also the Chairman and CEO of Cercacor Laboratories, Inc. (Cercacor). The Company is a party to the following agreements with Cercacor:
•Cross-Licensing Agreement - The Company and Cercacor are parties to a cross-licensing agreement (Cross-Licensing Agreement), which governs each party’s rights to certain intellectual property held by the two companies. The Company is subject to certain annual minimum aggregate royalty obligations for use of the rainbow® licensed technology. The current annual minimum royalty obligation is $5.0 million. Aggregate liabilities payable to Cercacor arising under the Cross-Licensing Agreement were $2.9 million and $3.5 million for the three months ended October 2, 2021 and September 26, 2020, respectively. Aggregate liabilities payable to Cercacor arising under the Cross-Licensing Agreement were $9.6 million and $9.7 million for the nine months ended October 2, 2021 and September 26, 2020, respectively.
•Administrative Services Agreement - The Company is a party to an administrative services agreement with Cercacor (G&A Services Agreement), which governs certain general and administrative services that the Company provides to Cercacor. Amounts charged by the Company pursuant to the G&A Services Agreement were less than $0.1 million for each of the three months ended October 2, 2021 and September 26, 2020. Amounts charged by the Company pursuant to the G&A Services Agreement were $0.2 million for each of the nine months ended October 2, 2021 and September 26, 2020.
•Lease and Sublease Agreements - Effective December 2019, the Company entered into a lease agreement with Cercacor for approximately 34,000 square feet of office, research and development space at one of the Company’s owned facilities in Irvine (Cercacor Lease). The term of the Cercacor Lease expires on December 31, 2024. In March 2016, the Company entered into a sublease agreement with Cercacor for approximately 16,830 square feet of excess office and laboratory space located at 40 Parker, Irvine, California (Cercacor Sublease). The Cercacor Sublease began on May 1, 2016 and expired on December 15, 2019. The Company recognized approximately $0.3 million of lease income for each of the three months ended October 2, 2021 and September 26, 2020. The Company recognized approximately $0.9 million and $0.8 million of lease income for the nine months ended October 2, 2021 and September 26, 2020, respectively.
Net amounts due to Cercacor at October 2, 2021 and January 2, 2021 were approximately $3.3 million and $3.6 million, respectively.
The Company’s CEO is also the Chairman of the Masimo Foundation for Ethics, Innovation and Competition in Healthcare (Masimo Foundation), a non-profit organization that was founded in 2010 to provide a platform for encouraging ethics, innovation and competition in healthcare. In addition, the Company’s Executive Vice President (EVP), Chief Financial Officer (CFO) serves as the Treasurer of the Masimo Foundation and the Company’s EVP, General Counsel and Corporate Secretary serves as the Secretary for the Masimo Foundation. During the three months ended October 2, 2021 and September 26, 2020, the Company made no cash contributions to the Masimo Foundation. During the nine months ended October 2, 2021, the Company made no contributions to the Masimo Foundation. During the nine months ended September 26, 2020, the Company made cash contributions of approximately $1.5 million to the Masimo Foundation.
During the three and nine months ended October 2, 2021 and September 26, 2020, the Company made various in-kind contributions to the Masimo Foundation, mainly in the form of donated administrative services.
The Company’s CEO is also a co-founder and a member of the board of directors of Like Minded Media Ventures (LMMV), a team of storytellers that create content focused in the areas of true stories, social causes and science. LMMV creates stories with a multi-platform strategy, bridging the gap between film, television, digital and social media. The Company entered into a marketing service agreement with LMMV for audiovisual production services promoting brand awareness, including television commercials and digital advertising, during the second quarter of 2020. During the three and nine months ended October 2, 2021, the Company incurred no marketing expenses to LMMV under the marketing service agreement. During the three and nine months ended September 26, 2020, the Company incurred $0.2 million and $3.5 million, respectively, in marketing expenses to LMMV under the marketing service agreement. At October 2, 2021 and January 2, 2021, there was no amount due to LMMV for services rendered.
The Company entered into a software license and professional services agreement with Like Minded Labs (LML), a subsidiary of LMMV, during the second quarter of 2021. Pursuant to the software license agreement, LML granted the Company a perpetual, non-exclusive and fully paid-up right and license to integrate LML’s software into the Company’s products in exchange for a $3.0 million one-time license fee. Pursuant to the professional services agreement, LML will provide professional services to the Company, including the development of custom software intended to support the integration of the licensed software into the Company’s products, as well as future support services upon the Company’s acceptance of deliverables.
In July 2021, the Company entered into a patent purchase and option agreement with Vantrix Corporation (Vantrix), an acquiree of LML, for certain patents for $0.5 million, and the right to purchase two pools of additional patents from Vantrix for an exercise fee of up to $1.1 million. The agreements with LML and Vantrix include sublicensing provisions whereby the software and patents are licensed back to LML or Vantrix, respectively, for further advancement of the technologies.
The Company maintains an aircraft time share agreement, pursuant to which the Company has agreed from time to time to make its aircraft available to the Company’s CEO for lease on a time-sharing basis. The Company charges the Company’s CEO for personal use based on agreed upon reimbursement rates. For each of the three and nine months ended October 2, 2021 and September 26, 2020, the Company charged the Company’s CEO less than $0.1 million related to such disbursements.
    
Cercacor Laboratories            
Related Party Transaction [Line Items]            
Payments for Royalties   $ 2,900,000 $ 3,500,000 $ 9,600,000 $ 9,700,000  
Payment for Administrative Fees   100,000 100,000 $ 200,000 200,000  
Related Party Transaction, Date       Dec. 31, 2024    
Sublease Income   300,000 300,000 $ 900,000 800,000  
Related Party Transaction, Due from (to) Related Party   (3,300,000)   $ (3,300,000)   $ (3,600,000)
Leased Property            
Related Party Transaction [Line Items]            
Property Plant and Equipment, Occupied Square Feet | ft²       34,000    
Subleased Property            
Related Party Transaction [Line Items]            
Property Plant and Equipment, Occupied Square Feet | ft²       16,830    
Not for Profit Organization            
Related Party Transaction [Line Items]            
Related Party Transaction, Amounts of Transaction   0 0 $ 0 1,500,000  
Like Minded Media Ventures            
Related Party Transaction [Line Items]            
Related Party Transaction, Due from (to) Related Party   0   0   $ 0
Related Party Transaction, Expenses from Transactions with Related Party   0 200,000 0 3,500,000  
Reimbursement Fee            
Related Party Transaction [Line Items]            
Related Party Transaction, Expenses from Transactions with Related Party   100,000 $ 100,000 100,000 $ 100,000  
Like Minded Labs            
Related Party Transaction [Line Items]            
Finite-Lived License Agreements, Gross   $ 3,000,000   3,000,000    
Vantrix Corp | Purchase Commitment            
Related Party Transaction [Line Items]            
Related Party Transaction, Purchases from Related Party $ 500,000          
Vantrix Corp | Options Held            
Related Party Transaction [Line Items]            
Related Party Transaction, Purchases from Related Party $ 1,100,000          
Minimum            
Related Party Transaction [Line Items]            
Payments for Royalties       $ 5,000,000    
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.21.2
Inventories - Components of Inventory (Details) - USD ($)
$ in Thousands
Oct. 02, 2021
Jan. 02, 2021
Inventory Disclosure [Abstract]    
Raw materials $ 121,593 $ 133,098
Work-in-process 14,383 15,985
Finished goods 66,352 66,869
Total inventories $ 202,328 $ 215,952
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.21.2
Other Current Assets (Details) - USD ($)
Oct. 02, 2021
Jan. 02, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
Prepaid expenses $ 30,351,000 $ 30,235,000
Lease receivable, current 26,685,000 23,206,000
Prepaid income taxes 15,501,000 14,782,000
Indirect taxes receivable 10,715,000 14,545,000
Prepaid rebates and royalties, current 3,066,000 3,081,000
Restricted cash(1) 1,496,000 3,397,000
Customer notes receivable 1,359,000 2,283,000
Deposit to acquire noncontrolling interest(2) 0 3,374,000
Other current assets 2,599,000 7,513,000
Total other current assets $ 91,772,000 $ 102,416,000
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.21.2
Lease Receivable (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Oct. 02, 2021
Sep. 26, 2020
Oct. 02, 2021
Sep. 26, 2020
Leases [Abstract]        
Operating Lease, Variable Lease Income $ 12.0 $ 13.0 $ 40.0 $ 31.0
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.21.2
Lease Receivable Sales-Type (Details) - USD ($)
$ in Thousands
Oct. 02, 2021
Jan. 02, 2021
Leases [Abstract]    
Lease receivable $ 93,879 $ 81,074
Allowance for credit loss (239) (202)
Lease receivable, net 93,640 80,872
Less: current portion of lease receivable (26,685) (23,206)
Lease receivable, noncurrent $ 66,955 $ 57,666
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.21.2
Lease Receivable Sales-type Lease, Maturity (Details) - USD ($)
$ in Thousands
Oct. 02, 2021
Jan. 02, 2021
Leases [Abstract]    
2021 (balance of year) $ 6,888  
2022 25,995  
2023 21,371  
2024 17,349  
2025 11,535  
Thereafter 10,502  
Total $ 93,640 $ 80,872
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.21.2
Deferred Costs and Other Contract Assets (Details) - USD ($)
$ in Thousands
Oct. 02, 2021
Jan. 02, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
Deferred commissions $ 9,976 $ 7,477
Prepaid contract allowances 6,820 7,336
Unbilled contract receivables 4,317 3,925
Equipment leased to customers, net 1,486 1,338
Deferred costs and other contract assets $ 22,599 $ 20,076
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.21.2
Property and Equipment (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Oct. 02, 2021
Sep. 26, 2020
Oct. 02, 2021
Sep. 26, 2020
Jan. 02, 2021
Property, Plant and Equipment [Line Items]          
Total property and equipment $ 426,081   $ 426,081   $ 406,647
Accumulated depreciation (151,152)   (151,152)   (134,136)
Property and equipment, net 274,929   274,929   272,511
Depreciation 6,500 $ 5,800 18,800 $ 16,000  
Building and building improvements          
Property, Plant and Equipment [Line Items]          
Total property and equipment 141,990   141,990   122,310
Machinery, equipment and tooling          
Property, Plant and Equipment [Line Items]          
Total property and equipment 101,833   101,833   90,843
Land          
Property, Plant and Equipment [Line Items]          
Total property and equipment 56,938   56,938   57,151
Transportation, vehicles and other          
Property, Plant and Equipment [Line Items]          
Total property and equipment 33,114   33,114   33,175
Computer equipment and software          
Property, Plant and Equipment [Line Items]          
Total property and equipment 32,131   32,131   24,693
Leasehold improvements          
Property, Plant and Equipment [Line Items]          
Total property and equipment 20,885   20,885   19,295
Furniture and office equipment          
Property, Plant and Equipment [Line Items]          
Total property and equipment 14,186   14,186   13,567
Demonstration units          
Property, Plant and Equipment [Line Items]          
Total property and equipment 1,049   1,049   1,024
Construction-in-progress (CIP)          
Property, Plant and Equipment [Line Items]          
Total property and equipment $ 23,955   $ 23,955   $ 44,589
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.21.2
Intangible Assets - Schedule of Finite-Lived Intangible Assets (Details) - USD ($)
$ in Thousands
Oct. 02, 2021
Jan. 02, 2021
Finite-Lived Intangible Assets [Line Items]    
Total intangible assets $ 117,676 $ 110,589
Accumulated amortization (43,587) (36,666)
Intangible assets, net 74,089 73,923
Patents    
Finite-Lived Intangible Assets [Line Items]    
Total intangible assets 30,528 26,875
Acquired technologies    
Finite-Lived Intangible Assets [Line Items]    
Total intangible assets 28,567 29,039
Customer relationships    
Finite-Lived Intangible Assets [Line Items]    
Total intangible assets 24,636 24,666
Trademarks    
Finite-Lived Intangible Assets [Line Items]    
Total intangible assets 12,080 11,708
Licenses-related party    
Finite-Lived Intangible Assets [Line Items]    
Total intangible assets 8,108 5,108
Licenses-related party | Cercacor Laboratories    
Finite-Lived Intangible Assets [Line Items]    
Total intangible assets 7,500 7,500
Other    
Finite-Lived Intangible Assets [Line Items]    
Total intangible assets $ 6,257 $ 5,693
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.21.2
Intangible Assets - Additional Information (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Oct. 02, 2021
Sep. 26, 2020
Oct. 02, 2021
Sep. 26, 2020
Finite-Lived Intangible Assets [Line Items]        
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life     12 years  
Amortization of Intangible Assets $ 2.7 $ 1.6 $ 7.6 $ 5.2
Patents        
Finite-Lived Intangible Assets [Line Items]        
Weighted average number of years until the next renewal     2 years  
Trademarks        
Finite-Lived Intangible Assets [Line Items]        
Weighted average number of years until the next renewal     4 years  
Patents And Trademarks        
Finite-Lived Intangible Assets [Line Items]        
Finite-Lived Intangible Assets, Cost Incurred to Renew or Extend 0.9 0.6 $ 1.3 1.2
Acquired Indefinite-lived Intangible Assets [Line Items]        
Finite-Lived Intangible Assets, Cost Incurred to Renew or Extend $ 0.9 $ 0.6 $ 1.3 $ 1.2
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.21.2
Intangible Assets - Future Amortization Expense (Details) - USD ($)
$ in Thousands
Oct. 02, 2021
Jan. 02, 2021
Goodwill and Intangible Assets Disclosure [Abstract]    
2021 (balance of year) $ 9,211  
2022 8,377  
2023 7,964  
2024 7,352  
2025 6,274  
Thereafter 34,911  
Intangible assets, net $ 74,089 $ 73,923
XML 74 R63.htm IDEA: XBRL DOCUMENT v3.21.2
Goodwill (Details) - USD ($)
$ in Thousands
 9 Months Ended
Oct. 02, 2021
Jan. 02, 2021
Goodwill [Line Items]    
Goodwill $ 101,242 $ 103,206
Foreign currency translation adjustment $ (1,964)  
XML 75 R64.htm IDEA: XBRL DOCUMENT v3.21.2
Lessee ROU Assets and Lease Liabilities (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Oct. 02, 2021
Sep. 26, 2020
Oct. 02, 2021
Sep. 26, 2020
Jan. 02, 2021
Leases [Abstract]          
Lessee, Operating Lease, Renewal Term 5 years   5 years    
Operating Lease, Weighted Average Discount Rate, Percent 2.60%   2.60%    
Operating Lease, Right-of-Use Asset, Accumulated Amortization $ 13,000   $ 13,000   $ 9,200
Operating Lease, Weighted Average Remaining Lease Term 6 years 8 months 12 days   6 years 8 months 12 days    
Operating lease costs $ 2,100 $ 1,800 $ 6,200 $ 5,200  
XML 76 R65.htm IDEA: XBRL DOCUMENT v3.21.2
Lessee ROU Assets and Lease Liabilities Lessee Operating Lease Balance Sheet Classification (Details) - USD ($)
$ in Thousands
Oct. 02, 2021
Jan. 02, 2021
Leases [Abstract]    
Lessee ROU assets, net $ 31,561 $ 32,324
Lessee lease liabilities, current 6,147 5,975
Lessee non-current lease liabilities 27,471 28,373
Present value $ 33,618 $ 34,348
XML 77 R66.htm IDEA: XBRL DOCUMENT v3.21.2
Lessee ROU Assets and Lease Liabilities Future Maturities Operating Lease Payments (Details) - USD ($)
$ in Thousands
Oct. 02, 2021
Jan. 02, 2021
Leases [Abstract]    
2021 (balance of year) $ 1,509  
2022 7,093  
2023 6,649  
2024 5,123  
2025 3,998  
Thereafter(1) 12,317  
Total 36,689  
Imputed interest (3,071)  
Present value $ 33,618 $ 34,348
XML 78 R67.htm IDEA: XBRL DOCUMENT v3.21.2
Other Non-Current Assets (Details) - USD ($)
$ in Thousands
Oct. 02, 2021
Jan. 02, 2021
Other Assets, Longterm [Abstract]    
Lessee ROU assets, net $ 31,561 $ 32,324
Strategic investments 13,928 8,002
Prepaid deposits and other 4,397 4,316
Other non-current assets $ 49,886 $ 44,642
XML 79 R68.htm IDEA: XBRL DOCUMENT v3.21.2
Deferred Revenue and Other Contract Liabilities (Details) - USD ($)
$ in Thousands
Oct. 02, 2021
Jan. 02, 2021
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Unrecognized contract revenue $ 987,300  
Deferred revenue 34,392 $ 33,221
Accrued rebates and allowances 11,322 12,127
Accrued customer reimbursements 4,744 3,829
Total deferred revenue and other contract liabilities 50,458 49,177
Less: Non-current portion of deferred revenue (3,817) (4,242)
Deferred revenue and other contract liabilities - current 46,641 $ 44,935
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Unrecognized contract revenue $ 272,700  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period 12 months  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-10-01    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period 1 year  
XML 80 R69.htm IDEA: XBRL DOCUMENT v3.21.2
Deferred Revenue and Other Contract Liabilities - Changes in Deferred Revenue (Details)
$ in Thousands
 9 Months Ended
Oct. 02, 2021
USD ($)
Movement in Deferred Revenue [Roll Forward]  
Deferred revenue, beginning of the period $ 33,221
Revenue deferred during the period 23,425
Recognition of revenue deferred in prior periods (22,254)
Deferred revenue, end of the period $ 34,392
XML 81 R70.htm IDEA: XBRL DOCUMENT v3.21.2
Other Current Liabilities (Details) - USD ($)
Oct. 02, 2021
Jan. 02, 2021
Accrued Liabilities [Abstract]    
Accrued indirect taxes payable $ 12,081,000 $ 14,365,000
Accrued expenses 12,046,000 6,794,000
Lessee lease liabilities, current 6,147,000 5,975,000
Income tax payable 4,443,000 5,910,000
Accrued legal fees 3,947,000 4,058,000
Related party payables 3,446,000 3,655,000
Accrued warranty 2,944,000 2,740,000
Accrued property taxes 1,686,000 1,682,000
Accrued donations 1,307,000 495,000
Other current liabilities 3,071,000 4,096,000
Noncontrolling interest(1) 0 3,469,000
Total other current liabilities $ 51,118,000 $ 53,239,000
XML 82 R71.htm IDEA: XBRL DOCUMENT v3.21.2
Credit Facility (Details) - USD ($)
 3 Months Ended 9 Months Ended
Oct. 02, 2021
Sep. 26, 2020
Oct. 02, 2021
Sep. 26, 2020
Jan. 02, 2021
Dec. 17, 2018
Debt Instrument [Line Items]            
Letters of Credit Outstanding, Amount $ 2,400,000   $ 2,400,000   $ 1,700,000  
Revolving Credit Facility [Member]            
Debt Instrument [Line Items]            
Line of Credit Facility, Maximum Sublimit           $ 25,000,000
Foreign Line of Credit [Member]            
Debt Instrument [Line Items]            
Line of Credit Facility, Maximum Sublimit           75,000,000
Revolving Credit Facility [Member]            
Debt Instrument [Line Items]            
Current Borrowing Capacity           150,000,000
Line of Credit Facility, Maximum Borrowing Capacity           $ 550,000,000
Long-term Line of Credit, Noncurrent 0   0   $ 0  
Interest Expense, Debt $ 100,000 $ 100,000 $ 200,000 $ 200,000    
XML 83 R72.htm IDEA: XBRL DOCUMENT v3.21.2
Other Non-Current Liabilities - (Detail) - USD ($)
$ in Thousands
Oct. 02, 2021
Jan. 02, 2021
Other Liabilities, Long Term [Abstract]    
Lessee non-current lease liabilities $ 27,471 $ 28,373
Income tax payable, non-current 16,980 19,245
Unrecognized tax benefits 15,352 11,777
Deferred tax liabilities 6,063 6,247
Other 4,511 5,434
Total other non-current liabilities $ 70,377 $ 71,076
XML 84 R73.htm IDEA: XBRL DOCUMENT v3.21.2
Stock Repurchase Program - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended 36 Months Ended
Oct. 02, 2021
Apr. 03, 2021
Sep. 26, 2020
Jun. 27, 2020
Mar. 28, 2020
Oct. 02, 2021
Sep. 26, 2020
Oct. 29, 2024
Sep. 11, 2021
Oct. 29, 2021
Jul. 01, 2018
Class of Stock [Line Items]                      
Treasury Stock, Shares, Acquired 0   0     547,000 4,000        
Treasury Stock Acquired, Average Cost Per Share $ 0   $ 0     $ 235.88 $ 164.44        
Value of shares repurchased $ 0 $ 128,917 $ 0 $ 220 $ 371 $ 128,917 $ 591        
Stock Repurchase Program          
17. Stock Repurchase Program
In October 2021, the Company’s Board of Directors (Board) approved a stock repurchase program, authorizing the Company to purchase up to 3.0 million shares of its common stock over a period of up to three years (2021 Repurchase Program). The Company expects to fund the 2021 Repurchase Program through its available cash, cash expected to be generated from future operations, the credit facility and other potential sources of capital. The 2021 Repurchase Program can be carried out at the discretion of a committee comprised of the CEO and CFO through open market purchases, one or more Rule 10b5-1 trading plans, block trades and privately negotiated transactions.
In July 2018, the Company’s Board approved a stock repurchase program, authorizing the Company to purchase up to 5.0 million additional shares of its common stock over a period of up to three years (2018 Repurchase Program). During the third quarter of 2021, the 2018 Repurchase Program expired.
The following table provides a summary of the Company’s stock repurchase activities (in thousands, except per share amounts):
Three Months EndedNine Months Ended
October 2,
2021		September 26,
2020		October 2,
2021		September 26,
2020
Shares repurchased(1)
— — 547 4 
Average cost per share$— $— $235.88 $164.44 
Value of shares repurchased$— $— $128,917 $591 
______________
(1)     Excludes shares withheld from the shares of its common stock actually issued in connection with the vesting of PSU or RSU awards to satisfy certain U.S. federal and state tax withholding obligations.
          
2021 Repurchase Program | Common Stock | Subsequent Event                      
Class of Stock [Line Items]                      
Number of common shares authorized to be repurchased under new stock repurchase program                   3,000,000  
Stock Repurchase Program, Period               3 years      
2018 Repurchase Program | Common Stock                      
Class of Stock [Line Items]                      
Number of common shares authorized to be repurchased under new stock repurchase program                     5,000,000
Stock Repurchase Program, Period                 3 years    
XML 85 R74.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-Based Compensation - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 9 Months Ended
Oct. 02, 2021
Sep. 26, 2020
Oct. 02, 2021
Sep. 26, 2020
Jan. 02, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Share-based Payment Arrangement, Expensed and Capitalized, Amount $ 12.6 $ 11.9 $ 33.5 $ 36.4  
Common Stock, Capital Shares Reserved for Future Issuance 10,700,000   10,700,000    
Options available for grant, end of period 4,400,000   4,400,000    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 3,105,000   3,105,000   3,448,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights     three years    
Aggregate intrinsic value of options outstanding $ 589.6   $ 589.6    
Aggregate intrinsic value of options exercisable 484.5   484.5    
Aggregate intrinsic value of options exercised 35.4   56.9    
Employee Stock Option          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Share-based Payment Arrangement, Expensed and Capitalized, Amount 3.2 3.8 9.9 11.9  
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount 30.7   $ 30.7    
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition     2 years 7 months 6 days    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term     5 years 3 months 18 days    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term     4 years 4 months 24 days    
Restricted Stock Units (RSUs)          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Share-based Payment Arrangement, Expensed and Capitalized, Amount 2.4 1.5 $ 6.7 4.0  
Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount $ 34.7   $ 34.7    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms     3 years 7 months 6 days    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number 2,900,000   2,900,000   2,862,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period     89,000    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period     17,000    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expired in Period     0    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $ 102.88   $ 102.88   $ 99.66
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value     248.57    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value     199.02    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value     $ 163.57    
Performance Shares          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Share-based Payment Arrangement, Expensed and Capitalized, Amount $ 7.0 $ 6.6 $ 16.9 $ 20.5  
Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount $ 41.1   $ 41.1    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms     1 year 1 month 6 days    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number 302,000   302,000   444,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period     17,000    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expired in Period     0    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $ 168.68   $ 168.68   $ 120.28
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value     162.99    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value     166.84    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value     $ 86.95    
Performance Shares | Minimum          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period     148,000    
Performance Shares | Minimum | 2021 PSU Grant [Domain]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period     68,600    
Share-based compensation arrangement by share-based payment award, range of percentage payout 0.00%   0.00%    
Performance Shares | Maximum | 2021 PSU Grant [Domain]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period     137,200    
Share-based compensation arrangement by share-based payment award, range of percentage payout 200.00%   200.00%    
Chief Executive Officer | Restricted Stock Units (RSUs)          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period     2,700,000 2,700,000  
2017 Equity Incentive Plan [Domain]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized 2,500,000        
2017 Equity Incentive Plan [Domain] | Minimum          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Options available for grant, end of period 5,000,000   5,000,000    
2017 Equity Incentive Plan [Domain] | Maximum          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Options available for grant, end of period 7,500,000   7,500,000    
2007 Stock Incentive Plan [Domain] | Maximum          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Options available for grant, end of period 5,000,000   5,000,000    
XML 86 R75.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-Based Compensation - Number and Weighted Average Exercise Price of Options Issued and Outstanding under all Stock Option Plans (Detail) - $ / shares
shares in Thousands
 9 Months Ended
Oct. 02, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]  
Options outstanding, beginning of period 3,448
Granted 85
Canceled (150)
Exercised (278)
Options outstanding, end of period 3,105
Options exercisable, end of period 2,255
Weighted-Average Exercise Price  
Options outstanding, beginning of period $ 77.44
Granted 250.15
Canceled 146.62
Exercised 57.88
Options outstanding, end of period 80.55
Options exercisable, end of period $ 55.57
XML 87 R76.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-Based Compensation Stock-Based Compensation - Summary of Unvested RSU Activity (Details) - USD ($)
$ / shares in Units, $ in Millions
 9 Months Ended
Oct. 02, 2021
Sep. 26, 2020
Jan. 02, 2021
Restricted Stock Units (RSUs)      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number 2,900,000   2,862,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 89,000    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period (17,000)    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expired in Period 0    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (34,000)    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $ 102.88   $ 99.66
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value 248.57    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 199.02    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expired, Weighed Average Grant Date Fair Value 0    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value $ 163.57    
Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount $ 34.7    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms 3 years 7 months 6 days    
Performance Shares      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number 302,000   444,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period (17,000)    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expired in Period 0    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (273,000)    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $ 168.68   $ 120.28
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value 162.99    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 166.84    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expired, Weighed Average Grant Date Fair Value 0    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value $ 86.95    
Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount $ 41.1    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms 1 year 1 month 6 days    
Chief Executive Officer | Restricted Stock Units (RSUs)      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 2,700,000 2,700,000  
XML 88 R77.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-Based Compensation - Range of Assumptions Used and Resulting Weighted-Average Fair Value of Options Granted at Date of Grant (Detail) - $ / shares
 3 Months Ended 9 Months Ended
Oct. 02, 2021
Sep. 26, 2020
Oct. 02, 2021
Sep. 26, 2020
Range of assumptions used and resulting weighted-average fair value of options granted at the date of grant        
Risk-free interest rate, minimum 0.00% 0.20% 0.30% 0.20%
Risk-free interest rate, maximum   0.30% 0.90% 1.70%
Expected term (in years) 0 years 5 years 1 month 6 days 5 years 7 months 6 days 5 years 1 month 6 days
Estimated volatility, minimum 0.00% 32.70% 30.90% 26.90%
Estimated volatility, maximum   33.60% 34.70% 35.50%
Expected dividends 0.00% 0.00% 0.00% 0.00%
Weighted-average fair value of options granted $ 0 $ 66.24 $ 75.72 $ 50.39
XML 89 R78.htm IDEA: XBRL DOCUMENT v3.21.2
Non-operating income (Detail) - USD ($)
 3 Months Ended 9 Months Ended
Oct. 02, 2021
Sep. 26, 2020
Oct. 02, 2021
Sep. 26, 2020
Nonoperating Income (Expense) [Abstract]        
Interest income $ 242,000 $ 797,000 $ 677,000 $ 5,120,000
Interest expense (87,000) (84,000) (259,000) (250,000)
Realized and unrealized foreign currency (losses) gains (233,000) 647,000 (1,153,000) 1,246,000
Other 0 (3,000) 0 (8,000)
Non-operating (loss) income $ (78,000) $ 1,357,000 $ (735,000) $ 6,108,000
XML 90 R79.htm IDEA: XBRL DOCUMENT v3.21.2
Income Taxes - Additional Information (Detail) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Oct. 02, 2021
Sep. 26, 2020
Oct. 02, 2021
Sep. 26, 2020
Income Tax Disclosure [Abstract]        
Other Tax Expense (Benefit) $ 6.4 $ 3.1 $ 12.0 $ 20.2
Gross unrecognized tax benefit 21.6   21.6  
Unrecognized tax benefit that would affect effective tax rate $ 19.6   $ 19.6  
XML 91 R80.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies - Additional Information (Detail)
 3 Months Ended 6 Months Ended 9 Months Ended
Jul. 08, 2019
USD ($)
Jul. 27, 2017
Jan. 03, 2014
USD ($)
Oct. 02, 2021
USD ($)
distributor
Customer
Agreement
Sep. 26, 2020
USD ($)
distributor
Jun. 30, 2018
USD ($)
Jun. 27, 2020
USD ($)
Oct. 02, 2021
USD ($)
distributor
Customer
Agreement
Sep. 26, 2020
USD ($)
distributor
Jan. 02, 2021
Contingencies And Commitments [Line Items]                    
Company contribution percentage based on employee contribution of up to 3% of employee's compensation               3.00%    
Company's contribution to employee retirement savings plan       $ 900,000 $ 800,000     $ 2,800,000 $ 2,400,000  
Severance plan participation agreements | Agreement       5       5    
Supplemental Unemployment Benefits, Severance Benefits, Required Notice of Resignation               6 months    
Purchase Commitment, Remaining Minimum Amount Committed       $ 155,900,000       $ 155,900,000    
Other Commitment       3,400,000       3,400,000    
Bank Balances       652,400,000       652,400,000    
Bank balance covered by Federal Deposit Insurance Corporation limit       $ 5,000,000       $ 5,000,000    
Percentage Of Revenue One Customer       15.00% 11.00%     14.60% 11.20%  
Percentage Of Revenue Two Customer       10.40% 9.30%     10.40% 10.00%  
Concentration Risk, AR Balance One Customer | Customer       1       1    
Loss Contingency, Damages Awarded, Value $ 10,500,000                  
Sales                    
Contingencies And Commitments [Line Items]                    
Concentration Risk, Just-in-time Distributors | distributor       2 2     2 2  
Accounts Receivable                    
Contingencies And Commitments [Line Items]                    
Percentage of Accounts Receivable Balance       9.40%       9.40%   9.10%
Sales Revenue, Product Line                    
Contingencies And Commitments [Line Items]                    
Percentage of Revenue - Customer Concentration       55.00% 48.10%     51.80% 49.60%  
Masimo vs Former Agency Tender                    
Contingencies And Commitments [Line Items]                    
Litigation Settlement, Expense           $ 10,500,000        
Proceeds from Legal Settlements             $ 2,000,000      
Masimo vs. Physicians Healthsource, Inc.                    
Contingencies And Commitments [Line Items]                    
Loss contingency, damages sought     $ 500              
Chief Executive Officer                    
Contingencies And Commitments [Line Items]                    
Employment Agreement, Severance Benefits, Special Payment, Qualifying Termination               $ 292,900,000    
Chief Executive Officer | Cash Distribution                    
Contingencies And Commitments [Line Items]                    
Employment Agreement, Severance Terms   50.00%                
Chief Executive Officer | Restricted Stock Units (RSUs)                    
Contingencies And Commitments [Line Items]                    
Employment Agreement, Severance Terms   50.00%                
XML 92 R81.htm IDEA: XBRL DOCUMENT v3.21.2
Segment Information and Enterprise Reporting - Analysis of Product Revenues Based upon Geographic Area Shipped (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Oct. 02, 2021
Sep. 26, 2020
Oct. 02, 2021
Sep. 26, 2020
Revenue, Major Customer [Line Items]        
Product revenue $ 307,413 $ 278,112 $ 911,574 $ 848,690
Concentration Risk, Percentage 100.00% 100.00% 100.00% 100.00%
United States (U.S.) | Reportable Geographical Components        
Revenue, Major Customer [Line Items]        
Product revenue $ 207,060 $ 186,919 $ 613,197 $ 571,158
Europe, Middle East and Africa | Reportable Geographical Components        
Revenue, Major Customer [Line Items]        
Product revenue 56,223 54,257 177,053 176,781
Asia and Australia | Reportable Geographical Components        
Revenue, Major Customer [Line Items]        
Product revenue 34,878 27,583 94,134 73,155
North and South America (excluding the U.S.) | Reportable Geographical Components        
Revenue, Major Customer [Line Items]        
Product revenue $ 9,252 $ 9,353 $ 27,190 $ 27,596
XML 93 R82.htm IDEA: XBRL DOCUMENT v3.21.2
Segment Information and Enterprise Reporting Long-lived assets by geographic area (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Oct. 02, 2021
Sep. 26, 2020
Oct. 02, 2021
Sep. 26, 2020
Jan. 02, 2021
Revenues from External Customers and Long-Lived Assets [Line Items]          
Long-Lived Assets $ 276,415   $ 276,415   $ 273,849
Concentration Risk, Long-lived Asset Geographic Area, Percentage 100.00%   100.00%   100.00%
Product $ 307,413 $ 278,112 $ 911,574 $ 848,690  
Concentration Risk, Percentage 100.00% 100.00% 100.00% 100.00%  
United States (U.S.) | Geographic Concentration Risk | Revenue Benchmark          
Revenues from External Customers and Long-Lived Assets [Line Items]          
Concentration Risk, Percentage 67.40% 67.20% 67.30% 67.30%  
EMEA [Member] | Geographic Concentration Risk | Revenue Benchmark          
Revenues from External Customers and Long-Lived Assets [Line Items]          
Concentration Risk, Percentage 18.30% 19.50% 19.40% 20.80%  
Asia Pacific [Member] | Geographic Concentration Risk | Revenue Benchmark          
Revenues from External Customers and Long-Lived Assets [Line Items]          
Concentration Risk, Percentage 11.30% 9.90% 10.30% 8.60%  
North and South America (excluding the U.S.) | Geographic Concentration Risk | Revenue Benchmark          
Revenues from External Customers and Long-Lived Assets [Line Items]          
Concentration Risk, Percentage 3.00% 3.40% 3.00% 3.30%  
Reportable Geographical Components | United States (U.S.)          
Revenues from External Customers and Long-Lived Assets [Line Items]          
Long-Lived Assets $ 239,435   $ 239,435   $ 238,094
Concentration Risk, Long-lived Asset Geographic Area, Percentage 86.60%   86.60%   86.90%
Product $ 207,060 $ 186,919 $ 613,197 $ 571,158  
Reportable Geographical Components | International          
Revenues from External Customers and Long-Lived Assets [Line Items]          
Long-Lived Assets $ 36,980   $ 36,980   $ 35,755
Concentration Risk, Long-lived Asset Geographic Area, Percentage 13.40%   13.40%   13.10%
Reportable Geographical Components | EMEA [Member]          
Revenues from External Customers and Long-Lived Assets [Line Items]          
Product $ 56,223 54,257 $ 177,053 176,781  
Reportable Geographical Components | Asia Pacific [Member]          
Revenues from External Customers and Long-Lived Assets [Line Items]          
Product 34,878 27,583 94,134 73,155  
Reportable Geographical Components | North and South America (excluding the U.S.)          
Revenues from External Customers and Long-Lived Assets [Line Items]          
Product $ 9,252 $ 9,353 $ 27,190 $ 27,596  
EXCEL 94 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 95 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 96 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 97 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 258 461 1 false 65 0 false 9 false false R1.htm 0001001 - Document - Document and Entity Information Sheet http://www.masimo.com/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.masimo.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.masimo.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - Condensed Consolidated Statements of Operations Condensed Consolidated Statement of Operations Sheet http://www.masimo.com/role/CondensedConsolidatedStatementsofOperationsCondensedConsolidatedStatementofOperations Condensed Consolidated Statements of Operations Condensed Consolidated Statement of Operations Statements 4 false false R5.htm 1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income Sheet http://www.masimo.com/role/CondensedConsolidatedStatementsofComprehensiveIncome Condensed Consolidated Statements of Comprehensive Income Statements 5 false false R6.htm 1005006 - Statement - Consolidated Statement of Stockholders' Equity Consolidated Statement of Stockholders' Equity Sheet http://www.masimo.com/role/ConsolidatedStatementofStockholdersEquityConsolidatedStatementofStockholdersEquity Consolidated Statement of Stockholders' Equity Consolidated Statement of Stockholders' Equity Statements 6 false false R7.htm 1006007 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 2101101 - Disclosure - Description of the Company Sheet http://www.masimo.com/role/DescriptionoftheCompany Description of the Company Notes 8 false false R9.htm 2102102 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.masimo.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 2110103 - Disclosure - Related Party Disclosures Sheet http://www.masimo.com/role/RelatedPartyDisclosures Related Party Disclosures Notes 10 false false R11.htm 2112104 - Disclosure - Inventories Sheet http://www.masimo.com/role/Inventories Inventories Notes 11 false false R12.htm 2115105 - Disclosure - Other Current Assets Sheet http://www.masimo.com/role/OtherCurrentAssets Other Current Assets Notes 12 false false R13.htm 2118106 - Disclosure - Lease Receivable Sheet http://www.masimo.com/role/LeaseReceivable Lease Receivable Notes 13 false false R14.htm 2123107 - Disclosure - Deferred Costs and Other Contract Assets Sheet http://www.masimo.com/role/DeferredCostsandOtherContractAssets Deferred Costs and Other Contract Assets Notes 14 false false R15.htm 2126108 - Disclosure - Property and Equipment, net Sheet http://www.masimo.com/role/PropertyandEquipmentnet Property and Equipment, net Notes 15 false false R16.htm 2129109 - Disclosure - Intangible Assets Sheet http://www.masimo.com/role/IntangibleAssets Intangible Assets Notes 16 false false R17.htm 2134110 - Disclosure - Goodwill Sheet http://www.masimo.com/role/Goodwill Goodwill Notes 17 false false R18.htm 2137111 - Disclosure - Lessee ROU Assets and Lease Liabilities Sheet http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilities Lessee ROU Assets and Lease Liabilities Notes 18 false false R19.htm 2142112 - Disclosure - Other Non-Current Assets Sheet http://www.masimo.com/role/OtherNonCurrentAssets Other Non-Current Assets Notes 19 false false R20.htm 2145113 - Disclosure - Deferred Revenue and Other Contract Liabilities Sheet http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilities Deferred Revenue and Other Contract Liabilities Notes 20 false false R21.htm 2149114 - Disclosure - Other Current Liabilities Sheet http://www.masimo.com/role/OtherCurrentLiabilities Other Current Liabilities Notes 21 false false R22.htm 2152115 - Disclosure - Credit Facility Sheet http://www.masimo.com/role/CreditFacility Credit Facility Notes 22 false false R23.htm 2155116 - Disclosure - Other Non-Current Liabilities Sheet http://www.masimo.com/role/OtherNonCurrentLiabilities Other Non-Current Liabilities Notes 23 false false R24.htm 2158117 - Disclosure - Stock Repurchase Program Sheet http://www.masimo.com/role/StockRepurchaseProgram Stock Repurchase Program Notes 24 false false R25.htm 2161118 - Disclosure - Stock-Based Compensation Sheet http://www.masimo.com/role/StockBasedCompensation Stock-Based Compensation Notes 25 false false R26.htm 2167119 - Disclosure - Non-operating income Sheet http://www.masimo.com/role/Nonoperatingincome Non-operating income Notes 26 false false R27.htm 2170120 - Disclosure - Income Taxes Sheet http://www.masimo.com/role/IncomeTaxes Income Taxes Notes 27 false false R28.htm 2172121 - Disclosure - Commitments and Contingencies Sheet http://www.masimo.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 28 false false R29.htm 2176122 - Disclosure - Segment Information and Enterprise Reporting Sheet http://www.masimo.com/role/SegmentInformationandEnterpriseReporting Segment Information and Enterprise Reporting Notes 29 false false R30.htm 2203201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.masimo.com/role/SummaryofSignificantAccountingPolicies 30 false false R31.htm 2304301 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.masimo.com/role/SummaryofSignificantAccountingPolicies 31 false false R32.htm 2313302 - Disclosure - Inventories (Tables) Sheet http://www.masimo.com/role/InventoriesTables Inventories (Tables) Tables http://www.masimo.com/role/Inventories 32 false false R33.htm 2316303 - Disclosure - Other Current Assets (Tables) Sheet http://www.masimo.com/role/OtherCurrentAssetsTables Other Current Assets (Tables) Tables http://www.masimo.com/role/OtherCurrentAssets 33 false false R34.htm 2319304 - Disclosure - Lease Receivable (Tables) Sheet http://www.masimo.com/role/LeaseReceivableTables Lease Receivable (Tables) Tables http://www.masimo.com/role/LeaseReceivable 34 false false R35.htm 2324305 - Disclosure - Deferred Costs and Other Contract Assets (Tables) Sheet http://www.masimo.com/role/DeferredCostsandOtherContractAssetsTables Deferred Costs and Other Contract Assets (Tables) Tables http://www.masimo.com/role/DeferredCostsandOtherContractAssets 35 false false R36.htm 2327306 - Disclosure - Property and Equipment (Tables) Sheet http://www.masimo.com/role/PropertyandEquipmentTables Property and Equipment (Tables) Tables http://www.masimo.com/role/PropertyandEquipmentnet 36 false false R37.htm 2330307 - Disclosure - Intangible Assets (Tables) Sheet http://www.masimo.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://www.masimo.com/role/IntangibleAssets 37 false false R38.htm 2335308 - Disclosure - Goodwill (Table) Sheet http://www.masimo.com/role/GoodwillTable Goodwill (Table) Tables http://www.masimo.com/role/Goodwill 38 false false R39.htm 2338309 - Disclosure - Lessee ROU Assets and Lease Liabilities (Tables) Sheet http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesTables Lessee ROU Assets and Lease Liabilities (Tables) Tables http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilities 39 false false R40.htm 2343310 - Disclosure - Other Non-Current Assets (Tables) Sheet http://www.masimo.com/role/OtherNonCurrentAssetsTables Other Non-Current Assets (Tables) Tables http://www.masimo.com/role/OtherNonCurrentAssets 40 false false R41.htm 2346311 - Disclosure - Deferred Revenue and Other Contract Liabilities (Tables) Sheet http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesTables Deferred Revenue and Other Contract Liabilities (Tables) Tables http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilities 41 false false R42.htm 2350312 - Disclosure - Other Current Liabilities (Tables) Sheet http://www.masimo.com/role/OtherCurrentLiabilitiesTables Other Current Liabilities (Tables) Tables http://www.masimo.com/role/OtherCurrentLiabilities 42 false false R43.htm 2356314 - Disclosure - Other Non-Current Liabilities (Tables) Sheet http://www.masimo.com/role/OtherNonCurrentLiabilitiesTables Other Non-Current Liabilities (Tables) Tables http://www.masimo.com/role/OtherNonCurrentLiabilities 43 false false R44.htm 2362316 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.masimo.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.masimo.com/role/StockBasedCompensation 44 false false R45.htm 2368317 - Disclosure - Non-operating income (Tables) Sheet http://www.masimo.com/role/NonoperatingincomeTables Non-operating income (Tables) Tables http://www.masimo.com/role/Nonoperatingincome 45 false false R46.htm 2377319 - Disclosure - Segment Information and Enterprise Reporting (Tables) Sheet http://www.masimo.com/role/SegmentInformationandEnterpriseReportingTables Segment Information and Enterprise Reporting (Tables) Tables http://www.masimo.com/role/SegmentInformationandEnterpriseReporting 46 false false R47.htm 2405401 - Disclosure - Summary of Significant Accounting Policies - Revenue, Performance Obligation (Details) Sheet http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesRevenuePerformanceObligationDetails Summary of Significant Accounting Policies - Revenue, Performance Obligation (Details) Details 47 false false R48.htm 2406402 - Disclosure - Summary of Significant Accounting Policies - Changes in Product Warranty Accrual (Detail) Sheet http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesChangesinProductWarrantyAccrualDetail Summary of Significant Accounting Policies - Changes in Product Warranty Accrual (Detail) Details 48 false false R49.htm 2407403 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Basic and Diluted Net Income Per Share (Detail) Sheet http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesReconciliationofBasicandDilutedNetIncomePerShareDetail Summary of Significant Accounting Policies - Reconciliation of Basic and Diluted Net Income Per Share (Detail) Details 49 false false R50.htm 2408404 - Disclosure - Summary of Significant Accounting Policies - Supplemental Cash Flow Information (Detail) Sheet http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesSupplementalCashFlowInformationDetail Summary of Significant Accounting Policies - Supplemental Cash Flow Information (Detail) Details 50 false false R51.htm 2409405 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail Summary of Significant Accounting Policies - Additional Information (Detail) Details 51 false false R52.htm 2411406 - Disclosure - Related Party Transactions Related Party Transactions - (Details) Sheet http://www.masimo.com/role/RelatedPartyTransactionsRelatedPartyTransactionsDetails Related Party Transactions Related Party Transactions - (Details) Details 52 false false R53.htm 2414407 - Disclosure - Inventories - Components of Inventory (Details) Sheet http://www.masimo.com/role/InventoriesComponentsofInventoryDetails Inventories - Components of Inventory (Details) Details 53 false false R54.htm 2417408 - Disclosure - Other Current Assets (Details) Sheet http://www.masimo.com/role/OtherCurrentAssetsDetails Other Current Assets (Details) Details http://www.masimo.com/role/OtherCurrentAssetsTables 54 false false R55.htm 2420409 - Disclosure - Lease Receivable (Details) Sheet http://www.masimo.com/role/LeaseReceivableDetails Lease Receivable (Details) Details http://www.masimo.com/role/LeaseReceivableTables 55 false false R56.htm 2421410 - Disclosure - Lease Receivable Sales-Type (Details) Sheet http://www.masimo.com/role/LeaseReceivableSalesTypeDetails Lease Receivable Sales-Type (Details) Details 56 false false R57.htm 2422411 - Disclosure - Lease Receivable Sales-type Lease, Maturity (Details) Sheet http://www.masimo.com/role/LeaseReceivableSalestypeLeaseMaturityDetails Lease Receivable Sales-type Lease, Maturity (Details) Details 57 false false R58.htm 2425412 - Disclosure - Deferred Costs and Other Contract Assets (Details) Sheet http://www.masimo.com/role/DeferredCostsandOtherContractAssetsDetails Deferred Costs and Other Contract Assets (Details) Details http://www.masimo.com/role/DeferredCostsandOtherContractAssetsTables 58 false false R59.htm 2428413 - Disclosure - Property and Equipment (Details) Sheet http://www.masimo.com/role/PropertyandEquipmentDetails Property and Equipment (Details) Details http://www.masimo.com/role/PropertyandEquipmentTables 59 false false R60.htm 2431414 - Disclosure - Intangible Assets - Schedule of Finite-Lived Intangible Assets (Details) Sheet http://www.masimo.com/role/IntangibleAssetsScheduleofFiniteLivedIntangibleAssetsDetails Intangible Assets - Schedule of Finite-Lived Intangible Assets (Details) Details 60 false false R61.htm 2432415 - Disclosure - Intangible Assets - Additional Information (Details) Sheet http://www.masimo.com/role/IntangibleAssetsAdditionalInformationDetails Intangible Assets - Additional Information (Details) Details 61 false false R62.htm 2433416 - Disclosure - Intangible Assets - Future Amortization Expense (Details) Sheet http://www.masimo.com/role/IntangibleAssetsFutureAmortizationExpenseDetails Intangible Assets - Future Amortization Expense (Details) Details 62 false false R63.htm 2436417 - Disclosure - Goodwill (Details) Sheet http://www.masimo.com/role/GoodwillDetails Goodwill (Details) Details http://www.masimo.com/role/GoodwillTable 63 false false R64.htm 2439418 - Disclosure - Lessee ROU Assets and Lease Liabilities (Details) Sheet http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesDetails Lessee ROU Assets and Lease Liabilities (Details) Details http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesTables 64 false false R65.htm 2440419 - Disclosure - Lessee ROU Assets and Lease Liabilities Lessee Operating Lease Balance Sheet Classification (Details) Sheet http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesLesseeOperatingLeaseBalanceSheetClassificationDetails Lessee ROU Assets and Lease Liabilities Lessee Operating Lease Balance Sheet Classification (Details) Details 65 false false R66.htm 2441420 - Disclosure - Lessee ROU Assets and Lease Liabilities Future Maturities Operating Lease Payments (Details) Sheet http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesFutureMaturitiesOperatingLeasePaymentsDetails Lessee ROU Assets and Lease Liabilities Future Maturities Operating Lease Payments (Details) Details 66 false false R67.htm 2444421 - Disclosure - Other Non-Current Assets (Details) Sheet http://www.masimo.com/role/OtherNonCurrentAssetsDetails Other Non-Current Assets (Details) Details http://www.masimo.com/role/OtherNonCurrentAssetsTables 67 false false R68.htm 2447422 - Disclosure - Deferred Revenue and Other Contract Liabilities (Details) Sheet http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesDetails Deferred Revenue and Other Contract Liabilities (Details) Details http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesTables 68 false false R69.htm 2448423 - Disclosure - Deferred Revenue and Other Contract Liabilities - Changes in Deferred Revenue (Details) Sheet http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesChangesinDeferredRevenueDetails Deferred Revenue and Other Contract Liabilities - Changes in Deferred Revenue (Details) Details 69 false false R70.htm 2451424 - Disclosure - Other Current Liabilities (Details) Sheet http://www.masimo.com/role/OtherCurrentLiabilitiesDetails Other Current Liabilities (Details) Details http://www.masimo.com/role/OtherCurrentLiabilitiesTables 70 false false R71.htm 2454425 - Disclosure - Credit Facility (Details) Sheet http://www.masimo.com/role/CreditFacilityDetails Credit Facility (Details) Details http://www.masimo.com/role/CreditFacility 71 false false R72.htm 2457426 - Disclosure - Other Non-Current Liabilities - (Detail) Sheet http://www.masimo.com/role/OtherNonCurrentLiabilitiesDetail Other Non-Current Liabilities - (Detail) Details http://www.masimo.com/role/OtherNonCurrentLiabilitiesTables 72 false false R73.htm 2460427 - Disclosure - Stock Repurchase Program - Additional Information (Detail) Sheet http://www.masimo.com/role/StockRepurchaseProgramAdditionalInformationDetail Stock Repurchase Program - Additional Information (Detail) Details 73 false false R74.htm 2463428 - Disclosure - Stock-Based Compensation - Additional Information (Detail) Sheet http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail Stock-Based Compensation - Additional Information (Detail) Details 74 false false R75.htm 2464429 - Disclosure - Stock-Based Compensation - Number and Weighted Average Exercise Price of Options Issued and Outstanding under all Stock Option Plans (Detail) Sheet http://www.masimo.com/role/StockBasedCompensationNumberandWeightedAverageExercisePriceofOptionsIssuedandOutstandingunderallStockOptionPlansDetail Stock-Based Compensation - Number and Weighted Average Exercise Price of Options Issued and Outstanding under all Stock Option Plans (Detail) Details 75 false false R76.htm 2465430 - Disclosure - Stock-Based Compensation Stock-Based Compensation - Summary of Unvested RSU Activity (Details) Sheet http://www.masimo.com/role/StockBasedCompensationStockBasedCompensationSummaryofUnvestedRSUActivityDetails Stock-Based Compensation Stock-Based Compensation - Summary of Unvested RSU Activity (Details) Details 76 false false R77.htm 2466431 - Disclosure - Stock-Based Compensation - Range of Assumptions Used and Resulting Weighted-Average Fair Value of Options Granted at Date of Grant (Detail) Sheet http://www.masimo.com/role/StockBasedCompensationRangeofAssumptionsUsedandResultingWeightedAverageFairValueofOptionsGrantedatDateofGrantDetail Stock-Based Compensation - Range of Assumptions Used and Resulting Weighted-Average Fair Value of Options Granted at Date of Grant (Detail) Details 77 false false R78.htm 2469432 - Disclosure - Non-operating income (Detail) Sheet http://www.masimo.com/role/NonoperatingincomeDetail Non-operating income (Detail) Details http://www.masimo.com/role/NonoperatingincomeTables 78 false false R79.htm 2471433 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.masimo.com/role/IncomeTaxesAdditionalInformationDetail Income Taxes - Additional Information (Detail) Details 79 false false R80.htm 2474434 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 80 false false R81.htm 2478436 - Disclosure - Segment Information and Enterprise Reporting - Analysis of Product Revenues Based upon Geographic Area Shipped (Detail) Sheet http://www.masimo.com/role/SegmentInformationandEnterpriseReportingAnalysisofProductRevenuesBaseduponGeographicAreaShippedDetail Segment Information and Enterprise Reporting - Analysis of Product Revenues Based upon Geographic Area Shipped (Detail) Details 81 false false R82.htm 2479437 - Disclosure - Segment Information and Enterprise Reporting Long-lived assets by geographic area (Details) Sheet http://www.masimo.com/role/SegmentInformationandEnterpriseReportingLonglivedassetsbygeographicareaDetails Segment Information and Enterprise Reporting Long-lived assets by geographic area (Details) Details 82 false false All Reports Book All Reports masi-20211002.htm masi-20211002.xsd masi-20211002_cal.xml masi-20211002_def.xml masi-20211002_lab.xml masi-20211002_pre.xml masi-20211002x10qex311.htm masi-20211002x10qex312.htm masi-20211002x10qex321.htm masi-20211002_g1.jpg http://xbrl.sec.gov/country/2021 http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021 http://fasb.org/srt/2021-01-31 true true JSON 99 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "masi-20211002.htm": { "axisCustom": 0, "axisStandard": 22, "contextCount": 258, "dts": { "calculationLink": { "local": [ "masi-20211002_cal.xml" ] }, "definitionLink": { "local": [ "masi-20211002_def.xml" ] }, "inline": { "local": [ "masi-20211002.htm" ] }, "labelLink": { "local": [ "masi-20211002_lab.xml" ] }, "presentationLink": { "local": [ "masi-20211002_pre.xml" ] }, "schema": { "local": [ "masi-20211002.xsd" ], "remote": [ "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd" ] } }, "elementCount": 594, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 5, "total": 5 }, "keyCustom": 40, "keyStandard": 421, "memberCustom": 19, "memberStandard": 44, "nsprefix": "masi", "nsuri": "http://www.masimo.com/20211002", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Document and Entity Information", "role": "http://www.masimo.com/role/DocumentandEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110103 - Disclosure - Related Party Disclosures", "role": "http://www.masimo.com/role/RelatedPartyDisclosures", "shortName": "Related Party Disclosures", "subGroupType": "", "uniqueAnchor": null }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112104 - Disclosure - Inventories", "role": "http://www.masimo.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115105 - Disclosure - Other Current Assets", "role": "http://www.masimo.com/role/OtherCurrentAssets", "shortName": "Other Current Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LessorSalesTypeLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2118106 - Disclosure - Lease Receivable", "role": "http://www.masimo.com/role/LeaseReceivable", "shortName": "Lease Receivable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LessorSalesTypeLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "masi:DeferredCostsandOtherContractAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2123107 - Disclosure - Deferred Costs and Other Contract Assets", "role": "http://www.masimo.com/role/DeferredCostsandOtherContractAssets", "shortName": "Deferred Costs and Other Contract Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "masi:DeferredCostsandOtherContractAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2126108 - Disclosure - Property and Equipment, net", "role": "http://www.masimo.com/role/PropertyandEquipmentnet", "shortName": "Property and Equipment, net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2129109 - Disclosure - Intangible Assets", "role": "http://www.masimo.com/role/IntangibleAssets", "shortName": "Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2134110 - Disclosure - Goodwill", "role": "http://www.masimo.com/role/Goodwill", "shortName": "Goodwill", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2137111 - Disclosure - Lessee ROU Assets and Lease Liabilities", "role": "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilities", "shortName": "Lessee ROU Assets and Lease Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2142112 - Disclosure - Other Non-Current Assets", "role": "http://www.masimo.com/role/OtherNonCurrentAssets", "shortName": "Other Non-Current Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "icdd7bc6c6e4344eea0ce14ed45a6f944_I20211002", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "icdd7bc6c6e4344eea0ce14ed45a6f944_I20211002", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2145113 - Disclosure - Deferred Revenue and Other Contract Liabilities", "role": "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilities", "shortName": "Deferred Revenue and Other Contract Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2149114 - Disclosure - Other Current Liabilities", "role": "http://www.masimo.com/role/OtherCurrentLiabilities", "shortName": "Other Current Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2152115 - Disclosure - Credit Facility", "role": "http://www.masimo.com/role/CreditFacility", "shortName": "Credit Facility", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2155116 - Disclosure - Other Non-Current Liabilities", "role": "http://www.masimo.com/role/OtherNonCurrentLiabilities", "shortName": "Other Non-Current Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2158117 - Disclosure - Stock Repurchase Program", "role": "http://www.masimo.com/role/StockRepurchaseProgram", "shortName": "Stock Repurchase Program", "subGroupType": "", "uniqueAnchor": null }, "R25": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2161118 - Disclosure - Stock-Based Compensation", "role": "http://www.masimo.com/role/StockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2167119 - Disclosure - Non-operating income", "role": "http://www.masimo.com/role/Nonoperatingincome", "shortName": "Non-operating income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2170120 - Disclosure - Income Taxes", "role": "http://www.masimo.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2172121 - Disclosure - Commitments and Contingencies", "role": "http://www.masimo.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2176122 - Disclosure - Segment Information and Enterprise Reporting", "role": "http://www.masimo.com/role/SegmentInformationandEnterpriseReporting", "shortName": "Segment Information and Enterprise Reporting", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "icdd7bc6c6e4344eea0ce14ed45a6f944_I20211002", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.masimo.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "icdd7bc6c6e4344eea0ce14ed45a6f944_I20211002", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StandardProductWarrantyPolicy", "ix:continuation", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "lang": "en-US", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313302 - Disclosure - Inventories (Tables)", "role": "http://www.masimo.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2316303 - Disclosure - Other Current Assets (Tables)", "role": "http://www.masimo.com/role/OtherCurrentAssetsTables", "shortName": "Other Current Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R34": { "firstAnchor": { "ancestors": [ "us-gaap:LessorSalesTypeLeasesTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "masi:SaleTypeLeaseReceivableTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2319304 - Disclosure - Lease Receivable (Tables)", "role": "http://www.masimo.com/role/LeaseReceivableTables", "shortName": "Lease Receivable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LessorSalesTypeLeasesTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "masi:SaleTypeLeaseReceivableTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "masi:DeferredCostsandOtherContractAssetsTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2324305 - Disclosure - Deferred Costs and Other Contract Assets (Tables)", "role": "http://www.masimo.com/role/DeferredCostsandOtherContractAssetsTables", "shortName": "Deferred Costs and Other Contract Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "masi:DeferredCostsandOtherContractAssetsTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2327306 - Disclosure - Property and Equipment (Tables)", "role": "http://www.masimo.com/role/PropertyandEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R37": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2330307 - Disclosure - Intangible Assets (Tables)", "role": "http://www.masimo.com/role/IntangibleAssetsTables", "shortName": "Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "us-gaap:GoodwillDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2335308 - Disclosure - Goodwill (Table)", "role": "http://www.masimo.com/role/GoodwillTable", "shortName": "Goodwill (Table)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:GoodwillDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "masi:LesseeOperatingLeaseBalanceSheetClassificationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2338309 - Disclosure - Lessee ROU Assets and Lease Liabilities (Tables)", "role": "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesTables", "shortName": "Lessee ROU Assets and Lease Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "masi:LesseeOperatingLeaseBalanceSheetClassificationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i9272ce446efd4fe3809108f853b8b623_D20210704-20211002", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations Condensed Consolidated Statement of Operations", "role": "http://www.masimo.com/role/CondensedConsolidatedStatementsofOperationsCondensedConsolidatedStatementofOperations", "shortName": "Condensed Consolidated Statements of Operations Condensed Consolidated Statement of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i9272ce446efd4fe3809108f853b8b623_D20210704-20211002", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2343310 - Disclosure - Other Non-Current Assets (Tables)", "role": "http://www.masimo.com/role/OtherNonCurrentAssetsTables", "shortName": "Other Non-Current Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R41": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2346311 - Disclosure - Deferred Revenue and Other Contract Liabilities (Tables)", "role": "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesTables", "shortName": "Deferred Revenue and Other Contract Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2350312 - Disclosure - Other Current Liabilities (Tables)", "role": "http://www.masimo.com/role/OtherCurrentLiabilitiesTables", "shortName": "Other Current Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "masi:ComponentsOfOtherLiabilitiesLongTermTableTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2356314 - Disclosure - Other Non-Current Liabilities (Tables)", "role": "http://www.masimo.com/role/OtherNonCurrentLiabilitiesTables", "shortName": "Other Non-Current Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "masi:ComponentsOfOtherLiabilitiesLongTermTableTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2362316 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://www.masimo.com/role/StockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2368317 - Disclosure - Non-operating income (Tables)", "role": "http://www.masimo.com/role/NonoperatingincomeTables", "shortName": "Non-operating income (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2377319 - Disclosure - Segment Information and Enterprise Reporting (Tables)", "role": "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingTables", "shortName": "Segment Information and Enterprise Reporting (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "if1b421180dd44479b0f4ea61bc411018_I20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405401 - Disclosure - Summary of Significant Accounting Policies - Revenue, Performance Obligation (Details)", "role": "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesRevenuePerformanceObligationDetails", "shortName": "Summary of Significant Accounting Policies - Revenue, Performance Obligation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "iaded0da769d34d2fa8d11582d4aeadcd_I20211002", "decimals": null, "lang": "en-US", "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "us-gaap:StandardProductWarrantyPolicy", "ix:continuation", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i0e5eb2b504d643c6b324ebe58e56729f_I20210102", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProductWarrantyAccrual", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Changes in Product Warranty Accrual (Detail)", "role": "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesChangesinProductWarrantyAccrualDetail", "shortName": "Summary of Significant Accounting Policies - Changes in Product Warranty Accrual (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "us-gaap:StandardProductWarrantyPolicy", "ix:continuation", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i0e5eb2b504d643c6b324ebe58e56729f_I20210102", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProductWarrantyAccrual", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i9272ce446efd4fe3809108f853b8b623_D20210704-20211002", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Basic and Diluted Net Income Per Share (Detail)", "role": "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesReconciliationofBasicandDilutedNetIncomePerShareDetail", "shortName": "Summary of Significant Accounting Policies - Reconciliation of Basic and Diluted Net Income Per Share (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i9272ce446efd4fe3809108f853b8b623_D20210704-20211002", "decimals": "-3", "lang": "en-US", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i9272ce446efd4fe3809108f853b8b623_D20210704-20211002", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income", "role": "http://www.masimo.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "shortName": "Condensed Consolidated Statements of Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i9272ce446efd4fe3809108f853b8b623_D20210704-20211002", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InterestPaidNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408404 - Disclosure - Summary of Significant Accounting Policies - Supplemental Cash Flow Information (Detail)", "role": "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesSupplementalCashFlowInformationDetail", "shortName": "Summary of Significant Accounting Policies - Supplemental Cash Flow Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InterestPaidNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:RevenueRecognitionPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": "INF", "first": true, "lang": "en-US", "name": "masi:NumberofSourcesofProductRevenue", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409405 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)", "role": "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail", "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:RevenueRecognitionPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": "INF", "first": true, "lang": "en-US", "name": "masi:NumberofSourcesofProductRevenue", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411406 - Disclosure - Related Party Transactions Related Party Transactions - (Details)", "role": "http://www.masimo.com/role/RelatedPartyTransactionsRelatedPartyTransactionsDetails", "shortName": "Related Party Transactions Related Party Transactions - (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i234aecef1de441818ccfe8c46a7ebd93_D20210704-20211002", "decimals": "-5", "lang": "en-US", "name": "us-gaap:PaymentsForRoyalties", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "icdd7bc6c6e4344eea0ce14ed45a6f944_I20211002", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414407 - Disclosure - Inventories - Components of Inventory (Details)", "role": "http://www.masimo.com/role/InventoriesComponentsofInventoryDetails", "shortName": "Inventories - Components of Inventory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "icdd7bc6c6e4344eea0ce14ed45a6f944_I20211002", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "icdd7bc6c6e4344eea0ce14ed45a6f944_I20211002", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417408 - Disclosure - Other Current Assets (Details)", "role": "http://www.masimo.com/role/OtherCurrentAssetsDetails", "shortName": "Other Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "icdd7bc6c6e4344eea0ce14ed45a6f944_I20211002", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:LessorSalesTypeLeasesTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i9272ce446efd4fe3809108f853b8b623_D20210704-20211002", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseVariableLeaseIncome", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420409 - Disclosure - Lease Receivable (Details)", "role": "http://www.masimo.com/role/LeaseReceivableDetails", "shortName": "Lease Receivable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:LessorSalesTypeLeasesTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i9272ce446efd4fe3809108f853b8b623_D20210704-20211002", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseVariableLeaseIncome", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "masi:SaleTypeLeaseReceivableTableTextBlock", "us-gaap:LessorSalesTypeLeasesTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "icdd7bc6c6e4344eea0ce14ed45a6f944_I20211002", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421410 - Disclosure - Lease Receivable Sales-Type (Details)", "role": "http://www.masimo.com/role/LeaseReceivableSalesTypeDetails", "shortName": "Lease Receivable Sales-Type (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "masi:SaleTypeLeaseReceivableTableTextBlock", "us-gaap:LessorSalesTypeLeasesTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "icdd7bc6c6e4344eea0ce14ed45a6f944_I20211002", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "icdd7bc6c6e4344eea0ce14ed45a6f944_I20211002", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422411 - Disclosure - Lease Receivable Sales-type Lease, Maturity (Details)", "role": "http://www.masimo.com/role/LeaseReceivableSalestypeLeaseMaturityDetails", "shortName": "Lease Receivable Sales-type Lease, Maturity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "icdd7bc6c6e4344eea0ce14ed45a6f944_I20211002", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "masi:DeferredCostsandOtherContractAssetsTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "icdd7bc6c6e4344eea0ce14ed45a6f944_I20211002", "decimals": "-3", "first": true, "lang": "en-US", "name": "masi:DeferredSalesCommissions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425412 - Disclosure - Deferred Costs and Other Contract Assets (Details)", "role": "http://www.masimo.com/role/DeferredCostsandOtherContractAssetsDetails", "shortName": "Deferred Costs and Other Contract Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "masi:DeferredCostsandOtherContractAssetsTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "icdd7bc6c6e4344eea0ce14ed45a6f944_I20211002", "decimals": "-3", "first": true, "lang": "en-US", "name": "masi:DeferredSalesCommissions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "icdd7bc6c6e4344eea0ce14ed45a6f944_I20211002", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428413 - Disclosure - Property and Equipment (Details)", "role": "http://www.masimo.com/role/PropertyandEquipmentDetails", "shortName": "Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i0e5eb2b504d643c6b324ebe58e56729f_I20210102", "decimals": "-3", "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i8eb48c27b7a6413f94f48b6dfc260d4a_I20191228", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SharesIssued", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Consolidated Statement of Stockholders' Equity Consolidated Statement of Stockholders' Equity", "role": "http://www.masimo.com/role/ConsolidatedStatementofStockholdersEquityConsolidatedStatementofStockholdersEquity", "shortName": "Consolidated Statement of Stockholders' Equity Consolidated Statement of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i7b3c3417c3d6431dacba79affbf49aea_D20191229-20200328", "decimals": "-3", "lang": "en-US", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "icdd7bc6c6e4344eea0ce14ed45a6f944_I20211002", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431414 - Disclosure - Intangible Assets - Schedule of Finite-Lived Intangible Assets (Details)", "role": "http://www.masimo.com/role/IntangibleAssetsScheduleofFiniteLivedIntangibleAssetsDetails", "shortName": "Intangible Assets - Schedule of Finite-Lived Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "icdd7bc6c6e4344eea0ce14ed45a6f944_I20211002", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432415 - Disclosure - Intangible Assets - Additional Information (Details)", "role": "http://www.masimo.com/role/IntangibleAssetsAdditionalInformationDetails", "shortName": "Intangible Assets - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "icdd7bc6c6e4344eea0ce14ed45a6f944_I20211002", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433416 - Disclosure - Intangible Assets - Future Amortization Expense (Details)", "role": "http://www.masimo.com/role/IntangibleAssetsFutureAmortizationExpenseDetails", "shortName": "Intangible Assets - Future Amortization Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "icdd7bc6c6e4344eea0ce14ed45a6f944_I20211002", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "icdd7bc6c6e4344eea0ce14ed45a6f944_I20211002", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436417 - Disclosure - Goodwill (Details)", "role": "http://www.masimo.com/role/GoodwillDetails", "shortName": "Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": "-3", "lang": "en-US", "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "icdd7bc6c6e4344eea0ce14ed45a6f944_I20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseRenewalTerm", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439418 - Disclosure - Lessee ROU Assets and Lease Liabilities (Details)", "role": "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesDetails", "shortName": "Lessee ROU Assets and Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i0e5eb2b504d643c6b324ebe58e56729f_I20210102", "decimals": "-5", "lang": "en-US", "name": "masi:OperatingLeaseRightOfUseAssetAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "icdd7bc6c6e4344eea0ce14ed45a6f944_I20211002", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2440419 - Disclosure - Lessee ROU Assets and Lease Liabilities Lessee Operating Lease Balance Sheet Classification (Details)", "role": "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesLesseeOperatingLeaseBalanceSheetClassificationDetails", "shortName": "Lessee ROU Assets and Lease Liabilities Lessee Operating Lease Balance Sheet Classification (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "icdd7bc6c6e4344eea0ce14ed45a6f944_I20211002", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2441420 - Disclosure - Lessee ROU Assets and Lease Liabilities Future Maturities Operating Lease Payments (Details)", "role": "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesFutureMaturitiesOperatingLeasePaymentsDetails", "shortName": "Lessee ROU Assets and Lease Liabilities Future Maturities Operating Lease Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "icdd7bc6c6e4344eea0ce14ed45a6f944_I20211002", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "icdd7bc6c6e4344eea0ce14ed45a6f944_I20211002", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2444421 - Disclosure - Other Non-Current Assets (Details)", "role": "http://www.masimo.com/role/OtherNonCurrentAssetsDetails", "shortName": "Other Non-Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "icdd7bc6c6e4344eea0ce14ed45a6f944_I20211002", "decimals": "-3", "lang": "en-US", "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "icdd7bc6c6e4344eea0ce14ed45a6f944_I20211002", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2447422 - Disclosure - Deferred Revenue and Other Contract Liabilities (Details)", "role": "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesDetails", "shortName": "Deferred Revenue and Other Contract Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "icdd7bc6c6e4344eea0ce14ed45a6f944_I20211002", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i0e5eb2b504d643c6b324ebe58e56729f_I20210102", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredRevenue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448423 - Disclosure - Deferred Revenue and Other Contract Liabilities - Changes in Deferred Revenue (Details)", "role": "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesChangesinDeferredRevenueDetails", "shortName": "Deferred Revenue and Other Contract Liabilities - Changes in Deferred Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DeferredRevenueAdditions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "icdd7bc6c6e4344eea0ce14ed45a6f944_I20211002", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2451424 - Disclosure - Other Current Liabilities (Details)", "role": "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails", "shortName": "Other Current Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "icdd7bc6c6e4344eea0ce14ed45a6f944_I20211002", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "icdd7bc6c6e4344eea0ce14ed45a6f944_I20211002", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LettersOfCreditOutstandingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2454425 - Disclosure - Credit Facility (Details)", "role": "http://www.masimo.com/role/CreditFacilityDetails", "shortName": "Credit Facility (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i0e5eb2b504d643c6b324ebe58e56729f_I20210102", "decimals": "-5", "lang": "en-US", "name": "us-gaap:LettersOfCreditOutstandingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "masi:ComponentsOfOtherLiabilitiesLongTermTableTableTextBlock", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "icdd7bc6c6e4344eea0ce14ed45a6f944_I20211002", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseLiabilityNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2457426 - Disclosure - Other Non-Current Liabilities - (Detail)", "role": "http://www.masimo.com/role/OtherNonCurrentLiabilitiesDetail", "shortName": "Other Non-Current Liabilities - (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "masi:ComponentsOfOtherLiabilitiesLongTermTableTableTextBlock", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "icdd7bc6c6e4344eea0ce14ed45a6f944_I20211002", "decimals": "-3", "lang": "en-US", "name": "masi:IncomeTaxPayableNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i9272ce446efd4fe3809108f853b8b623_D20210704-20211002", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:TreasuryStockSharesAcquired", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2460427 - Disclosure - Stock Repurchase Program - Additional Information (Detail)", "role": "http://www.masimo.com/role/StockRepurchaseProgramAdditionalInformationDetail", "shortName": "Stock Repurchase Program - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i9272ce446efd4fe3809108f853b8b623_D20210704-20211002", "decimals": "2", "lang": "en-US", "name": "us-gaap:TreasuryStockAcquiredAverageCostPerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i9272ce446efd4fe3809108f853b8b623_D20210704-20211002", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2463428 - Disclosure - Stock-Based Compensation - Additional Information (Detail)", "role": "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail", "shortName": "Stock-Based Compensation - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i9272ce446efd4fe3809108f853b8b623_D20210704-20211002", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i0e5eb2b504d643c6b324ebe58e56729f_I20210102", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2464429 - Disclosure - Stock-Based Compensation - Number and Weighted Average Exercise Price of Options Issued and Outstanding under all Stock Option Plans (Detail)", "role": "http://www.masimo.com/role/StockBasedCompensationNumberandWeightedAverageExercisePriceofOptionsIssuedandOutstandingunderallStockOptionPlansDetail", "shortName": "Stock-Based Compensation - Number and Weighted Average Exercise Price of Options Issued and Outstanding under all Stock Option Plans (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i590a3b3cb93744209703014ed921e118_I20211002", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2465430 - Disclosure - Stock-Based Compensation Stock-Based Compensation - Summary of Unvested RSU Activity (Details)", "role": "http://www.masimo.com/role/StockBasedCompensationStockBasedCompensationSummaryofUnvestedRSUActivityDetails", "shortName": "Stock-Based Compensation Stock-Based Compensation - Summary of Unvested RSU Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i211686d67b1346bc9780e4646dfb6b27_D20210103-20211002", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i9272ce446efd4fe3809108f853b8b623_D20210704-20211002", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2466431 - Disclosure - Stock-Based Compensation - Range of Assumptions Used and Resulting Weighted-Average Fair Value of Options Granted at Date of Grant (Detail)", "role": "http://www.masimo.com/role/StockBasedCompensationRangeofAssumptionsUsedandResultingWeightedAverageFairValueofOptionsGrantedatDateofGrantDetail", "shortName": "Stock-Based Compensation - Range of Assumptions Used and Resulting Weighted-Average Fair Value of Options Granted at Date of Grant (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i9272ce446efd4fe3809108f853b8b623_D20210704-20211002", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i9272ce446efd4fe3809108f853b8b623_D20210704-20211002", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InterestIncomeOther", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2469432 - Disclosure - Non-operating income (Detail)", "role": "http://www.masimo.com/role/NonoperatingincomeDetail", "shortName": "Non-operating income (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i9272ce446efd4fe3809108f853b8b623_D20210704-20211002", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InterestIncomeOther", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i9272ce446efd4fe3809108f853b8b623_D20210704-20211002", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2471433 - Disclosure - Income Taxes - Additional Information (Detail)", "role": "http://www.masimo.com/role/IncomeTaxesAdditionalInformationDetail", "shortName": "Income Taxes - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i9272ce446efd4fe3809108f853b8b623_D20210704-20211002", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Description of the Company", "role": "http://www.masimo.com/role/DescriptionoftheCompany", "shortName": "Description of the Company", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2474434 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "role": "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i9272ce446efd4fe3809108f853b8b623_D20210704-20211002", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2478436 - Disclosure - Segment Information and Enterprise Reporting - Analysis of Product Revenues Based upon Geographic Area Shipped (Detail)", "role": "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingAnalysisofProductRevenuesBaseduponGeographicAreaShippedDetail", "shortName": "Segment Information and Enterprise Reporting - Analysis of Product Revenues Based upon Geographic Area Shipped (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R82": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "icdd7bc6c6e4344eea0ce14ed45a6f944_I20211002", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2479437 - Disclosure - Segment Information and Enterprise Reporting Long-lived assets by geographic area (Details)", "role": "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingLonglivedassetsbygeographicareaDetails", "shortName": "Segment Information and Enterprise Reporting Long-lived assets by geographic area (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i0e5eb2b504d643c6b324ebe58e56729f_I20210102", "decimals": "-3", "lang": "en-US", "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102102 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.masimo.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "masi-20211002.htm", "contextRef": "i4cc59c6c44ce4c12a17152435fe01941_D20210103-20211002", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 65, "tag": { "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States (U.S.)" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingAnalysisofProductRevenuesBaseduponGeographicAreaShippedDetail", "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingLonglivedassetsbygeographicareaDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.masimo.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.masimo.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.masimo.com/role/DocumentandEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.masimo.com/role/DocumentandEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.masimo.com/role/DocumentandEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.masimo.com/role/DocumentandEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r701" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.masimo.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r702" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.masimo.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.masimo.com/role/DocumentandEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.masimo.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.masimo.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.masimo.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.masimo.com/role/DocumentandEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r703" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.masimo.com/role/DocumentandEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.masimo.com/role/DocumentandEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.masimo.com/role/DocumentandEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r703" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.masimo.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.masimo.com/role/DocumentandEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r703" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.masimo.com/role/DocumentandEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.masimo.com/role/DocumentandEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r705" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.masimo.com/role/DocumentandEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r703" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.masimo.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r703" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.masimo.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r703" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Smaller Reporting Company" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.masimo.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r703" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.masimo.com/role/DocumentandEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.masimo.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r699" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.masimo.com/role/DocumentandEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r700" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.masimo.com/role/DocumentandEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.masimo.com/role/DocumentandEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "masi_A2007StockIncentivePlanDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2007 Stock Incentive Plan [Domain]", "label": "2007 Stock Incentive Plan [Domain]", "terseLabel": "2007 Stock Incentive Plan [Domain]" } } }, "localname": "A2007StockIncentivePlanDomain", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "masi_A2017EquityIncentivePlanDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2017 Equity Incentive Plan [Domain]", "label": "2017 Equity Incentive Plan [Domain]", "terseLabel": "2017 Equity Incentive Plan [Domain]" } } }, "localname": "A2017EquityIncentivePlanDomain", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "masi_A2018RepurchaseProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2018 Repurchase Program", "label": "2018 Repurchase Program [Member]", "terseLabel": "2018 Repurchase Program" } } }, "localname": "A2018RepurchaseProgramMember", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/StockRepurchaseProgramAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "masi_A2021PSUGrantDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2021 PSU Grant", "label": "2021 PSU Grant [Domain]", "terseLabel": "2021 PSU Grant [Domain]" } } }, "localname": "A2021PSUGrantDomain", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "masi_A2021RepurchaseProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2021 Repurchase Program", "label": "2021 Repurchase Program [Member]", "terseLabel": "2021 Repurchase Program" } } }, "localname": "A2021RepurchaseProgramMember", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/StockRepurchaseProgramAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "masi_AccruedDonationsCurrent": { "auth_ref": [], "calculation": { "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Donations, Current", "label": "Accrued Donations, Current", "terseLabel": "Accrued donations" } } }, "localname": "AccruedDonationsCurrent", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "masi_Accruedrebatesandallowances": { "auth_ref": [], "calculation": { "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued rebates and allowances", "label": "Accrued rebates and allowances", "verboseLabel": "Accrued rebates and allowances" } } }, "localname": "Accruedrebatesandallowances", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "masi_AcquiredTechnologyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Acquired Technology [Member]", "label": "Acquired Technology [Member]", "terseLabel": "Acquired technologies" } } }, "localname": "AcquiredTechnologyMember", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsAdditionalInformationDetails", "http://www.masimo.com/role/IntangibleAssetsScheduleofFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "masi_BankBalances": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Bank Balances", "terseLabel": "Bank Balances" } } }, "localname": "BankBalances", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "masi_CercacorLaboratoriesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cercacor Laboratories [Member]", "label": "Cercacor Laboratories [Member]", "terseLabel": "Cercacor Laboratories" } } }, "localname": "CercacorLaboratoriesMember", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.masimo.com/role/RelatedPartyTransactionsRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "masi_ComponentsOfOtherLiabilitiesLongTermTableTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element may be used as a single block of text to encapsulate the entire disclosure for other liabilities including data and tables.", "label": "Components Of Other Liabilities Long Term Table [Table Text Block]", "terseLabel": "Schedule of Components Of Other Liabilities Long Term Table" } } }, "localname": "ComponentsOfOtherLiabilitiesLongTermTableTableTextBlock", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/OtherNonCurrentLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "masi_ConcentrationRiskARCustomer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Concentration Risk, Customer, Percentage of Receivable Balance", "label": "ConcentrationRiskARCustomer", "terseLabel": "Concentration Risk, AR Balance One Customer" } } }, "localname": "ConcentrationRiskARCustomer", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "masi_ConcentrationRiskJustintimeDistributors": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Concentration Risk, Just-in-time Distributors", "label": "Concentration Risk, Just-in-time Distributors", "terseLabel": "Concentration Risk, Just-in-time Distributors" } } }, "localname": "ConcentrationRiskJustintimeDistributors", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "masi_ConcentrationRiskLonglivedAssetGeographicAreaPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Concentration Risk, Long-lived Asset Geographic Area, Percentage", "label": "Concentration Risk, Long-lived Asset Geographic Area, Percentage", "terseLabel": "Concentration Risk, Long-lived Asset Geographic Area, Percentage" } } }, "localname": "ConcentrationRiskLonglivedAssetGeographicAreaPercentage", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingLonglivedassetsbygeographicareaDetails" ], "xbrltype": "percentItemType" }, "masi_ContingenciesAndCommitmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contingencies And Commitments [Line Items]", "label": "Contingencies And Commitments [Line Items]", "terseLabel": "Contingencies And Commitments [Line Items]" } } }, "localname": "ContingenciesAndCommitmentsLineItems", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "masi_ContingenciesAndCommitmentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contingencies And Commitments [Table]", "label": "Contingencies And Commitments [Table]", "terseLabel": "Contingencies And Commitments [Table]" } } }, "localname": "ContingenciesAndCommitmentsTable", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "masi_DeferredCostsandOtherContractAssetsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Costs and Other Contract Assets [Policy Text Block]", "label": "Deferred Costs and Other Contract Assets [Policy Text Block]", "terseLabel": "Deferred Costs and Other Contract Assets" } } }, "localname": "DeferredCostsandOtherContractAssetsPolicyTextBlock", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "masi_DeferredCostsandOtherContractAssetsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Costs and Other Contract Assets [Text Block]", "label": "Deferred Costs and Other Contract Assets [Text Block]", "terseLabel": "Deferred Costs and Other Contract Assets" } } }, "localname": "DeferredCostsandOtherContractAssetsTextBlock", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/DeferredCostsandOtherContractAssets" ], "xbrltype": "textBlockItemType" }, "masi_DeferredSalesCommissions": { "auth_ref": [], "calculation": { "http://www.masimo.com/role/DeferredCostsandOtherContractAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredCostsAndOtherAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Sales Commissions", "label": "Deferred Sales Commissions", "terseLabel": "Deferred commissions" } } }, "localname": "DeferredSalesCommissions", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/DeferredCostsandOtherContractAssetsDetails" ], "xbrltype": "monetaryItemType" }, "masi_DemonstrationUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Demonstration units.", "label": "Demonstration Units [Member]", "terseLabel": "Demonstration units", "verboseLabel": "Demonstration units" } } }, "localname": "DemonstrationUnitsMember", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/PropertyandEquipmentDetails", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "masi_DocumentAndEntityInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Document and Entity Information [Abstract]", "label": "Document And Entity Information [Abstract]", "terseLabel": "Document And Entity Information [Abstract]" } } }, "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.masimo.com/20211002", "xbrltype": "stringItemType" }, "masi_EmploymentAgreementSeveranceBenefitsSpecialPaymentQualifyingTermination": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Employment Agreement, Severance Benefits, Special Payment, Qualifying Termination", "label": "Employment Agreement, Severance Benefits, Special Payment, Qualifying Termination", "terseLabel": "Employment Agreement, Severance Benefits, Special Payment, Qualifying Termination" } } }, "localname": "EmploymentAgreementSeveranceBenefitsSpecialPaymentQualifyingTermination", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "masi_EmploymentAgreementSeveranceTerms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employment Agreement, Severance Terms", "label": "Employment Agreement, Severance Terms", "terseLabel": "Employment Agreement, Severance Terms" } } }, "localname": "EmploymentAgreementSeveranceTerms", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "masi_Equipmentleasedtocustomers": { "auth_ref": [], "calculation": { "http://www.masimo.com/role/DeferredCostsandOtherContractAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredCostsAndOtherAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equipment leased to customers", "label": "Equipment leased to customers", "terseLabel": "Equipment leased to customers, net" } } }, "localname": "Equipmentleasedtocustomers", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/DeferredCostsandOtherContractAssetsDetails" ], "xbrltype": "monetaryItemType" }, "masi_Fairvalueofcommonstockreceivedforpaymentofstockoptionexerciseprice": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of common stock received for payment of stock option exercise price", "label": "Fair value of common stock received for payment of stock option exercise price", "terseLabel": "Fair value of common stock received for payment of stock option exercise price" } } }, "localname": "Fairvalueofcommonstockreceivedforpaymentofstockoptionexerciseprice", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesSupplementalCashFlowInformationDetail" ], "xbrltype": "monetaryItemType" }, "masi_FurnitureandOfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Furniture and Office Equipment [Member]", "label": "Furniture and Office Equipment [Member]", "terseLabel": "Furniture and office equipment" } } }, "localname": "FurnitureandOfficeEquipmentMember", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "masi_GoodwillAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Goodwill [Abstract]", "label": "Goodwill [Abstract]", "terseLabel": "Goodwill [Abstract]" } } }, "localname": "GoodwillAbstract", "nsuri": "http://www.masimo.com/20211002", "xbrltype": "stringItemType" }, "masi_IncomeTaxPayableNoncurrent": { "auth_ref": [], "calculation": { "http://www.masimo.com/role/OtherNonCurrentLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_DeferredCreditsAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income Tax Payable, Noncurrent", "label": "Income Tax Payable, Noncurrent", "terseLabel": "Income tax payable, non-current" } } }, "localname": "IncomeTaxPayableNoncurrent", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/OtherNonCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "masi_LeasedPropertyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Leased Property [Member]", "label": "Leased Property [Member]", "terseLabel": "Leased Property" } } }, "localname": "LeasedPropertyMember", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "masi_LesseeOperatingLeaseBalanceSheetClassificationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Table Text Block] for Lessee Operating Lease Balance Sheet Classification [Table]", "label": "Lessee Operating Lease Balance Sheet Classification [Table Text Block]", "terseLabel": "Lessee Operating Lease Balance Sheet Classification" } } }, "localname": "LesseeOperatingLeaseBalanceSheetClassificationTableTextBlock", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "masi_LikeMindedEntertainmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Like Minded Entertainment [Member]", "label": "Like Minded Entertainment [Member]", "terseLabel": "Like Minded Media Ventures" } } }, "localname": "LikeMindedEntertainmentMember", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "masi_LikeMindedLabsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Like Minded Labs [Member]", "label": "Like Minded Labs [Member]", "terseLabel": "Like Minded Labs" } } }, "localname": "LikeMindedLabsMember", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "masi_LineofCreditFacilityMaximumSublimit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Line of Credit Facility, Maximum Sublimit", "label": "Line of Credit Facility, Maximum Sublimit", "terseLabel": "Line of Credit Facility, Maximum Sublimit" } } }, "localname": "LineofCreditFacilityMaximumSublimit", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/CreditFacilityDetails" ], "xbrltype": "monetaryItemType" }, "masi_LossContingencyDamagesSoughtValuePerViolation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Damages Sought, Value Per Violation", "label": "Loss Contingency, Damages Sought, Value Per Violation", "terseLabel": "Loss contingency, damages sought" } } }, "localname": "LossContingencyDamagesSoughtValuePerViolation", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "masi_Masimovs.PhysiciansHealthsourceInc.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Masimo vs. Physicians Healthsource, Inc. [Member]", "label": "Masimo vs. Physicians Healthsource, Inc. [Member]", "terseLabel": "Masimo vs. Physicians Healthsource, Inc." } } }, "localname": "Masimovs.PhysiciansHealthsourceInc.Member", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "masi_MasimovsFormerAgencyTenderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Masimo vs Former Agency Tender [Domain]", "label": "Masimo vs Former Agency Tender [Member]", "terseLabel": "Masimo vs Former Agency Tender" } } }, "localname": "MasimovsFormerAgencyTenderMember", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "masi_MinorityInterestCurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails": { "order": 8.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minority Interest - Current Liabilities", "label": "Minority Interest - Current Liabilities", "terseLabel": "Noncontrolling interest(1)" } } }, "localname": "MinorityInterestCurrentLiabilities", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "masi_NotforProfitOrganizationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Not for Profit Organization [Member]", "label": "Not for Profit Organization [Member]", "terseLabel": "Not for Profit Organization" } } }, "localname": "NotforProfitOrganizationMember", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "masi_NumberofSourcesofProductRevenue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Sources of Product Revenue", "label": "Number of Sources of Product Revenue", "terseLabel": "Number of Sources of Product Revenue" } } }, "localname": "NumberofSourcesofProductRevenue", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "masi_OperatingLeaseRightOfUseAssetAccumulatedAmortization": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating Lease, Right-of-Use Asset, Accumulated Amortization", "label": "Operating Lease, Right-of-Use Asset, Accumulated Amortization", "terseLabel": "Operating Lease, Right-of-Use Asset, Accumulated Amortization" } } }, "localname": "OperatingLeaseRightOfUseAssetAccumulatedAmortization", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "masi_OtherAssetsLongtermAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Assets, Longterm [Abstract]", "label": "Other Assets, Longterm [Abstract]", "terseLabel": "Other Assets, Longterm [Abstract]" } } }, "localname": "OtherAssetsLongtermAbstract", "nsuri": "http://www.masimo.com/20211002", "xbrltype": "stringItemType" }, "masi_OtherLiabilitiesLongTermAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Liabilities, Long Term [Abstract]", "label": "Other Liabilities, Long Term [Abstract]", "terseLabel": "Other Liabilities, Long Term [Abstract]" } } }, "localname": "OtherLiabilitiesLongTermAbstract", "nsuri": "http://www.masimo.com/20211002", "xbrltype": "stringItemType" }, "masi_PatentsAndTrademarksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Patents and Trademarks.", "label": "Patents And Trademarks [Member]", "terseLabel": "Patents And Trademarks" } } }, "localname": "PatentsAndTrademarksMember", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "masi_PercentageOfRevenueOneCustomer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of the Company's total revenue that is from one customer.", "label": "Percentage Of Revenue One Customer", "terseLabel": "Percentage Of Revenue One Customer" } } }, "localname": "PercentageOfRevenueOneCustomer", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "masi_PercentageOfRevenueTwoCustomer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of revenue two customer.", "label": "Percentage Of Revenue Two Customer", "terseLabel": "Percentage Of Revenue Two Customer" } } }, "localname": "PercentageOfRevenueTwoCustomer", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "masi_PercentageofAccountsReceivableBalance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of Accounts Receivable Balance", "label": "Percentage of Accounts Receivable Balance", "terseLabel": "Percentage of Accounts Receivable Balance" } } }, "localname": "PercentageofAccountsReceivableBalance", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "masi_PercentageofRevenueCustomerConcentration": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of Revenue - Customer Concentration", "label": "Percentage of Revenue - Customer Concentration", "terseLabel": "Percentage of Revenue - Customer Concentration" } } }, "localname": "PercentageofRevenueCustomerConcentration", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "masi_PrepaidDiscount": { "auth_ref": [], "calculation": { "http://www.masimo.com/role/DeferredCostsandOtherContractAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredCostsAndOtherAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid Discount", "label": "Prepaid Discount", "terseLabel": "Prepaid contract allowances" } } }, "localname": "PrepaidDiscount", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/DeferredCostsandOtherContractAssetsDetails" ], "xbrltype": "monetaryItemType" }, "masi_Proceedsfromstockoptionsexercisedunsettledatperiodend": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from stock options exercised, unsettled at period end", "label": "Proceeds from stock options exercised, unsettled at period end", "terseLabel": "Unsettled common stock proceeds from option exercises" } } }, "localname": "Proceedsfromstockoptionsexercisedunsettledatperiodend", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesSupplementalCashFlowInformationDetail" ], "xbrltype": "monetaryItemType" }, "masi_PropertyPlantandEquipmentOccupiedSquareFeet": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The amount of square feet occupied.", "label": "Property Plant and Equipment, Occupied Square Feet", "terseLabel": "Property Plant and Equipment, Occupied Square Feet" } } }, "localname": "PropertyPlantandEquipmentOccupiedSquareFeet", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsRelatedPartyTransactionsDetails" ], "xbrltype": "areaItemType" }, "masi_ReimbursementFeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reimbursement Fee [Member]", "label": "Reimbursement Fee [Member]", "terseLabel": "Reimbursement Fee" } } }, "localname": "ReimbursementFeeMember", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "masi_SaleTypeLeaseReceivableTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale-Type Lease Receivable [Table Text Block]", "label": "Sale-Type Lease Receivable [Table Text Block]", "terseLabel": "Sale-Type Lease Receivable" } } }, "localname": "SaleTypeLeaseReceivableTableTextBlock", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/LeaseReceivableTables" ], "xbrltype": "textBlockItemType" }, "masi_SalestypeleaseAllowanceforCreditLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sales-type lease, Allowance for Credit Loss", "label": "Sales-type lease, Allowance for Credit Loss", "negatedTerseLabel": "Allowance for credit loss" } } }, "localname": "SalestypeleaseAllowanceforCreditLoss", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/LeaseReceivableSalesTypeDetails" ], "xbrltype": "monetaryItemType" }, "masi_Settlementofpromissorynoteinconnectionwithacquisitionoptionexercise": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Settlement of promissory note in connection with acquisition option exercise", "label": "Settlement of promissory note in connection with acquisition option exercise", "terseLabel": "Settlement of promissory note receivable in connection with business combination" } } }, "localname": "Settlementofpromissorynoteinconnectionwithacquisitionoptionexercise", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesSupplementalCashFlowInformationDetail" ], "xbrltype": "monetaryItemType" }, "masi_SeverancePlanParticipationAgreements": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Severance plan participation agreements.", "label": "Severance Plan Participation Agreements", "terseLabel": "Severance plan participation agreements" } } }, "localname": "SeverancePlanParticipationAgreements", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "masi_ShareBasedCompensationArrangementByShareBasedPaymentAwardRangeOfPercentagePayout": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, range of percentage payout", "label": "Share-based compensation arrangement by share-based payment award, range of percentage payout", "terseLabel": "Share-based compensation arrangement by share-based payment award, range of percentage payout" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRangeOfPercentagePayout", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "masi_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpiredWeighedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expired, Weighed Average Grant Date Fair Value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expired, Weighed Average Grant Date Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expired, Weighed Average Grant Date Fair Value" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpiredWeighedAverageGrantDateFairValue", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationStockBasedCompensationSummaryofUnvestedRSUActivityDetails" ], "xbrltype": "perShareItemType" }, "masi_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpiredinPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expired in Period", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expired in Period", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expired in Period" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpiredinPeriod", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.masimo.com/role/StockBasedCompensationStockBasedCompensationSummaryofUnvestedRSUActivityDetails" ], "xbrltype": "sharesItemType" }, "masi_ShippingandHandlingcostsandFeesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shipping and Handling costs and Fees [Policy Text Block]", "label": "Shipping and Handling costs and Fees [Policy Text Block]", "terseLabel": "Shipping and Handling Costs and Fees" } } }, "localname": "ShippingandHandlingcostsandFeesPolicyTextBlock", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "masi_SubleasedPropertyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subleased Property [Domain]", "label": "Subleased Property [Domain]", "terseLabel": "Subleased Property" } } }, "localname": "SubleasedPropertyDomain", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "masi_SummaryOfSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary Of Significant Accounting Policies [Line Items]", "label": "Summary Of Significant Accounting Policies [Line Items]", "terseLabel": "Summary Of Significant Accounting Policies [Line Items]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesRevenuePerformanceObligationDetails" ], "xbrltype": "stringItemType" }, "masi_SummaryOfSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary Of Significant Accounting Policies [Table]", "label": "Summary Of Significant Accounting Policies [Table]", "terseLabel": "Summary Of Significant Accounting Policies [Table]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesTable", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesRevenuePerformanceObligationDetails" ], "xbrltype": "stringItemType" }, "masi_SupplementalUnemploymentBenefitsSeveranceBenefitsRequiredNoticeofResignation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supplemental Unemployment Benefits, Severance Benefits, Required Notice of Resignation", "label": "Supplemental Unemployment Benefits, Severance Benefits, Required Notice of Resignation", "terseLabel": "Supplemental Unemployment Benefits, Severance Benefits, Required Notice of Resignation" } } }, "localname": "SupplementalUnemploymentBenefitsSeveranceBenefitsRequiredNoticeofResignation", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "masi_TaxesCollectedFromCustomersAndRemittedToGovernmentalAuthoritiesPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for taxes collected from customers and remitted to government authorities.", "label": "Taxes Collected From Customers And Remitted To Governmental Authorities Policy [Policy Text Block]", "terseLabel": "Taxes Collected From Customers And Remitted To Governmental Authorities" } } }, "localname": "TaxesCollectedFromCustomersAndRemittedToGovernmentalAuthoritiesPolicyPolicyTextBlock", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "masi_UnrecognizedTaxBenefitsLiabilitiesNoncurrent": { "auth_ref": [], "calculation": { "http://www.masimo.com/role/OtherNonCurrentLiabilitiesDetail": { "order": 3.0, "parentTag": "us-gaap_DeferredCreditsAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Unrecognized tax benefits liabilities noncurrent.", "label": "Unrecognized Tax Benefits Liabilities Noncurrent", "terseLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefitsLiabilitiesNoncurrent", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/OtherNonCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "masi_VantrixCorpMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vantrix Corp [Member]", "label": "Vantrix Corp [Member]", "terseLabel": "Vantrix Corp" } } }, "localname": "VantrixCorpMember", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "masi_WarrantyPeriodForDefectsInMaterialAndWorkmanship": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warranty period for defects in material and workmanship.", "label": "Warranty Period For Defects In Material And Workmanship", "terseLabel": "Warranty period for defects in material and workmanship" } } }, "localname": "WarrantyPeriodForDefectsInMaterialAndWorkmanship", "nsuri": "http://www.masimo.com/20211002", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "srt_AmericasMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Americas [Member]", "terseLabel": "North and South America (excluding the U.S.)" } } }, "localname": "AmericasMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingAnalysisofProductRevenuesBaseduponGeographicAreaShippedDetail", "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingLonglivedassetsbygeographicareaDetails" ], "xbrltype": "domainItemType" }, "srt_AsiaPacificMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Asia Pacific [Member]", "terseLabel": "Asia Pacific [Member]", "verboseLabel": "Asia and Australia" } } }, "localname": "AsiaPacificMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingAnalysisofProductRevenuesBaseduponGeographicAreaShippedDetail", "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingLonglivedassetsbygeographicareaDetails" ], "xbrltype": "domainItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]", "terseLabel": "Chief Executive Officer", "verboseLabel": "Chief Executive Officer" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.masimo.com/role/StockBasedCompensationStockBasedCompensationSummaryofUnvestedRSUActivityDetails", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r143", "r199", "r217", "r218", "r219", "r220", "r221", "r223", "r227", "r319", "r320", "r321", "r322", "r323", "r324", "r326", "r327", "r329", "r331", "r332" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.masimo.com/role/IntangibleAssetsAdditionalInformationDetails", "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingAnalysisofProductRevenuesBaseduponGeographicAreaShippedDetail", "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingLonglivedassetsbygeographicareaDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r143", "r199", "r217", "r218", "r219", "r220", "r221", "r223", "r227", "r319", "r320", "r321", "r322", "r323", "r324", "r326", "r327", "r329", "r331", "r332" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.masimo.com/role/IntangibleAssetsAdditionalInformationDetails", "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingAnalysisofProductRevenuesBaseduponGeographicAreaShippedDetail", "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingLonglivedassetsbygeographicareaDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r234", "r409", "r413", "r666" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingAnalysisofProductRevenuesBaseduponGeographicAreaShippedDetail" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r337", "r373", "r418", "r420", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r664", "r667", "r696", "r697" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum", "verboseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesRevenuePerformanceObligationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r337", "r373", "r418", "r420", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r664", "r667", "r696", "r697" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum", "verboseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.masimo.com/role/RelatedPartyTransactionsRelatedPartyTransactionsDetails", "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesRevenuePerformanceObligationDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r234", "r409", "r413", "r666" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingAnalysisofProductRevenuesBaseduponGeographicAreaShippedDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r337", "r373", "r415", "r418", "r420", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r664", "r667", "r696", "r697" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.masimo.com/role/GoodwillDetails", "http://www.masimo.com/role/IntangibleAssetsAdditionalInformationDetails", "http://www.masimo.com/role/RelatedPartyTransactionsRelatedPartyTransactionsDetails", "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.masimo.com/role/StockBasedCompensationStockBasedCompensationSummaryofUnvestedRSUActivityDetails", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesRevenuePerformanceObligationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r337", "r373", "r415", "r418", "r420", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r664", "r667", "r696", "r697" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.masimo.com/role/GoodwillDetails", "http://www.masimo.com/role/IntangibleAssetsAdditionalInformationDetails", "http://www.masimo.com/role/RelatedPartyTransactionsRelatedPartyTransactionsDetails", "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.masimo.com/role/StockBasedCompensationStockBasedCompensationSummaryofUnvestedRSUActivityDetails", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesRevenuePerformanceObligationDetails" ], "xbrltype": "domainItemType" }, "srt_ReportableGeographicalComponentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Reportable Geographical Components [Member]", "terseLabel": "Reportable Geographical Components" } } }, "localname": "ReportableGeographicalComponentsMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingAnalysisofProductRevenuesBaseduponGeographicAreaShippedDetail", "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingLonglivedassetsbygeographicareaDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r230", "r231", "r409", "r412", "r665", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingAnalysisofProductRevenuesBaseduponGeographicAreaShippedDetail", "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingLonglivedassetsbygeographicareaDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r230", "r231", "r409", "r412", "r665", "r681", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingAnalysisofProductRevenuesBaseduponGeographicAreaShippedDetail", "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingLonglivedassetsbygeographicareaDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r236", "r589" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.masimo.com/role/StockBasedCompensationStockBasedCompensationSummaryofUnvestedRSUActivityDetails", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.masimo.com/role/StockBasedCompensationStockBasedCompensationSummaryofUnvestedRSUActivityDetails", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201613Member": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.", "label": "Accounting Standards Update 2016-13 [Member]", "terseLabel": "Cumulative effect of adoption of ASU 2016-13" } } }, "localname": "AccountingStandardsUpdate201613Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/ConsolidatedStatementofStockholdersEquityConsolidatedStatementofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Other Current Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/OtherCurrentLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r53", "r595" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableOtherCurrentAndNoncurrent": { "auth_ref": [ "r638", "r658" ], "calculation": { "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligations incurred and payable classified as other.", "label": "Accounts Payable, Other", "terseLabel": "Accrued customer reimbursements" } } }, "localname": "AccountsPayableOtherCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r682" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r10", "r33", "r237", "r238" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Trade accounts receivable, net of allowance for credit losses" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent": { "auth_ref": [ "r19", "r58", "r467" ], "calculation": { "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrual for Taxes Other than Income Taxes, Current", "terseLabel": "Accrued indirect taxes payable" } } }, "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r27", "r634", "r651" ], "calculation": { "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "terseLabel": "Income tax payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "auth_ref": [], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.", "label": "Accrued Liabilities and Other Liabilities", "terseLabel": "Other current liabilities", "totalLabel": "Total other current liabilities" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets", "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r58" ], "calculation": { "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Liabilities [Abstract]", "terseLabel": "Accrued Liabilities [Abstract]" } } }, "localname": "AccruedLiabilitiesCurrentAndNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent": { "auth_ref": [ "r638", "r658" ], "calculation": { "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails": { "order": 11.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received.", "label": "Accrued Professional Fees", "terseLabel": "Accrued legal fees" } } }, "localname": "AccruedProfessionalFeesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r51", "r293" ], "calculation": { "http://www.masimo.com/role/PropertyandEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/PropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": { "auth_ref": [ "r74", "r76", "r77", "r78", "r531" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.", "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax", "terseLabel": "Accumulated other comprehensive (loss) income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r75", "r78", "r84", "r85", "r86", "r145", "r146", "r147", "r511", "r670", "r671", "r710" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/ConsolidatedStatementofStockholdersEquityConsolidatedStatementofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Acquired Indefinite-lived Intangible Assets [Line Items]", "terseLabel": "Acquired Indefinite-lived Intangible Assets [Line Items]" } } }, "localname": "AcquiredIndefiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r34", "r461", "r595" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r145", "r146", "r147", "r458", "r459", "r460", "r527" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/ConsolidatedStatementofStockholdersEquityConsolidatedStatementofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r148", "r149", "r150", "r151", "r160", "r247", "r248", "r252", "r253", "r254", "r255", "r256", "r257", "r318", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r481", "r482", "r483", "r484", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r583", "r612", "r613", "r614", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r706", "r707", "r708", "r709", "r710" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/ConsolidatedStatementofStockholdersEquityConsolidatedStatementofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedTerseLabel": "Shares paid for tax withholding, value" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/ConsolidatedStatementofStockholdersEquityConsolidatedStatementofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r421", "r423", "r464", "r465" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based Compensation Expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/ConsolidatedStatementofStockholdersEquityConsolidatedStatementofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r423", "r450", "r463" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Share-based Compensation Expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/ConsolidatedStatementofStockholdersEquityConsolidatedStatementofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r39", "r243", "r258" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r119", "r277", "r285" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of Intangible Assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r172" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Options to purchase of shares of common stock" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r138", "r207", "r219", "r225", "r250", "r319", "r320", "r321", "r323", "r324", "r325", "r326", "r328", "r330", "r332", "r333", "r507", "r512", "r535", "r593", "r595", "r632", "r650" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r14", "r16", "r73", "r138", "r250", "r319", "r320", "r321", "r323", "r324", "r325", "r326", "r328", "r330", "r332", "r333", "r507", "r512", "r535", "r593", "r595" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateAxis": { "auth_ref": [ "r424", "r452" ], "lang": { "en-us": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "Award Date [Axis]", "terseLabel": "Award Date [Axis]" } } }, "localname": "AwardDateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.masimo.com/role/StockBasedCompensationStockBasedCompensationSummaryofUnvestedRSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted.", "label": "Award Date [Domain]", "terseLabel": "Award Date [Domain]" } } }, "localname": "AwardDateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.masimo.com/role/StockBasedCompensationStockBasedCompensationSummaryofUnvestedRSUActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r424", "r452" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.masimo.com/role/StockBasedCompensationStockBasedCompensationSummaryofUnvestedRSUActivityDetails", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingAndBuildingImprovementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Building and Building Improvements [Member]", "terseLabel": "Building and building improvements" } } }, "localname": "BuildingAndBuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/PropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r417", "r419" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesDetails", "http://www.masimo.com/role/GoodwillDetails", "http://www.masimo.com/role/IntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r417", "r419", "r497", "r498" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesDetails", "http://www.masimo.com/role/GoodwillDetails", "http://www.masimo.com/role/IntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r496" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "Business Combinations" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r125", "r126", "r127" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Unpaid purchases of property and equipment" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesSupplementalCashFlowInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r8", "r47", "r121" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets", "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesSupplementalCashFlowInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r22", "r123" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r112", "r121", "r128" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesSupplementalCashFlowInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r112", "r548" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashDistributionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Distribution of cash made by the entity based on a contractual agreement such as a partnership or employment agreement.", "label": "Cash Distribution [Member]", "terseLabel": "Cash Distribution" } } }, "localname": "CashDistributionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CashFDICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.", "label": "Cash, FDIC Insured Amount", "terseLabel": "Bank balance covered by Federal Deposit Insurance Corporation limit" } } }, "localname": "CashFDICInsuredAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r135", "r138", "r163", "r167", "r168", "r169", "r171", "r179", "r180", "r181", "r250", "r319", "r324", "r325", "r326", "r332", "r333", "r371", "r372", "r376", "r380", "r535", "r704" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.masimo.com/role/StockBasedCompensationStockBasedCompensationSummaryofUnvestedRSUActivityDetails", "http://www.masimo.com/role/StockRepurchaseProgramAdditionalInformationDetail", "http://www.masimo.com/role/StockRepurchaseProgramTables" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockRepurchaseProgramAdditionalInformationDetail", "http://www.masimo.com/role/StockRepurchaseProgramTables" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r63", "r302", "r639", "r657" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies - (Note 21)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r299", "r300", "r301", "r305", "r683" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r65" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common Stock, Capital Shares Reserved for Future Issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r145", "r146", "r527" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/ConsolidatedStatementofStockholdersEquityConsolidatedStatementofStockholdersEquity", "http://www.masimo.com/role/StockRepurchaseProgramAdditionalInformationDetail", "http://www.masimo.com/role/StockRepurchaseProgramTables" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r32", "r387" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common Stock, Shares, Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValueOutstanding": { "auth_ref": [ "r32" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.", "label": "Common Stock, Value, Outstanding", "terseLabel": "Common Stock, Value, Outstanding" } } }, "localname": "CommonStockValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r80", "r82", "r83", "r90", "r641", "r659" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Income" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer equipment and software" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/PropertyandEquipmentDetails", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r189", "r190", "r234", "r533", "r534", "r682" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.masimo.com/role/CommitmentsandContingenciesTables", "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingAnalysisofProductRevenuesBaseduponGeographicAreaShippedDetail", "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingLonglivedassetsbygeographicareaDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r189", "r190", "r234", "r533", "r534", "r680", "r682" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.masimo.com/role/CommitmentsandContingenciesTables", "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingAnalysisofProductRevenuesBaseduponGeographicAreaShippedDetail", "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingLonglivedassetsbygeographicareaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r189", "r190", "r234", "r533", "r534", "r680", "r682" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.masimo.com/role/CommitmentsandContingenciesTables", "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingAnalysisofProductRevenuesBaseduponGeographicAreaShippedDetail", "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingLonglivedassetsbygeographicareaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r189", "r190", "r234", "r533", "r534" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration Risk, Percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingAnalysisofProductRevenuesBaseduponGeographicAreaShippedDetail", "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingLonglivedassetsbygeographicareaDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r189", "r190", "r234", "r533", "r534", "r682" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.masimo.com/role/CommitmentsandContingenciesTables", "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingAnalysisofProductRevenuesBaseduponGeographicAreaShippedDetail", "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingLonglivedassetsbygeographicareaDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction-in-progress (CIP)" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/PropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "terseLabel": "Contract with Customer, Asset and Liability" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r97", "r610" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofOperationsCondensedConsolidatedStatementofOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of goods sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofOperationsCondensedConsolidatedStatementofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CreditFacilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CreditFacilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r500" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsAdditionalInformationDetails", "http://www.masimo.com/role/IntangibleAssetsScheduleofFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r134", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r351", "r358", "r359", "r361", "r367" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Credit Facility" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CreditFacility" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r26", "r27", "r28", "r137", "r143", "r334", "r335", "r336", "r337", "r338", "r339", "r341", "r347", "r348", "r349", "r350", "r352", "r353", "r354", "r355", "r356", "r357", "r363", "r364", "r365", "r366", "r560", "r633", "r635", "r648" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CreditFacilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CreditFacilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r61", "r137", "r143", "r334", "r335", "r336", "r337", "r338", "r339", "r341", "r347", "r348", "r349", "r350", "r352", "r353", "r354", "r355", "r356", "r357", "r363", "r364", "r365", "r366", "r560" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CreditFacilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "auth_ref": [ "r646" ], "lang": { "en-us": { "role": { "documentation": "Information about timing of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period [Axis]", "terseLabel": "Debt Instrument, Redemption, Period [Axis]" } } }, "localname": "DebtInstrumentRedemptionPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CreditFacilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "auth_ref": [ "r646" ], "lang": { "en-us": { "role": { "documentation": "Period as defined under terms of the debt agreement for debt redemption features.", "label": "Debt Instrument, Redemption, Period [Domain]", "terseLabel": "Debt Instrument, Redemption, Period [Domain]" } } }, "localname": "DebtInstrumentRedemptionPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CreditFacilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r61", "r137", "r143", "r334", "r335", "r336", "r337", "r338", "r339", "r341", "r347", "r348", "r349", "r350", "r352", "r353", "r354", "r355", "r356", "r357", "r360", "r363", "r364", "r365", "r366", "r388", "r391", "r392", "r393", "r557", "r558", "r560", "r561", "r647" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CreditFacilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCosts": { "auth_ref": [ "r25", "r631", "r649" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.", "label": "Deferred Costs, Noncurrent", "terseLabel": "Deferred costs and other contract assets" } } }, "localname": "DeferredCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCostsAndOtherAssets": { "auth_ref": [], "calculation": { "http://www.masimo.com/role/DeferredCostsandOtherContractAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred cost assets and assets classified as other.", "label": "Deferred Costs and Other Assets", "totalLabel": "Deferred costs and other contract assets" } } }, "localname": "DeferredCostsAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/DeferredCostsandOtherContractAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]", "terseLabel": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "terseLabel": "Schedule of Deferred Costs and Other Contract Assets" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/DeferredCostsandOtherContractAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredCreditsAndOtherLiabilities": { "auth_ref": [], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.masimo.com/role/OtherNonCurrentLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income in future periods and obligations not separately disclosed in the balance sheet (other liabilities).", "label": "Deferred Credits and Other Liabilities", "terseLabel": "Other non-current liabilities", "totalLabel": "Total other non-current liabilities" } } }, "localname": "DeferredCreditsAndOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets", "http://www.masimo.com/role/OtherNonCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r470", "r471" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax assets" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r119", "r139", "r479", "r487", "r488", "r489" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Provision for deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenue": { "auth_ref": [ "r40" ], "calculation": { "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred Revenue", "periodEndLabel": "Deferred revenue, end of the period", "periodStartLabel": "Deferred revenue, beginning of the period", "terseLabel": "Deferred revenue" } } }, "localname": "DeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesChangesinDeferredRevenueDetails", "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueAdditions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.", "label": "Deferred Revenue, Additions", "terseLabel": "Revenue deferred during the period" } } }, "localname": "DeferredRevenueAdditions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesChangesinDeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueArrangementByTypeTable": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Schedule of deferred revenue disclosure which includes the type of arrangements and the corresponding amount that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.", "label": "Deferred Revenue Arrangement, by Type [Table]", "terseLabel": "Deferred Revenue Arrangement, by Type [Table]" } } }, "localname": "DeferredRevenueArrangementByTypeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred Revenue, Current", "terseLabel": "Deferred revenue and other contract liabilities - current", "verboseLabel": "Deferred revenue and other contract liabilities, current" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets", "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueNoncurrent": { "auth_ref": [ "r40" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Deferred Revenue, Noncurrent", "negatedLabel": "Less: Non-current portion of deferred revenue" } } }, "localname": "DeferredRevenueNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueRevenueRecognized1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue.", "label": "Deferred Revenue, Revenue Recognized", "negatedTerseLabel": "Recognition of revenue deferred in prior periods" } } }, "localname": "DeferredRevenueRevenueRecognized1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesChangesinDeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r471", "r477" ], "calculation": { "http://www.masimo.com/role/OtherNonCurrentLiabilitiesDetail": { "order": 4.0, "parentTag": "us-gaap_DeferredCreditsAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "terseLabel": "Deferred tax liabilities" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/OtherNonCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount", "terseLabel": "Company's contribution to employee retirement savings plan" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.", "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent", "terseLabel": "Company contribution percentage based on employee contribution of up to 3% of employee's compensation" } } }, "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DepositAssets": { "auth_ref": [ "r72" ], "calculation": { "http://www.masimo.com/role/OtherCurrentAssetsDetails": { "order": 8.0, "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.", "label": "Deposit Assets", "terseLabel": "Deposit to acquire noncontrolling interest(2)" } } }, "localname": "DepositAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/OtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositsAssetsNoncurrent": { "auth_ref": [ "r52" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.", "label": "Deposits Assets, Noncurrent", "terseLabel": "Prepaid deposits and other" } } }, "localname": "DepositsAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/OtherNonCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r119", "r291" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/PropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r119", "r202" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r53", "r142", "r322", "r324", "r325", "r331", "r332", "r333", "r587" ], "calculation": { "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails": { "order": 9.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "terseLabel": "Related party payables" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EMEAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Regions of Europe, Middle East and Africa.", "label": "EMEA [Member]", "terseLabel": "EMEA [Member]", "verboseLabel": "Europe, Middle East and Africa" } } }, "localname": "EMEAMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingAnalysisofProductRevenuesBaseduponGeographicAreaShippedDetail", "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingLonglivedassetsbygeographicareaDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r91", "r152", "r153", "r154", "r155", "r156", "r161", "r163", "r169", "r170", "r171", "r174", "r175", "r528", "r529", "r642", "r660" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic", "verboseLabel": "Net income per basic share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofOperationsCondensedConsolidatedStatementofOperations", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesReconciliationofBasicandDilutedNetIncomePerShareDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r91", "r152", "r153", "r154", "r155", "r156", "r163", "r169", "r170", "r171", "r174", "r175", "r528", "r529", "r642", "r660" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted", "verboseLabel": "Net income per diluted share" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofOperationsCondensedConsolidatedStatementofOperations", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesReconciliationofBasicandDilutedNetIncomePerShareDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r172", "r173" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Income Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share Reconciliation [Abstract]", "terseLabel": "Net income attributable to stockholders of Masimo Corporation:" } } }, "localname": "EarningsPerShareReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesReconciliationofBasicandDilutedNetIncomePerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r548" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "Effect of foreign currency exchange rates on cash" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r58" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r451" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r451" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.masimo.com/role/StockBasedCompensationStockBasedCompensationSummaryofUnvestedRSUActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r451" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r448" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Employee Stock Option" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.masimo.com/role/StockBasedCompensationStockBasedCompensationSummaryofUnvestedRSUActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue from External Customer [Line Items]", "terseLabel": "Revenue from External Customer [Line Items]" } } }, "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesTables" ], "xbrltype": "stringItemType" }, "us-gaap_EntityWideRevenueMajorCustomerLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue, Major Customer [Line Items]", "terseLabel": "Revenue, Major Customer [Line Items]" } } }, "localname": "EntityWideRevenueMajorCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingAnalysisofProductRevenuesBaseduponGeographicAreaShippedDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r84", "r85", "r86", "r145", "r146", "r147", "r149", "r157", "r159", "r178", "r255", "r387", "r394", "r458", "r459", "r460", "r483", "r484", "r527", "r549", "r550", "r551", "r552", "r553", "r554", "r670", "r671", "r672", "r710" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/ConsolidatedStatementofStockholdersEquityConsolidatedStatementofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r48", "r208", "r249" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Strategic investments" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/OtherNonCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r530", "r532" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Measurements" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Finite-Lived Intangible Asset, Useful Life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "Weighted average period before the next renewal or extension (both explicit and implicit) for intangible assets that have been renewed or extended, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Weighted Average Period before Next Renewal or Extension", "terseLabel": "Weighted average number of years until the next renewal" } } }, "localname": "FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r284" ], "calculation": { "http://www.masimo.com/role/IntangibleAssetsScheduleofFiniteLivedIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsScheduleofFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "calculation": { "http://www.masimo.com/role/IntangibleAssetsFutureAmortizationExpenseDetails": { "order": 6.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r286" ], "calculation": { "http://www.masimo.com/role/IntangibleAssetsFutureAmortizationExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2021 (balance of year)" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r286" ], "calculation": { "http://www.masimo.com/role/IntangibleAssetsFutureAmortizationExpenseDetails": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r286" ], "calculation": { "http://www.masimo.com/role/IntangibleAssetsFutureAmortizationExpenseDetails": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r286" ], "calculation": { "http://www.masimo.com/role/IntangibleAssetsFutureAmortizationExpenseDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r286" ], "calculation": { "http://www.masimo.com/role/IntangibleAssetsFutureAmortizationExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r278", "r281", "r284", "r287", "r611", "r615" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsAdditionalInformationDetails", "http://www.masimo.com/role/IntangibleAssetsScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsCostIncurredToRenewOrExtend": { "auth_ref": [ "r288" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of capitalized costs incurred in the period to renew or extend the term of a recognized finite-lived (amortizing and amortizable) intangible asset.", "label": "Finite-Lived Intangible Assets, Cost Incurred to Renew or Extend", "terseLabel": "Finite-Lived Intangible Assets, Cost Incurred to Renew or Extend" } } }, "localname": "FiniteLivedIntangibleAssetsCostIncurredToRenewOrExtend", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r284", "r615" ], "calculation": { "http://www.masimo.com/role/IntangibleAssetsScheduleofFiniteLivedIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Total intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsScheduleofFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsAdditionalInformationDetails", "http://www.masimo.com/role/IntangibleAssetsScheduleofFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r278", "r283" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsAdditionalInformationDetails", "http://www.masimo.com/role/IntangibleAssetsScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r284", "r611" ], "calculation": { "http://www.masimo.com/role/IntangibleAssetsFutureAmortizationExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.masimo.com/role/IntangibleAssetsScheduleofFiniteLivedIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Intangible assets, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsFutureAmortizationExpenseDetails", "http://www.masimo.com/role/IntangibleAssetsScheduleofFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedLicenseAgreementsGross": { "auth_ref": [ "r284" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross carrying amount as of the balance sheet date of certain rights acquired to exercise a certain privilege or pursue a particular business or occupation and which is deemed to have a finite economic life.", "label": "Finite-Lived License Agreements, Gross", "terseLabel": "Finite-Lived License Agreements, Gross" } } }, "localname": "FiniteLivedLicenseAgreementsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsRelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiscalPeriod": { "auth_ref": [ "r503" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.", "label": "Fiscal Period, Policy [Policy Text Block]", "terseLabel": "Fiscal Periods" } } }, "localname": "FiscalPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r544", "r545", "r546", "r547" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "terseLabel": "Realized and unrealized foreign currency (losses) gains" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/NonoperatingincomeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignLineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars, outside the reporting entity's home country.", "label": "Foreign Line of Credit [Member]", "terseLabel": "Foreign Line of Credit [Member]" } } }, "localname": "ForeignLineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CreditFacilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "verboseLabel": "Furniture and office equipment" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/PropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r119" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedTerseLabel": "Loss on disposal of equipment, intangibles and other assets" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossRelatedToLitigationSettlement": { "auth_ref": [ "r302" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofOperationsCondensedConsolidatedStatementofOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.", "label": "Gain (Loss) Related to Litigation Settlement", "negatedTerseLabel": "Litigation awards" } } }, "localname": "GainLossRelatedToLitigationSettlement", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofOperationsCondensedConsolidatedStatementofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeographicConcentrationRiskMember": { "auth_ref": [ "r188", "r682" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).", "label": "Geographic Concentration Risk [Member]", "terseLabel": "Geographic Concentration Risk" } } }, "localname": "GeographicConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingLonglivedassetsbygeographicareaDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r268", "r269", "r595", "r630" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets", "http://www.masimo.com/role/GoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillDisclosureTextBlock": { "auth_ref": [ "r275" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill.", "label": "Goodwill Disclosure [Text Block]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/Goodwill" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r270" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/GoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/GoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r96", "r138", "r207", "r218", "r221", "r224", "r227", "r250", "r319", "r320", "r321", "r324", "r325", "r326", "r328", "r330", "r332", "r333", "r535" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofOperationsCondensedConsolidatedStatementofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofOperationsCondensedConsolidatedStatementofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]", "verboseLabel": "Impairment of Goodwill, Intangible Assets and Other Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r89", "r207", "r218", "r221", "r224", "r227", "r628", "r640", "r644", "r661" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofOperationsCondensedConsolidatedStatementofOperations": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofOperationsCondensedConsolidatedStatementofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r140", "r473", "r476", "r478", "r485", "r490", "r493", "r494", "r495" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityCumulativeEffectOfChangeInAccountingPrinciple": { "auth_ref": [ "r486", "r491" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cumulative tax effect on beginning retained earnings from change in accounting principle.", "label": "Income Tax Effects Allocated Directly to Equity, Cumulative Effect of Change in Accounting Principle", "terseLabel": "Income Tax Effects Allocated Directly to Equity, Cumulative Effect of Change in Accounting Principle" } } }, "localname": "IncomeTaxEffectsAllocatedDirectlyToEquityCumulativeEffectOfChangeInAccountingPrinciple", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/ConsolidatedStatementofStockholdersEquityConsolidatedStatementofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r141", "r158", "r159", "r205", "r472", "r486", "r492", "r662" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofOperationsCondensedConsolidatedStatementofOperations": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofOperationsCondensedConsolidatedStatementofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r115", "r124" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesSupplementalCashFlowInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r118" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "(Decrease) increase in accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r118" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Increase in accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r118" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "Decrease in income tax payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r118" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "(Decrease) increase in accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredCharges": { "auth_ref": [ "r118" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.", "label": "Increase (Decrease) in Deferred Charges", "negatedLabel": "Increase in deferred costs and other contract assets" } } }, "localname": "IncreaseDecreaseInDeferredCharges", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r118" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Deferred Revenue", "terseLabel": "Increase in deferred revenue and other contract-related liabilities" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r118" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase (Decrease) in Employee Related Liabilities", "terseLabel": "(Decrease) increase in accrued compensation" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r118" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Decrease (increase) in inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r118" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedTerseLabel": "Decrease (increase) in other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r118" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedTerseLabel": "Increase in other non-current assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r118" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Increase in other non-current liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r164", "r165", "r166", "r171" ], "calculation": { "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesReconciliationofBasicandDilutedNetIncomePerShareDetail": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Diluted share equivalent: stock options, RSUs and PSUs" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesReconciliationofBasicandDilutedNetIncomePerShareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/IntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "auth_ref": [ "r130", "r283", "r607", "r608", "r609", "r611" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.", "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "IntangibleAssetsFiniteLivedPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r276", "r282" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r87", "r201", "r556", "r559", "r643" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/NonoperatingincomeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r100", "r355", "r362", "r365", "r366" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "terseLabel": "Interest Expense, Debt" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CreditFacilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income earned from interest bearing assets classified as other.", "label": "Interest Income, Other", "terseLabel": "Interest income" } } }, "localname": "InterestIncomeOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/NonoperatingincomeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r109", "r114", "r124" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest expense" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesSupplementalCashFlowInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r41", "r262" ], "calculation": { "http://www.masimo.com/role/InventoriesComponentsofInventoryDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/InventoriesComponentsofInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r9", "r69", "r595" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.masimo.com/role/InventoriesComponentsofInventoryDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "totalLabel": "Total inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets", "http://www.masimo.com/role/InventoriesComponentsofInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r21", "r70", "r131", "r176", "r260", "r261", "r263", "r605" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r43", "r262" ], "calculation": { "http://www.masimo.com/role/InventoriesComponentsofInventoryDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/InventoriesComponentsofInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r42", "r262" ], "calculation": { "http://www.masimo.com/role/InventoriesComponentsofInventoryDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work-in-process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/InventoriesComponentsofInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandBuildingsAndImprovementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Real estate held and additions or improvements to real estate held and structures used in the conduct of business.", "label": "Land, Buildings and Improvements [Member]", "verboseLabel": "Building and building improvements" } } }, "localname": "LandBuildingsAndImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r411" ], "lang": { "en-us": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/PropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/PropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.", "label": "Legal Matters and Contingencies [Text Block]", "terseLabel": "Litigation Costs and Contingencies" } } }, "localname": "LegalMattersAndContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r572" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Lessee, Operating Lease, Liability, Maturity" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r572" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "terseLabel": "Total" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesFutureMaturitiesOperatingLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r572" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter(1)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesFutureMaturitiesOperatingLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r572" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2021 (balance of year)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesFutureMaturitiesOperatingLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r572" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesFutureMaturitiesOperatingLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r572" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesFutureMaturitiesOperatingLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r572" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesFutureMaturitiesOperatingLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r572" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesFutureMaturitiesOperatingLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r572" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesFutureMaturitiesOperatingLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r565" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Lessee, Operating Lease, Renewal Term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r574" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Lessee, ROU Assets and Lease Liabilities" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorSalesTypeLeasesTextBlock": { "auth_ref": [ "r582" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of lessor's sales-type leases.", "label": "Lessor, Sales-type Leases [Text Block]", "terseLabel": "Lease Receivable" } } }, "localname": "LessorSalesTypeLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/LeaseReceivable" ], "xbrltype": "textBlockItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters of Credit Outstanding, Amount", "terseLabel": "Letters of Credit Outstanding, Amount" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CreditFacilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r57", "r138", "r220", "r250", "r319", "r320", "r321", "r324", "r325", "r326", "r328", "r330", "r332", "r333", "r508", "r512", "r513", "r535", "r593", "r594" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r38", "r138", "r250", "r535", "r595", "r637", "r655" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r60", "r138", "r250", "r319", "r320", "r321", "r324", "r325", "r326", "r328", "r330", "r332", "r333", "r508", "r512", "r513", "r535", "r593", "r594", "r595" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r501" ], "lang": { "en-us": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "terseLabel": "Licenses-related party" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsScheduleofFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "auth_ref": [ "r55" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Current Borrowing Capacity", "terseLabel": "Current Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CreditFacilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r55" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CreditFacilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationSettlementExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.", "label": "Litigation Settlement, Expense", "terseLabel": "Litigation Settlement, Expense" } } }, "localname": "LitigationSettlementExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.", "label": "Long-lived Assets by Geographic Areas [Table Text Block]", "terseLabel": "Schedule of Long-lived Assets by Geographic Areas" } } }, "localname": "LongLivedAssetsByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermLineOfCredit": { "auth_ref": [ "r61", "r315", "r316" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit, Noncurrent", "terseLabel": "Long-term Line of Credit, Noncurrent" } } }, "localname": "LongTermLineOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CreditFacilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CreditFacilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r61", "r317" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CreditFacilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyDamagesAwardedValue": { "auth_ref": [ "r302", "r303", "r304" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of damages awarded to the plaintiff in the legal matter.", "label": "Loss Contingency, Damages Awarded, Value", "terseLabel": "Loss Contingency, Damages Awarded, Value" } } }, "localname": "LossContingencyDamagesAwardedValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment [Member]", "terseLabel": "Machinery, equipment and tooling" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/PropertyandEquipmentDetails", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MovementInDeferredRevenueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Movement in Deferred Revenue [Roll Forward]", "terseLabel": "Movement in Deferred Revenue [Roll Forward]" } } }, "localname": "MovementInDeferredRevenueRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesChangesinDeferredRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]", "terseLabel": "Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]" } } }, "localname": "MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesChangesinProductWarrantyAccrualDetail" ], "xbrltype": "stringItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r182", "r194" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "Description of the Company" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/DescriptionoftheCompany" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r112" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r112" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r112", "r117", "r120" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]", "terseLabel": "Basic net income per share:" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesReconciliationofBasicandDilutedNetIncomePerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]", "terseLabel": "Diluted net income per share:" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesReconciliationofBasicandDilutedNetIncomePerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_NetInvestmentInLeaseCurrent": { "auth_ref": [ "r258", "r575", "r576" ], "calculation": { "http://www.masimo.com/role/OtherCurrentAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of net investment in sales-type and direct financing leases, classified as current.", "label": "Net Investment in Lease, before Allowance for Credit Loss, Current", "negatedTerseLabel": "Less: current portion of lease receivable", "terseLabel": "Lease receivable, current" } } }, "localname": "NetInvestmentInLeaseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/LeaseReceivableSalesTypeDetails", "http://www.masimo.com/role/OtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetInvestmentInLeaseNoncurrent": { "auth_ref": [ "r258", "r575", "r576" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of net investment in sales-type and direct financing leases, classified as noncurrent.", "label": "Net Investment in Lease, before Allowance for Credit Loss, Noncurrent", "terseLabel": "Lease receivable, noncurrent" } } }, "localname": "NetInvestmentInLeaseNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets", "http://www.masimo.com/role/LeaseReceivableSalesTypeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "International" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingLonglivedassetsbygeographicareaDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NoncurrentAssets": { "auth_ref": [ "r231" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.", "label": "Long-Lived Assets", "terseLabel": "Long-Lived Assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingLonglivedassetsbygeographicareaDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r99" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofOperationsCondensedConsolidatedStatementofOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "terseLabel": "Non-operating (loss) income" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofOperationsCondensedConsolidatedStatementofOperations", "http://www.masimo.com/role/NonoperatingincomeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Nonoperating Income (Expense) [Abstract]" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_NontradeReceivablesCurrent": { "auth_ref": [ "r71" ], "calculation": { "http://www.masimo.com/role/OtherCurrentAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The sum of amounts currently receivable other than from customers. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.", "label": "Nontrade Receivables, Current", "terseLabel": "Customer notes receivable" } } }, "localname": "NontradeReceivablesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/OtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofOperationsCondensedConsolidatedStatementofOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofOperationsCondensedConsolidatedStatementofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r207", "r218", "r221", "r224", "r227" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofOperationsCondensedConsolidatedStatementofOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofOperationsCondensedConsolidatedStatementofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r566", "r573" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease costs" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r563" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Present value" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesFutureMaturitiesOperatingLeasePaymentsDetails", "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesLesseeOperatingLeaseBalanceSheetClassificationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r563" ], "calculation": { "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Lessee lease liabilities, current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesLesseeOperatingLeaseBalanceSheetClassificationDetails", "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r563" ], "calculation": { "http://www.masimo.com/role/OtherNonCurrentLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_DeferredCreditsAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Lessee non-current lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesLesseeOperatingLeaseBalanceSheetClassificationDetails", "http://www.masimo.com/role/OtherNonCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r564", "r568" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesSupplementalCashFlowInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r562" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Lessee ROU assets, net" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesLesseeOperatingLeaseBalanceSheetClassificationDetails", "http://www.masimo.com/role/OtherNonCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseVariableLeaseIncome": { "auth_ref": [ "r177", "r580" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease income from variable lease payments paid and payable to lessor, excluding amount included in measurement of lease receivable.", "label": "Operating Lease, Variable Lease Income", "terseLabel": "Operating Lease, Variable Lease Income" } } }, "localname": "OperatingLeaseVariableLeaseIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/LeaseReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r571", "r573" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r570", "r573" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OptionMember": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific commodity, or financial or equity instrument, at a specified price during a specified period (an American option) or at a specified date (a European option) which were purchased or otherwise acquired, excluding options written (for which a premium was received).", "label": "Options Held [Member]", "terseLabel": "Options Held" } } }, "localname": "OptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r17", "r19", "r20", "r58" ], "calculation": { "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails": { "order": 10.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r71", "r595" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.masimo.com/role/OtherCurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets", "totalLabel": "Total other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets", "http://www.masimo.com/role/OtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.", "label": "Other Assets Disclosure [Text Block]", "terseLabel": "Other Non-Current Assets" } } }, "localname": "OtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/OtherNonCurrentAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsMiscellaneousCurrent": { "auth_ref": [], "calculation": { "http://www.masimo.com/role/OtherCurrentAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer.", "label": "Other Assets, Miscellaneous, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsMiscellaneousCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/OtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r52" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other non-current assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets", "http://www.masimo.com/role/OtherNonCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.", "label": "Other Commitment", "terseLabel": "Other Commitment" } } }, "localname": "OtherCommitment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income, net of tax:" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r74" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Unrealized (losses) gains from foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "http://www.masimo.com/role/ConsolidatedStatementofStockholdersEquityConsolidatedStatementofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other current assets.", "label": "Other Current Assets [Text Block]", "terseLabel": "Other Current Assets" } } }, "localname": "OtherCurrentAssetsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/OtherCurrentAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "terseLabel": "Other" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsAdditionalInformationDetails", "http://www.masimo.com/role/IntangibleAssetsScheduleofFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent": { "auth_ref": [], "calculation": { "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations and noncurrent portion of deferred revenue not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer). Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months.", "label": "Other Liabilities and Deferred Revenue, Noncurrent", "totalLabel": "Total deferred revenue and other contract liabilities" } } }, "localname": "OtherLiabilitiesAndDeferredRevenueNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r59" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other liabilities.", "label": "Other Liabilities Disclosure [Text Block]", "terseLabel": "Other Non-Current Liabilities" } } }, "localname": "OtherLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/OtherNonCurrentLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r62" ], "calculation": { "http://www.masimo.com/role/OtherNonCurrentLiabilitiesDetail": { "order": 5.0, "parentTag": "us-gaap_DeferredCreditsAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/OtherNonCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock": { "auth_ref": [ "r93", "r94" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.", "label": "Other Nonoperating Income and Expense [Text Block]", "terseLabel": "Non-operating income" } } }, "localname": "OtherNonoperatingIncomeAndExpenseTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/Nonoperatingincome" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r101" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedTerseLabel": "Other" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/NonoperatingincomeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherSignificantNoncashTransactionConsiderationGiven": { "auth_ref": [ "r125", "r126", "r127" ], "lang": { "en-us": { "role": { "documentation": "The noncash (or part noncash) consideration given (for example, liability, equity) in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.", "label": "Other Significant Noncash Transaction, Consideration Given", "terseLabel": "Transfer to Investments" } } }, "localname": "OtherSignificantNoncashTransactionConsiderationGiven", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesSupplementalCashFlowInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_OtherTaxExpenseBenefit": { "auth_ref": [ "r139", "r472", "r480" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other income tax expense (benefit).", "label": "Other Tax Expense (Benefit)", "terseLabel": "Other Tax Expense (Benefit)" } } }, "localname": "OtherTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r502" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]", "terseLabel": "Patents" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsAdditionalInformationDetails", "http://www.masimo.com/role/IntangibleAssetsScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentForAdministrativeFees": { "auth_ref": [ "r110", "r586" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount paid to managing member or general partner, affiliate of managing member or general partner, or affiliate of limited liability company (LLC) or limited partnership (LP) for administrative services provided to the LLC or LP, for example, but not limited to, salaries, rent, or overhead costs.", "label": "Payment for Administrative Fees", "terseLabel": "Payment for Administrative Fees" } } }, "localname": "PaymentForAdministrativeFees", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsRelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromShortTermInvestments": { "auth_ref": [ "r102", "r103", "r122" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount paid (received) by the reporting entity through acquisition or sale and maturities of short-term investments with an original maturity that is three months or less which qualify for treatment as an investing activity based on management's intention and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Payments for (Proceeds from) Short-term Investments", "terseLabel": "Maturities of short-term investments" } } }, "localname": "PaymentsForProceedsFromShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r108" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Repurchases of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRoyalties": { "auth_ref": [ "r116" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid for royalties during the current period.", "label": "Payments for Royalties", "terseLabel": "Payments for Royalties" } } }, "localname": "PaymentsForRoyalties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsRelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r108" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedTerseLabel": "Payroll tax withholdings on behalf of employees for vested equity awards" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries": { "auth_ref": [ "r104" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of noncontrolling interest during the period.", "label": "Payments to Acquire Additional Interest in Subsidiaries", "terseLabel": "Deposit release to acquire noncontrolling interest(1)" } } }, "localname": "PaymentsToAcquireAdditionalInterestInSubsidiaries", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesSupplementalCashFlowInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r104" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "terseLabel": "Business combinations, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r105" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedLabel": "Increase in intangible assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireLongtermInvestments": { "auth_ref": [ "r106" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.", "label": "Payments to Acquire Long-term Investments", "negatedTerseLabel": "Other strategic investing activities" } } }, "localname": "PaymentsToAcquireLongtermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r105" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment, net" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance Shares" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.masimo.com/role/StockBasedCompensationStockBasedCompensationSummaryofUnvestedRSUActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r424", "r452" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.masimo.com/role/StockBasedCompensationStockBasedCompensationSummaryofUnvestedRSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.masimo.com/role/StockBasedCompensationStockBasedCompensationSummaryofUnvestedRSUActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r31", "r371" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r31" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r31", "r371" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r31" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValueOutstanding": { "auth_ref": [ "r31" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.", "label": "Preferred Stock, Value, Outstanding", "terseLabel": "Preferred Stock, Value, Outstanding" } } }, "localname": "PreferredStockValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r11", "r15", "r266", "r267" ], "calculation": { "http://www.masimo.com/role/OtherCurrentAssetsDetails": { "order": 7.0, "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "verboseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/OtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidRoyalties": { "auth_ref": [ "r13", "r15", "r265", "r267" ], "calculation": { "http://www.masimo.com/role/OtherCurrentAssetsDetails": { "order": 9.0, "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for royalties that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Royalties", "terseLabel": "Prepaid rebates and royalties, current" } } }, "localname": "PrepaidRoyalties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/OtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidTaxes": { "auth_ref": [ "r12", "r15", "r264", "r267" ], "calculation": { "http://www.masimo.com/role/OtherCurrentAssetsDetails": { "order": 5.0, "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Taxes", "verboseLabel": "Prepaid income taxes" } } }, "localname": "PrepaidTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/OtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "terseLabel": "Reclassifications" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromLeasePayments": { "auth_ref": [ "r577", "r578" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from lease payment, classified as operating activity.", "label": "Proceeds from Lease Payment, Operating Activity", "terseLabel": "Increase in lease receivable, net" } } }, "localname": "ProceedsFromLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLegalSettlements": { "auth_ref": [ "r113" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received for the settlement of litigation during the current period.", "label": "Proceeds from Legal Settlements", "terseLabel": "Proceeds from Legal Settlements" } } }, "localname": "ProceedsFromLegalSettlements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r107", "r453" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from issuance of common stock" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrual": { "auth_ref": [ "r312", "r313", "r638" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.", "label": "Standard and Extended Product Warranty Accrual", "periodEndLabel": "Warranty accrual, end of period", "periodStartLabel": "Warranty accrual, beginning of period" } } }, "localname": "ProductWarrantyAccrual", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesChangesinProductWarrantyAccrualDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrualClassifiedCurrent": { "auth_ref": [ "r58", "r306", "r307" ], "calculation": { "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Product Warranty Accrual, Current", "terseLabel": "Accrued warranty" } } }, "localname": "ProductWarrantyAccrualClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrualPeriodIncreaseDecrease": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the standard and extended product warranty liability.", "label": "Standard and Extended Product Warranty Accrual, Period Increase (Decrease)", "terseLabel": "Accrual for warranties issued" } } }, "localname": "ProductWarrantyAccrualPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesChangesinProductWarrantyAccrualDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrualPreexistingIncreaseDecrease": { "auth_ref": [ "r309" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the standard and extended product warranty accrual from changes in estimates attributable to preexisting product warranties.", "label": "Standard and Extended Product Warranty Accrual, Increase (Decrease) for Preexisting Warranties", "terseLabel": "Changes in pre-existing warranties (including changes in estimates)" } } }, "localname": "ProductWarrantyAccrualPreexistingIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesChangesinProductWarrantyAccrualDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyExpense": { "auth_ref": [ "r118", "r308" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The expense charged against earnings for the period pertaining to standard and extended warranties on the entity's goods and services granted to customers.", "label": "Product Warranty Expense", "negatedLabel": "Settlements made" } } }, "localname": "ProductWarrantyExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesChangesinProductWarrantyAccrualDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r7", "r79", "r81", "r86", "r111", "r138", "r148", "r158", "r159", "r207", "r218", "r221", "r224", "r227", "r250", "r319", "r320", "r321", "r324", "r325", "r326", "r328", "r330", "r332", "r333", "r506", "r509", "r510", "r515", "r516", "r529", "r535", "r644" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.masimo.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.masimo.com/role/CondensedConsolidatedStatementsofOperationsCondensedConsolidatedStatementofOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income", "totalLabel": "Net income", "verboseLabel": "Net income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.masimo.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "http://www.masimo.com/role/CondensedConsolidatedStatementsofOperationsCondensedConsolidatedStatementofOperations", "http://www.masimo.com/role/ConsolidatedStatementofStockholdersEquityConsolidatedStatementofStockholdersEquity", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesReconciliationofBasicandDilutedNetIncomePerShareDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]", "terseLabel": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r51", "r294" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.masimo.com/role/PropertyandEquipmentDetails", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r296", "r684", "r685", "r686" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/PropertyandEquipmentnet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r50", "r292" ], "calculation": { "http://www.masimo.com/role/PropertyandEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Total property and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/PropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/PropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r23", "r24", "r294", "r595", "r645", "r656" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.masimo.com/role/PropertyandEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets", "http://www.masimo.com/role/PropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r49", "r294", "r684", "r685" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r23", "r294" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Property, Plant and Equipment", "verboseLabel": "Schedule of Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/PropertyandEquipmentTables", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r23", "r292" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.masimo.com/role/PropertyandEquipmentDetails", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property, Plant and Equipment, Useful Life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r92", "r259" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Provision for credit losses" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseCommitmentMember": { "auth_ref": [ "r29", "r636", "r652" ], "lang": { "en-us": { "role": { "documentation": "Purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier. Excludes long-term commitments.", "label": "Purchase Commitment [Member]", "terseLabel": "Purchase Commitment" } } }, "localname": "PurchaseCommitmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": { "auth_ref": [ "r29", "r636", "r652" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.", "label": "Purchase Commitment, Remaining Minimum Amount Committed", "terseLabel": "Purchase Commitment, Remaining Minimum Amount Committed" } } }, "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r416", "r586", "r587" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r586", "r590" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "Related Party Transaction, Amounts of Transaction", "terseLabel": "Related Party Transaction, Amounts of Transaction" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsRelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r416", "r586", "r587", "r590" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.masimo.com/role/RelatedPartyTransactionsRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date of maturity or expiration of arrangements with a related party (for example, but not limited to, leasing and debt arrangements between related parties), in YYYY-MM-DD format.", "label": "Related Party Transaction, Date", "terseLabel": "Related Party Transaction, Date" } } }, "localname": "RelatedPartyTransactionDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsRelatedPartyTransactionsDetails" ], "xbrltype": "dateItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.masimo.com/role/RelatedPartyTransactionsRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionDueFromToRelatedParty": { "auth_ref": [ "r142", "r322", "r324", "r325", "r331", "r332", "r333", "r587" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.", "label": "Related Party Transaction, Due from (to) Related Party", "terseLabel": "Related Party Transaction, Due from (to) Related Party" } } }, "localname": "RelatedPartyTransactionDueFromToRelatedParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsRelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r586" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Expenses from Transactions with Related Party", "terseLabel": "Related Party Transaction, Expenses from Transactions with Related Party" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsRelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Purchases from Related Party", "terseLabel": "Related Party Transaction, Purchases from Related Party" } } }, "localname": "RelatedPartyTransactionPurchasesFromRelatedParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsRelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]", "terseLabel": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r416", "r586", "r590", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r584", "r585", "r587", "r591", "r592" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions Disclosure" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/RelatedPartyDisclosures", "http://www.masimo.com/role/RelatedPartyTransactionsRelatedPartyTransactionsDetails" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReportingUnitAxis": { "auth_ref": [ "r272", "r273" ], "lang": { "en-us": { "role": { "documentation": "Information by reporting unit.", "label": "Reporting Unit [Axis]", "terseLabel": "Reporting Unit [Axis]" } } }, "localname": "ReportingUnitAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/GoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReportingUnitDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Level of reporting at which goodwill is tested for impairment.", "label": "Reporting Unit [Domain]", "terseLabel": "Reporting Unit [Domain]" } } }, "localname": "ReportingUnitDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/GoodwillDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r468", "r606", "r698" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofOperationsCondensedConsolidatedStatementofOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "verboseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofOperationsCondensedConsolidatedStatementofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r128", "r629", "r653" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesSupplementalCashFlowInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r8", "r22", "r128" ], "calculation": { "http://www.masimo.com/role/OtherCurrentAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "terseLabel": "Restricted cash(1)" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/OtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.masimo.com/role/StockBasedCompensationStockBasedCompensationSummaryofUnvestedRSUActivityDetails", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r35", "r394", "r461", "r595", "r654", "r674", "r679" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r145", "r146", "r147", "r149", "r157", "r159", "r255", "r458", "r459", "r460", "r483", "r484", "r527", "r670", "r672" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/ConsolidatedStatementofStockholdersEquityConsolidatedStatementofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r198", "r199", "r217", "r222", "r223", "r229", "r230", "r234", "r408", "r409", "r610" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue from Contract with Customer, Including Assessed Tax", "terseLabel": "Product", "verboseLabel": "Product revenue" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingAnalysisofProductRevenuesBaseduponGeographicAreaShippedDetail", "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingLonglivedassetsbygeographicareaDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r398", "r399", "r400", "r401", "r402", "r403", "r406", "r407", "r410", "r414" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Deferred Revenue and Other Contract Liabilities" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue Recognition and Deferred Revenue [Abstract]", "terseLabel": "Revenue Recognition and Deferred Revenue [Abstract]" } } }, "localname": "RevenueRecognitionAndDeferredRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue Recognition, Multiple-deliverable Arrangements [Line Items]", "terseLabel": "Revenue Recognition, Multiple-deliverable Arrangements [Line Items]" } } }, "localname": "RevenueRecognitionMultipleDeliverableArrangementsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r132", "r133" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition, and Deferred Revenue and Other Contract Liabilities" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r404" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Unrecognized contract revenue" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesDetails", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesRevenuePerformanceObligationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesDetails", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesRevenuePerformanceObligationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r88", "r138", "r198", "r199", "r217", "r222", "r223", "r229", "r230", "r234", "r250", "r319", "r320", "r321", "r324", "r325", "r326", "r328", "r330", "r332", "r333", "r535", "r644" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofOperationsCondensedConsolidatedStatementofOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Product revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofOperationsCondensedConsolidatedStatementofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]" } } }, "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingLonglivedassetsbygeographicareaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility [Member]" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CreditFacilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r569", "r573" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "ROU assets obtained in exchange for lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesSupplementalCashFlowInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesMember": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.", "label": "Sales [Member]", "terseLabel": "Sales" } } }, "localname": "SalesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r189", "r234" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Revenue Benchmark" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingLonglivedassetsbygeographicareaDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueProductLineMember": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "documentation": "Revenue from specified product or service, when it serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources.", "label": "Revenue, Product and Service Benchmark [Member]", "terseLabel": "Sales Revenue, Product Line" } } }, "localname": "SalesRevenueProductLineMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.masimo.com/role/CommitmentsandContingenciesTables" ], "xbrltype": "domainItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock": { "auth_ref": [ "r579" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received on annual basis for sales-type and direct financing leases receivable. Includes, but is not limited to, reconciliation to lease receivable recognized in statement of financial position.", "label": "Sales-type and Direct Financing Leases, Lease Receivable, Maturity [Table Text Block]", "terseLabel": "Sales-type Lease, Lease Receivable, Maturity" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/LeaseReceivableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived": { "auth_ref": [ "r579" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases.", "label": "Sales-type and Direct Financing Leases, Lease Receivable, Payments to be Received", "terseLabel": "Lease receivable" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/LeaseReceivableSalesTypeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears": { "auth_ref": [ "r579" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Five", "terseLabel": "2025" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/LeaseReceivableSalestypeLeaseMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears": { "auth_ref": [ "r579" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Four", "terseLabel": "2024" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/LeaseReceivableSalestypeLeaseMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths": { "auth_ref": [ "r579" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year One", "terseLabel": "2021 (balance of year)" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/LeaseReceivableSalestypeLeaseMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter": { "auth_ref": [ "r579" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/LeaseReceivableSalestypeLeaseMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears": { "auth_ref": [ "r579" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Three", "terseLabel": "2023" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/LeaseReceivableSalestypeLeaseMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears": { "auth_ref": [ "r579" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Two", "terseLabel": "2022" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/LeaseReceivableSalestypeLeaseMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesTypeLeaseLeaseReceivable": { "auth_ref": [ "r581" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Present value of lease payments not yet received by lessor and amount expected to be derived from underlying asset, following end of lease term guaranteed by lessee or other third party unrelated to lessor, from sales-type lease.", "label": "Sales-type Lease, Lease Receivable", "terseLabel": "Lease receivable, net", "verboseLabel": "Total" } } }, "localname": "SalesTypeLeaseLeaseReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/LeaseReceivableSalesTypeDetails", "http://www.masimo.com/role/LeaseReceivableSalestypeLeaseMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule Other Current Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/OtherCurrentLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of major classes of indefinite-lived intangible assets acquired showing attributes such as amounts and totals. Indefinite-lived intangible assets are assets that have no physical form, but have expected future economic benefit. Indefinite-lived assets are assets that are not subject to amortization. Acquired indefinite-lived intangible assets are disclosed by major class (assets that can be grouped together because they are similar, either by their nature or by their use in operations of the entity) and in total.", "label": "Schedule of Acquired Indefinite-lived Intangible Assets by Major Class [Table]", "terseLabel": "Schedule of Acquired Indefinite-lived Intangible Assets by Major Class [Table]" } } }, "localname": "ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "terseLabel": "Supplemental Cash Flow Information" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r171" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Reconciliation of Basic and Diluted Net Income Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table]", "terseLabel": "Revenue from External Customers by Products and Services [Table]" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.", "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]", "terseLabel": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]" } } }, "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingAnalysisofProductRevenuesBaseduponGeographicAreaShippedDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r278", "r283", "r611" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsAdditionalInformationDetails", "http://www.masimo.com/role/IntangibleAssetsScheduleofFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r278", "r283" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r271", "r274" ], "lang": { "en-us": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/GoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r271", "r274" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of Goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/GoodwillTable" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r21", "r44", "r45", "r46" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Components of Inventory" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": { "auth_ref": [ "r434" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units.", "label": "Schedule of Nonvested Performance-based Units Activity [Table Text Block]", "terseLabel": "Schedule of Nonvested Performance-based Units Activity" } } }, "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.", "label": "Schedule of Other Assets [Table Text Block]", "terseLabel": "Schedule of Other Non-Current Assets", "verboseLabel": "Schedule of Other Non-Current Assets" } } }, "localname": "ScheduleOfOtherAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/OtherCurrentAssetsTables", "http://www.masimo.com/role/OtherNonCurrentAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "terseLabel": "Schedule of Other Nonoperating Income (Expense)" } } }, "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/NonoperatingincomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.", "label": "Schedule of Product Warranty Liability [Table Text Block]", "terseLabel": "Changes in Product Warranty Accrual" } } }, "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r51", "r294" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/PropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r588", "r590" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": { "auth_ref": [ "r95", "r230" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]", "terseLabel": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area" } } }, "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r88", "r233" ], "lang": { "en-us": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingLonglivedassetsbygeographicareaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r424", "r452" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.masimo.com/role/StockBasedCompensationStockBasedCompensationSummaryofUnvestedRSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of Share-based Compensation, Restricted Stock Units Award Activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r427", "r439", "r442" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of Number and Weighted Average Exercise Price of Options Issued and Outstanding under all Stock Option Plans" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r445" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Range of Assumptions Used and Resulting Weighted-Average Fair Value of Options Granted at Date of Grant" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r64", "r135", "r179", "r180", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r376", "r380", "r385", "r388", "r389", "r390", "r391", "r392", "r393", "r394" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockRepurchaseProgramAdditionalInformationDetail", "http://www.masimo.com/role/StockRepurchaseProgramTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r283" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r195", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r227", "r234", "r297", "r298", "r663" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsAdditionalInformationDetails", "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingAnalysisofProductRevenuesBaseduponGeographicAreaShippedDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r195", "r196", "r197", "r207", "r210", "r221", "r225", "r226", "r227", "r228", "r229", "r233", "r234", "r235" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Information and Enterprise Reporting" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SegmentInformationandEnterpriseReporting" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting Information, Revenue for Reportable Segment [Abstract]", "terseLabel": "Analysis of Product Revenues Based upon the Geographic Area Shipped" } } }, "localname": "SegmentReportingInformationRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingAnalysisofProductRevenuesBaseduponGeographicAreaShippedDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r211", "r212", "r213", "r214", "r215", "r216", "r230" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r98" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofOperationsCondensedConsolidatedStatementofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofOperationsCondensedConsolidatedStatementofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r118" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.masimo.com/role/StockBasedCompensationStockBasedCompensationSummaryofUnvestedRSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.masimo.com/role/StockBasedCompensationStockBasedCompensationSummaryofUnvestedRSUActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r436" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.masimo.com/role/StockBasedCompensationStockBasedCompensationSummaryofUnvestedRSUActivityDetails", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r436" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.masimo.com/role/StockBasedCompensationStockBasedCompensationSummaryofUnvestedRSUActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r435" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.masimo.com/role/StockBasedCompensationStockBasedCompensationSummaryofUnvestedRSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r435" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.masimo.com/role/StockBasedCompensationStockBasedCompensationSummaryofUnvestedRSUActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.masimo.com/role/StockBasedCompensationStockBasedCompensationSummaryofUnvestedRSUActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r437" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationStockBasedCompensationSummaryofUnvestedRSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r437" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.masimo.com/role/StockBasedCompensationStockBasedCompensationSummaryofUnvestedRSUActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]", "terseLabel": "Range of assumptions used and resulting weighted-average fair value of options granted at the date of grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationRangeofAssumptionsUsedandResultingWeightedAverageFairValueofOptionsGrantedatDateofGrantDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividends" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationRangeofAssumptionsUsedandResultingWeightedAverageFairValueofOptionsGrantedatDateofGrantDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Estimated volatility, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationRangeofAssumptionsUsedandResultingWeightedAverageFairValueofOptionsGrantedatDateofGrantDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Estimated volatility, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationRangeofAssumptionsUsedandResultingWeightedAverageFairValueofOptionsGrantedatDateofGrantDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Risk-free interest rate, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationRangeofAssumptionsUsedandResultingWeightedAverageFairValueofOptionsGrantedatDateofGrantDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk-free interest rate, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationRangeofAssumptionsUsedandResultingWeightedAverageFairValueofOptionsGrantedatDateofGrantDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.masimo.com/role/StockBasedCompensationStockBasedCompensationSummaryofUnvestedRSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r452" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Options available for grant, end of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r430" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Options exercisable, end of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationNumberandWeightedAverageExercisePriceofOptionsIssuedandOutstandingunderallStockOptionPlansDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r430" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Options exercisable, end of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationNumberandWeightedAverageExercisePriceofOptionsIssuedandOutstandingunderallStockOptionPlansDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r441" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Aggregate intrinsic value of options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Canceled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationNumberandWeightedAverageExercisePriceofOptionsIssuedandOutstandingunderallStockOptionPlansDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r431" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationNumberandWeightedAverageExercisePriceofOptionsIssuedandOutstandingunderallStockOptionPlansDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r440" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average fair value of options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationRangeofAssumptionsUsedandResultingWeightedAverageFairValueofOptionsGrantedatDateofGrantDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r452" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value of options outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r429", "r452" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Options outstanding, end of period", "periodStartLabel": "Options outstanding, beginning of period", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.masimo.com/role/StockBasedCompensationNumberandWeightedAverageExercisePriceofOptionsIssuedandOutstandingunderallStockOptionPlansDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationNumberandWeightedAverageExercisePriceofOptionsIssuedandOutstandingunderallStockOptionPlansDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Options outstanding, end of period", "periodStartLabel": "Options outstanding, beginning of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationNumberandWeightedAverageExercisePriceofOptionsIssuedandOutstandingunderallStockOptionPlansDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted-Average Exercise\u00a0Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationNumberandWeightedAverageExercisePriceofOptionsIssuedandOutstandingunderallStockOptionPlansDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r444" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Aggregate intrinsic value of options exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r422", "r426" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.masimo.com/role/StockBasedCompensationStockBasedCompensationSummaryofUnvestedRSUActivityDetails", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationNumberandWeightedAverageExercisePriceofOptionsIssuedandOutstandingunderallStockOptionPlansDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Canceled" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationNumberandWeightedAverageExercisePriceofOptionsIssuedandOutstandingunderallStockOptionPlansDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationNumberandWeightedAverageExercisePriceofOptionsIssuedandOutstandingunderallStockOptionPlansDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockRepurchaseProgramAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockRepurchaseProgramAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1": { "auth_ref": [ "r449" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost expensed and capitalized for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r446", "r462" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationRangeofAssumptionsUsedandResultingWeightedAverageFairValueofOptionsGrantedatDateofGrantDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r452" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r387" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Shares, Issued, Ending Balance", "periodStartLabel": "Shares, Issued, Beginning Balance" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/ConsolidatedStatementofStockholdersEquityConsolidatedStatementofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "terseLabel": "Shares paid for tax withholding, shares" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/ConsolidatedStatementofStockholdersEquityConsolidatedStatementofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r129", "r144" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StandardProductWarrantyPolicy": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.", "label": "Standard Product Warranty, Policy [Policy Text Block]", "terseLabel": "Product Warranty" } } }, "localname": "StandardProductWarrantyPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r6", "r195", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r227", "r234", "r271", "r295", "r297", "r298", "r663" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsAdditionalInformationDetails", "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingAnalysisofProductRevenuesBaseduponGeographicAreaShippedDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r30", "r31", "r32", "r135", "r138", "r163", "r167", "r168", "r169", "r171", "r179", "r180", "r181", "r250", "r319", "r324", "r325", "r326", "r332", "r333", "r371", "r372", "r376", "r380", "r387", "r535", "r704" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.masimo.com/role/StockBasedCompensationStockBasedCompensationSummaryofUnvestedRSUActivityDetails", "http://www.masimo.com/role/StockRepurchaseProgramAdditionalInformationDetail", "http://www.masimo.com/role/StockRepurchaseProgramTables" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r67", "r84", "r85", "r86", "r145", "r146", "r147", "r149", "r157", "r159", "r178", "r255", "r387", "r394", "r458", "r459", "r460", "r483", "r484", "r527", "r549", "r550", "r551", "r552", "r553", "r554", "r670", "r671", "r672", "r710" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/ConsolidatedStatementofStockholdersEquityConsolidatedStatementofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/ConsolidatedStatementofStockholdersEquityConsolidatedStatementofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r145", "r146", "r147", "r178", "r610" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/ConsolidatedStatementofStockholdersEquityConsolidatedStatementofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r387", "r394" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Restricted/Performance stock units vested" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/ConsolidatedStatementofStockholdersEquityConsolidatedStatementofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r31", "r32", "r387", "r394", "r432" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised", "terseLabel": "Stock options exercised, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/ConsolidatedStatementofStockholdersEquityConsolidatedStatementofStockholdersEquity", "http://www.masimo.com/role/StockBasedCompensationNumberandWeightedAverageExercisePriceofOptionsIssuedandOutstandingunderallStockOptionPlansDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r67", "r387", "r394" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Stock options exercised, value" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/ConsolidatedStatementofStockholdersEquityConsolidatedStatementofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.", "label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased", "terseLabel": "Number of common shares authorized to be repurchased under new stock repurchase program" } } }, "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockRepurchaseProgramAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchaseProgramPeriodInForce1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period which shares may be purchased under a stock repurchase plan authorized by an entity's Board of Directors, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Stock Repurchase Program, Period in Force", "terseLabel": "Stock Repurchase Program, Period" } } }, "localname": "StockRepurchaseProgramPeriodInForce1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockRepurchaseProgramAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r32", "r36", "r37", "r138", "r245", "r250", "r535", "r595" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Stockholders' Equity Attributable to Parent" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r2", "r3", "r85", "r138", "r145", "r146", "r147", "r149", "r157", "r250", "r255", "r394", "r458", "r459", "r460", "r483", "r484", "r504", "r505", "r514", "r527", "r535", "r549", "r550", "r554", "r671", "r672", "r710" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance", "periodStartLabel": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/ConsolidatedStatementofStockholdersEquityConsolidatedStatementofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Stockholders\u2019 equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r136", "r372", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r386", "r394", "r397" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stock Repurchase Program" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockRepurchaseProgram", "http://www.masimo.com/role/StockRepurchaseProgramAdditionalInformationDetail" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r567", "r573" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "terseLabel": "Sublease Income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsRelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsegmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by business subsegments.", "label": "Subsegments [Axis]", "terseLabel": "Subsegments [Axis]" } } }, "localname": "SubsegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingAnalysisofProductRevenuesBaseduponGeographicAreaShippedDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsegmentsConsolidationItemsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by subsegments, eliminations and reconciling items used in consolidating a reportable segment and its subsegments.", "label": "Subsegments Consolidation Items [Axis]", "terseLabel": "Subsegments Consolidation Items [Axis]" } } }, "localname": "SubsegmentsConsolidationItemsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingAnalysisofProductRevenuesBaseduponGeographicAreaShippedDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsegmentsConsolidationItemsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subsegments, eliminations and reconciling items used in consolidating a reportable segment and its subsegments.", "label": "Subsegments Consolidation Items [Domain]", "terseLabel": "Subsegments Consolidation Items [Domain]" } } }, "localname": "SubsegmentsConsolidationItemsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingAnalysisofProductRevenuesBaseduponGeographicAreaShippedDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsegmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Subsegments [Domain]", "terseLabel": "Subsegments [Domain]" } } }, "localname": "SubsegmentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SegmentInformationandEnterpriseReportingAnalysisofProductRevenuesBaseduponGeographicAreaShippedDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r555", "r596" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockRepurchaseProgramAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r555", "r596" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockRepurchaseProgramAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r555", "r596" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockRepurchaseProgramAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r56" ], "calculation": { "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Taxes Payable, Current", "terseLabel": "Accrued property taxes" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r239", "r240", "r241", "r242", "r244", "r246" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable and Allowance for Credit Losses" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TrademarksMember": { "auth_ref": [ "r499" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.", "label": "Trademarks [Member]", "terseLabel": "Trademarks" } } }, "localname": "TrademarksMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsAdditionalInformationDetails", "http://www.masimo.com/role/IntangibleAssetsScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TransportationEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment used for the primary purpose of moving people and products from one place to another.", "label": "Transportation Equipment [Member]", "terseLabel": "Transportation, vehicles and other", "verboseLabel": "Transportation, vehicles and other" } } }, "localname": "TransportationEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/PropertyandEquipmentDetails", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.", "label": "Treasury Stock Acquired, Average Cost Per Share", "terseLabel": "Treasury Stock Acquired, Average Cost Per Share" } } }, "localname": "TreasuryStockAcquiredAverageCostPerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockRepurchaseProgramAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r66", "r395" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/ConsolidatedStatementofStockholdersEquityConsolidatedStatementofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r66", "r395" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Treasury Stock, Shares" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r32", "r387", "r394" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "negatedTerseLabel": "Repurchases of common stock, shares", "terseLabel": "Treasury Stock, Shares, Acquired" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/ConsolidatedStatementofStockholdersEquityConsolidatedStatementofStockholdersEquity", "http://www.masimo.com/role/StockRepurchaseProgramAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r66", "r395", "r396" ], "calculation": { "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury Stock, Value" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r387", "r394", "r395" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedLabel": "Repurchases of common stock, value", "terseLabel": "Value of shares repurchased" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/ConsolidatedStatementofStockholdersEquityConsolidatedStatementofStockholdersEquity", "http://www.masimo.com/role/StockRepurchaseProgramAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r148", "r149", "r150", "r151", "r160", "r247", "r248", "r252", "r253", "r254", "r255", "r256", "r257", "r318", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r481", "r482", "r483", "r484", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r583", "r612", "r613", "r614", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r706", "r707", "r708", "r709", "r710" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/ConsolidatedStatementofStockholdersEquityConsolidatedStatementofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_UnbilledContractsReceivable": { "auth_ref": [ "r68", "r604" ], "calculation": { "http://www.masimo.com/role/DeferredCostsandOtherContractAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredCostsAndOtherAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.", "label": "Unbilled Contracts Receivable", "terseLabel": "Unbilled contract receivables" } } }, "localname": "UnbilledContractsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/DeferredCostsandOtherContractAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r469", "r474" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Gross unrecognized tax benefit" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r475" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefit that would affect effective tax rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r183", "r184", "r185", "r186", "r191", "r192", "r193" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValueAddedTaxReceivableCurrent": { "auth_ref": [ "r71" ], "calculation": { "http://www.masimo.com/role/OtherCurrentAssetsDetails": { "order": 6.0, "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.", "label": "Value Added Tax Receivable, Current", "terseLabel": "Indirect taxes receivable" } } }, "localname": "ValueAddedTaxReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/OtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r452" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]", "terseLabel": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.masimo.com/role/StockBasedCompensationStockBasedCompensationSummaryofUnvestedRSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r452" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]", "terseLabel": "Vesting [Domain]" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.masimo.com/role/StockBasedCompensationStockBasedCompensationSummaryofUnvestedRSUActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r162", "r171" ], "calculation": { "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesReconciliationofBasicandDilutedNetIncomePerShareDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted", "totalLabel": "Weighted-average shares outstanding - diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofOperationsCondensedConsolidatedStatementofOperations", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesReconciliationofBasicandDilutedNetIncomePerShareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r161", "r171" ], "calculation": { "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesReconciliationofBasicandDilutedNetIncomePerShareDetail": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic", "verboseLabel": "Weighted-average shares outstanding - basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.masimo.com/role/CondensedConsolidatedStatementsofOperationsCondensedConsolidatedStatementofOperations", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesReconciliationofBasicandDilutedNetIncomePerShareDetail" ], "xbrltype": "sharesItemType" } }, "unitCount": 9 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3098-108585" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(5)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r144": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124502072&loc=SL77927221-108306" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r194": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "b", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r235": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL82887624-210437" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r263": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r275": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/subtopic&trid=2144439" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r296": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r301": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r305": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123377177&loc=d3e11281-110244" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12524-110249" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(3,4))", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(4))", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(5)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1314-112600" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1336-112600" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S65", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r367": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r397": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r414": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r466": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6419918&loc=d3e35281-107843" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e39076-109324" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r495": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=d3e5291-111683" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "83", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125514181&loc=d3e34841-113949" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=SL116692626-108610" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r574": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123420820&loc=SL77919306-209978" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123420820&loc=SL77919308-209978" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123420820&loc=SL77919320-209978" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123420820&loc=SL77919327-209978" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919391-209981" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919379-209981" }, "r582": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888252" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r592": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55302-109406" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(b)", "Topic": "920", "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(17))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3(c)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r699": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r700": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r701": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r702": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r703": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r704": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r705": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8,17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(9))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" } }, "version": "2.1" } ZIP 100 0000937556-21-000124-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000937556-21-000124-xbrl.zip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Ŝ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

*^]S>?.*I/DXLU<=W64D9A--9GC-'_@;^=IJ3'[)JE37K M#K'[O>**FU@B3>Y6F>>>3F4Y:W(&@U5X,Z8%3QA2MO%!/$A,_O0U_>UAJGPP M;J&!]-4]V4<]V@F(>/(9AO8\O]T'/?^HYP09UDNW3 (KS>=_)GSTGCX66&2( MI&O#\X7<:7C2:S&^?'V'ZBAXL?]WV?]]H@C,T===$9BCNWO->P]_E*IMN#Y-XO]7YR='2T=_#(?>> Y"X* M-W9@9:8T)'6>'"^:HN2'.GB"Y?CP";/%"UGMU*U)4$XFX/NOB+>V56;DG)68 MW*M@_=;,I21/KM^'U RXG_2Q;'K^NLMTF^?X\'?/\:8I/A&*_PZCT].]'\/L M19;FZ"$W#]W<_+E[_QGF[.C&YNP:!-1^[E[F9TTXTP\.:/,]O M=2K$G\BY]>2KO]TEV^_IO M#(Z#6;T#NZD'<^2C54/\W"Y,9XU"170*+ABH9Z\G7'1P%U1D3_>?,4O7 MQU*1.>ORZ,FC&^#W>GIT]-FO>K#_^ 9XTS[]JI<-[)$;UV=;-*Z7/>N3_2=? MW\2X'AQ^V@A<.JZ/]I\]NAYUW#5SXG>>/][XT4_GH[L6T/%&B>9^OA%=A>MQ MNQV?OOKY]>T([0X_0')RAV__^NV;UV^/W[UZ_? M[:J?ERB1^2/OHC#TW(7'WP2R&4X_WQ#ORI=;?OMN_%YT#Y(?K@5DSE\_]S/L?ON8NGY!HU/ 9-L[S3=EO.P)5-,5[R6QAAC089;<43D)BL: M=\^A];!S&G=.X\YIW#F--^TT7L]Q@<]XEU[;[20X-CAM)\??W^G+_]^[=-9_ M_>7O.X_U2_583:OPSF?]J.G/1N^GC1NW\9[,U83^;]MF_R.=V>#&_B]4!@&9 MATS<\C+)QH\ +7^1DF./-\,?'IS5X[7[SVPY+__V_P-02P,$% @ SHA: M4^ @VYD4%0 =N< !$ !M87-I+3(P,C$Q,# R+GAS9.T]:W/;.)+?YU?@ M_.7VJD:Q*-+/FF1+L>.LMYS89]F3_38%D9"$"@EP -"V]M6W_^KU_O7Y_@9<4C^)$!'@@B$H4 ">L9B!'P'B/\&$T0C\H.PG?H*] MWB<-=$'C.]H.<&;K_GP4F_=QKT_9YS'$#YXFR, MW.#7Z;E[#OI]Y_!?WVY&NNE!UC;$Y.=*ZY8QX-8Q\?:A>JW[ZO;[3&SC%G@*Q "MVYUMRC26Y42TM#Q=34_SN'S&WE MUO./$(X_2$KR)J4.5E5?O3Z4("B\68XDAU7:]_% &N@X1"EOVCSPF*&F Y<@ M7"Y<6M#_[\?OP[#I^"6(GX3_&<,/T*3I\"4()GB+T2OH!_D>X.#C0>[F0A)\ M(0*+^;6T$BS27#T JNGC_76=TZ/I,&+(>\[[7A+]J2]=4_D/Z"U=[<*?$AM( MT8$"OM\.U[&LX4\X"F[))_WW^OS(@+,F!L UQ;*&6Y5()5CV,!>!03 7E 2( M2&#Y!ZYE5>#Q'61R>#,DL"1X5X);16J6HK(;VT@1_&VEE__INE07#.1T#J&T48:4GD';5+1E7S;^1H/[/&0T#Q/B7/Q/IT%@WM-: M7?=KUH^C?O^XK!\UT[V(_;]!BK]A\V[IT(;9#/GL*J3/NUI'EOC,,C_N]T^V ML@D2/] ==$B*EXC[#,<*&YU(STD91D@LIW,=L$$^ Z5B M!LD4<4SN& T27_R C,F&<]F2)3!,^;9+?;'KT*POQ]YK?$ 5>Z5$ $Q 1@;( MZ0 9(;G.[%6F/.-]2GP<8I@&69^E'LB6P24.$QG!?DXR&.:9 MED(U<_>*9=>A68]./5T'V%Z/BD0L$T#%,NY>8^H$. P"W2$,WU1/3-V8M>/, MT\6![;5CV777->(>A2IC>@>9F"_Y:1D*U0$;DT].WRFO$1DFH%$57G4IUU3D MYH-THSCT=8FR[GFCJ'5;Y,:)Z#B>KL(81%G$:7K5ZV1X<4V>5/F+6><.BP#F M639PRBMH ;J;3&Z2TRN#&1-WCNN6XZD"CBYFY@K#5T4?2M)Z7_YXWLB"V2(S M6RS/TS7$6BGUP!*Y\B46Z#MIGV[%#+&+A*G-5T/.K??[5<"9K=614_;H-!*0 M80$IFD[SOHGUJH4V&[%CM^R;5W&RQ3F0T;">2#AJH&Z2W MG/L(/RE]M)/$.I#9-)TZ91]78P!+%-WE>!.;5 UJ-DAG;MF-7>=^%XW1&B\; M6:(:6*,9&O2]_MEF0>Q-T A*350O7R.2$A*S;!S/Z6^4C<;9TV3OQ91R6!U0 MTL^_09$P+)H%)(TPF@6H4BF6 E0]I.]^!7DGG13H)9H@Z?\$%Y0+#DF0^E>4 M" ;]1L&*#2*CBR"7J7)0F6,%&JVN7V5>6X:Y>Q&-!:.;N!/VZ(PNQL!SR[&G MK?2ZZ'I8\+V1'6V SVQ%CSRGE(&S%V0'3>A=>CYXKD[-_IG@6)5+"1)V8JL# M-IO*8Z<:8TO.V.:Y?@<36<6$T,8<&>+/].W'+ 6ZU2+IH[:K8VLB\F1"8 M[=FIYY22<76"Z:#UNE;'_:=8*F03;Z\$9;979TXY[%VBZ)X/M\Z^9A6U2EBC M=7+[;E7!9DT 731,Z]Q4MZL%28CHY$IU@F[P$PK6&S6LN+VB!Z-IZU2@;T)-&VIVE+F1HQF&0\\IQ1754_,4JN:;=@&(_(.NHD\+]2FGPC$/+ M/92+UD;_1,JBG/K-03O(VP?[*N JB-D).7++46L.G_D>7=3D1E9H'0>MQ@Z1=1?>WCZE]E>&?+@+<8#C&(1;6.P@M\)@MSHE35:M02('$ MFIM_%9ZF%8P"YKVX"LQH5CFWQ&8V8Z=N50W72G1=C+ V<[UAO= 6G=DTGGE. M:3&REN+>J)G[18$ M94U6;N0#JT3MU:I2LFD E!7IY>]5&=_!N;ZA:,?JU*Q3LQHYWJ!B7XF=&F71 MWY*0DD;EM'12>W01\CLEVVZN+H$:G39/'0BIWD0J$?6ZO<=ZG96-MUG7(##Z M8I[KE@/W.HETT?FJY&SS#==U&,R&SY,3QEXX'31?^;:*[,Z0]5T;C:/2!OC, MAN[(*==,%WM ,NQ5NT"Z&:7:LWV;C5G66,V6\M@M)QP:BK2+!M1>"EOMUK)' M:S:U)]Z@?M.6K73W%GBS'&QOK-H&\5[$[ROBQ7U0:R!O-+,W=6=6AU-O\-HE M>O7VJ1)P%Y6E>+RPL?M5!VSVMP/KJ;6__W9= MOI\E=P)U[Q\B7-/30(AE6*,1/':<\NX]C:BG,8$BJL[+H;$1K,-@-(+'ZN([ M6YETU@B66+L;(]@(K=D(NM[ >FKMC>!&^7Y/HC%BD 0_$)[.! J&3_+G%'UY M05L"7=0!,.).79 I\V M!YKXO?+F7*]YFG^8X)$\(2[%<#]Z'/H"/S5-N>VZ4[.Z'7EN::]@K;H9]+#P MC82<%B") 3DUG))J'8QKUF>*XC9[S!, MEE;GJ_H4DH01EU#(I_KGZRW?VQ)FUL-CSRU_8JQ>W32I2MD*Q )%K;9I"WH7 M-K&7VT1%,M T%^UA1C: BC"U2O]J(M&[SLE--].CQM\J;T"SARNG#CEDR0J MB[; G#7OK%>YF&3,*46VARBG+KEW%F5'+H8GI19VL3,UD*;;>&9YY9V650+ MI'O6Z3K3ZQ?[FX&6 $9[=-)WRD>2LF_!:?!NI9]14FT M/%1R,L8"A;M0H$?EVW9N5YLASRSNU-BA-?O@ZI6C]O+4FJG < M6V-(Z4J;=C./B*:*/85)IFYL)0*QF&%UT7^L[C$C4\ODC2TV\U)][)2/SF2H M5\R!O@UV@1TLT._E5^)XHYIB,YSF-?W$+:=2FLBRBTN\K0"&:UX-1SRX7J)BHD_8F, M/)4^S0C,STUQD*9Q%8U@22105(*,S/W*4"_Y&TJFH;J=%NJ+ <;SZ8*'4+*P M68%IMWV:U>K,<\N[AYJHE:*BI\D *1U@/ =+2H BY3^]N/3;X0L_AW&,)7'@R!AV>XFGDC<6"3JUU=&D_CC M0=H<"Q0= )$V%TQ_;8B?![J+:_E.(3HXK!V+]$-]I(YKZDH5YC\7ZJGORE@U M?'>(J<9PBHICG<"0+P:[-;[-S,!$5=1%8U[$:2\6S/@2Q2'5+O=PRI!^.4*J MPB7']!D1J6:"CV+D8QAFKOG_)C#$D[ER*!"+,,FD5<.%OHCGINW%Z&9A\ M@<;8EH?IDX@2:0;8W(*!EQ8?^$$OXG-(_9^U7&J&Y TGDP[AF*( ^6BTX34&_12NP;V^*]///VXA*0] MB538)5WTPH]';+ME=K79YS?2JMO*.?+7/S\$D92H'Q$$SDLO9]-BOEW M3$,S3QIB::_[+AOS+'A[E"'UA@E>W[X-TSO;.WL[&>$IT3K4[35(=5K&2$ M>^]I*)GM(Q3P":,15UNN:>JHHNSX2)#(OX4(U;;NE"HYUPQ>XE;8VKK22 ,J MZ0DN:9K1XMD1_]KAU[9OZVQ=W7^B=A\LZO_9%X]JTAH;X7:@UX$XG\V5^YB, M]:*UI89+Z^*C1[3@Q:;AE-NVH8QW*S4 M'#:D+"K;MF$45PF3?F7"].66$^E]H<4G=,U#L@!LP_@,\WVC9VH'^][KH*GH MH59LOE6Y)(-\0Q':A]??J9A0)F?/!(M;-H4DBWK-"KH)J@W:NW M!%TDT@.)5D=6DQJI!FN%U(:^M ?2!WA _HS0D$XWV,CZ]FV0U"-AR*7'<.O7NWZ_\M5FRMYV[=346XCH!U1C M%O.TV'9%F;*4ON#7Y)LDEV$82G_T!V4_(TCX#,>U'&V.Z(TF70YDHY^Y$ZK" MUCO(!/9QG&I"[J<:3*L5\*ZK1DT-RS=,*-,:*X4@EX*JRU5K!F@#VMZ5(XIE M:S4_)W491IV&2?^ST7_8&E];G BKVH1+G-*0*;K^RB0CG"?!7;_B,,&U=ZM,;WNADI/6J=/:G=K ; MX=X]*,S3^,K!5%?0+=:E6]]/8HR"T9^)]/*OI"DVE1OM<;SA1%3'4"R&?(]P M-$X8UX\E468;4]>Z#09E<:V'C!X5+199.Q-(6V=?/T&0P?"5H49A:G5M:/L=RC-%O^G0I] MK^<]XM+_-\MTMYV\?YZ@H@SR\$RWJ9ZL@+5"H56&6#5)-X$NMKU:A@B6T"V) M!?152!W MZ:PEG,SK*;J^H,O5,A*4 =#& DP9H*41]6=(?F;!;OVH5ANU="27U->IZJ$^ MQ:P3>HMSQ9MVY]G!OO?.A)'>,)>&VK&<:%*W*)L3*I"Z") 0.0-E;\]8S*"J M_7)]Q'@U'#>D>7> NZU1_O*$TQ>5Y!72A]B\(6<#4!N\G.&@WS_1U^,VV\]F M FK#N+Y2&CQ+.C9-VW*[OVR*ZK/WW)^A"'[ZY?\ 4$L#!!0 ( ,Z(6E,M M"M596!\ HR 0 5 ;6%S:2TR,#(Q,3 P,E]C86PN>&ULW7UIKY.Q]B7U,V=3I_]\/3/]_^ M"N[I?_SC;W_[^_\#^*\?7[]X\O,BG1SC?/WDIR6&->8G'Z?KHR=_95S]ZTE9 M+HZ?_+58_FOZ(0#\8_BEGQ;O/R^G[X[63P03_/*_+K_W,?*45 :9)0,5"@.7 M60)NEDP$6+D(1EJ%%H*_3PT-ET_J_OZQ\Q MK/ )#6Z^&K[]X>G1>OW^^V?//G[\^-VGN)Q]MUB^>R88D\]./_UT^_%/5S[_ M40Z?YM[[9\._GGUT-;WN@_18_NR_?G_Q)AWA<8#I?+4.\U1?L)I^OQI^^&*1 MPGJ8\SMQ/;GQ$_4[./T8U!\!%R#Y=Y]6^>D__O;DR68ZEHL9OL;RI/[]Y^O? M+KSR.*RFQXOOTN+X6?WG9S\MYAGG*\STQ6HQF^8JY!_#K.)_N M/[_''Y[2;[^?X>G/CI98?GA:GPE5W)PQ4;'\VPY/??8%;PJS=#(;IN<%?;]] M=H77%#I^6B/]QF:F3M\]6Z0+'YI5.2V6I[\Y"Q%GPT\G)RMX%\+[R8MIB-/9 M=#W%U<2&D$,1) -;!"C+)812)&AN4C"N%*O2Q;FJXUG1@ ;!EK"*@W2WSWY6 M)_$9SM:KTY\,TPJ,;X7\;]> V,QDD_'\=+)7Y,CU9+#,N28L]??(1J\[9*K0-L+!,5RAT<3EM M/_%L=7)\/#P3IFL\/OW]JMW:2'Z]:#KC&\$2^'TE_S,6I-=G4NUYNEX]G^>7 MZR-K*L!KS[1Q!>92XH(ADM=AUD@*$$+TZB@/%/.L3ZJ M\!908]*)>S+C\@)H)8IFS'^>R/^MTXN;I4@ WR_QB/R.Z0?\C3SG8WRQ6*U^ M72QIMN<;=9X^OUV&^6HKD_S_3U;KZD+_@>N7Y6WX-!&1!U5, 18T*7LF%?CD M,J"2J)51.<;N):A"QUOQ[4+L^37R:R& FFGZ#)Y'#038?8J3/-O\Y_"^^DZS"9% M"D\#)$UH.<4JG"@<*QA&@T_)(9?&="'( M52R[$,)\(01\38S8<^:;,: Z[]/!WZF1ZT^+^9KX23Y1#5MY2L&BLL M)YO& M8P$7G2*;5ICA43&%?73%+:!VX83].I5$*U$TX\:Y% 8!NF:TF(PAHX:08R#& MRJPINK.DL[@NQO@2A9&]:_.K^'+F\(O840X^%,*&5QE(Q#I@B]UX9$R%&P:!$6H_1,.9R'QZ, M/XW:G@ /G?AV$=9JA>NSC+_(/ 9-\9TMDK2PUPC>&Y)4)NN<7+(V]_&-+L#8 MV^2'U5$U,/17%=&',!M,SOJGL%Q^)I.S\4:,Q8#1($1C!8FM6 IHI0+.DK): M.*5*GX373O#&I (?SI$K'D!SR;3,J2Y.",QK3$C X@S_P/7IF&VT1EF9(3'C M0254X)D7$#U-1;%!2=4IWW +JC$IR784:2:'9LSX;?Z!WKU8?B8@$Y;)!E>' M%U-(-+2:[^V!&:*(\I1QG )6/)]FBR/=DF M\ 6%8\S$8OH4SVS>W]:=DY)$@>24DF,900W)-Q<\.*-R$L:(%..AW;DQN#+W MDO(5 _7@*6[&55*055ENMO%^F[_ L,(_%O-T6K-!0".V+IQ8K&IUG)@OG!-@0*3!ED8'SUH+&2!A, M0*7[\. "C/$Y*WN)_>%3W'#K?/$>E^O/KV9AOJ9PJH92[[<[^A/&;7(Z>^ Z M:E"">P@A"M"2/&139+!>=-HXOQG5^%R7O3C03 -8Y1UF+^;4K2T&1X!^>53 MFIW4K?M_+A;YXW0VFX1HA&04,S%K%?E52&0U4@.68 -W**SMX]OL@FY,FZ,- M*-)<(,VHSH5.P MY^3W2&2<";(T'DDE91HC$TBJ*>7BB_E7X7+/#IR-T M,9OLI0?-0G6[))(M91ILSK32"JN;IUU3]!?QC"GIL2]QQGUO M()V.Q;>=H$8GZ;>/G[_[1_LM2!]?'>[X& MS-[IGR4]Y-5R46I)/B+7LA@*1S2MGA@$C9!<-D+CO=69'+H^ >$Y$&-RE/>5 M_96,T /GNET>X'1 OWQZ7]<4A;@1C@]($*-HU[^*&UY/>;^(;; F<'0FG(FXK[$T+U18?^B&6QQ+.\%:Y^^;1>!IK^ MZ3PL/_]&DS:D,^@W:3YGPP2M<8FK]<3HG$J2FN(]BZ",%N!C'HX&9I^"E,+T M\9H[#JK9>CM'(Q&4#M:2;4UA- MI)8T:2(#=XYBS2 =6=J8@&:T-L')GOL^^YJG",:D91\JY:L'?!\PNPT/<:[6 M+TO=8!W.X.#RPS3AZLUBEB="R1)H58*PA59DD1D\K410/F D3#[:/F[(S9A& MY=FV(D C$70,;43Q49-M)K4<'=2N)1 XIX K2&6"5BSP/J7Y=X0V]Q_;&QRL MSC]Q3@^>T70_S\?3^72UKJ_Y<&8V)%-:H1/@3*1Y#ZR0V:!Y+]H;B4H4Q3N= MV-P)WYC4X'YLN7)LL[U\&K;(6"$]IAZS^IET]FPQ%*:=0HJ6,15C!AN$H:'; M0N&L+F"M"2P*S8+HD\Z^%=:8O,>V3&DGC79^7YC.JW.\W9M[NW@Q74_?#5/S M!M?KV9!FG21.P)+3P&6J[5VL)T>7H!6FESX;6#< &E6$U)1,^\W]8VY17]-)LLL. M]'7O.< &\YW#:[1_?,U[SAIM\L*3KI7@0M<6:%98\.3P@ M:E)J?(\NI"$-ZWR>;^]):K+CW-)($A-#>K66ADD.UMELDQKBZ*7KM.')PPE"0EF@V0D@17-)1!.6LUF&%U].ML\;%/I=:7IQ_".EX_E$8VL79PH1>0B#],Z6D_?OYS5<_* M_$I.]#R1T_R<-,&'34%?##YZJ3R@(X]9:5D@1E-WQI3QB))KU6>W?'>,#71+ M0LQ#S#&T$WOY?H@U?OF$RS2EMTY8]%D&B6"UCZ 8&J#U(" Z86E^A'+:]U(Y MMT,;DQWKQ*IK%%-#<;6S4.'SL';/\D2D@/^:KH]J;SH:/!G<-T=AB3^&8=4? MUY!DF-2)%]FBR0:PU,UFZHC9@L; H$R>CVLF>/1#QJ(+%0Y'N$-)MSD6" M]1K?GRS3$>%Z6<[=FS&QE@RW<30%J;8(,H%L>J1I"<[6["4&K_J4K-R-;53) MY /SJY'$VFWTT]@O=0=\C:OUN)4P1!*!F-BK!LP$EQD#'@4/-0#NL'UB3(/ M.\X&_8:N(^79QLG#6E5^O7W3&. M*N3_ZDFZ+PEZD_0Z\VXX1Z5-;2 B+"BK YEW1*A6GYPX'D+N4\;XT$CX<4^J M?OTDW9<$[0[5#T-\6 MZ)GNM6MA@O?:")*X=ZE*(U$W%_78M'CE7N"]/;MG$N(\ M&C:X>+_$-!UFA+Z>X7:'[?GQ8KF>_N\F121<(/>$(I/"'0T[2\"H'(W3*Y7[ M5!,]/#]\*"_T0)1I()CF]<0OYV_($WA9+C1'/>N,.JDW@Y7L$S!6+PX3Q4-D MRH#4VH9@BU2LC_G=#=\]/<1'20*W9E$'R;4LP/@P7=%4_;I8_KPXB>MR,CMM M/#9!+T6R4D#DM7F4T!)J60!]E67FGM2A[&/!;D,UI@:VAW-WV@BI90'LII.7CKE/^F\7=*.Z$_1 /&HNM8Y\.KVE MIHZY>%%2ECE=KRK*WJ-M.\Z:Q"*R3,.UZ$!A/9&K383BZ8&Q"&XZ7;JY"[I[=NC]1HFTI]1:>D1G M=4C#92.G>_@3%YE#KU-MM4J84@S$;)>A#C9(+PKS?<[JW0AI%^;X;\X7:B"> MCMKG[.(2BAW?U894)?F0N06K I%81P4^)0LNY$R4-BZ6/AG".Z'ME#ADW[SB MV4=@O:W8EQ;G6Y7H%!E8:3/(R F<=1*<3H10RF+KMK\K?4I6=P2X$Z?X-\^I M_85W@%!MVUA\0NHR.LP.LI015,@18LD!(M:6XJK0C/2YONY.:#NQZ1M+4[>5 M5T<:W=Q\?&*ML,:*#);5/75G:F\.%4%*IX*GD#*(/DG(^Z#+TG(4&=%J4*,Q[[=.VY!\B=V/6-Y;][R? M4>"VG]_$*DPIDQH522"H+ 3$0-^F)$*TB5G7J3OMG=!V(M2AKH=[]"#P(?+J M'02>C?Z\,M6VI&B4K9??)1J^R12E*G("C2L\:PI4L4\RZAX@=Z+6H:Z?>]Q8 M<&\9]KO \%(?E204#X5CC2X,,;]D"&@UF"BYCSJY4/JDRN\ MA.9#G61W<%* MEMK)ZC$.@&@O2ZB-]X(LFO!9!R$Q#\Y9F3)%%#GU:5_VT ,@#S^3^7;Q//W/ MR72)-UY:/,F)>YH0 3;79G**I.6U1>#:.\&T0"/Z='_>'>,]:TD?)7NW+]%N M.J/96(+-3_V>X7NQF+];X_)X,Q&;S0^A48E<[WS2MFH9FR"0$0'IC"]1,]2^ MCW^Y"[JOX61Y=U;M*[5^?+I\A_8D5YOD?($B6*$8*A>(CBFP)EH5@S1"'DA1 M78;V-9PA[\ZDO>35HQG!A=8=1XOE^NTEGD?&4BGU8I]2,S_UAN;(O +*:SI%HOQJZ80UGI#;_DB:)X?GC;HOQ(3Z%/YI^GLY,U9AK=)G1[A9M& M,C_C.DQG%^'OUL>L*Y[].Y\=;KH:]4K[:UA@F)]_H)#]'?YQ*V"QNOY.EDI]#2B=DU+0XF!]?*)[ MU7X][PNBOO M&40WL;JDD,B!C6IHY*OJ;7LJ &F&7'0.):H^R:)[P1S3"O+NL=_O)LFW* MNQJ',-LV11K /5^OE]-XLJY;.F\77XYA;2W)\^6RGI/>."8Z<56BB;4_4[W^ M0Y#W2[X(8-%*!,M8X'V:"^V/?4RG, ])S -+O:.;<*[\O1X17,PW?3Y/?_QY M8\$>U+ETUT?O;[P?-(A&=OCL)63\)R)'S01YE;K$VE6/)%M[.T(H+AL7M1/= MJAN_H-A?I6V?]3I\_#VL<3D-LXV?6V^I67ZHC9N0QZQ"@"*C(F?:UPO"!K?: M%>-"3,GT4EEW81N3K7PP-Z[JFZ8B:6C]MKC^6BS_]=M\B,%7EX#9K%4VJE;[ MJ7H%C2"SK+@#C[(T$DI[MOQ:+T$[PCS<$GB)QJED M*16'4*N+"6,&YPEB(-L<#:9 W_1ER\W@QM1 H#U;&@FEHZ]R]835'M[)S0_; MWQ_9$6@C#V1XV^8UVW=.G*FG8'WMI"@=*&4%B4YYD,K;@*@EZW3P_2J6)O>& M;)[X^W25<#8+)P2@ZT4LZ)Y&7V M?0JF;P$U)B^C-34:B:+E);CG^B>>0E%6BX#UNE6L'4E\">!-D) IM"HAF)!$ MGWVX:^&,J2=E8S[L/_T-3\WC^S#-0RG^!+4NFJL$CHM4S^UK\(%SR#X[Y@IJ M M%G(_88G>#S3,XW@?ABJ4X'A[FDJ#,'L6G*2%]% M9 QTY,&E9$/L5$-\.ZY[]OSYFBC14""M=<*V9OD4BK$IF8!$4#),]?(R!)_( MB2DH0BH\*9YZ=4R]!LX]F_A\3938?_I;]DM=K*;KLW(UIJ7+9)9TO6E0<4UD M)(UEM+-)(0]&]KD9Z0*,>W;=^9HD__#I;KWV7R\^A]E0/Y2"E=I5#<1K[!*, M)=XQ!TEE%1DKF:5.-:67D(RI9TZ?%?^P2>^8>#SKL+)8K5=AGK_WS[^NTZ5S:)&+0$84GB*LL,3DD!!FUB6B@9.H5= MMX!ZJ!JITWY*YY^GJZ&.C#S=9 S3M"I"O>K=T2*).420ME@K/*;B]5UDN>[! M8THUMA+PJ6K8>R+WM@@#@M-AU0:XM<;@>+JJ_4S).+G("I,&=+$1:JH"HM>9 M_DBB]KQ%;]-.,KWI#6/*%'81;I.I;6;W_YS'Z6PV7( [J,3SG44U\2L['H"& M5/L_U&VV&.J=*QA8MC[IU*?JX1908\H6MJ9':YFT405GI^EF-7V9UXMTLEHO MCG&YFIB<*E=#O<7,U88S!:+(%ARM=731R&AV4P8WOV-,V< NZJ#1]';T!D^/ M5X9S)ROW]S^_M[.8!LY>#>>/:UU"B5')6,J4')=HED'"(YGR#KRY+3. M4G5K0'HCJ@;]5J]_]C^7P_TNR?MR%&/'577)2%&%P0IJ6X7[-R" M:TP^8S/.7--KM95HFCD8SU,Z.3X9>I7MY2_;HJ@YT.-P>E!GI15\@ M",\3MT':3C@3O MXH?VJB+?XWTM2LM;#;>1@;WEM96JGI%''+@B]ZCJM"B(JIYBJ!1,=+;$H$R? M),KMN/;5FK<\?:/+:PED3IPTN,VDP3.3]1;R!+PP);1"R66?V.PN9&,RM VY MOG"!6K.2T_C-, "JQ>H>0HHO6<45<:L#8_"V#X%R/?' M.BH#^CC<:B'% QK+7T_6)TL\CW2[N]G00-[YCO9&\7[#.HPA#((<-L9IF1EK M:L6 AF E@HQ%:A&Y%*S/L9-',X37S/\?--=O/^+L _Z^F*^/5I.8(BUN"G14 MU+4Y0:R[YP[!J.+1T,*@'Q]_C(MY]A?E(Q'M>UK@\ RR##3[5 M(SWU-(_*)D$PAD%07"4G2PGJX''87:#'5&<_&@H^7*P'J,S<7GMPN:#Q7+/Z M!@6:N[^D79WF P?6\FCYN7<]G^=+P+[<$3=!'JQWSH%+M4L !:/@LD!@1B.B MLE'D/C'=?5"VNGW@])Z-Q%&S$BQP2X&/4ID< 92"EF/$Y H/CONYZR9@R$]W%WG3&6Q9TG+_=\$+OCWD^-^0<@U7!"PH7 MZI!KV;8=S(,?E MZNU]I_6IY^\O\DX:-)*!#,G7]!$'QU@F&J5H@Q Q7-;0[5;DW? :%";FD[3^ M*]2VD^O/PSO#[*=96*VF98KY],16$60D.2K@*!3Y\^@@1NF *]3<:9>M[C,+ M.P(&$I@61Z MV]V6U)BB\*YH8YR,)?^7?^G$WR[ M>(U#G?FKL#S/3NFE)#BU T7BH JILV3HG_G$.9.:&/:/VK,HAUS_P\44YM@ZBPCM(W_SX$QIECML@-3*QA5SHK, M;,R0HXT,N=+"V;OTS1WO&-/>3R?AMYSE-B+_<[[$M'@WG_[OT,[Y1YQCH0&? M&^AY6^AI9)@%6,_)%J)UFWM#A,BLQ.2B"68G$MSGK6/:Y.E)BVZ2:-A:>3-Z M0G=^Q"R:S(TW4$I-&FN)$+B*D&1&5KB15O39%[P>SYBVB#K;D 8":1M+7T]6 M%(7K' 3HK&MLGQ/$>A:G(-?%,6.,Z%1K<".F,>T ]78TV@AFQ]AF^_/Z1R2_ MYA]_^S]02P,$% @ SHA:4UP0WR466P ^#H$ !4 !M87-I+3(P,C$Q M,# R7V1E9BYX;6SLO5MS6T>2+OH^O\+'^_5DN^Z7CNG9(CGY]'4Z^O!Q_IU@@B_^=?I7'R-/266063)0H3!PF27@)@?Z@X\H\__]X:_2 MFJ)-4B -_W/O^G[+[-O?>_]#]]?JK ML]&R+])C^0__Z]?7[])'/ LP&L_F89QN7D"OS_/K?W@;C?[AXH_TU=GHK[/N MW[^>I##OU//H$+Y;^8WZ&UQ]#>I'P 5(_I%._D+(R&%/"]1P^ MGL0G.%9Q.F04.\\]Q;.*Y"+".LCSP*]<_*7-#G[ MH0/W34Y'N2ZJ[^;TW[K*3LJ[^23]Z^/D--,2_?._ST?SK[V_^/@(*P:H MZS)G3'1#:8#BECR(>*/QJ*YEK^G72RAU]'N5#'Z9XSAC_OZ[4?[;]R-K7!;2 M8O(Y*,-RP&1YP)BY]<)X==( 3Q71E9!.)^D.O-.Z_$^N^7H:(IYVGYZO74"7VXSK%HJ[([HA]8OIU=@N5YP-EZ1J1PVJX?ED()%> MZ(S ?__=9$K\_=OW;&OUWIL-K\;I]+P:H+]/IIU8Y_/I*)[/0SS%]Y/?)F2> MCN3?#%?NC^^^53',OOY"UE_HQE-GXB)]@G/*C\T M"4T5""PRR$QQ'45,*JEVQ%L+ZW&0K)UZ[A-*-"+4/\+I.2X'+%)A')V"8I&6 M8VL\>"$*%(F*\121A[1+/JV&>JQT&D@Y]]DDFRY/;VG]G(Y29VO2UU[\&:;Y M[]/);'922LR,MG*(3D62D3<0(Q&@2.6TBRS$U'!O7!OOL?)J2#7=)Y<:QL[^ M/8SR+Y/I^_#EGZ/YQ[JA$W[ZH/OKCX$FP'WD[[0 M38HE*H,0>,B@6-'@/4M0'%,8& NHVGA[6X!^\B3;E<+N<\ULS;73[CN8E\/[ M^4O]$4^T]<5Z+) L(YLPFP2>10%G] MY$7.G8S#:5U=7XU?AD^C>3CM!A 7!_ 6R<&=C>;X#J>?1PDOMO>WF"8?+C35 M69 G/B2-D4S$3+0')9F!$**#A)XV>)L2>;JM5Z\F(WOZ!#TDU=^GMMN6VN^G M&&;GTZ^=A7EA-+Q(!'Q:PWV&24@>=D8&+1L90EYR #L/(! M4$^>4$,)_#X7_*!SE9#;_%>7 MIUKG9^=D%HX^X\4WWY27'\/X [X:OTAI5X>7O-XT^G2*G=QD)FFY4@2H MHC4X)QSD%+GAZ# IVX19;<;SY+EX &I>PMZM _>_3R=E-']=PRA1VAB45Z"Y M0I(.UQ!54H!":JT9%N;;1+MN,#QYEFPHSB6:W3J"_F;^$:?5!)OBQYH0\ADO M*%S!D2.*HP_CE^?3*8[3U_?30&9:ZB0]SMUOIYW5=F/O_89$9&+_B4TH61(1 M6'(.E**QA>JINNP<]X69F-L8YVW&\^09=P!J7L+>[2/VMT_:K0Q96L\!O6*T MQ2<"8[4"8]$4'1 3:\.YUSNO5U$DU)*LXF0S*",">*D=.!LB8PRYHTWA MJ9S7;Y&R\[Z^Y22Z0E.F(+"@:?L,/H,GP=#,<5QDZ[,2LFVZ3H=CP%7D5D;H M#LY;-A;FLAR"[R[R^_Z:3B?D_?_M^_GT'&\^)"[@E_G/I]T+__;]##_4'P;C MPU7FV-FGR;C&)UY\&9%P&#-(WB(4G6BR)*G(A52*3*R(EOP%5V3C;*YEL 9D MRP.YN@^P9P-UKV+.UF)OD(RR@.FG;E_N!>ID(7MX4$XLA36D_;$J!_H!)FRO MODDKV>^,&#DEGW51D)FQH!!I!2TTHXK/)FDTTN0VGO8."7$GR7S_?%A'Y UX M0'#.)N/.H/FUL]9/R$=SI@@#J*,&1=X9T-J8('MM-/$R:>&:<. >E-T[) .H M:#*D?!ODRMX))%Y"LL4D$VV P'P=H&'@&5$[*68M.>HA\3:'F4O '(/2MY5Q M@WF^XH3J$ES,QOE8R'_RDBQG9AD$93TPRPOYN#;&*!H=,SX ZQBH,)S<&V26 MODCI(D*+>57LY!*H+T'P"I1K7U-@/4(L0H,,!NE_I0JZS:;0&^)1D*6)/AHD MD;[%.8T5\\]A.AZ-/\RN4!E6T$<#)>9(=&:!4*D,.O*DO,K@K!+@51$04U&!5D34F3UQ=CP2I=@S.=910 MG MYGJPM'B.'YK]DQ.1VE4K]A\QO%YS2P4 E!E*)DX-XY510M0TX:PWA..M&BPZ4\&0[&9FM*%WF_KQ/@6ZX)Q<:GLOCQK M;GV]6_9^=$9?(6CTZ:Q<)$MHU!';A,K%LLK"22V2<;&=3 MH[X*#41Z.S 7E.#")^YZ);S14V]QCGY;Y-N=UQXE3387[("AL&L0EZY2'QCK M1+_ZZWD?@:XM5+"HQ"WDUV*R7L(QRC"TTH'1@;9CYSA$E^LUU20DH=$N],JF M.0PUKHA(#:_%=<0VL/9^)4F=G9]= 4E,:J4%Y.PBJ.@$!,89Z,1,\LX([7H= M>O;2WYU7[\X[V4KXDR$D-Z#GT $)7VX!T4(HE\DB-@II:Z#?P#F+0$,)R@9C MBNA5_:&?"F^_^@FJ<&/)K9R%AQBV.UG8R7<*T3=J@ MS2H'X3"+H+PIV;,8/1LN>$= GL-WS^&[Y_#=<_CN.7SW'+Y[CGX\G>C'8.[R M<_3C.?IQL&I\CGX\1S^>HQ_/T8^#CG[<7#9Y->Y\AAL/NUW,XZ&7[BC2T7O< M"_$-%HU [6G(VBN9N+>")BOY385E3,'WC&\\]/H=1C6<8Y*&D(GYM4B-<+U%\JF[#'S,LYZ>O1P7);(E* M!D7# M?<;\:CRGC6!$3M&+V0QO8[1.%E,(F2>JUTHQ%J((51HQ2B2CK80V-U#ZH#MB M_@RNG $MWDX8OYU72='Z/CF?)IQ-"C$^GZ?Y91#N) E+ (*%(F*MIY\9N% 0 M#-/.JU"O;HE>:^HC+SI"#@PNWP$3+SIL_PS3*8W[ZT6\])?)]"?LRAF^&O\: MYO19.*45KS8;/0OCVUHN4[3.=3T@+.?OY2:W]A_H6D6*]^GL\[ _!-N;JS M2].*LBK%$")IWUH%4.%[Y%0%2 17KON'':M;F]- C\(^3B_M3;J@7+ MO7KY+^I$^]!%Y7_\>O.5W\/7^E'70.:JD-UL/NVZ,\^Z*^CO/X;Q90NCO]>Y M2G/S8K:>",]M2MJ"#;7-FJAMUCAYS")*08:?*V71W1BR$N$.1GC$3#](D@S8 M.&;M0Q0R/T1*(M%4-1D4I@(N90-9:^FD3<(D.Z#O?+AGD!OOY:VD?5AGD"SY M)"5+P+2TH )))C(R160MP6^]KG4=OL$SR+44NO0,374)U6F:P=\5(HX6@U8P5H_:K=5+H*.<)9/7#*P-[/((?0XCIB:WH& MZ4,)OD@%S'C:C2(!B*RR4[T\G:?TAGDQBK<6'(MBFQ4>[_6C.B6E1QH%

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�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

  •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

    •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